<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY b025-005a-9780702070280 SYSTEM "b025-005a-9780702070280" NDATA IMAGE><!ENTITY b025-005b-9780702070280 SYSTEM "b025-005b-9780702070280" NDATA IMAGE><!ENTITY b025-005c-9780702070280 SYSTEM "b025-005c-9780702070280" NDATA IMAGE><!ENTITY f025-001-9780702070280 SYSTEM "f025-001-9780702070280" NDATA IMAGE><!ENTITY f025-002-9780702070280 SYSTEM "f025-002-9780702070280" NDATA IMAGE><!ENTITY f025-003-9780702070280 SYSTEM "f025-003-9780702070280" NDATA IMAGE><!ENTITY f025-004-9780702070280 SYSTEM "f025-004-9780702070280" NDATA IMAGE><!ENTITY f025-005-9780702070280 SYSTEM "f025-005-9780702070280" NDATA IMAGE><!ENTITY f025-006-9780702070280 SYSTEM "f025-006-9780702070280" NDATA IMAGE><!ENTITY f025-007-9780702070280 SYSTEM "f025-007-9780702070280" NDATA IMAGE><!ENTITY f025-008-9780702070280 SYSTEM "f025-008-9780702070280" NDATA IMAGE><!ENTITY f025-009-9780702070280 SYSTEM "f025-009-9780702070280" NDATA IMAGE><!ENTITY f025-010-9780702070280 SYSTEM "f025-010-9780702070280" NDATA IMAGE><!ENTITY f025-011-9780702070280 SYSTEM "f025-011-9780702070280" NDATA IMAGE><!ENTITY f025-012ad-9780702070280 SYSTEM "f025-012ad-9780702070280" NDATA IMAGE><!ENTITY f025-013-9780702070280 SYSTEM "f025-013-9780702070280" NDATA IMAGE><!ENTITY f025-014-9780702070280 SYSTEM "f025-014-9780702070280" NDATA IMAGE><!ENTITY f025-015-9780702070280 SYSTEM "f025-015-9780702070280" NDATA IMAGE><!ENTITY f025-016-9780702070280 SYSTEM "f025-016-9780702070280" NDATA IMAGE><!ENTITY f025-017-9780702070280 SYSTEM "f025-017-9780702070280" NDATA IMAGE><!ENTITY f025-018ah-9780702070280 SYSTEM "f025-018ah-9780702070280" NDATA IMAGE><!ENTITY f025-019-9780702070280 SYSTEM "f025-019-9780702070280" NDATA IMAGE><!ENTITY f025-020-9780702070280 SYSTEM "f025-020-9780702070280" NDATA IMAGE><!ENTITY f025-021-9780702070280 SYSTEM "f025-021-9780702070280" NDATA IMAGE><!ENTITY f025-022-9780702070280 SYSTEM "f025-022-9780702070280" NDATA IMAGE><!ENTITY f025-023ac-9780702070280 SYSTEM "f025-023ac-9780702070280" NDATA IMAGE><!ENTITY f025-024-9780702070280 SYSTEM "f025-024-9780702070280" NDATA IMAGE><!ENTITY f025-025-9780702070280 SYSTEM "f025-025-9780702070280" NDATA IMAGE><!ENTITY f025-026ab-9780702070280 SYSTEM "f025-026ab-9780702070280" NDATA IMAGE><!ENTITY f025-027ac-9780702070280 SYSTEM "f025-027ac-9780702070280" NDATA IMAGE><!ENTITY f025-028-9780702070280 SYSTEM "f025-028-9780702070280" NDATA IMAGE><!ENTITY f025-029-9780702070280 SYSTEM "f025-029-9780702070280" NDATA IMAGE><!ENTITY f025-030ab-9780702070280 SYSTEM "f025-030ab-9780702070280" NDATA IMAGE><!ENTITY f025-031-9780702070280 SYSTEM "f025-031-9780702070280" NDATA IMAGE><!ENTITY f025-032-9780702070280 SYSTEM "f025-032-9780702070280" NDATA IMAGE><!ENTITY f025-033-9780702070280 SYSTEM "f025-033-9780702070280" NDATA IMAGE><!ENTITY f025-034-9780702070280 SYSTEM "f025-034-9780702070280" NDATA IMAGE><!ENTITY f025-035-9780702070280 SYSTEM "f025-035-9780702070280" NDATA IMAGE><!ENTITY f025-036a-9780702070280 SYSTEM "f025-036a-9780702070280" NDATA IMAGE><!ENTITY f025-036b-9780702070280 SYSTEM "f025-036b-9780702070280" NDATA IMAGE><!ENTITY f025-037-9780702070280 SYSTEM "f025-037-9780702070280" NDATA IMAGE><!ENTITY f025-038-9780702070280 SYSTEM "f025-038-9780702070280" NDATA IMAGE><!ENTITY f025-039-9780702070280 SYSTEM "f025-039-9780702070280" NDATA IMAGE><!ENTITY f025-040-9780702070280 SYSTEM "f025-040-9780702070280" NDATA IMAGE><!ENTITY f025-041-9780702070280 SYSTEM "f025-041-9780702070280" NDATA IMAGE><!ENTITY f025-042a-9780702070280 SYSTEM "f025-042a-9780702070280" NDATA IMAGE><!ENTITY f025-042b-9780702070280 SYSTEM "f025-042b-9780702070280" NDATA IMAGE><!ENTITY f025-043-9780702070280 SYSTEM "f025-043-9780702070280" NDATA IMAGE><!ENTITY f025-044-9780702070280 SYSTEM "f025-044-9780702070280" NDATA IMAGE><!ENTITY f025-045a-9780702070280 SYSTEM "f025-045a-9780702070280" NDATA IMAGE><!ENTITY f025-045b-9780702070280 SYSTEM "f025-045b-9780702070280" NDATA IMAGE><!ENTITY f025-046-9780702070280 SYSTEM "f025-046-9780702070280" NDATA IMAGE><!ENTITY f025-047-9780702070280 SYSTEM "f025-047-9780702070280" NDATA IMAGE><!ENTITY f025-048-9780702070280 SYSTEM "f025-048-9780702070280" NDATA IMAGE><!ENTITY f025-049-9780702070280 SYSTEM "f025-049-9780702070280" NDATA IMAGE><!ENTITY f025-050-9780702070280 SYSTEM "f025-050-9780702070280" NDATA IMAGE><!ENTITY f025-051-9780702070280 SYSTEM "f025-051-9780702070280" NDATA IMAGE><!ENTITY f025-052-9780702070280 SYSTEM "f025-052-9780702070280" NDATA IMAGE><!ENTITY f025-053-9780702070280 SYSTEM "f025-053-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon04-9780702070280 SYSTEM "icon04-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u025-001-9780702070280 SYSTEM "u025-001-9780702070280" NDATA IMAGE><!ENTITY u025-002-9780702070280 SYSTEM "u025-002-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00025" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00025-1</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00025-1</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0020"><ce:label>Fig. 25.1</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" role="title">Cells of the nervous system.</ce:simple-para><ce:simple-para id="sp0025" role="caption">(CSF = cerebrospinal fluid)</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 25.1</ce:alt-text><ce:link id="ln0020" locator="f025-001-9780702070280" xlink:href="pii:B9780702070280000251/f025-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 25.2</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0030" role="title">Neurotransmission and neurotransmitters.</ce:simple-para><ce:simple-para id="sp0035" role="caption">(1) An action potential arriving at the nerve terminal depolarises the membrane and this opens voltage-gated calcium channels. (2) Entry of calcium causes the fusion of synaptic vesicles containing neurotransmitters with the pre-synaptic membrane and release of the neurotransmitter across the synaptic cleft. (3) The neurotransmitter binds to receptors on the post-synaptic membrane either (A) to open ligand-gated ion channels that, by allowing ion entry, depolarise the membrane and initiate an action potential (4), or (B) to bind to metabotropic receptors that activate an effector enzyme (e.g. adenylyl cyclase) and thus modulate gene transcription via the intracellular second messenger system, leading to changes in synthesis of ion channels or modulating enzymes. (5) Neurotransmitters are taken up at the pre-synaptic membrane and/or metabolised. (cAMP = cyclic adenosine monophosphate; DNA = deoxyribonucleic acid; mRNA = messenger ribonucleic acid)</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 25.2</ce:alt-text><ce:link id="ln0025" locator="f025-002-9780702070280" xlink:href="pii:B9780702070280000251/f025-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 25.3</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0040" role="title">The major anatomical components of the nervous system.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 25.3</ce:alt-text><ce:link id="ln0030" locator="f025-003-9780702070280" xlink:href="pii:B9780702070280000251/f025-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 25.4</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0045" role="title">Anatomy of the cerebral cortex.</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 25.4</ce:alt-text><ce:link id="ln0035" locator="f025-004-9780702070280" xlink:href="pii:B9780702070280000251/f025-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 25.5</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0050" role="title">Anatomy of the brainstem.</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 25.5</ce:alt-text><ce:link id="ln0040" locator="f025-005-9780702070280" xlink:href="pii:B9780702070280000251/f025-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 25.6</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0055" role="title">The motor system.</ce:simple-para><ce:simple-para id="sp0060" role="caption">Neurons from the motor cortex descend as the pyramidal tract in the internal capsule and cerebral peduncle to the ventral brainstem, where most cross low in the medulla (A). In the spinal cord the upper motor neurons form the corticospinal tract in the lateral column before synapsing with the lower motor neurons in the anterior horns. The activity in the motor cortex is modulated by influences from the basal ganglia and cerebellum. Pathways descending from these structures control posture and balance (B).</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 25.6</ce:alt-text><ce:link id="ln0045" locator="f025-006-9780702070280" xlink:href="pii:B9780702070280000251/f025-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 25.7</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0065" role="title">Visual pathways and visual field defects.</ce:simple-para><ce:simple-para id="sp0070" role="caption">Schematic representation of eyes and brain in transverse section.</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 25.7</ce:alt-text><ce:link id="ln0050" locator="f025-007-9780702070280" xlink:href="pii:B9780702070280000251/f025-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 25.8</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0075" role="title">Control of conjugate eye movements.</ce:simple-para><ce:simple-para id="sp0080" role="caption">Downward projections pass from the cortex to the pontine lateral gaze centre (A). The pontine gaze centre projects to the 6th cranial nerve nucleus (B), which innervates the ipsilateral lateral rectus and projects to the contralateral 3rd nerve nucleus (and hence medial rectus) via the medial longitudinal fasciculus (MLF). Tonic inputs from the vestibular apparatus (C) project to the contralateral 6th nerve nucleus via the vestibular nuclei.</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 25.8</ce:alt-text><ce:link id="ln0055" locator="f025-008-9780702070280" xlink:href="pii:B9780702070280000251/f025-008-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 25.9</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0085" role="title">Areas of the cerebral cortex involved in the generation of spoken language.</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 25.9</ce:alt-text><ce:link id="ln0060" locator="f025-009-9780702070280" xlink:href="pii:B9780702070280000251/f025-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 25.10</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0090" role="title">The areas supplied by specific levels of the spinal cord.</ce:simple-para><ce:simple-para id="sp0095" role="caption">These are approximations and in practice there is much overlap. The clinical utility of these dermatomes has diminished somewhat with the advent of good magnetic resonance imaging of the spinal cord but it remains important to ascertain the presence of a ‘spinal level’ of sensation, to remember the supply of saddle area, and to note the cervical descent of some facial spinothalamic pathways. <ce:bold>A</ce:bold> Anterior. <ce:bold>B</ce:bold> Posterior.</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 25.10</ce:alt-text><ce:link id="ln0065" locator="f025-010-9780702070280" xlink:href="pii:B9780702070280000251/f025-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 25.11</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0100" role="title">The main somatic sensory pathways.</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 25.11</ce:alt-text><ce:link id="ln0070" locator="f025-011-9780702070280" xlink:href="pii:B9780702070280000251/f025-011-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 25.12</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0110" role="title">Different techniques of imaging the head and brain.</ce:simple-para><ce:simple-para id="sp0115" role="caption"><ce:bold>A</ce:bold> Computed tomogram showing complete middle cerebral artery infarct (arrows). <ce:bold>B</ce:bold> Magnetic resonance image showing widespread areas of high signal in multiple sclerosis (arrows). <ce:bold>C</ce:bold> Single photon emission computed tomography scan after caudate infarct showing relative hypoperfusion of overlying right cerebral cortex (arrows). <ce:bold>D</ce:bold> Normal positron emission tomogram (PET scan) of brain.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 25.12</ce:alt-text><ce:source>A–C, Courtesy of Dr D. Collie. D, Courtesy of Dr Ravi Jampana, Consultant Neuroradiologist, Dept of Neuroradiology, Institute of Neuroscience, Queen Elizabeth University Hospital, Glasgow.</ce:source><ce:link id="ln0090" locator="f025-012ad-9780702070280" xlink:href="pii:B9780702070280000251/f025-012ad-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 25.13</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0120" role="title">Different techniques of imaging the cervical spine.</ce:simple-para><ce:simple-para id="sp0125" role="caption"><ce:bold>A</ce:bold> Lateral X-ray showing bilateral C6/7 facet dislocation. <ce:bold>B</ce:bold> Myelogram showing widening of cervical cord due to astrocytoma (arrows). <ce:bold>C</ce:bold> Magnetic resonance image showing posterior epidural compression from adenocarcinomatous metastasis to the posterior arch of T1 (arrows).</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 25.13</ce:alt-text><ce:source>A–C, Courtesy of Dr D. Collie.</ce:source><ce:link id="ln0095" locator="f025-013-9780702070280" xlink:href="pii:B9780702070280000251/f025-013-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0100"><ce:label>Fig. 25.14</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0130" role="title">Electroencephalograms in epilepsy.</ce:simple-para><ce:simple-para id="sp0135" role="caption"><ce:bold>A</ce:bold> Generalised epileptic discharge, as seen in epilepsy syndromes such as childhood absence or juvenile myoclonic epilepsy. <ce:bold>B</ce:bold> Focal sharp waves over the right parietal region (circled), with spread of discharge to cause a generalised tonic–clonic seizure.</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 25.14</ce:alt-text><ce:link id="ln0100" locator="f025-014-9780702070280" xlink:href="pii:B9780702070280000251/f025-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0105"><ce:label>Fig. 25.15</ce:label><ce:caption id="ca0085"><ce:simple-para id="sp0140" role="title">Motor nerve conduction tests.</ce:simple-para><ce:simple-para id="sp0145" role="caption">Electrodes (R) on the muscle (abductor pollicis here) record the compound muscle action potential (CMAP) after stimulation at the median nerve at the wrist (S<ce:inf loc="post">1</ce:inf>) and from the elbow (S<ce:inf loc="post">2</ce:inf>). The velocity from elbow to wrist can be determined if the distance between the two stimulating electrodes (d) is known. A prolonged L<ce:inf loc="post">1</ce:inf> (L = latency) would be caused by dysfunction distally in the median nerve (e.g. in carpal tunnel syndrome). A prolonged L<ce:inf loc="post">2</ce:inf> is caused by slow nerve conduction (as in demyelinating neuropathy). The F wave is a small delayed response that appears when the electrical signal travels backwards to the anterior horn cell, sparking a second action potential in a minority of fibres (see text). (NCV = nerve conduction velocity)</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 25.15</ce:alt-text><ce:link id="ln0105" locator="f025-015-9780702070280" xlink:href="pii:B9780702070280000251/f025-015-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0110"><ce:label>Fig. 25.16</ce:label><ce:caption id="ca0090"><ce:simple-para id="sp0150" role="title">Visual evoked potential (VEP) recording.</ce:simple-para><ce:simple-para id="sp0155" role="caption">The abnormality is in the left hemisphere, with delay in latency and a reduction in signal of the P<ce:inf loc="post">100</ce:inf>.</ce:simple-para></ce:caption><ce:alt-text id="atte0085" role="short">Fig. 25.16</ce:alt-text><ce:link id="ln0110" locator="f025-016-9780702070280" xlink:href="pii:B9780702070280000251/f025-016-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0115"><ce:label>Fig. 25.17</ce:label><ce:caption id="ca0095"><ce:simple-para id="sp0165" role="title">Patterns of motor loss according to the anatomical site of the lesion.</ce:simple-para></ce:caption><ce:alt-text id="atte0090" role="short">Fig. 25.17</ce:alt-text><ce:link id="ln0115" locator="f025-017-9780702070280" xlink:href="pii:B9780702070280000251/f025-017-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0120"><ce:label>Fig. 25.18</ce:label><ce:caption id="ca0100"><ce:simple-para id="sp0170" role="title">Patterns of sensory loss.</ce:simple-para><ce:simple-para id="sp0175" role="caption"><ce:bold>A</ce:bold> Generalised peripheral neuropathy. <ce:bold>B</ce:bold> Sensory roots: some common examples. <ce:bold>C</ce:bold> Single dorsal column lesion (proprioception and some touch loss). <ce:bold>D</ce:bold> Transverse thoracic spinal cord lesion. <ce:bold>E</ce:bold> Unilateral cord lesion (Brown–Séquard): ipsilateral dorsal column (and motor) deficit and contralateral spinothalamic deficit. <ce:bold>F</ce:bold> Central cord lesion: ‘cape’ distribution of spinothalamic loss. <ce:bold>G</ce:bold> Mid-brainstem lesion: ipsilateral facial sensory loss and contralateral loss on body below the vertex. <ce:bold>H</ce:bold> Hemisphere (thalamic) lesion: contralateral loss on one side of face and body.</ce:simple-para></ce:caption><ce:alt-text id="atte0095" role="short">Fig. 25.18</ce:alt-text><ce:link id="ln0120" locator="f025-018ah-9780702070280" xlink:href="pii:B9780702070280000251/f025-018ah-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0125"><ce:label>Fig. 25.19</ce:label><ce:caption id="ca0105"><ce:simple-para id="sp0180" role="title">Classification of cortical speech problems.</ce:simple-para><ce:simple-para id="sp0185" role="caption">(1) Wernicke's aphasia: fluent dysphasia with poor comprehension and poor repetition. (2) Conduction aphasia: fluent aphasia with good comprehension and poor repetition. (3) Broca's aphasia: non-fluent aphasia with good comprehension and poor repetition. (4) Transcortical sensory aphasia: fluent aphasia with poor comprehension and good repetition. (5) Transcortical motor aphasia: non-fluent aphasia with good comprehension and good repetition. Large lesions affecting all of regions 1–5 cause global aphasia.</ce:simple-para></ce:caption><ce:alt-text id="atte0100" role="short">Fig. 25.19</ce:alt-text><ce:link id="ln0125" locator="f025-019-9780702070280" xlink:href="pii:B9780702070280000251/f025-019-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0130"><ce:label>Fig. 25.20</ce:label><ce:caption id="ca0110"><ce:simple-para id="sp0190" role="title">Examination findings in 3rd, 4th and 6th nerve palsy.</ce:simple-para><ce:simple-para id="sp0195" role="caption">Diplopia tends to be more obvious on lateral gaze compared to primary position.</ce:simple-para></ce:caption><ce:alt-text id="atte0105" role="short">Fig. 25.20</ce:alt-text><ce:link id="ln0130" locator="f025-020-9780702070280" xlink:href="pii:B9780702070280000251/f025-020-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0135"><ce:label>Fig. 25.21</ce:label><ce:caption id="ca0115"><ce:simple-para id="sp0200" role="title">Differential diagnosis of unilateral ptosis.</ce:simple-para><ce:simple-para id="sp0205" role="caption">(CPEO = chronic progressive external ophthalmoplegia)</ce:simple-para></ce:caption><ce:alt-text id="atte0110" role="short">Fig. 25.21</ce:alt-text><ce:link id="ln0135" locator="f025-021-9780702070280" xlink:href="pii:B9780702070280000251/f025-021-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0140"><ce:label>Fig. 25.22</ce:label><ce:caption id="ca0120"><ce:simple-para id="sp0210" role="title">Right-sided Horner's syndrome due to paravertebral metastasis at T1.</ce:simple-para><ce:simple-para id="sp0215" role="caption">There is ipsilateral partial ptosis and a small pupil.</ce:simple-para></ce:caption><ce:alt-text id="atte0115" role="short">Fig. 25.22</ce:alt-text><ce:link id="ln0140" locator="f025-022-9780702070280" xlink:href="pii:B9780702070280000251/f025-022-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0145"><ce:label>Fig. 25.23</ce:label><ce:caption id="ca0125"><ce:simple-para id="sp0220" role="title">Mechanism of optic disc oedema (papilloedema).</ce:simple-para><ce:simple-para id="sp0225" role="caption"><ce:bold>A</ce:bold> Normal. <ce:bold>B</ce:bold> Disc oedema (e.g. due to cerebral tumour). <ce:bold>C</ce:bold> Fundus photograph of the left eye showing optic disc oedema with a small haemorrhage on the nasal side of the disc. (CSF = cerebrospinal fluid)</ce:simple-para></ce:caption><ce:alt-text id="atte0120" role="short">Fig. 25.23</ce:alt-text><ce:source>C, Courtesy of Dr B. Cullen.</ce:source><ce:link id="ln0145" locator="f025-023ac-9780702070280" xlink:href="pii:B9780702070280000251/f025-023ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0150"><ce:label>Fig. 25.24</ce:label><ce:caption id="ca0130"><ce:simple-para id="sp0230" role="title">Fundus photograph of the left eye of a patient with familial optic atrophy.</ce:simple-para><ce:simple-para id="sp0235" role="caption">Note the marked pallor of the optic disc.</ce:simple-para></ce:caption><ce:alt-text id="atte0125" role="short">Fig. 25.24</ce:alt-text><ce:link id="ln0150" locator="f025-024-9780702070280" xlink:href="pii:B9780702070280000251/f025-024-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0155"><ce:label>Fig. 25.25</ce:label><ce:caption id="ca0135"><ce:simple-para id="sp0240" role="title">The pathophysiological classification of seizures.</ce:simple-para><ce:simple-para id="sp0245" role="caption"><ce:bold>A</ce:bold> A focal seizure originates from a paroxysmal discharge in a focal area of the cerebral cortex (often the temporal lobe); the seizure may subsequently spread to the rest of the brain (secondary generalisation) via diencephalic activating pathways. <ce:bold>B</ce:bold> In genetic generalised epilepsies (GGEs) the abnormal electrical discharges originate from the diencephalic activating system and spread simultaneously to all areas of the cortex.</ce:simple-para></ce:caption><ce:alt-text id="atte0130" role="short">Fig. 25.25</ce:alt-text><ce:link id="ln0155" locator="f025-025-9780702070280" xlink:href="pii:B9780702070280000251/f025-025-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0160"><ce:label>Fig. 25.26</ce:label><ce:caption id="ca0140"><ce:simple-para id="sp0260" role="title">The Hallpike manœuvre for diagnosis of benign paroxysmal positional vertigo (BPPV).</ce:simple-para><ce:simple-para id="sp0265" role="caption">Patients are asked to keep their eyes open and look at the examiner as their head is swung briskly backwards through 120° to overhang the edge of the couch. <ce:bold>A</ce:bold> Perform first with the right ear down. <ce:bold>B</ce:bold> Perform next with the left ear down. The examiner looks for nystagmus (usually accompanied by vertigo). In BPPV, the nystagmus typically occurs in A or B only and is torsional, the fast phase beating towards the lower ear. Its onset is usually delayed a few seconds and it lasts 10–20 seconds. As the patient is returned to the upright position, transient nystagmus may occur in the opposite direction. Both nystagmus and vertigo typically decrease (fatigue) on repeat testing.</ce:simple-para></ce:caption><ce:alt-text id="atte0135" role="short">Fig. 25.26</ce:alt-text><ce:link id="ln0160" locator="f025-026ab-9780702070280" xlink:href="pii:B9780702070280000251/f025-026ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0165"><ce:label>Fig. 25.27</ce:label><ce:caption id="ca0145"><ce:simple-para id="sp0270" role="title">Multiple sclerosis.</ce:simple-para><ce:simple-para id="sp0275" role="caption"><ce:bold>A</ce:bold> Photomicrograph from demyelinating plaque, showing perivascular cuffing of blood vessel by lymphocytes. <ce:bold>B</ce:bold> Brain magnetic resonance imaging in multiple sclerosis. Multiple high-signal lesions (arrows) seen particularly in the paraventricular region on T2 image. <ce:bold>C</ce:bold> In T1 image with gadolinium enhancement, recent lesions (A arrows) show enhancement, suggesting active inflammation (enhancement persists for 4 weeks); older lesions (B arrows) show no enhancement but low signal, suggesting gliosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0140" role="short">Fig. 25.27</ce:alt-text><ce:link id="ln0165" locator="f025-027ac-9780702070280" xlink:href="pii:B9780702070280000251/f025-027ac-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0170"><ce:label>Fig. 25.28</ce:label><ce:caption id="ca0150"><ce:simple-para id="sp0280" role="title">The progression of disability in fulminant, relapsing–remitting and progressive multiple sclerosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0145" role="short">Fig. 25.28</ce:alt-text><ce:source>Courtesy of Prof. D.A.S. Compston.</ce:source><ce:link id="ln0170" locator="f025-028-9780702070280" xlink:href="pii:B9780702070280000251/f025-028-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0175"><ce:label>Fig. 25.29</ce:label><ce:caption id="ca0155"><ce:simple-para id="sp0285" role="title">Investigations in a patient suspected of having multiple sclerosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0150" role="short">Fig. 25.29</ce:alt-text><ce:link id="ln0175" locator="f025-029-9780702070280" xlink:href="pii:B9780702070280000251/f025-029-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0180"><ce:label>Fig. 25.30</ce:label><ce:caption id="ca0160"><ce:simple-para id="sp0290" role="title">Multiple sclerosis: demyelinating lesion in cervical spinal cord, high-signal T2 images (arrows).</ce:simple-para><ce:simple-para id="sp0295" role="caption"><ce:bold>A</ce:bold> Sagittal plane. <ce:bold>B</ce:bold> Axial plane.</ce:simple-para></ce:caption><ce:alt-text id="atte0155" role="short">Fig. 25.30</ce:alt-text><ce:link id="ln0180" locator="f025-030ab-9780702070280" xlink:href="pii:B9780702070280000251/f025-030ab-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0185"><ce:label>Fig. 25.31</ce:label><ce:caption id="ca0165"><ce:simple-para id="sp0315" role="title">Parkinson's disease.</ce:simple-para><ce:simple-para id="sp0320" role="caption">High power (× 400) view of substantia nigra of a patient with Parkinson's disease showing classical Lewy body (haematoxylin and eosin).</ce:simple-para></ce:caption><ce:alt-text id="atte0160" role="short">Fig. 25.31</ce:alt-text><ce:source>Courtesy of Dr J. Xuereb.</ce:source><ce:link id="ln0185" locator="f025-031-9780702070280" xlink:href="pii:B9780702070280000251/f025-031-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0190"><ce:label>Fig. 25.32</ce:label><ce:caption id="ca0170"><ce:simple-para id="sp0325" role="title">Imaging in Parkinson's disease.</ce:simple-para><ce:simple-para id="sp0330" role="caption"><ce:bold>A</ce:bold> Single photon emission computed tomography (SPECT) in Parkinson's disease showing reduced dopamine activity in the basal ganglia. <ce:bold>B</ce:bold> Normal.</ce:simple-para></ce:caption><ce:alt-text id="atte0165" role="short">Fig. 25.32</ce:alt-text><ce:link id="ln0190" locator="f025-032-9780702070280" xlink:href="pii:B9780702070280000251/f025-032-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0195"><ce:label>Fig. 25.33</ce:label><ce:caption id="ca0175"><ce:simple-para id="sp0340" role="title">Patterns of involvement in motor neuron disease.</ce:simple-para><ce:simple-para id="sp0345" role="caption">(LMN = lower motor neuron; UMN = upper motor neuron)</ce:simple-para></ce:caption><ce:alt-text id="atte0170" role="short">Fig. 25.33</ce:alt-text><ce:link id="ln0195" locator="f025-033-9780702070280" xlink:href="pii:B9780702070280000251/f025-033-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0200"><ce:label>Fig. 25.34</ce:label><ce:caption id="ca0180"><ce:simple-para id="sp0350" role="title">The investigation of meningitis.</ce:simple-para></ce:caption><ce:alt-text id="atte0175" role="short">Fig. 25.34</ce:alt-text><ce:link id="ln0200" locator="f025-034-9780702070280" xlink:href="pii:B9780702070280000251/f025-034-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0205"><ce:label>Fig. 25.35</ce:label><ce:caption id="ca0185"><ce:simple-para id="sp0360" role="title">Poliomyelitis.</ce:simple-para><ce:simple-para id="sp0365" role="caption">Possible consequences of infection.</ce:simple-para></ce:caption><ce:alt-text id="atte0180" role="short">Fig. 25.35</ce:alt-text><ce:link id="ln0205" locator="f025-035-9780702070280" xlink:href="pii:B9780702070280000251/f025-035-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0210"><ce:label>Fig. 25.36</ce:label><ce:caption id="ca0190"><ce:simple-para id="sp0370" role="title">Right temporal cerebral abscess (arrows), with surrounding oedema and midline shift to the left.</ce:simple-para><ce:simple-para id="sp0375" role="caption"><ce:bold>A</ce:bold> Unenhanced computed tomography (CT) image. <ce:bold>B</ce:bold> Contrast-enhanced CT image.</ce:simple-para></ce:caption><ce:alt-text id="atte0185" role="short">Fig. 25.36</ce:alt-text><ce:link id="ln0210" locator="f025-036a-9780702070280" xlink:href="pii:B9780702070280000251/f025-036a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0215" locator="f025-036b-9780702070280" xlink:href="pii:B9780702070280000251/f025-036b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0215"><ce:label>Fig. 25.37</ce:label><ce:caption id="ca0195"><ce:simple-para id="sp0380" role="title">Magnetic resonance imaging in variant Creutzfeldt–Jakob disease.</ce:simple-para><ce:simple-para id="sp0385" role="caption">Arrows indicate bilateral pulvinar hyperintensity.</ce:simple-para></ce:caption><ce:alt-text id="atte0190" role="short">Fig. 25.37</ce:alt-text><ce:link id="ln0220" locator="f025-037-9780702070280" xlink:href="pii:B9780702070280000251/f025-037-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0220"><ce:label>Fig. 25.38</ce:label><ce:caption id="ca0200"><ce:simple-para id="sp0395" role="title">Cerebral tumour displacing medial temporal lobe and causing pressure on the mid-brain and 3rd cranial nerve.</ce:simple-para></ce:caption><ce:alt-text id="atte0195" role="short">Fig. 25.38</ce:alt-text><ce:link id="ln0225" locator="f025-038-9780702070280" xlink:href="pii:B9780702070280000251/f025-038-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0225"><ce:label>Fig. 25.39</ce:label><ce:caption id="ca0205"><ce:simple-para id="sp0400" role="title">Tonsillar cone.</ce:simple-para><ce:simple-para id="sp0405" role="caption">Downward displacement of the cerebellar tonsils below the level of the foramen magnum.</ce:simple-para></ce:caption><ce:alt-text id="atte0200" role="short">Fig. 25.39</ce:alt-text><ce:link id="ln0230" locator="f025-039-9780702070280" xlink:href="pii:B9780702070280000251/f025-039-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0230"><ce:label>Fig. 25.40</ce:label><ce:caption id="ca0210"><ce:simple-para id="sp0410" role="title">Contrast-enhanced computed tomogram of the head showing a large metastasis within the left hemisphere (large arrow).</ce:simple-para><ce:simple-para id="sp0415" role="caption">There is surrounding cerebral oedema, and a smaller metastasis (small arrow) within the wall of the right lateral ventricle. The primary lesion was a lung carcinoma.</ce:simple-para></ce:caption><ce:alt-text id="atte0205" role="short">Fig. 25.40</ce:alt-text><ce:link id="ln0235" locator="f025-040-9780702070280" xlink:href="pii:B9780702070280000251/f025-040-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0235"><ce:label>Fig. 25.41</ce:label><ce:caption id="ca0215"><ce:simple-para id="sp0420" role="title">Magnetic resonance image showing a meningioma in the frontal lobe (arrow A) with associated oedema (arrow B).</ce:simple-para></ce:caption><ce:alt-text id="atte0210" role="short">Fig. 25.41</ce:alt-text><ce:link id="ln0240" locator="f025-041-9780702070280" xlink:href="pii:B9780702070280000251/f025-041-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0240"><ce:label>Fig. 25.42</ce:label><ce:caption id="ca0220"><ce:simple-para id="sp0425" role="title">Magnetic resonance image of an acoustic neuroma (arrows) in the posterior fossa compressing the brainstem.</ce:simple-para><ce:simple-para id="sp0430" role="caption"><ce:bold>A</ce:bold> Axial image. <ce:bold>B</ce:bold> Coronal image.</ce:simple-para></ce:caption><ce:alt-text id="atte0215" role="short">Fig. 25.42</ce:alt-text><ce:link id="ln0245" locator="f025-042a-9780702070280" xlink:href="pii:B9780702070280000251/f025-042a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0250" locator="f025-042b-9780702070280" xlink:href="pii:B9780702070280000251/f025-042b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0245"><ce:label>Fig. 25.43</ce:label><ce:caption id="ca0225"><ce:simple-para id="sp0435" role="title">A café au lait spot (arrow A) and subcutaneous nodules (arrows B) on the forearm of a patient with neurofibromatosis type 1.</ce:simple-para></ce:caption><ce:alt-text id="atte0220" role="short">Fig. 25.43</ce:alt-text><ce:link id="ln0255" locator="f025-043-9780702070280" xlink:href="pii:B9780702070280000251/f025-043-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0250"><ce:label>Fig. 25.44</ce:label><ce:caption id="ca0230"><ce:simple-para id="sp0440" role="title">The circulation of cerebrospinal fluid (CSF).</ce:simple-para><ce:simple-para id="sp0445" role="caption">(1) CSF is synthesised in the choroid plexus of the ventricles and flows from the lateral and third ventricles through the aqueduct to the fourth ventricle. (2) At the foramina of Luschka and Magendie it exits the brain, flowing over the hemispheres (3) and down around the spinal cord and roots in the subarachnoid space. (4) It is then absorbed into the dural venous sinuses via the arachnoid villi.</ce:simple-para></ce:caption><ce:alt-text id="atte0225" role="short">Fig. 25.44</ce:alt-text><ce:link id="ln0260" locator="f025-044-9780702070280" xlink:href="pii:B9780702070280000251/f025-044-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0255"><ce:label>Fig. 25.45</ce:label><ce:caption id="ca0235"><ce:simple-para id="sp0450" role="title">Magnetic resonance image of hydrocephalus due to aqueduct stenosis.</ce:simple-para><ce:simple-para id="sp0455" role="caption"><ce:bold>A</ce:bold> Axial T2-weighted image (cerebrospinal fluid appears white): note the dilated lateral ventricles. <ce:bold>B</ce:bold> Sagittal T1-weighted image (cerebrospinal fluid appears black): note the dilated ventricles (top arrow) and narrowed aqueduct (bottom arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0230" role="short">Fig. 25.45</ce:alt-text><ce:link id="ln0265" locator="f025-045a-9780702070280" xlink:href="pii:B9780702070280000251/f025-045a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:link id="ln0270" locator="f025-045b-9780702070280" xlink:href="pii:B9780702070280000251/f025-045b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0260"><ce:label>Fig. 25.46</ce:label><ce:caption id="ca0240"><ce:simple-para id="sp0460" role="title">Magnetic resonance image showing cervical cord compression (arrow) in cervical spondylosis.</ce:simple-para></ce:caption><ce:alt-text id="atte0235" role="short">Fig. 25.46</ce:alt-text><ce:link id="ln0275" locator="f025-046-9780702070280" xlink:href="pii:B9780702070280000251/f025-046-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0265"><ce:label>Fig. 25.47</ce:label><ce:caption id="ca0245"><ce:simple-para id="sp0465" role="title">Findings in cervical nerve root compression.</ce:simple-para></ce:caption><ce:alt-text id="atte0240" role="short">Fig. 25.47</ce:alt-text><ce:link id="ln0280" locator="f025-047-9780702070280" xlink:href="pii:B9780702070280000251/f025-047-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0270"><ce:label>Fig. 25.48</ce:label><ce:caption id="ca0250"><ce:simple-para id="sp0470" role="title">Findings in lumbar nerve root compression.</ce:simple-para></ce:caption><ce:alt-text id="atte0245" role="short">Fig. 25.48</ce:alt-text><ce:link id="ln0285" locator="f025-048-9780702070280" xlink:href="pii:B9780702070280000251/f025-048-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0275"><ce:label>Fig. 25.49</ce:label><ce:caption id="ca0255"><ce:simple-para id="sp0475" role="title">Axial magnetic resonance image of thoracic spine.</ce:simple-para><ce:simple-para id="sp0480" role="caption">A neurofibroma (N) is compressing the spinal cord (SC) and emerging in a ‘dumbbell’ fashion through the vertebral foramen into the paraspinal space.</ce:simple-para></ce:caption><ce:alt-text id="atte0250" role="short">Fig. 25.49</ce:alt-text><ce:link id="ln0290" locator="f025-049-9780702070280" xlink:href="pii:B9780702070280000251/f025-049-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0280"><ce:label>Fig. 25.50</ce:label><ce:caption id="ca0260"><ce:simple-para id="sp0485" role="title">Computed tomographic myelogram of cervical spine at the level of C2 showing bony erosion of vertebra by a metastasis (arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0255" role="short">Fig. 25.50</ce:alt-text><ce:link id="ln0295" locator="f025-050-9780702070280" xlink:href="pii:B9780702070280000251/f025-050-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0285"><ce:label>Fig. 25.51</ce:label><ce:caption id="ca0265"><ce:simple-para id="sp0495" role="title">Sagittal magnetic resonance image showing descent of cerebellar tonsils and central syrinx.</ce:simple-para><ce:simple-para id="sp0500" role="caption">The MRI shows descent of the cerebellar tonsils (top arrow), with a large central cord syrinx extending down from the cervical cord (middle arrow) to the thoracic cord (bottom arrow).</ce:simple-para></ce:caption><ce:alt-text id="atte0260" role="short">Fig. 25.51</ce:alt-text><ce:link id="ln0300" locator="f025-051-9780702070280" xlink:href="pii:B9780702070280000251/f025-051-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0290"><ce:label>Fig. 25.52</ce:label><ce:caption id="ca0270"><ce:simple-para id="sp0505" role="title">Myasthenia gravis and Lambert–Eaton myasthenic syndrome (LEMS).</ce:simple-para><ce:simple-para id="sp0510" role="caption">In myasthenia there are antibodies to the acetylcholine receptors on the post-synaptic membrane, which block conduction across the neuromuscular junction (NMJ). Myasthenic symptoms can be transiently improved by inhibition of acetylcholinesterase (e.g. with Tensilon – edrophonium bromide), which normally removes the acetylcholine. A cell-mediated immune response produces simplification of the post-synaptic membrane, further impairing the ‘safety factor’ of neuromuscular conduction. In LEMS, antibodies to the pre-synaptic voltage calcium channels impair release of acetylcholine from the motor nerve ending; calcium is required for the acetylcholine-containing vesicle to fuse with the pre-synaptic membrane for release into the NMJ.</ce:simple-para></ce:caption><ce:alt-text id="atte0265" role="short">Fig. 25.52</ce:alt-text><ce:link id="ln0305" locator="f025-052-9780702070280" xlink:href="pii:B9780702070280000251/f025-052-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0295"><ce:label>Fig. 25.53</ce:label><ce:caption id="ca0275"><ce:simple-para id="sp0515" role="title">Causes of acquired proximal myopathy.</ce:simple-para></ce:caption><ce:alt-text id="atte0270" role="short">Fig. 25.53</ce:alt-text><ce:link id="ln0310" locator="f025-053-9780702070280" xlink:href="pii:B9780702070280000251/f025-053-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0025" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9000" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0275" role="short">Image 1</ce:alt-text></ce:inline-figure> 25.1</ce:label><ce:alt-text id="atte0280" role="short">25.1</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Neurological emergencies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0565"><ce:list id="ulist0110"><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0570">Status epilepticus (p. 1080)</ce:para></ce:list-item><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0575">Stroke (if thrombolysis available) (<ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0200">p. 1158</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0580">Guillain–Barré syndrome (p. 1140)</ce:para></ce:list-item><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0585">Myasthenia gravis (if bulbar and/or respiratory) (p. 1141)</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0590">Spinal cord compression (p. 1136)</ce:para></ce:list-item><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0595">Subarachnoid haemorrhage (<ce:intra-ref id="ii0035" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0285">p. 1160</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0600">Neuroleptic malignant syndrome (<ce:intra-ref id="ii0040" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0760">p. 1197</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9005" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0285" role="short">Image 2</ce:alt-text></ce:inline-figure> 25.2</ce:label><ce:alt-text id="atte0290" role="short">25.2</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Cortical lobar functions</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0635"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0295" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry morerows="1" align="left">Lobe</entry><entry morerows="1" align="left">Function</entry><entry namest="col3" nameend="col5" align="center">Effects of damage</entry></row><row role="tcolhead1" rowsep="1"><entry align="left">Cognitive/behavioural</entry><entry align="left">Associated physical signs</entry><entry align="left">Positive phenomena</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Frontal</ce:bold></entry><entry align="left"><ce:list id="ulist0115"><ce:list-item id="u0565"><ce:para id="p0640">Personality</ce:para></ce:list-item><ce:list-item id="u0570"><ce:para id="p0645">Emotional control</ce:para></ce:list-item><ce:list-item id="u0575"><ce:para id="p0650">Social behaviour</ce:para></ce:list-item><ce:list-item id="u0580"><ce:para id="p0655">Contralateral motor control</ce:para></ce:list-item><ce:list-item id="u0585"><ce:para id="p0660">Language</ce:para></ce:list-item><ce:list-item id="u0590"><ce:para id="p0665">Micturition</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0120"><ce:list-item id="u0595"><ce:para id="p0670">Disinhibition</ce:para></ce:list-item><ce:list-item id="u0600"><ce:para id="p0675">Lack of initiation</ce:para></ce:list-item><ce:list-item id="u0605"><ce:para id="p0680">Antisocial behaviour</ce:para></ce:list-item><ce:list-item id="u0610"><ce:para id="p0685">Impaired memory</ce:para></ce:list-item><ce:list-item id="u0615"><ce:para id="p0690">Expressive dysphasia</ce:para></ce:list-item><ce:list-item id="u0620"><ce:para id="p0695">Incontinence</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0125"><ce:list-item id="u0625"><ce:para id="p0700">Impaired smell</ce:para></ce:list-item><ce:list-item id="u0630"><ce:para id="p0705">Contralateral hemiparesis</ce:para></ce:list-item><ce:list-item id="u0635"><ce:para id="p0710">Frontal release signs<ce:cross-ref id="crf0445" refid="tn0010"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0130"><ce:list-item id="u0640"><ce:para id="p0715">Seizures – often nocturnal with motor activity</ce:para></ce:list-item><ce:list-item id="u0645"><ce:para id="p0720">Versive head movements</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Parietal: dominant</ce:bold></entry><entry align="left"><ce:list id="ulist0135"><ce:list-item id="u0650"><ce:para id="p0725">Language</ce:para></ce:list-item><ce:list-item id="u0655"><ce:para id="p0730">Calculation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0140"><ce:list-item id="u0660"><ce:para id="p0735">Dysphasia</ce:para></ce:list-item><ce:list-item id="u0665"><ce:para id="p0740">Acalculia</ce:para></ce:list-item><ce:list-item id="u0670"><ce:para id="p0745">Dyslexia</ce:para></ce:list-item><ce:list-item id="u0675"><ce:para id="p0750">Apraxia<ce:cross-ref id="crf0450" refid="tn0020"><ce:sup loc="post">3</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0680"><ce:para id="p0755">Agnosia<ce:cross-ref id="crf0455" refid="tn0030"><ce:sup loc="post">5</ce:sup></ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0145"><ce:list-item id="u0685"><ce:para id="p0760">Contralateral hemisensory loss</ce:para></ce:list-item><ce:list-item id="u0690"><ce:para id="p0765">Astereognosis<ce:cross-ref id="crf0460" refid="tn0015"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0695"><ce:para id="p0770">Agraphaesthesia<ce:cross-ref id="crf0465" refid="tn0025"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0700"><ce:para id="p0775">Contralateral homonymous lower quadrantanopia</ce:para></ce:list-item><ce:list-item id="u0705"><ce:para id="p0780">Asymmetry of optokinetic nystagmus (OKN)</ce:para></ce:list-item></ce:list></entry><entry align="left">Focal sensory seizures</entry></row><row rowsep="1"><entry align="left"><ce:bold>Parietal: non-dominant</ce:bold></entry><entry align="left"><ce:list id="ulist0150"><ce:list-item id="u0710"><ce:para id="p0785">Spatial orientation</ce:para></ce:list-item><ce:list-item id="u0715"><ce:para id="p0790">Constructional skills</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0155"><ce:list-item id="u0720"><ce:para id="p0795">Neglect of contralateral side</ce:para></ce:list-item><ce:list-item id="u0725"><ce:para id="p0800">Spatial disorientation</ce:para></ce:list-item><ce:list-item id="u0730"><ce:para id="p0805">Constructional apraxia</ce:para></ce:list-item><ce:list-item id="u0735"><ce:para id="p0810">Dressing apraxia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0160"><ce:list-item id="u0740"><ce:para id="p0815">Contralateral hemisensory loss</ce:para></ce:list-item><ce:list-item id="u0745"><ce:para id="p0820">Astereognosis<ce:cross-ref id="crf0470" refid="tn0015"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0750"><ce:para id="p0825">Agraphaesthesia<ce:cross-ref id="crf0475" refid="tn0025"><ce:sup loc="post">4</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0755"><ce:para id="p0830">Contralateral homonymous lower quadrantanopia</ce:para></ce:list-item><ce:list-item id="u0760"><ce:para id="p0835">Asymmetry of OKN</ce:para></ce:list-item></ce:list></entry><entry align="left">Focal sensory seizures</entry></row><row rowsep="1"><entry align="left"><ce:bold>Temporal: dominant</ce:bold></entry><entry align="left"><ce:list id="ulist0165"><ce:list-item id="u0765"><ce:para id="p0840">Auditory perception</ce:para></ce:list-item><ce:list-item id="u0770"><ce:para id="p0845">Language</ce:para></ce:list-item><ce:list-item id="u0775"><ce:para id="p0850">Verbal memory</ce:para></ce:list-item><ce:list-item id="u0780"><ce:para id="p0855">Smell</ce:para></ce:list-item><ce:list-item id="u0785"><ce:para id="p0860">Balance</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0170"><ce:list-item id="u0790"><ce:para id="p0865">Receptive aphasia</ce:para></ce:list-item><ce:list-item id="u0795"><ce:para id="p0870">Dyslexia</ce:para></ce:list-item><ce:list-item id="u0800"><ce:para id="p0875">Impaired verbal memory</ce:para></ce:list-item></ce:list></entry><entry align="left">Contralateral homonymous upper quadrantanopia</entry><entry align="left">Complex hallucinations (smell, sound, vision, memory)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Temporal: non-dominant</ce:bold></entry><entry align="left"><ce:list id="ulist0175"><ce:list-item id="u0805"><ce:para id="p0880">Auditory perception</ce:para></ce:list-item><ce:list-item id="u0810"><ce:para id="p0885">Melody/pitch perception</ce:para></ce:list-item><ce:list-item id="u0815"><ce:para id="p0890">Non-verbal memory</ce:para></ce:list-item><ce:list-item id="u0820"><ce:para id="p0895">Smell</ce:para></ce:list-item><ce:list-item id="u0825"><ce:para id="p0900">Balance</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0180"><ce:list-item id="u0830"><ce:para id="p0905">Impaired non-verbal memory</ce:para></ce:list-item><ce:list-item id="u0835"><ce:para id="p0910">Impaired musical skills (tonal perception)</ce:para></ce:list-item></ce:list></entry><entry align="left">Contralateral homonymous upper quadrantanopia</entry><entry align="left">Complex hallucinations (smell, sound, vision, memory)</entry></row><row><entry align="left"><ce:bold>Occipital</ce:bold></entry><entry align="left">Visual processing</entry><entry align="left"><ce:list id="ulist0185"><ce:list-item id="u0840"><ce:para id="p0915">Visual inattention</ce:para></ce:list-item><ce:list-item id="u0845"><ce:para id="p0920">Visual loss</ce:para></ce:list-item><ce:list-item id="u0850"><ce:para id="p0925">Visual agnosia</ce:para></ce:list-item></ce:list></entry><entry align="left">Homonymous hemianopia (macular sparing)</entry><entry align="left">Simple visual hallucinations (e.g. phosphenes, zigzag lines)</entry></row></tbody></tgroup><ce:table-footnote id="tn0010"><ce:label>1</ce:label><ce:note-para id="np0010">Grasp reflex, palmomental response, pout response.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0015"><ce:label>2</ce:label><ce:note-para id="np0015">Inability to determine three-dimensional shape by touch.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0020"><ce:label>3</ce:label><ce:note-para id="np0020">Inability to perform complex movements in the presence of normal motor, sensory and cerebellar function.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0025"><ce:label>4</ce:label><ce:note-para id="np0025">Inability to ‘read’ numbers or letters drawn on hand, with the eyes shut.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0030"><ce:label>5</ce:label><ce:note-para id="np0030">Inability to recognise familiar objects, e.g. faces.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9010" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0300" role="short">Image 3</ce:alt-text></ce:inline-figure> 25.3</ce:label><ce:alt-text id="atte0305" role="short">25.3</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Major focal brainstem syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1090"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0310" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Name of syndrome</entry><entry align="left">Site of lesions</entry><entry align="left">Clinical features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Weber</ce:bold></entry><entry align="left">Anterior cerebral peduncle (mid-brain)</entry><entry align="left"><ce:list id="ulist0190"><ce:list-item id="u0855"><ce:para id="p1095">Ipsilateral 3rd palsy</ce:para></ce:list-item><ce:list-item id="u0860"><ce:para id="p1100">Contralateral upper motor neuron 7th palsy</ce:para></ce:list-item><ce:list-item id="u0865"><ce:para id="p1105">Contralateral hemiplegia</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Claude</ce:bold></entry><entry align="left"><ce:list id="ulist0195"><ce:list-item id="u0870"><ce:para id="p1110">Cerebral peduncle</ce:para></ce:list-item><ce:list-item id="u0875"><ce:para id="p1115">Involving red nucleus</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0200"><ce:list-item id="u0880"><ce:para id="p1120">Ipsilateral 3rd palsy</ce:para></ce:list-item><ce:list-item id="u0885"><ce:para id="p1125">Contralateral cerebellar signs</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Parinaud</ce:bold></entry><entry align="left">Dorsal mid-brain (tectum)</entry><entry align="left"><ce:list id="ulist0205"><ce:list-item id="u0890"><ce:para id="p1130">Vertical gaze palsy</ce:para></ce:list-item><ce:list-item id="u0895"><ce:para id="p1135">Convergence disorders</ce:para></ce:list-item><ce:list-item id="u0900"><ce:para id="p1140">Convergence retraction nystagmus</ce:para></ce:list-item><ce:list-item id="u0905"><ce:para id="p1145">Pupillary and lid disorders</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Millard–Gubler</ce:bold></entry><entry align="left">Ponto-medullary junction</entry><entry align="left"><ce:list id="ulist0210"><ce:list-item id="u0910"><ce:para id="p1150">Ipsilateral 6th palsy</ce:para></ce:list-item><ce:list-item id="u0915"><ce:para id="p1155">Ipsilateral lower motor neuron 7th palsy</ce:para></ce:list-item><ce:list-item id="u0920"><ce:para id="p1160">Contralateral hemiplegia</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Wallenberg</ce:bold></entry><entry align="left">Lateral medulla</entry><entry align="left"><ce:list id="ulist0215"><ce:list-item id="u0925"><ce:para id="p1165">Ipsilateral 5th, 9th, 10th, 11th palsy</ce:para></ce:list-item><ce:list-item id="u0930"><ce:para id="p1170">Ipsilateral Horner's syndrome</ce:para></ce:list-item><ce:list-item id="u0935"><ce:para id="p1175">Ipsilateral cerebellar signs</ce:para></ce:list-item><ce:list-item id="u0940"><ce:para id="p1180">Contralateral spinothalamic sensory loss</ce:para></ce:list-item><ce:list-item id="u0945"><ce:para id="p1185">Vestibular disturbance</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9015" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0315" role="short">Image 4</ce:alt-text></ce:inline-figure> 25.4</ce:label><ce:alt-text id="atte0320" role="short">25.4</ce:alt-text><ce:textbox-head><ce:title id="tit0045">Imaging techniques for the nervous system</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1200"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0325" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Technique</entry><entry align="left">Applications</entry><entry align="left">Advantages</entry><entry align="left">Disadvantages</entry><entry align="left">Comments</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>X-ray/CT</ce:bold></entry><entry align="left"><ce:list id="ulist0220"><ce:list-item id="u0950"><ce:para id="p1205">Plain X-rays, CT, CTA</ce:para></ce:list-item><ce:list-item id="u0955"><ce:para id="p1210">Radiculography</ce:para></ce:list-item><ce:list-item id="u0960"><ce:para id="p1215">Myelography</ce:para></ce:list-item><ce:list-item id="u0965"><ce:para id="p1220">Intra-arterial angiography</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0225"><ce:list-item id="u0970"><ce:para id="p1225">Widely available</ce:para></ce:list-item><ce:list-item id="u0975"><ce:para id="p1230">Relatively cheap</ce:para></ce:list-item><ce:list-item id="u0980"><ce:para id="p1235">Relatively quick</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0230"><ce:list-item id="u0985"><ce:para id="p1240">Ionising radiation</ce:para></ce:list-item><ce:list-item id="u0990"><ce:para id="p1245">Contrast reactions</ce:para></ce:list-item><ce:list-item id="u0995"><ce:para id="p1250">Invasive (myelography and angiography)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0235"><ce:list-item id="u1000"><ce:para id="p1255">X-rays: used for fractures or foreign bodies</ce:para></ce:list-item><ce:list-item id="u1005"><ce:para id="p1260">CT: first line for stroke</ce:para></ce:list-item><ce:list-item id="u1010"><ce:para id="p1265">Intra-arterial angiography: gold standard for vascular lesions</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>MRI</ce:bold></entry><entry align="left"><ce:list id="ulist0240"><ce:list-item id="u1015"><ce:para id="p1270">Structural imaging</ce:para></ce:list-item><ce:list-item id="u1020"><ce:para id="p1275">MRA</ce:para></ce:list-item><ce:list-item id="u1025"><ce:para id="p1280">Functional MRI</ce:para></ce:list-item><ce:list-item id="u1030"><ce:para id="p1285">MR spectroscopy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0245"><ce:list-item id="u1035"><ce:para id="p1290">High-quality soft tissue images, useful for posterior fossa and temporal lobes</ce:para></ce:list-item><ce:list-item id="u1040"><ce:para id="p1295">No ionising radiation</ce:para></ce:list-item><ce:list-item id="u1045"><ce:para id="p1300">Non-invasive</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0250"><ce:list-item id="u1050"><ce:para id="p1305">Expensive</ce:para></ce:list-item><ce:list-item id="u1055"><ce:para id="p1310">Less widely available</ce:para></ce:list-item><ce:list-item id="u1060"><ce:para id="p1315">MRA images blood flow, not vessel anatomy</ce:para></ce:list-item><ce:list-item id="u1065"><ce:para id="p1320">Claustrophobic</ce:para></ce:list-item><ce:list-item id="u1070"><ce:para id="p1325">Pacemakers are a contraindication</ce:para></ce:list-item><ce:list-item id="u1075"><ce:para id="p1330">Contrast (gadolinium) reactions</ce:para></ce:list-item></ce:list></entry><entry align="left">Functional MR and spectroscopy: mainly research tools</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ultrasound</ce:bold></entry><entry align="left"><ce:list id="ulist0255"><ce:list-item id="u1080"><ce:para id="p1335">Doppler</ce:para></ce:list-item><ce:list-item id="u1085"><ce:para id="p1340">Duplex scans</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0260"><ce:list-item id="u1090"><ce:para id="p1345">Cheap</ce:para></ce:list-item><ce:list-item id="u1095"><ce:para id="p1350">Quick</ce:para></ce:list-item><ce:list-item id="u1100"><ce:para id="p1355">Non-invasive</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0265"><ce:list-item id="u1105"><ce:para id="p1360">Operator-dependent</ce:para></ce:list-item><ce:list-item id="u1110"><ce:para id="p1365">Poor anatomical definition</ce:para></ce:list-item></ce:list></entry><entry align="left">Screening tool to assess need for carotid endarterectomy</entry></row><row><entry align="left"><ce:bold>Radioisotope</ce:bold></entry><entry align="left"><ce:list id="ulist0270"><ce:list-item id="u1115"><ce:para id="p1370">Isotope brain scan</ce:para></ce:list-item><ce:list-item id="u1120"><ce:para id="p1375">SPECT</ce:para></ce:list-item><ce:list-item id="u1125"><ce:para id="p1380">PET</ce:para></ce:list-item></ce:list></entry><entry align="left">In vivo imaging of functional anatomy (ligand binding, blood flow)</entry><entry align="left"><ce:list id="ulist0275"><ce:list-item id="u1130"><ce:para id="p1385">Poor spatial resolution</ce:para></ce:list-item><ce:list-item id="u1135"><ce:para id="p1390">Ionising radiation</ce:para></ce:list-item><ce:list-item id="u1140"><ce:para id="p1395">Expensive</ce:para></ce:list-item><ce:list-item id="u1145"><ce:para id="p1400">Not widely available</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0280"><ce:list-item id="u1150"><ce:para id="p1405">Isotope scans: obsolete</ce:para></ce:list-item><ce:list-item id="u1155"><ce:para id="p1410">SPECT: useful in movement disorders, epilepsy and dementias</ce:para></ce:list-item><ce:list-item id="u1160"><ce:para id="p1415">PET: mainly research tool</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0105">(CT = computed tomography; CTA = computed tomographic angiography; MRA = magnetic resonance angiography; MRI = magnetic resonance imaging; PET = positron emission tomography; SPECT = single photon emission computed tomography)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9020" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0330" role="short">Image 5</ce:alt-text></ce:inline-figure> 25.5</ce:label><ce:alt-text id="atte0335" role="short">25.5</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Different magnetic resonance imaging (MRI) sequences</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1420"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0340" role="short">Unlabelled table</ce:alt-text><ce:source>Insets courtesy of Dr Ravi Jampana, Consultant Neuroradiologist, Dept of Neuroradiology, Institute of Neuroscience, Queen Elizabeth University Hospital, Glasgow.</ce:source><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left"/><entry align="left">T1</entry><entry align="left">T2</entry><entry align="left">T2-FLAIR</entry></row></thead><tbody><row rowsep="1"><entry align="left"/><entry align="left"><ce:display><ce:figure id="f0075"><ce:alt-text id="atte0345" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0075" locator="b025-005a-9780702070280" xlink:href="pii:B9780702070280000251/b025-005a-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:br/>‘Anatomically correct’</entry><entry align="left"><ce:display><ce:figure id="f0080"><ce:alt-text id="atte0350" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0080" locator="b025-005b-9780702070280" xlink:href="pii:B9780702070280000251/b025-005b-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:br/>‘Reverse T1’</entry><entry align="left"><ce:display><ce:figure id="f0085"><ce:alt-text id="atte0355" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0085" locator="b025-005c-9780702070280" xlink:href="pii:B9780702070280000251/b025-005c-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:br/>T2 with CSF signal dampened</entry></row><row rowsep="1"><entry align="left"><ce:bold>Grey matter (cortex)</ce:bold></entry><entry align="left">Grey</entry><entry align="left">White</entry><entry align="left">White</entry></row><row rowsep="1"><entry align="left"><ce:bold>White matter</ce:bold></entry><entry align="left">White</entry><entry align="left">Grey</entry><entry align="left">Grey</entry></row><row><entry align="left"><ce:bold>Cerebrospinal fluid (CSF)</ce:bold></entry><entry align="left">Black</entry><entry align="left">White</entry><entry align="left">Black</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9025" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000251/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0360" role="short">Image 6</ce:alt-text></ce:inline-figure> 25.6</ce:label><ce:alt-text id="atte0365" role="short">25.6</ce:alt-text><ce:textbox-head><ce:title id="tit0055">How to interpret cerebrospinal fluid results</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1550"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0370" role="short">Unlabelled table</ce:alt-text><tgroup cols="7"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><colspec colname="col7" colnum="7"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Normal</entry><entry align="left">Subarachnoid haemorrhage</entry><entry align="left">Acute bacterial meningitis</entry><entry align="left">Viral meningitis</entry><entry align="left">Tuberculous meningitis</entry><entry align="left">Multiple sclerosis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Pressure</ce:bold></entry><entry align="left">50–250 mm of water</entry><entry align="left">Increased</entry><entry align="left">Normal/increased</entry><entry align="left">Normal</entry><entry align="left">Normal/increased</entry><entry align="left">Normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>Colour</ce:bold></entry><entry align="left">Clear</entry><entry align="left"><ce:list id="ulist0285"><ce:list-item id="u1165"><ce:para id="p1555">Blood-stained</ce:para></ce:list-item><ce:list-item id="u1170"><ce:para id="p1560">Xanthochromic</ce:para></ce:list-item></ce:list></entry><entry align="left">Cloudy</entry><entry align="left">Clear</entry><entry align="left">Clear/cloudy</entry><entry align="left">Clear</entry></row><row rowsep="1"><entry align="left"><ce:bold>Red cell count (× 10<ce:sup loc="post">6</ce:sup>/L)</ce:bold></entry><entry align="left">0–4</entry><entry align="left">Raised</entry><entry align="left">Normal</entry><entry align="left">Normal</entry><entry align="left">Normal</entry><entry align="left">Normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>White cell count (× 10<ce:sup loc="post">6</ce:sup>/L)</ce:bold></entry><entry align="left">0–4</entry><entry align="left">Normal/slightly raised</entry><entry align="left">1000–5000 polymorphs</entry><entry align="left">10–2000 lymphocytes</entry><entry align="left">50–5000 lymphocytes</entry><entry align="left">0–50 lymphocytes</entry></row><row rowsep="1"><entry align="left"><ce:bold>Glucose</ce:bold></entry><entry align="left">&#x003E; 50–60% of blood level</entry><entry align="left">Normal</entry><entry align="left">Decreased</entry><entry align="left">Normal</entry><entry align="left">Decreased</entry><entry align="left">Normal</entry></row><row rowsep="1"><entry align="left"><ce:bold>Protein</ce:bold></entry><entry align="left">&#x003C; 0.45 g/L</entry><entry align="left">Increased</entry><entry align="left">Increased</entry><entry align="left">Normal/increased</entry><entry align="left">Increased</entry><entry align="left">Normal/increased</entry></row><row rowsep="1"><entry align="left"><ce:bold>Microbiology</ce:bold></entry><entry align="left">Sterile</entry><entry align="left">Sterile</entry><entry align="left">Organisms on Gram stain and/or culture</entry><entry align="left">Sterile/virus detected</entry><entry align="left">Ziehl–Neelsen/auramine stain or tuberculosis culture positive</entry><entry align="left">Sterile</entry></row><row><entry align="left"><ce:bold>Oligoclonal bands</ce:bold></entry><entry align="left">Negative</entry><entry align="left">Negative</entry><entry align="left">Can be positive</entry><entry align="left">Can be positive</entry><entry align="left">Can be positive</entry><entry align="left">Often positive</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9030" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000251/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0375" role="short">Image 7</ce:alt-text></ce:inline-figure> 25.7</ce:label><ce:alt-text id="atte0380" role="short">25.7</ce:alt-text><ce:textbox-head><ce:title id="tit0060">How to take a neurological history</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0220"><ce:section-title id="st0215">Introduction</ce:section-title><ce:para id="p1615"><ce:list id="ulist0290"><ce:list-item id="u1175"><ce:label>•</ce:label><ce:para id="p1620">Age and sex</ce:para></ce:list-item><ce:list-item id="u1180"><ce:label>•</ce:label><ce:para id="p1625">Handedness</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0225"><ce:section-title id="st0220">Presenting complaint</ce:section-title><ce:para id="p1630"><ce:list id="ulist0295"><ce:list-item id="u1185"><ce:label>•</ce:label><ce:para id="p1635">Symptoms (clarify: see text)</ce:para></ce:list-item><ce:list-item id="u1190"><ce:label>•</ce:label><ce:para id="p1640">Overall pattern: intermittent or persistent?</ce:para></ce:list-item><ce:list-item id="u1195"><ce:label>•</ce:label><ce:para id="p1645">If intermittent, how often do symptoms occur and how long do they last?</ce:para></ce:list-item><ce:list-item id="u1200"><ce:label>•</ce:label><ce:para id="p1650">Speed of onset: seconds, minutes, hours, days, weeks, months, years, decades?</ce:para></ce:list-item><ce:list-item id="u1205"><ce:label>•</ce:label><ce:para id="p1655">Better, worse or the same over time?</ce:para></ce:list-item><ce:list-item id="u1210"><ce:label>•</ce:label><ce:para id="p1660">Associated symptoms (including non-neurological)</ce:para></ce:list-item><ce:list-item id="u1215"><ce:label>•</ce:label><ce:para id="p1665">Disability caused by symptoms</ce:para></ce:list-item><ce:list-item id="u1220"><ce:label>•</ce:label><ce:para id="p1670">Change in walking</ce:para></ce:list-item><ce:list-item id="u1225"><ce:label>•</ce:label><ce:para id="p1675">Difficulty with fine hand movements, e.g. writing, fastening buttons, using cutlery</ce:para></ce:list-item><ce:list-item id="u1230"><ce:label>•</ce:label><ce:para id="p1680">Effect on work, family life and leisure</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0230"><ce:section-title id="st0225">Background</ce:section-title><ce:para id="p1685"><ce:list id="ulist0300"><ce:list-item id="u1235"><ce:label>•</ce:label><ce:para id="p1690">Previous neurological symptoms and whether similar to current symptoms</ce:para></ce:list-item><ce:list-item id="u1240"><ce:label>•</ce:label><ce:para id="p1695">Previous medical history</ce:para></ce:list-item><ce:list-item id="u1245"><ce:label>•</ce:label><ce:para id="p1700">Domestic situation</ce:para></ce:list-item><ce:list-item id="u1250"><ce:label>•</ce:label><ce:para id="p1705">Driving licence status</ce:para></ce:list-item><ce:list-item id="u1255"><ce:label>•</ce:label><ce:para id="p1710">Medications (current and at time of symptom onset)</ce:para></ce:list-item><ce:list-item id="u1260"><ce:label>•</ce:label><ce:para id="p1715">Alcohol/smoking habits</ce:para></ce:list-item><ce:list-item id="u1265"><ce:label>•</ce:label><ce:para id="p1720">Recreational drug and other toxin exposure</ce:para></ce:list-item><ce:list-item id="u1270"><ce:label>•</ce:label><ce:para id="p1725">Family history and developmental history</ce:para></ce:list-item><ce:list-item id="u1275"><ce:label>•</ce:label><ce:para id="p1730">What are patient's thoughts/fears/concerns?</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9035" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0385" role="short">Image 8</ce:alt-text></ce:inline-figure> 25.8</ce:label><ce:alt-text id="atte0390" role="short">25.8</ce:alt-text><ce:textbox-head><ce:title id="tit0065">The key diagnostic questions</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0235"><ce:section-title id="st0230">Where is the lesion?</ce:section-title><ce:para id="p1745"><ce:list id="ulist0305"><ce:list-item id="u1280"><ce:label>•</ce:label><ce:para id="p1750">Is it neurological?</ce:para></ce:list-item><ce:list-item id="u1285"><ce:label>•</ce:label><ce:para id="p1755">If so, to which part of the nervous system does it localise?<ce:list id="ulist0310"><ce:list-item id="u1290"><ce:para id="p1760">Central versus peripheral</ce:para></ce:list-item><ce:list-item id="u1295"><ce:para id="p1765">Sensory versus motor versus both</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0240"><ce:section-title id="st0235">What is the lesion?</ce:section-title><ce:para id="p1770"><ce:list id="ulist0315"><ce:list-item id="u1300"><ce:label>•</ce:label><ce:para id="p1775">Hereditary or congenital</ce:para></ce:list-item><ce:list-item id="u1305"><ce:label>•</ce:label><ce:para id="p1780">Acquired:<ce:list id="ulist0320"><ce:list-item id="u1310"><ce:para id="p1785">Traumatic</ce:para></ce:list-item><ce:list-item id="u1315"><ce:para id="p1790">Infective</ce:para></ce:list-item><ce:list-item id="u1320"><ce:para id="p1795">Neoplastic</ce:para></ce:list-item><ce:list-item id="u1325"><ce:para id="p1800">Degenerative</ce:para></ce:list-item><ce:list-item id="u1330"><ce:para id="p1805">Inflammatory or immune-mediated</ce:para></ce:list-item><ce:list-item id="u1335"><ce:para id="p1810">Vascular</ce:para></ce:list-item><ce:list-item id="u1340"><ce:para id="p1815">Functional</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9040" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000251/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0395" role="short">Image 9</ce:alt-text></ce:inline-figure> 25.10</ce:label><ce:alt-text id="atte0400" role="short">25.10</ce:alt-text><ce:textbox-head><ce:title id="tit0070">How to ‘localise’ neurological disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1820"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0405" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Combination of symptoms/signs</entry><entry align="left">Probable site</entry><entry align="left">Possible pathology</entry><entry align="left">Other important information</entry></row></thead><tbody><row rowsep="1"><entry align="left">Painless loss of hemilateral function</entry><entry align="left">Cerebral cortex</entry><entry align="left">Usually vascular, inflammatory or neoplastic</entry><entry align="left"><ce:list id="ulist0325"><ce:list-item id="u1345"><ce:para id="p1825">Associated systemic symptoms</ce:para></ce:list-item><ce:list-item id="u1350"><ce:para id="p1830">Tempo of evolution</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Pyramidal weakness of all four limbs or both legs, bladder signs, sensory loss</entry><entry align="left">Spinal cord</entry><entry align="left">Usually vascular, inflammatory or neoplastic</entry><entry align="left"><ce:list id="ulist0330"><ce:list-item id="u1355"><ce:para id="p1835">Associated systemic symptoms</ce:para></ce:list-item><ce:list-item id="u1360"><ce:para id="p1840">Tempo of evolution</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Cranial nerve lesions, with limb pyramidal signs or sensory loss ± sphincter disturbance</entry><entry align="left"><ce:list id="ulist0335"><ce:list-item id="u1365"><ce:para id="p1845">Brainstem</ce:para></ce:list-item><ce:list-item id="u1370"><ce:para id="p1850">Mid-brain</ce:para></ce:list-item><ce:list-item id="u1375"><ce:para id="p1855">Pons</ce:para></ce:list-item><ce:list-item id="u1380"><ce:para id="p1860">Medulla</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0340"><ce:list-item id="u1385"><ce:para id="p1865">Usually vascular or inflammatory</ce:para></ce:list-item><ce:list-item id="u1390"><ce:para id="p1870">Rarely neoplastic</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0345"><ce:list-item id="u1395"><ce:para id="p1875">Associated systemic symptoms</ce:para></ce:list-item><ce:list-item id="u1400"><ce:para id="p1880">Tempo of evolution</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Visual loss + pyramidal signs and/or cerebellar signs</entry><entry align="left">Widespread cerebral lesions</entry><entry align="left"><ce:list id="ulist0350"><ce:list-item id="u1405"><ce:para id="p1885">Usually inflammatory</ce:para></ce:list-item><ce:list-item id="u1410"><ce:para id="p1890">Less commonly vasculitic</ce:para></ce:list-item></ce:list></entry><entry align="left">Tempo of evolution</entry></row><row rowsep="1"><entry align="left">Weakness and/or sensory loss in a combination of individual peripheral nerves</entry><entry align="left">Several peripheral nerves (‘mononeuritis multiplex’)</entry><entry align="left">Usually inflammatory or diabetic</entry><entry align="left">Associated systemic symptoms</entry></row><row rowsep="1"><entry align="left">Widespread LMN and UMN signs</entry><entry align="left">Upper and lower motor neurons</entry><entry align="left"><ce:list id="ulist0355"><ce:list-item id="u1415"><ce:para id="p1895">Motor neuron disease</ce:para></ce:list-item><ce:list-item id="u1420"><ce:para id="p1900">Cervical myeloradiculopathy</ce:para></ce:list-item></ce:list></entry><entry align="left">Associated localised cervical symptoms</entry></row><row><entry align="left">Distal loss of sensation and/or weakness</entry><entry align="left">Generalised peripheral nerves</entry><entry align="left">See causes of neuropathy (<ce:cross-ref id="crf9035" refid="s2035">p. 1138</ce:cross-ref>)</entry><entry align="left">Associated systemic symptoms</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0160">(LMN/UMN = lower/upper motor neuron)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9045" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0410" role="short">Image 10</ce:alt-text></ce:inline-figure> 25.11</ce:label><ce:alt-text id="atte0415" role="short">25.11</ce:alt-text><ce:textbox-head><ce:title id="tit0080">The evolution of symptoms</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1950"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0420" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Onset</entry><entry align="left">Evolution</entry><entry align="left">Possible causes</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Sudden (minutes to hours)</ce:bold></entry><entry align="left">Stable/improvement</entry><entry align="left"><ce:list id="ulist0365"><ce:list-item id="u1455"><ce:para id="p1955">Vascular (stroke/transient ischaemic attack (TIA))</ce:para></ce:list-item><ce:list-item id="u1460"><ce:para id="p1960">Nerve entrapment syndromes</ce:para></ce:list-item><ce:list-item id="u1465"><ce:para id="p1965">Functional</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Gradual</ce:bold></entry><entry align="left">Progressive over days</entry><entry align="left"><ce:list id="ulist0370"><ce:list-item id="u1470"><ce:para id="p1970">Demyelination</ce:para></ce:list-item><ce:list-item id="u1475"><ce:para id="p1975">Infection</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Gradual</ce:bold></entry><entry align="left">Progressive over weeks to months</entry><entry align="left">Neoplastic/paraneoplastic</entry></row><row><entry align="left"><ce:bold>Gradual</ce:bold></entry><entry align="left">Progressive over months to years</entry><entry align="left"><ce:list id="ulist0375"><ce:list-item id="u1480"><ce:para id="p1980">Genetic</ce:para></ce:list-item><ce:list-item id="u1485"><ce:para id="p1985">Degenerative</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9050" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0425" role="short">Image 11</ce:alt-text></ce:inline-figure> 25.12</ce:label><ce:alt-text id="atte0430" role="short">25.12</ce:alt-text><ce:textbox-head><ce:title id="tit0085">Management of status epilepticus</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0270"><ce:section-title id="st0265">Initial</ce:section-title><ce:para id="p2045"><ce:list id="ulist0380"><ce:list-item id="u1490"><ce:label>•</ce:label><ce:para id="p2050">Ensure airway is patent; give oxygen to prevent cerebral hypoxia</ce:para></ce:list-item><ce:list-item id="u1495"><ce:label>•</ce:label><ce:para id="p2055">Check pulse, blood pressure, BM stix and respiratory rate</ce:para></ce:list-item><ce:list-item id="u1500"><ce:label>•</ce:label><ce:para id="p2060">Secure intravenous access</ce:para></ce:list-item><ce:list-item id="u1505"><ce:label>•</ce:label><ce:para id="p2065">Send blood for:<ce:list id="ulist0385"><ce:list-item id="u1510"><ce:para id="p2070">Glucose, urea and electrolytes, calcium and magnesium, liver function, antiepileptic drug levels</ce:para></ce:list-item><ce:list-item id="u1515"><ce:para id="p2075">Full blood count and coagulation screen</ce:para></ce:list-item><ce:list-item id="u1520"><ce:para id="p2080">Storing a sample for future analysis (e.g. drug misuse)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1525"><ce:label>•</ce:label><ce:para id="p2085">If seizures continue for &#x003E; 5 mins: give midazolam 10 mg bucally or nasally or lorazepam 4 mg IV if access available or diazepam 10 mg rectally or IV if necessary; repeat <ce:italic>once only</ce:italic> after 15 mins</ce:para></ce:list-item><ce:list-item id="u1530"><ce:label>•</ce:label><ce:para id="p2090">Correct any metabolic trigger, e.g. hypoglycaemia</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0275"><ce:section-title id="st0270">Ongoing</ce:section-title><ce:section id="s0280"><ce:section-title id="st0275">If seizures continue after 30 mins</ce:section-title><ce:para id="p2095"><ce:list id="ulist0390"><ce:list-item id="u1535"><ce:label>•</ce:label><ce:para id="p2100">IV infusion (with cardiac monitoring) with one of:<ce:list id="ulist0395"><ce:list-item id="u1540"><ce:para id="p2105">Phenytoin: 15 mg/kg at 50 mg/min</ce:para></ce:list-item><ce:list-item id="u1545"><ce:para id="p2110">Sodium valproate: 20–30 mg/kg IV at 40 mg/min</ce:para></ce:list-item><ce:list-item id="u1550"><ce:para id="p2115">Phenobarbital: 10 mg/kg at 100 mg/min</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1555"><ce:label>•</ce:label><ce:para id="p2120">Cardiac monitor and pulse oximetry:<ce:list id="ulist0400"><ce:list-item id="u1560"><ce:para id="p2125">Monitor neurological condition, blood pressure, respiration; check blood gases</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0285"><ce:section-title id="st0280">If seizures still continue after 30–60 mins</ce:section-title><ce:para id="p2130"><ce:list id="ulist0405"><ce:list-item id="u1565"><ce:label>•</ce:label><ce:para id="p2135">Transfer to intensive care:<ce:list id="ulist0410"><ce:list-item id="u1570"><ce:para id="p2140">Start treatment for refractory status with intubation, ventilation and general anaesthesia using propofol or thiopental</ce:para></ce:list-item><ce:list-item id="u1575"><ce:para id="p2145">EEG monitor</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0285">Once status controlled</ce:section-title><ce:para id="p2150"><ce:list id="ulist0415"><ce:list-item id="u1580"><ce:label>•</ce:label><ce:para id="p2155">Commence longer-term antiepileptic medication with one of:<ce:list id="ulist0420"><ce:list-item id="u1585"><ce:para id="p2160">Sodium valproate 10 mg/kg IV over 3–5 mins, then 800–2000 mg/day</ce:para></ce:list-item><ce:list-item id="u1590"><ce:para id="p2165">Phenytoin: give loading dose (if not already used as above) of 15 mg/kg, infuse at &#x003C; 50 mg/min, then 300 mg/day</ce:para></ce:list-item><ce:list-item id="u1595"><ce:para id="p2170">Carbamazepine 400 mg by nasogastric tube, then 400–1200 mg/day</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1600"><ce:label>•</ce:label><ce:para id="p2175">Investigate cause</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9055" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0435" role="short">Image 12</ce:alt-text></ce:inline-figure> 25.13</ce:label><ce:alt-text id="atte0440" role="short">25.13</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Distinguishing signs in upper versus lower motor neuron syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2225"><ce:display><ce:table frame="topbot" id="t0060"><ce:alt-text id="atte0445" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Upper motor neuron lesion</entry><entry align="left">Lower motor neuron lesion</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Inspection</ce:bold></entry><entry align="left">Normal (may be wasting in chronic lesions)</entry><entry align="left">Wasting, fasciculation</entry></row><row rowsep="1"><entry align="left"><ce:bold>Tone</ce:bold></entry><entry align="left">Increased with clonus</entry><entry align="left">Normal or decreased, no clonus</entry></row><row rowsep="1"><entry align="left"><ce:bold>Pattern of weakness</ce:bold></entry><entry align="left"><ce:list id="ulist0425"><ce:list-item id="u1605"><ce:para id="p2230">Preferentially affects extensors in arms, flexors in leg</ce:para></ce:list-item><ce:list-item id="u1610"><ce:para id="p2235">Hemiparesis, paraparesis or tetraparesis</ce:para></ce:list-item></ce:list></entry><entry align="left">Typically focal, in distribution of nerve root or peripheral nerve, with associated sensory changes</entry></row><row rowsep="1"><entry align="left"><ce:bold>Deep tendon reflexes</ce:bold></entry><entry align="left">Increased</entry><entry align="left">Decreased/absent</entry></row><row><entry align="left"><ce:bold>Plantar response</ce:bold></entry><entry align="left">Extensor (Babinski sign)</entry><entry align="left">Flexor</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9060" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000251/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0450" role="short">Image 13</ce:alt-text></ce:inline-figure> 25.14</ce:label><ce:alt-text id="atte0455" role="short">25.14</ce:alt-text><ce:textbox-head><ce:title id="tit0095">How to assess weakness</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2240"><ce:display><ce:table frame="topbot" id="t0065"><ce:alt-text id="atte0460" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Clinical finding</entry><entry align="left">Likely level of lesion/diagnosis</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Pattern and distribution</ce:bold></entry></row><row rowsep="0"><entry align="left">Isolated muscles</entry><entry align="left">Radiculopathy or mononeuropathy</entry></row><row rowsep="0"><entry align="left">Both limbs on one side (hemiparesis)</entry><entry align="left">Cerebral hemisphere, less likely cord or brainstem</entry></row><row rowsep="0"><entry align="left">One limb</entry><entry align="left">Neuronopathy, plexopathy, cord/brain</entry></row><row rowsep="0"><entry align="left">Both lower limbs (paraparesis)</entry><entry align="left">Spinal cord; look for a sensory level</entry></row><row rowsep="0"><entry align="left">Fatigability</entry><entry align="left">Myasthenia gravis</entry></row><row rowsep="1"><entry align="left">Bizarre, fluctuating, not following anatomical rules</entry><entry align="left">Functional</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs</ce:bold></entry></row><row rowsep="0"><entry align="left">Upper motor neuron</entry><entry align="left">Brain/spinal cord</entry></row><row rowsep="1"><entry align="left">Lower motor neuron</entry><entry align="left">Peripheral nervous system</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Evolution of the weakness</ce:bold></entry></row><row rowsep="0"><entry align="left">Sudden and improving</entry><entry align="left">Stroke/mononeuropathy</entry></row><row rowsep="0"><entry align="left">Evolving over months or years</entry><entry align="left">Meningioma, cervical spondylotic myelopathy</entry></row><row rowsep="1"><entry align="left">Gradually worsening over days or weeks</entry><entry align="left">Cerebral mass, demyelination</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Associated symptoms</ce:bold></entry></row><row><entry align="left">Absence of sensory involvement</entry><entry align="left">Motor neuron disease, myopathy, myasthenia</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9065" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0465" role="short">Image 14</ce:alt-text></ce:inline-figure> 25.15</ce:label><ce:alt-text id="atte0470" role="short">25.15</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Movement disorders</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2350"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0475" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Description</entry><entry align="left">Features</entry><entry align="left">Examples</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Hypokinetic disorders</ce:bold></entry></row><row rowsep="0"><entry align="left">Parkinsonism</entry><entry align="left"><ce:list id="ulist0430"><ce:list-item id="u1615"><ce:para id="p2355">Akinesia</ce:para></ce:list-item><ce:list-item id="u1620"><ce:para id="p2360">Rigidity</ce:para></ce:list-item><ce:list-item id="u1625"><ce:para id="p2365">Tremor</ce:para></ce:list-item><ce:list-item id="u1630"><ce:para id="p2370">Loss of postural reflexes</ce:para></ce:list-item><ce:list-item id="u1635"><ce:para id="p2375">Other features depending on cause</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0435"><ce:list-item id="u1640"><ce:para id="p2380">Idiopathic Parkinson's disease</ce:para></ce:list-item><ce:list-item id="u1645"><ce:para id="p2385">Other degenerative syndromes</ce:para></ce:list-item><ce:list-item id="u1650"><ce:para id="p2390">Drug-induced</ce:para></ce:list-item><ce:list-item id="u1655"><ce:para id="p2395">(See <ce:cross-ref id="crf0675" refid="b0290">Box 25.54</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Catatonia</entry><entry align="left"><ce:list id="ulist0440"><ce:list-item id="u1660"><ce:para id="p2400">Mutism</ce:para></ce:list-item><ce:list-item id="u1665"><ce:para id="p2405">Sustained posturing and waxy flexibility</ce:para></ce:list-item></ce:list></entry><entry align="left">Usually psychiatric; if neurological, is most commonly of vascular origin</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Hyperkinetic disorders</ce:bold></entry></row><row rowsep="0"><entry align="left">Tremor</entry><entry align="left">Rhythmical oscillation of body part (see <ce:cross-ref id="crf0680" refid="b0100">Box 25.16</ce:cross-ref>)</entry><entry align="left"><ce:list id="ulist0445"><ce:list-item id="u1670"><ce:para id="p2410">Essential tremor</ce:para></ce:list-item><ce:list-item id="u1675"><ce:para id="p2415">Parkinson's disease</ce:para></ce:list-item><ce:list-item id="u1680"><ce:para id="p2420">Drug-induced</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Chorea</entry><entry align="left">Jerky, brief, involuntary movements</entry><entry align="left"><ce:list id="ulist0450"><ce:list-item id="u1685"><ce:para id="p2425">Huntington's disease</ce:para></ce:list-item><ce:list-item id="u1690"><ce:para id="p2430">Drug-induced</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Tics</entry><entry align="left">Stereotyped, repetitive movements, briefly suppressible</entry><entry align="left">Tourette's syndrome</entry></row><row rowsep="0"><entry align="left">Myoclonus</entry><entry align="left">Shock-like muscle jerks</entry><entry align="left"><ce:list id="ulist0455"><ce:list-item id="u1695"><ce:para id="p2435">Epilepsy</ce:para></ce:list-item><ce:list-item id="u1700"><ce:para id="p2440">Hypnic jerks (p. 1086)</ce:para></ce:list-item><ce:list-item id="u1705"><ce:para id="p2445">Focal cortical disease</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Dystonia</entry><entry align="left">Sustained muscle contraction causing abnormal postures ± tremor</entry><entry align="left"><ce:list id="ulist0460"><ce:list-item id="u1710"><ce:para id="p2450">Genetic</ce:para></ce:list-item><ce:list-item id="u1715"><ce:para id="p2455">Generalised dystonic syndromes</ce:para></ce:list-item><ce:list-item id="u1720"><ce:para id="p2460">Focal dystonias in adults (e.g. torticollis)</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left">Others</entry><entry align="left">Various</entry><entry align="left"><ce:list id="ulist0465"><ce:list-item id="u1725"><ce:para id="p2465">Paroxysmal hyperkinetic dyskinesias</ce:para></ce:list-item><ce:list-item id="u1730"><ce:para id="p2470">Hemifacial spasm</ce:para></ce:list-item><ce:list-item id="u1735"><ce:para id="p2475">Tardive syndromes</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9070" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0480" role="short">Image 15</ce:alt-text></ce:inline-figure> 25.16</ce:label><ce:alt-text id="atte0485" role="short">25.16</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Causes and characteristics of tremors</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2485"><ce:display><ce:table frame="topbot" id="t0075"><ce:alt-text id="atte0490" role="short">Unlabelled table</ce:alt-text><tgroup cols="6"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Body part affected</entry><entry align="left">Position</entry><entry align="left">Frequency</entry><entry align="left">Amplitude</entry><entry align="left">Character</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Physiological</ce:bold></entry><entry align="left">Both arms &#x003E; legs</entry><entry align="left">Posture, movement</entry><entry align="left">High</entry><entry align="left">Small (fine)</entry><entry align="left">Enhanced by anxiety, emotion, drugs, toxins</entry></row><row rowsep="1"><entry align="left"><ce:bold>Parkinsonism</ce:bold></entry><entry align="left"><ce:list id="ulist0470"><ce:list-item id="u1740"><ce:para id="p2490">Unilateral or asymmetrical</ce:para></ce:list-item><ce:list-item id="u1745"><ce:para id="p2495">Arm &#x003E; leg, chin, never head</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0475"><ce:list-item id="u1750"><ce:para id="p2500">Rest</ce:para></ce:list-item><ce:list-item id="u1755"><ce:para id="p2505">Postural and re-emergent may occur</ce:para></ce:list-item></ce:list></entry><entry align="left">Low (3–4 Hz)</entry><entry align="left">Moderate</entry><entry align="left">Typically pill-rolling, thumb and index finger, other features of parkinsonism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Essential tremor</ce:bold></entry><entry align="left">Bilateral arms, head</entry><entry align="left">Movement</entry><entry align="left">High (8–10 Hz)</entry><entry align="left">Low to moderate</entry><entry align="left">Family history; 50% respond to alcohol</entry></row><row rowsep="1"><entry align="left"><ce:bold>Dystonic</ce:bold></entry><entry align="left">Head, arms, legs</entry><entry align="left">Posture</entry><entry align="left">Variable</entry><entry align="left">Variable</entry><entry align="left">Other features of dystonia, often jerky tremors</entry></row><row><entry align="left"><ce:bold>Functional</ce:bold></entry><entry align="left">Any</entry><entry align="left">Any</entry><entry align="left">Variable</entry><entry align="left">Variable</entry><entry align="left">Distractible</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9075" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0495" role="short">Image 16</ce:alt-text></ce:inline-figure> 25.17</ce:label><ce:alt-text id="atte0500" role="short">25.17</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Causes of chorea</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2520"><ce:display><ce:table frame="topbot" id="t0080"><ce:alt-text id="atte0505" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Hereditary</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0480"><ce:list-item id="u1760"><ce:label>•</ce:label><ce:para id="p2525">Huntington's disease (HD) and HD-like syndromes</ce:para></ce:list-item><ce:list-item id="u1765"><ce:label>•</ce:label><ce:para id="p2530">Wilson's disease</ce:para></ce:list-item><ce:list-item id="u1770"><ce:label>•</ce:label><ce:para id="p2535">Neuroacanthocytosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0485"><ce:list-item id="u1775"><ce:label>•</ce:label><ce:para id="p2540">Dentato-rubro-pallidoluysian atrophy</ce:para></ce:list-item><ce:list-item id="u1780"><ce:label>•</ce:label><ce:para id="p2545">Benign hereditary chorea</ce:para></ce:list-item><ce:list-item id="u1785"><ce:label>•</ce:label><ce:para id="p2550">Paroxysmal dyskinesias</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebral birth injury (including kernicterus)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebral trauma</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0490"><ce:list-item id="u1790"><ce:label>•</ce:label><ce:para id="p2555">Levodopa (long-term with Parkinson's disease)</ce:para></ce:list-item><ce:list-item id="u1795"><ce:label>•</ce:label><ce:para id="p2560">Antipsychotics</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0495"><ce:list-item id="u1800"><ce:label>•</ce:label><ce:para id="p2565">Antiepileptics</ce:para></ce:list-item><ce:list-item id="u1805"><ce:label>•</ce:label><ce:para id="p2570">Oral contraceptive</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0500"><ce:list-item id="u1810"><ce:label>•</ce:label><ce:para id="p2575">Disorders affecting thyroid, parathyroid, glucose, sodium, calcium and magnesium balance</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0505"><ce:list-item id="u1815"><ce:label>•</ce:label><ce:para id="p2580">Pregnancy</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Autoimmune</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0510"><ce:list-item id="u1820"><ce:label>•</ce:label><ce:para id="p2585">Post-streptococcal (Sydenham's chorea)</ce:para></ce:list-item><ce:list-item id="u1825"><ce:label>•</ce:label><ce:para id="p2590">Antiphospholipid antibody syndrome</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0515"><ce:list-item id="u1830"><ce:label>•</ce:label><ce:para id="p2595">Autoimmune encephalitis</ce:para></ce:list-item><ce:list-item id="u1835"><ce:label>•</ce:label><ce:para id="p2600">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Structural lesions of basal ganglia (usually caudate)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0520"><ce:list-item id="u1840"><ce:label>•</ce:label><ce:para id="p2605">Vascular</ce:para></ce:list-item><ce:list-item id="u1845"><ce:label>•</ce:label><ce:para id="p2610">Demyelination</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0525"><ce:list-item id="u1850"><ce:label>•</ce:label><ce:para id="p2615">Brain tumour</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9080" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0510" role="short">Image 17</ce:alt-text></ce:inline-figure> 25.18</ce:label><ce:alt-text id="atte0515" role="short">25.18</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Causes of dysarthria</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2730"><ce:display><ce:table frame="topbot" id="t0085"><ce:alt-text id="atte0520" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Site</entry><entry align="left">Characteristics</entry><entry align="left">Associated features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Myopathic</ce:bold></entry><entry align="left">Muscles of speech</entry><entry align="left">Indistinct, poor articulation</entry><entry align="left">Weakness of face, tongue and neck</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myasthenic</ce:bold></entry><entry align="left">Motor end plate</entry><entry align="left"><ce:list id="ulist0530"><ce:list-item id="u1855"><ce:para id="p2735">Indistinct with fatigue and dysphonia</ce:para></ce:list-item><ce:list-item id="u1860"><ce:para id="p2740">Fluctuating severity</ce:para></ce:list-item></ce:list></entry><entry align="left">Ptosis, diplopia, facial and neck weakness</entry></row><row rowsep="1"><entry align="left"><ce:bold>Bulbar</ce:bold></entry><entry align="left">Brainstem</entry><entry align="left">Indistinct, slurred, often nasal</entry><entry align="left">Dysphagia, diplopia, ataxia</entry></row><row rowsep="1"><entry align="left"><ce:bold>‘Scanning’</ce:bold></entry><entry align="left">Cerebellum</entry><entry align="left">Slurred, impaired timing and cadence, ‘sing-song’</entry><entry align="left"><ce:list id="ulist0535"><ce:list-item id="u1865"><ce:para id="p2745">Ataxia of limbs and gait, tremor of head/limbs</ce:para></ce:list-item><ce:list-item id="u1870"><ce:para id="p2750">Nystagmus</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Spastic (‘pseudo-bulbar’)</ce:bold></entry><entry align="left">Pyramidal tracts</entry><entry align="left">Indistinct, nasal tone, mumbling</entry><entry align="left">Poor rapid tongue movements, increased reflexes and jaw jerk</entry></row><row rowsep="1"><entry align="left"><ce:bold>Parkinsonian</ce:bold></entry><entry align="left">Basal ganglia</entry><entry align="left">Indistinct, rapid, stammering, quiet</entry><entry align="left">Tremor, rigidity, slow shuffling gait</entry></row><row><entry align="left"><ce:bold>Dystonic</ce:bold></entry><entry align="left">Basal ganglia</entry><entry align="left">Strained, slow, high-pitched</entry><entry align="left">Dystonia, athetosis</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9085" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0525" role="short">Image 18</ce:alt-text></ce:inline-figure> 25.19</ce:label><ce:alt-text id="atte0530" role="short">25.19</ce:alt-text><ce:textbox-head><ce:title id="tit0120">Clinical manifestations of visual field loss</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2790"><ce:display><ce:table frame="topbot" id="t0090"><ce:alt-text id="atte0535" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Site of lesion</entry><entry align="left">Common causes</entry><entry align="left">Complaint</entry><entry align="left">Visual field loss</entry><entry align="left">Associated physical signs</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Retina/optic disc</ce:bold></entry><entry align="left"><ce:list id="ulist0540"><ce:list-item id="u1875"><ce:para id="p2795">Vascular disease (including vasculitis)</ce:para></ce:list-item><ce:list-item id="u1880"><ce:para id="p2800">Glaucoma</ce:para></ce:list-item><ce:list-item id="u1885"><ce:para id="p2805">Inflammation</ce:para></ce:list-item></ce:list></entry><entry align="left">Partial/complete visual loss depending on site, involving one or both eyes</entry><entry align="left"><ce:list id="ulist0545"><ce:list-item id="u1890"><ce:para id="p2810">Altitudinal field defect</ce:para></ce:list-item><ce:list-item id="u1895"><ce:para id="p2815">Arcuate scotoma</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0550"><ce:list-item id="u1900"><ce:para id="p2820">Reduced acuity</ce:para></ce:list-item><ce:list-item id="u1905"><ce:para id="p2825">Visual distortion (macula)</ce:para></ce:list-item><ce:list-item id="u1910"><ce:para id="p2830">Abnormal retinal appearance</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Optic nerve</ce:bold></entry><entry align="left"><ce:list id="ulist0555"><ce:list-item id="u1915"><ce:para id="p2835">Optic neuritis</ce:para></ce:list-item><ce:list-item id="u1920"><ce:para id="p2840">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u1925"><ce:para id="p2845">Tumour</ce:para></ce:list-item><ce:list-item id="u1930"><ce:para id="p2850">Leber's hereditary optic neuropathy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0560"><ce:list-item id="u1935"><ce:para id="p2855">Partial/complete loss of vision in one eye</ce:para></ce:list-item><ce:list-item id="u1940"><ce:para id="p2860">Often painful</ce:para></ce:list-item><ce:list-item id="u1945"><ce:para id="p2865">Central vision particularly affected</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0565"><ce:list-item id="u1950"><ce:para id="p2870">Central or paracentral scotoma</ce:para></ce:list-item><ce:list-item id="u1955"><ce:para id="p2875">Monocular blindness</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0570"><ce:list-item id="u1960"><ce:para id="p2880">Reduced acuity</ce:para></ce:list-item><ce:list-item id="u1965"><ce:para id="p2885">Reduced colour vision</ce:para></ce:list-item><ce:list-item id="u1970"><ce:para id="p2890">Relative afferent pupillary defect</ce:para></ce:list-item><ce:list-item id="u1975"><ce:para id="p2895">Optic atrophy (late)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Optic chiasm</ce:bold></entry><entry align="left"><ce:list id="ulist0575"><ce:list-item id="u1980"><ce:para id="p2900">Pituitary tumour</ce:para></ce:list-item><ce:list-item id="u1985"><ce:para id="p2905">Craniopharyngioma</ce:para></ce:list-item><ce:list-item id="u1990"><ce:para id="p2910">Sarcoidosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0580"><ce:list-item id="u1995"><ce:para id="p2915">May be none</ce:para></ce:list-item><ce:list-item id="u2000"><ce:para id="p2920">Rarely, diplopia (‘hemifield slide’)</ce:para></ce:list-item></ce:list></entry><entry align="left">Bitemporal hemianopia</entry><entry align="left">Pituitary function abnormalities</entry></row><row rowsep="1"><entry align="left"><ce:bold>Optic tract</ce:bold></entry><entry align="left"><ce:list id="ulist0585"><ce:list-item id="u2005"><ce:para id="p2925">Tumour</ce:para></ce:list-item><ce:list-item id="u2010"><ce:para id="p2930">Inflammatory disease</ce:para></ce:list-item></ce:list></entry><entry align="left">Disturbed vision to one side of midline</entry><entry align="left">Incongruous contralateral homonymous hemianopia</entry><entry align="left"/></row><row rowsep="1"><entry align="left"><ce:bold>Temporal lobe</ce:bold></entry><entry align="left"><ce:list id="ulist0590"><ce:list-item id="u2015"><ce:para id="p2935">Stroke</ce:para></ce:list-item><ce:list-item id="u2020"><ce:para id="p2940">Tumour</ce:para></ce:list-item><ce:list-item id="u2025"><ce:para id="p2945">Inflammatory disease</ce:para></ce:list-item></ce:list></entry><entry align="left">Disturbed vision to one side of midline</entry><entry align="left">Contralateral homonymous upper quadrantanopia</entry><entry align="left">Memory/language disorders</entry></row><row rowsep="1"><entry align="left"><ce:bold>Parietal lobe</ce:bold></entry><entry align="left"><ce:list id="ulist0595"><ce:list-item id="u2030"><ce:para id="p2950">Stroke</ce:para></ce:list-item><ce:list-item id="u2035"><ce:para id="p2955">Tumour</ce:para></ce:list-item><ce:list-item id="u2040"><ce:para id="p2960">Inflammatory disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0600"><ce:list-item id="u2045"><ce:para id="p2965">Disturbed vision to one side of midline</ce:para></ce:list-item><ce:list-item id="u2050"><ce:para id="p2970">Bumping into things</ce:para></ce:list-item></ce:list></entry><entry align="left">Contralateral homonymous lower quadrantanopia</entry><entry align="left"><ce:list id="ulist0605"><ce:list-item id="u2055"><ce:para id="p2975">Contralateral sensory disturbance</ce:para></ce:list-item><ce:list-item id="u2060"><ce:para id="p2980">Asymmetry of optokinetic nystagmus</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Occipital lobe</ce:bold></entry><entry align="left"><ce:list id="ulist0610"><ce:list-item id="u2065"><ce:para id="p2985">Stroke</ce:para></ce:list-item><ce:list-item id="u2070"><ce:para id="p2990">Tumour</ce:para></ce:list-item><ce:list-item id="u2075"><ce:para id="p2995">Inflammatory disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0615"><ce:list-item id="u2080"><ce:para id="p3000">Disturbed vision to one side of midline</ce:para></ce:list-item><ce:list-item id="u2085"><ce:para id="p3005">Difficulty reading</ce:para></ce:list-item><ce:list-item id="u2090"><ce:para id="p3010">Bumping into things</ce:para></ce:list-item></ce:list></entry><entry align="left">Homonymous hemianopia (may be macula-sparing)</entry><entry align="left">Damage to other structures supplied by posterior cerebral circulation</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9090" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0540" role="short">Image 19</ce:alt-text></ce:inline-figure> 25.20</ce:label><ce:alt-text id="atte0545" role="short">25.20</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Common causes of damage to cranial nerves 3, 4 and 6</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3045"><ce:display><ce:table frame="topbot" id="t0095"><ce:alt-text id="atte0550" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Site</entry><entry align="left">Common pathology</entry><entry align="left">Nerve(s) involved</entry><entry align="left">Associated features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Brainstem</ce:bold></entry><entry align="left"><ce:list id="ulist0620"><ce:list-item id="u2095"><ce:para id="p3050">Infarction</ce:para></ce:list-item><ce:list-item id="u2100"><ce:para id="p3055">Haemorrhage</ce:para></ce:list-item><ce:list-item id="u2105"><ce:para id="p3060">Demyelination</ce:para></ce:list-item><ce:list-item id="u2110"><ce:para id="p3065">Intrinsic tumour</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0625"><ce:list-item id="u2115"><ce:para id="p3070">3 (mid-brain)</ce:para></ce:list-item><ce:list-item id="u2120"><ce:para id="p3075">6 (ponto-medullary junction)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0630"><ce:list-item id="u2125"><ce:para id="p3080">Contralateral pyramidal signs</ce:para></ce:list-item><ce:list-item id="u2130"><ce:para id="p3085">Ipsilateral lower motor neuron facial palsy</ce:para></ce:list-item><ce:list-item id="u2135"><ce:para id="p3090">Other brainstem/cerebellar signs</ce:para></ce:list-item></ce:list></entry></row><row><entry morerows="5" rowsep="1" align="left"><ce:bold>Intrameningeal</ce:bold></entry><entry rowsep="0" align="left">Meningitis (infective/malignant)</entry><entry rowsep="0" align="left">3, 4 and/or 6</entry><entry rowsep="0" align="left">Meningism, features of primary disease course</entry></row><row rowsep="0"><entry morerows="1" align="left">Raised intracranial pressure</entry><entry align="left">6</entry><entry align="left">Papilloedema</entry></row><row rowsep="0"><entry align="left">3 (uncal herniation)</entry><entry align="left">Features of space-occupying lesion</entry></row><row rowsep="0"><entry align="left">Aneurysms</entry><entry align="left"><ce:list id="ulist0635"><ce:list-item id="u2140"><ce:para id="p3095">3 (posterior communicating artery)</ce:para></ce:list-item><ce:list-item id="u2145"><ce:para id="p3100">6 (basilar artery)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0640"><ce:list-item id="u2150"><ce:para id="p3105">Pain</ce:para></ce:list-item><ce:list-item id="u2155"><ce:para id="p3110">Features of subarachnoid haemorrhage</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Cerebello-pontine angle tumour</entry><entry align="left">6</entry><entry align="left"><ce:list id="ulist0645"><ce:list-item id="u2160"><ce:para id="p3115">8, 7, 5 nerve lesions (order of likelihood)</ce:para></ce:list-item><ce:list-item id="u2165"><ce:para id="p3120">Ipsilateral cerebellar signs</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Trauma</entry><entry align="left">3, 4 and/or 6</entry><entry align="left">Other features of trauma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cavernous sinus</ce:bold></entry><entry align="left"><ce:list id="ulist0650"><ce:list-item id="u2170"><ce:para id="p3125">Infection/thrombosis</ce:para></ce:list-item><ce:list-item id="u2175"><ce:para id="p3130">Carotid artery aneurysm</ce:para></ce:list-item><ce:list-item id="u2180"><ce:para id="p3135">Caroticocavernous fistula</ce:para></ce:list-item></ce:list></entry><entry align="left">3, 4 and/or 6</entry><entry align="left"><ce:list id="ulist0655"><ce:list-item id="u2185"><ce:para id="p3140">May be 5th nerve involvement also</ce:para></ce:list-item><ce:list-item id="u2190"><ce:para id="p3145">Pupil may be fixed, mid-position</ce:para></ce:list-item><ce:list-item id="u2195"><ce:para id="p3150">(Sympathetic plexus on carotid may also be affected)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Superior orbital fissure</ce:bold></entry><entry align="left"><ce:list id="ulist0660"><ce:list-item id="u2200"><ce:para id="p3155">Tumour (e.g. sphenoid wing meningioma)</ce:para></ce:list-item><ce:list-item id="u2205"><ce:para id="p3160">Granuloma</ce:para></ce:list-item></ce:list></entry><entry align="left">3, 4 and/or 6</entry><entry align="left">May be proptosis, chemosis</entry></row><row><entry align="left"><ce:bold>Orbit</ce:bold></entry><entry align="left"><ce:list id="ulist0665"><ce:list-item id="u2210"><ce:para id="p3165">Vascular (e.g. diabetes, vasculitis)</ce:para></ce:list-item><ce:list-item id="u2215"><ce:para id="p3170">Infections</ce:para></ce:list-item><ce:list-item id="u2220"><ce:para id="p3175">Tumour</ce:para></ce:list-item><ce:list-item id="u2225"><ce:para id="p3180">Granuloma</ce:para></ce:list-item><ce:list-item id="u2230"><ce:para id="p3185">Trauma</ce:para></ce:list-item></ce:list></entry><entry align="left">3, 4 and/or 6</entry><entry align="left"><ce:list id="ulist0670"><ce:list-item id="u2235"><ce:para id="p3190">Pain</ce:para></ce:list-item><ce:list-item id="u2240"><ce:para id="p3195">Pupil often spared in vascular 3rd nerve palsy</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0125" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9095" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0555" role="short">Image 20</ce:alt-text></ce:inline-figure> 25.21</ce:label><ce:alt-text id="atte0560" role="short">25.21</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Common causes of ptosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3230"><ce:display><ce:table frame="topbot" id="t0100"><ce:alt-text id="atte0565" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Mechanism</entry><entry align="left">Causes</entry><entry align="left">Associated clinical features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>3rd nerve palsy</ce:bold></entry><entry align="left"><ce:list id="ulist0675"><ce:list-item id="u2245"><ce:para id="p3235">Isolated palsy (see <ce:cross-ref id="crf0740" refid="b0120">Box 25.20</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u2250"><ce:para id="p3240">Central/supranuclear lesion</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0680"><ce:list-item id="u2255"><ce:para id="p3245">Ptosis is usually complete</ce:para></ce:list-item><ce:list-item id="u2260"><ce:para id="p3250">Extraocular muscle palsy (eye ‘down and out’)</ce:para></ce:list-item><ce:list-item id="u2265"><ce:para id="p3255">Depending on site of lesion, other cranial nerve palsies (e.g. 4, 5 and 6) or contralateral upper motor neuron signs</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Sympathetic lesion</ce:bold> (<ce:bold>Horner's syndrome</ce:bold>: see <ce:cross-ref id="crf0745" refid="f0140">Fig. 25.22</ce:cross-ref>)</entry><entry align="left"><ce:list id="ulist0685"><ce:list-item id="u2270"><ce:para id="p3260">Central (hypothalamus/brainstem)</ce:para></ce:list-item><ce:list-item id="u2275"><ce:para id="p3265">Peripheral (lung apex, carotid artery pathology)</ce:para></ce:list-item><ce:list-item id="u2280"><ce:para id="p3270">Idiopathic</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0690"><ce:list-item id="u2285"><ce:para id="p3275">Ptosis is partial</ce:para></ce:list-item><ce:list-item id="u2290"><ce:para id="p3280">Lack of sweating on affected side</ce:para></ce:list-item><ce:list-item id="u2295"><ce:para id="p3285">Depending on site of lesion, brainstem signs, signs of apical lung/brachial plexus disease, or ipsilateral carotid artery stroke</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Myopathic</ce:bold></entry><entry align="left"><ce:list id="ulist0695"><ce:list-item id="u2300"><ce:para id="p3290">Myasthenia gravis</ce:para></ce:list-item><ce:list-item id="u2305"><ce:para id="p3295">Dystrophia myotonica</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0700"><ce:list-item id="u2310"><ce:para id="p3300">Extraocular muscle palsies</ce:para></ce:list-item><ce:list-item id="u2315"><ce:para id="p3305">Usually bilateral</ce:para></ce:list-item><ce:list-item id="u2320"><ce:para id="p3310">More widespread muscle weakness, with fatigability in myasthenia</ce:para></ce:list-item><ce:list-item id="u2325"><ce:para id="p3315">Progressive external ophthalmoplegia</ce:para></ce:list-item><ce:list-item id="u2330"><ce:para id="p3320">Other characteristic features of individual causes</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Other</ce:bold></entry><entry align="left"><ce:list id="ulist0705"><ce:list-item id="u2335"><ce:para id="p3325">Functional ptosis</ce:para></ce:list-item><ce:list-item id="u2340"><ce:para id="p3330">Pseudo-ptosis (e.g. blepharospasm)</ce:para></ce:list-item><ce:list-item id="u2345"><ce:para id="p3335">Local orbital/lid disease</ce:para></ce:list-item><ce:list-item id="u2350"><ce:para id="p3340">Age-related levator dehiscence</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0710"><ce:list-item id="u2355"><ce:para id="p3345">Resistance to eye opening</ce:para></ce:list-item><ce:list-item id="u2360"><ce:para id="p3350">Eyebrows depressed rather than raised</ce:para></ce:list-item><ce:list-item id="u2365"><ce:para id="p3355">May be local orbital abnormality</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9100" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0570" role="short">Image 21</ce:alt-text></ce:inline-figure> 25.22</ce:label><ce:alt-text id="atte0575" role="short">25.22</ce:alt-text><ce:textbox-head><ce:title id="tit0135">Pupillary disorders</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3365"><ce:display><ce:table frame="topbot" id="t0105"><ce:alt-text id="atte0580" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Disorder</entry><entry align="left">Cause</entry><entry align="left">Ophthalmological features</entry><entry align="left">Associated features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>3rd nerve palsy</ce:bold></entry><entry align="left">See <ce:cross-ref id="crf0760" refid="b0125">Box 25.21</ce:cross-ref></entry><entry align="left"><ce:list id="ulist0715"><ce:list-item id="u2370"><ce:para id="p3370">Dilated pupil (especially with external compression)</ce:para></ce:list-item><ce:list-item id="u2375"><ce:para id="p3375">Extraocular muscle palsy (eye is typically ‘down and out’)</ce:para></ce:list-item><ce:list-item id="u2380"><ce:para id="p3380">Complete ptosis</ce:para></ce:list-item></ce:list></entry><entry align="left">Other features of 3rd nerve palsy (see <ce:cross-ref id="crf0765" refid="b0125">Box 25.21</ce:cross-ref>)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Horner's syndrome</ce:bold> (see <ce:cross-ref id="crf0770" refid="f0140">Fig. 25.22</ce:cross-ref>)</entry><entry align="left">Lesion to sympathetic supply</entry><entry align="left"><ce:list id="ulist0720"><ce:list-item id="u2385"><ce:para id="p3385">Small pupil</ce:para></ce:list-item><ce:list-item id="u2390"><ce:para id="p3390">Partial ptosis</ce:para></ce:list-item><ce:list-item id="u2395"><ce:para id="p3395">Iris heterochromia (if congenital)</ce:para></ce:list-item></ce:list></entry><entry align="left">Ipsilateral failure of sweating (anhidrosis)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Holmes–Adie syndrome (tonic pupil)</ce:bold></entry><entry align="left"><ce:list id="ulist0725"><ce:list-item id="u2400"><ce:para id="p3400">Lesion of ciliary ganglion (usually idiopathic)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0730"><ce:list-item id="u2405"><ce:para id="p3405">Dilated pupil</ce:para></ce:list-item><ce:list-item id="u2410"><ce:para id="p3410">Light-near dissociation (accommodate but do not react to light)</ce:para></ce:list-item><ce:list-item id="u2415"><ce:para id="p3415">Vermiform movement of iris during contraction</ce:para></ce:list-item><ce:list-item id="u2420"><ce:para id="p3420">Disturbance of accommodation</ce:para></ce:list-item></ce:list></entry><entry align="left">Generalised areflexia</entry></row><row rowsep="1"><entry align="left"><ce:bold>Argyll Robertson pupil</ce:bold></entry><entry align="left">Dorsal mid-brain lesion (syphilis or diabetes)</entry><entry align="left"><ce:list id="ulist0735"><ce:list-item id="u2425"><ce:para id="p3425">Small, irregular pupils</ce:para></ce:list-item><ce:list-item id="u2430"><ce:para id="p3430">Light-near dissociation</ce:para></ce:list-item></ce:list></entry><entry align="left">Other features of tabes dorsalis (p. 1125)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Local pupillary damage</ce:bold></entry><entry align="left">Trauma/inflammatory disease</entry><entry align="left"><ce:list id="ulist0740"><ce:list-item id="u2435"><ce:para id="p3435">Irregular pupils, often with adhesions to lens (synechiae)</ce:para></ce:list-item><ce:list-item id="u2440"><ce:para id="p3440">Variable degree of reactivity</ce:para></ce:list-item></ce:list></entry><entry align="left">Other features of trauma/underlying inflammatory disease (e.g. cataract, blindness etc.)</entry></row><row><entry align="left"><ce:bold>Relative afferent pupillary defect (Marcus Gunn pupil)</ce:bold></entry><entry align="left">Damage to optic nerve</entry><entry align="left">Pupils symmetrical – swinging torch test reveals dilatation in abnormal eye</entry><entry align="left"><ce:list id="ulist0745"><ce:list-item id="u2445"><ce:para id="p3445">Decreased visual acuity/colour vision</ce:para></ce:list-item><ce:list-item id="u2450"><ce:para id="p3450">Central scotoma</ce:para></ce:list-item><ce:list-item id="u2455"><ce:para id="p3455">Optic disc swelling or pallor</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0135" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9105" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0585" role="short">Image 22</ce:alt-text></ce:inline-figure> 25.23</ce:label><ce:alt-text id="atte0590" role="short">25.23</ce:alt-text><ce:textbox-head><ce:title id="tit0140">Common causes of optic disc swelling</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3465"><ce:display><ce:table frame="topbot" id="t0110"><ce:alt-text id="atte0595" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Raised intracranial pressure (papilloedema)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0750"><ce:list-item id="u2460"><ce:label>•</ce:label><ce:para id="p3470">Cerebral mass lesion (tumour, abscess)</ce:para></ce:list-item><ce:list-item id="u2465"><ce:label>•</ce:label><ce:para id="p3475">Obstructive hydrocephalus</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0755"><ce:list-item id="u2470"><ce:label>•</ce:label><ce:para id="p3480">Idiopathic intracranial hypertension</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Obstruction of ocular venous drainage</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0760"><ce:list-item id="u2475"><ce:label>•</ce:label><ce:para id="p3485">Central retinal vein occlusion</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0765"><ce:list-item id="u2480"><ce:label>•</ce:label><ce:para id="p3490">Cavernous sinus thrombosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic disorders affecting retinal vessels</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0770"><ce:list-item id="u2485"><ce:label>•</ce:label><ce:para id="p3495">Hypertension</ce:para></ce:list-item><ce:list-item id="u2490"><ce:label>•</ce:label><ce:para id="p3500">Vasculitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0775"><ce:list-item id="u2495"><ce:label>•</ce:label><ce:para id="p3505">Hypercapnia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Optic nerve damage</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0780"><ce:list-item id="u2500"><ce:label>•</ce:label><ce:para id="p3510">Demyelination (optic neuritis/papillitis)</ce:para></ce:list-item><ce:list-item id="u2505"><ce:label>•</ce:label><ce:para id="p3515">Leber's hereditary optic neuropathy</ce:para></ce:list-item><ce:list-item id="u2510"><ce:label>•</ce:label><ce:para id="p3520">Anterior ischaemic optic neuropathy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0785"><ce:list-item id="u2515"><ce:label>•</ce:label><ce:para id="p3525">Toxins (e.g. methanol)</ce:para></ce:list-item><ce:list-item id="u2520"><ce:label>•</ce:label><ce:para id="p3530">Infiltration of optic disc</ce:para></ce:list-item><ce:list-item id="u2525"><ce:label>•</ce:label><ce:para id="p3535">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u2530"><ce:label>•</ce:label><ce:para id="p3540">Glioma</ce:para></ce:list-item><ce:list-item id="u2535"><ce:label>•</ce:label><ce:para id="p3545">Lymphoma</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0140" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9110" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0600" role="short">Image 23</ce:alt-text></ce:inline-figure> 25.24</ce:label><ce:alt-text id="atte0605" role="short">25.24</ce:alt-text><ce:textbox-head><ce:title id="tit0145">Causes of pseudobulbar and bulbar palsy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3575"><ce:display><ce:table frame="topbot" id="t0115"><ce:alt-text id="atte0610" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Pseudobulbar</entry><entry align="left">Bulbar</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Genetic</ce:bold></entry><entry align="left">–</entry><entry align="left">Kennedy's disease (X-linked bulbospinal neuronopathy)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Vascular</ce:bold></entry><entry align="left">Bilateral hemisphere (lacunar) infarction</entry><entry align="left">Medullary infarction (see <ce:cross-ref id="crf0805" refid="b0035">Box 25.3</ce:cross-ref>, p. 1072)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Degenerative</ce:bold></entry><entry align="left">Motor neuron disease (p. 1116)</entry><entry align="left"><ce:list id="ulist0790"><ce:list-item id="u2540"><ce:para id="p3580">Motor neuron disease</ce:para></ce:list-item><ce:list-item id="u2545"><ce:para id="p3585">Syringobulbia</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Inflammatory/infective</ce:bold></entry><entry align="left"><ce:list id="ulist0795"><ce:list-item id="u2550"><ce:para id="p3590">Multiple sclerosis (p. 1106)</ce:para></ce:list-item><ce:list-item id="u2555"><ce:para id="p3595">Cerebral vasculitis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0800"><ce:list-item id="u2560"><ce:para id="p3600">Myasthenia (p. 1140)</ce:para></ce:list-item><ce:list-item id="u2565"><ce:para id="p3605">Guillain–Barré syndrome (p. 1140)</ce:para></ce:list-item><ce:list-item id="u2570"><ce:para id="p3610">Poliomyelitis (p. 1123)</ce:para></ce:list-item><ce:list-item id="u2575"><ce:para id="p3615">Lyme disease (<ce:intra-ref id="ii0475" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">p. 255</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u2580"><ce:para id="p3620">Vasculitis</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Neoplastic</ce:bold></entry><entry align="left">High brainstem tumours</entry><entry align="left"><ce:list id="ulist0805"><ce:list-item id="u2585"><ce:para id="p3625">Brainstem glioma</ce:para></ce:list-item><ce:list-item id="u2590"><ce:para id="p3630">Malignant meningitis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0145" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9115" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0615" role="short">Image 24</ce:alt-text></ce:inline-figure> 25.25</ce:label><ce:alt-text id="atte0620" role="short">25.25</ce:alt-text><ce:textbox-head><ce:title id="tit0150">Neurogenic bladder: clinical features and treatment</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3670"><ce:display><ce:table frame="topbot" id="t0120"><ce:alt-text id="atte0625" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Site of lesion</entry><entry align="left">Result</entry><entry align="left">Treatment</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Atonic</ce:bold> (lower motor neuron)</entry><entry align="left"><ce:list id="ulist0810"><ce:list-item id="u2595"><ce:para id="p3675">Sacral segments of cord (conus medullaris)</ce:para></ce:list-item><ce:list-item id="u2600"><ce:para id="p3680">Sacral roots and nerves</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0815"><ce:list-item id="u2605"><ce:para id="p3685">Loss of detrusor contraction</ce:para></ce:list-item><ce:list-item id="u2610"><ce:para id="p3690">Difficulty initiating micturition</ce:para></ce:list-item><ce:list-item id="u2615"><ce:para id="p3695">Bladder distension with overflow</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0820"><ce:list-item id="u2620"><ce:para id="p3700">Intermittent self-catheterisation</ce:para></ce:list-item><ce:list-item id="u2625"><ce:para id="p3705">In-dwelling catheterisation</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Hypertonic</ce:bold> (upper motor neuron)</entry><entry align="left">Pyramidal tract in spinal cord or brainstem</entry><entry align="left"><ce:list id="ulist0825"><ce:list-item id="u2630"><ce:para id="p3710">Urgency with urge incontinence</ce:para></ce:list-item><ce:list-item id="u2635"><ce:para id="p3715">Bladder sphincter incoordination (dyssynergia)</ce:para></ce:list-item><ce:list-item id="u2640"><ce:para id="p3720">Incomplete bladder emptying</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0830"><ce:list-item id="u2645"><ce:para id="p3725">Anticholinergics:<ce:list id="ulist0835"><ce:list-item id="u2650"><ce:para id="p3730">Solifenacin</ce:para></ce:list-item><ce:list-item id="u2655"><ce:para id="p3735">Tolterodine</ce:para></ce:list-item><ce:list-item id="u2660"><ce:para id="p3740">Imipramine</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2665"><ce:para id="p3745">Intermittent self-catheterisation</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Cortical</ce:bold></entry><entry align="left"><ce:list id="ulist0840"><ce:list-item id="u2670"><ce:para id="p3750">Post-central</ce:para></ce:list-item><ce:list-item id="u2675"><ce:para id="p3755">Pre-central</ce:para></ce:list-item><ce:list-item id="u2680"><ce:para id="p3760">Frontal</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0845"><ce:list-item id="u2685"><ce:para id="p3765">Loss of awareness of bladder fullness</ce:para></ce:list-item><ce:list-item id="u2690"><ce:para id="p3770">Difficulty initiating micturition</ce:para></ce:list-item><ce:list-item id="u2695"><ce:para id="p3775">Inappropriate micturition</ce:para></ce:list-item><ce:list-item id="u2700"><ce:para id="p3780">Loss of social control</ce:para></ce:list-item></ce:list></entry><entry align="left">Intermittent or in-dwelling catheterisation</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0150" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9120" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0630" role="short">Image 25</ce:alt-text></ce:inline-figure> 25.26</ce:label><ce:alt-text id="atte0635" role="short">25.26</ce:alt-text><ce:textbox-head><ce:title id="tit0155">Clinical features suggestive of functional disorder</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3835"><ce:list id="ulist0850"><ce:list-item id="u2705"><ce:label>•</ce:label><ce:para id="p3840">Inconsistent examination findings (e.g. Hoover's sign, p. 1082)</ce:para></ce:list-item><ce:list-item id="u2710"><ce:label>•</ce:label><ce:para id="p3845">Situational provocation of events (e.g. in medical settings)</ce:para></ce:list-item><ce:list-item id="u2715"><ce:label>•</ce:label><ce:para id="p3850">Associated mental health disorders:<ce:list id="ulist0855"><ce:list-item id="u2720"><ce:para id="p3855">Anxiety</ce:para></ce:list-item><ce:list-item id="u2725"><ce:para id="p3860">Depression</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2730"><ce:label>•</ce:label><ce:para id="p3865">Lack of anatomical coherence to neurological symptoms</ce:para></ce:list-item><ce:list-item id="u2735"><ce:label>•</ce:label><ce:para id="p3870">Florid or bizarre descriptions of individual symptoms</ce:para></ce:list-item><ce:list-item id="u2740"><ce:label>•</ce:label><ce:para id="p3875">History of multiple other systemic symptoms inadequately explained by disease (asthma/breathlessness, fatigue, pain, gastrointestinal symptoms)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0155" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9125" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0640" role="short">Image 26</ce:alt-text></ce:inline-figure> 25.27</ce:label><ce:alt-text id="atte0645" role="short">25.27</ce:alt-text><ce:textbox-head><ce:title id="tit0160">Benign paroxysmal headaches</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4010"><ce:display><ce:table frame="topbot" id="t0125"><ce:alt-text id="atte0650" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Character of pain</entry><entry align="left">Duration</entry><entry align="left">Location</entry><entry align="left">Comment</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Ice pick</ce:bold></entry><entry align="left">Stabbing</entry><entry align="left">Very brief (split-second)</entry><entry align="left">Variable, usually temporoparietal</entry><entry align="left">Benign, more common in migraine</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ice cream</ce:bold></entry><entry align="left">Sharp, severe</entry><entry align="left">30–120 secs</entry><entry align="left">Bitemporal/occipital</entry><entry align="left">Obvious trigger by cold stimuli</entry></row><row rowsep="1"><entry align="left"><ce:bold>Exertional/sexual activity</ce:bold></entry><entry align="left">Bursting, thunderclap</entry><entry align="left">Severe for mins, then less severe for hours</entry><entry align="left">Generalised</entry><entry align="left">Subarachnoid haemorrhage needs to be excluded</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cough</ce:bold></entry><entry align="left">Bursting</entry><entry align="left">Secs to mins</entry><entry align="left">Occipital or generalised</entry><entry align="left">Intracranial pathology needs to be excluded (especially craniocervical junction)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Cluster headache (migrainous neuralgia)</ce:bold></entry><entry align="left">Severe unilateral, with ptosis, tearing, conjunctival injection, unilateral nasal congestion</entry><entry align="left">30–90 mins 1–3 times per day</entry><entry align="left">Periorbital</entry><entry align="left">Usually in men, occurring in clusters over weeks/months</entry></row><row rowsep="1"><entry align="left"><ce:bold>Chronic paroxysmal hemicrania</ce:bold></entry><entry align="left">Severe unilateral with cluster headache-like autonomic features (see above)</entry><entry align="left">5–20 mins, frequently through day</entry><entry align="left">Periorbital/temporal</entry><entry align="left">Usually in women, responds to indometacin</entry></row><row><entry align="left"><ce:bold>SUNCT</ce:bold><ce:cross-ref id="crf0835" refid="tn0035"><ce:bold>*</ce:bold></ce:cross-ref></entry><entry align="left">Severe, sharp, triggered by touch or neck movements</entry><entry align="left">15–120 secs, repetitive through day</entry><entry align="left">Periorbital</entry><entry align="left">May respond to carbamazepine</entry></row></tbody></tgroup><ce:table-footnote id="tn0035"><ce:label>*</ce:label><ce:note-para id="np0035"><ce:bold>S</ce:bold>hort-lasting, <ce:bold>u</ce:bold>nilateral, <ce:bold>n</ce:bold>euralgiform headache with <ce:bold>c</ce:bold>onjunctival injection, <ce:bold>t</ce:bold>earing, rhinorrhoea and forehead sweating.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0160" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9130" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0655" role="short">Image 27</ce:alt-text></ce:inline-figure> 25.28</ce:label><ce:alt-text id="atte0660" role="short">25.28</ce:alt-text><ce:textbox-head><ce:title id="tit0165">Classification of seizures (2010 International League Against Epilepsy classification)</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4025"><ce:display><ce:table frame="topbot" id="t0130"><ce:alt-text id="atte0665" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Generalised seizures</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0860"><ce:list-item id="u2745"><ce:label>•</ce:label><ce:para id="p4030">Tonic–clonic (in any combination)</ce:para></ce:list-item><ce:list-item id="u2750"><ce:label>•</ce:label><ce:para id="p4035">Absence:<ce:list id="ulist0865"><ce:list-item id="u2755"><ce:para id="p4040">Typical</ce:para></ce:list-item><ce:list-item id="u2760"><ce:para id="p4045">Atypical</ce:para></ce:list-item><ce:list-item id="u2765"><ce:para id="p4050">Absence with special features</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2770"><ce:label>•</ce:label><ce:para id="p4055">Myoclonic absence</ce:para></ce:list-item><ce:list-item id="u2775"><ce:label>•</ce:label><ce:para id="p4060">Eyelid myoclonia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0870"><ce:list-item id="u2780"><ce:label>•</ce:label><ce:para id="p4065">Myoclonic:<ce:list id="ulist0875"><ce:list-item id="u2785"><ce:para id="p4070">Myoclonic</ce:para></ce:list-item><ce:list-item id="u2790"><ce:para id="p4075">Myoclonic–atonic</ce:para></ce:list-item><ce:list-item id="u2795"><ce:para id="p4080">Myoclonic–tonic</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2800"><ce:label>•</ce:label><ce:para id="p4085">Clonic</ce:para></ce:list-item><ce:list-item id="u2805"><ce:label>•</ce:label><ce:para id="p4090">Tonic</ce:para></ce:list-item><ce:list-item id="u2810"><ce:label>•</ce:label><ce:para id="p4095">Atonic</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Focal seizures</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0880"><ce:list-item id="u2815"><ce:label>•</ce:label><ce:para id="p4100">Without impairment of consciousness or awareness (was ‘simple partial’):<ce:list id="ulist0885"><ce:list-item id="u2820"><ce:para id="p4105">Focal motor</ce:para></ce:list-item><ce:list-item id="u2825"><ce:para id="p4110">Focal sensory</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u2830"><ce:label>•</ce:label><ce:para id="p4115">With impairment of consciousness or awareness (was ‘complex partial’)</ce:para></ce:list-item><ce:list-item id="u2835"><ce:label>•</ce:label><ce:para id="p4120">Evolving to a bilateral, convulsive seizure (was ‘secondarily generalised seizure’):<ce:list id="ulist0890"><ce:list-item id="u2840"><ce:para id="p4125">Tonic</ce:para></ce:list-item><ce:list-item id="u2845"><ce:para id="p4130">Clonic</ce:para></ce:list-item><ce:list-item id="u2850"><ce:para id="p4135">Tonic–clonic</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Unknown</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0895"><ce:list-item id="u2855"><ce:label>•</ce:label><ce:para id="p4140">Epileptic spasms</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0165" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9135" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0670" role="short">Image 28</ce:alt-text></ce:inline-figure> 25.29</ce:label><ce:alt-text id="atte0675" role="short">25.29</ce:alt-text><ce:textbox-head><ce:title id="tit0170">Trigger factors for seizures</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4170"><ce:list id="ulist0900"><ce:list-item id="u2860"><ce:label>•</ce:label><ce:para id="p4175">Sleep deprivation</ce:para></ce:list-item><ce:list-item id="u2865"><ce:label>•</ce:label><ce:para id="p4180">Missed doses of antiepileptic drugs in treated patients</ce:para></ce:list-item><ce:list-item id="u2870"><ce:label>•</ce:label><ce:para id="p4185">Alcohol (particularly withdrawal)</ce:para></ce:list-item><ce:list-item id="u2875"><ce:label>•</ce:label><ce:para id="p4190">Recreational drug misuse</ce:para></ce:list-item><ce:list-item id="u2880"><ce:label>•</ce:label><ce:para id="p4195">Physical and mental exhaustion</ce:para></ce:list-item><ce:list-item id="u2885"><ce:label>•</ce:label><ce:para id="p4200">Flickering lights, including TV and computer screens (generalised epilepsy syndromes only)</ce:para></ce:list-item><ce:list-item id="u2890"><ce:label>•</ce:label><ce:para id="p4205">Intercurrent infections and metabolic disturbances</ce:para></ce:list-item><ce:list-item id="u2895"><ce:label>•</ce:label><ce:para id="p4210">Uncommon: loud noises, music, reading, hot baths</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0170" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9140" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0680" role="short">Image 29</ce:alt-text></ce:inline-figure> 25.30</ce:label><ce:alt-text id="atte0685" role="short">25.30</ce:alt-text><ce:textbox-head><ce:title id="tit0175">Causes of focal seizures</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4240"><ce:display><ce:table frame="topbot" id="t0135"><ce:alt-text id="atte0690" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Idiopathic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0905"><ce:list-item id="u2900"><ce:label>•</ce:label><ce:para id="p4245">Benign Rolandic epilepsy of childhood</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0910"><ce:list-item id="u2905"><ce:label>•</ce:label><ce:para id="p4250">Benign occipital epilepsy of childhood</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Focal structural lesions</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0915"><ce:list-item id="u2910"><ce:label>•</ce:label><ce:para id="p4255">Tuberous sclerosis (<ce:intra-ref id="ii0575" xlink:href="pii:B978-0-7020-7028-0.00029-9#p3490">p. 1264</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u2915"><ce:label>•</ce:label><ce:para id="p4260">Autosomal dominant nocturnal frontal lobe epilepsy</ce:para></ce:list-item><ce:list-item id="u2920"><ce:label>•</ce:label><ce:para id="p4265">Autosomal dominant partial epilepsy with auditory features (ADPEAF)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0920"><ce:list-item id="u2925"><ce:label>•</ce:label><ce:para id="p4270">von Hippel–Lindau disease (p. 1132)</ce:para></ce:list-item><ce:list-item id="u2930"><ce:label>•</ce:label><ce:para id="p4275">Neurofibromatosis (p. 1131)</ce:para></ce:list-item><ce:list-item id="u2935"><ce:label>•</ce:label><ce:para id="p4280">Cerebral migration abnormalities</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infantile hemiplegia</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Dysembryonic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0925"><ce:list-item id="u2940"><ce:label>•</ce:label><ce:para id="p4285">Cortical dysgenesis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0930"><ce:list-item id="u2945"><ce:label>•</ce:label><ce:para id="p4290">Sturge–Weber syndrome</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Mesial temporal sclerosis (associated with febrile convulsions)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebrovascular disease</ce:bold> (<ce:intra-ref id="ii0590" xlink:href="pii:B978-0-7020-7028-0.00026-3#c00026">Ch. 26</ce:intra-ref>)</entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0935"><ce:list-item id="u2950"><ce:label>•</ce:label><ce:para id="p4295">Intracerebral haemorrhage</ce:para></ce:list-item><ce:list-item id="u2955"><ce:label>•</ce:label><ce:para id="p4300">Cerebral infarction</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0940"><ce:list-item id="u2960"><ce:label>•</ce:label><ce:para id="p4305">Arteriovenous malformation</ce:para></ce:list-item><ce:list-item id="u2965"><ce:label>•</ce:label><ce:para id="p4310">Cavernous haemangioma</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Tumours (primary and secondary)</ce:bold> (p. 1129)</entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Trauma (including neurosurgery)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infective</ce:bold> (p. 1117)</entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0945"><ce:list-item id="u2970"><ce:label>•</ce:label><ce:para id="p4315">Cerebral abscess (pyogenic)</ce:para></ce:list-item><ce:list-item id="u2975"><ce:label>•</ce:label><ce:para id="p4320">Toxoplasmosis</ce:para></ce:list-item><ce:list-item id="u2980"><ce:label>•</ce:label><ce:para id="p4325">Cysticercosis</ce:para></ce:list-item><ce:list-item id="u2985"><ce:label>•</ce:label><ce:para id="p4330">Tuberculoma</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0950"><ce:list-item id="u2990"><ce:label>•</ce:label><ce:para id="p4335">Subdural empyema</ce:para></ce:list-item><ce:list-item id="u2995"><ce:label>•</ce:label><ce:para id="p4340">Encephalitis</ce:para></ce:list-item><ce:list-item id="u3000"><ce:label>•</ce:label><ce:para id="p4345">Human immunodeficiency virus (HIV)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0955"><ce:list-item id="u3005"><ce:label>•</ce:label><ce:para id="p4350">Autoimmune encephalopathies (e.g. anti-voltage-gated potassium channel antibodies, anti-NMDA receptor antibodies, anti-glycine receptor antibodies)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0960"><ce:list-item id="u3010"><ce:label>•</ce:label><ce:para id="p4355">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u3015"><ce:label>•</ce:label><ce:para id="p4360">Vasculitis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0175" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9145" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0695" role="short">Image 30</ce:alt-text></ce:inline-figure> 25.31</ce:label><ce:alt-text id="atte0700" role="short">25.31</ce:alt-text><ce:textbox-head><ce:title id="tit0180">Causes of generalised tonic–clonic seizures</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4370"><ce:display><ce:table frame="topbot" id="t0140"><ce:alt-text id="atte0705" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Generalisation from focal seizures</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist0965"><ce:list-item id="u3020"><ce:label>•</ce:label><ce:para id="p4375">See <ce:cross-ref id="crf0890" refid="b0170">Box 25.30</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0970"><ce:list-item id="u3025"><ce:label>•</ce:label><ce:para id="p4380">Inborn errors of metabolism (p. 1144)</ce:para></ce:list-item><ce:list-item id="u3030"><ce:label>•</ce:label><ce:para id="p4385">Storage diseases</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0975"><ce:list-item id="u3035"><ce:label>•</ce:label><ce:para id="p4390">Phakomatoses (e.g. tuberous sclerosis, <ce:intra-ref id="ii0615" xlink:href="pii:B978-0-7020-7028-0.00029-9#p3490">p. 1264</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebral birth injury</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Hydrocephalus</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebral anoxia</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0980"><ce:list-item id="u3040"><ce:label>•</ce:label><ce:para id="p4395">Antibiotics: penicillin, isoniazid, metronidazole</ce:para></ce:list-item><ce:list-item id="u3045"><ce:label>•</ce:label><ce:para id="p4400">Antimalarials: chloroquine, mefloquine</ce:para></ce:list-item><ce:list-item id="u3050"><ce:label>•</ce:label><ce:para id="p4405">Ciclosporin</ce:para></ce:list-item><ce:list-item id="u3065"><ce:label>•</ce:label><ce:para id="p4420">Amphetamines (withdrawal)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0985"><ce:list-item id="u3055"><ce:label>•</ce:label><ce:para id="p4410">Cardiac anti-arrhythmics: lidocaine, disopyramide</ce:para></ce:list-item><ce:list-item id="u3060"><ce:label>•</ce:label><ce:para id="p4415">Psychotropic agents: phenothiazines, tricyclic antidepressants, lithium</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Alcohol (especially withdrawal)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0990"><ce:list-item id="u3070"><ce:label>•</ce:label><ce:para id="p4425">Organophosphates (sarin)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0995"><ce:list-item id="u3075"><ce:label>•</ce:label><ce:para id="p4430">Heavy metals (lead, tin)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1000"><ce:list-item id="u3080"><ce:label>•</ce:label><ce:para id="p4435">Hypocalcaemia</ce:para></ce:list-item><ce:list-item id="u3085"><ce:label>•</ce:label><ce:para id="p4440">Hyponatraemia</ce:para></ce:list-item><ce:list-item id="u3090"><ce:label>•</ce:label><ce:para id="p4445">Hypomagnesaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1005"><ce:list-item id="u3095"><ce:label>•</ce:label><ce:para id="p4450">Hypoglycaemia</ce:para></ce:list-item><ce:list-item id="u3100"><ce:label>•</ce:label><ce:para id="p4455">Renal failure</ce:para></ce:list-item><ce:list-item id="u3105"><ce:label>•</ce:label><ce:para id="p4460">Liver failure</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infective</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1010"><ce:list-item id="u3110"><ce:label>•</ce:label><ce:para id="p4465">Post-infectious encephalopathy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1015"><ce:list-item id="u3115"><ce:label>•</ce:label><ce:para id="p4470">Meningitis (p. 1118)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1020"><ce:list-item id="u3120"><ce:label>•</ce:label><ce:para id="p4475">Multiple sclerosis (uncommon; (p. 1106)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1025"><ce:list-item id="u3125"><ce:label>•</ce:label><ce:para id="p4480">Systemic lupus erythematosus (<ce:intra-ref id="ii0630" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1310">p. 1034</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Diffuse degenerative diseases</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1030"><ce:list-item id="u3130"><ce:label>•</ce:label><ce:para id="p4485">Alzheimer's disease (uncommonly; p. 1992)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1035"><ce:list-item id="u3135"><ce:label>•</ce:label><ce:para id="p4490">Creutzfeldt–Jakob disease (rarely; p. 1127)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0180" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9150" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0710" role="short">Image 31</ce:alt-text></ce:inline-figure> 25.32</ce:label><ce:alt-text id="atte0715" role="short">25.32</ce:alt-text><ce:textbox-head><ce:title id="tit0185">Electroclinical epilepsy syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4530"><ce:display><ce:table frame="topbot" id="t0145"><ce:alt-text id="atte0720" role="short">Unlabelled table</ce:alt-text><tgroup cols="1"><colspec colname="col1" colnum="1"/><tbody><row role="thead2" rowsep="0"><entry align="left"><ce:bold>Adolescence to adulthood</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1040"><ce:list-item id="u3140"><ce:label>•</ce:label><ce:para id="p4535">Juvenile absence epilepsy (JAE)</ce:para></ce:list-item><ce:list-item id="u3145"><ce:label>•</ce:label><ce:para id="p4540">Juvenile myoclonic epilepsy (JME)</ce:para></ce:list-item><ce:list-item id="u3150"><ce:label>•</ce:label><ce:para id="p4545">Epilepsy with generalised tonic–clonic seizures alone</ce:para></ce:list-item><ce:list-item id="u3155"><ce:label>•</ce:label><ce:para id="p4550">Progressive myoclonus epilepsies (PMEs)</ce:para></ce:list-item><ce:list-item id="u3160"><ce:label>•</ce:label><ce:para id="p4555">Autosomal dominant epilepsy with auditory features (ADEAF)</ce:para></ce:list-item><ce:list-item id="u3165"><ce:label>•</ce:label><ce:para id="p4560">Other familial temporal lobe epilepsies</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry align="left"><ce:bold>Less specific age relationship</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1045"><ce:list-item id="u3170"><ce:label>•</ce:label><ce:para id="p4565">Familial focal epilepsy with variable foci (childhood to adult)</ce:para></ce:list-item><ce:list-item id="u3175"><ce:label>•</ce:label><ce:para id="p4570">Reflex epilepsies</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry align="left"><ce:bold>Distinctive constellations</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1050"><ce:list-item id="u3180"><ce:label>•</ce:label><ce:para id="p4575">Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS)</ce:para></ce:list-item><ce:list-item id="u3185"><ce:label>•</ce:label><ce:para id="p4580">Rasmussen's syndrome</ce:para></ce:list-item><ce:list-item id="u3190"><ce:label>•</ce:label><ce:para id="p4585">Gelastic (from the Greek word for laughter) seizures with hypothalamic hamartoma</ce:para></ce:list-item><ce:list-item id="u3195"><ce:label>•</ce:label><ce:para id="p4590">Hemiconvulsion–hemiplegia–epilepsy</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry align="left"><ce:bold>Epilepsies with structural–metabolic causes</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1055"><ce:list-item id="u3200"><ce:label>•</ce:label><ce:para id="p4595">Malformations of cortical development (hemimegalencephaly, heterotopias etc.)</ce:para></ce:list-item><ce:list-item id="u3205"><ce:label>•</ce:label><ce:para id="p4600">Neurocutaneous syndromes (tuberous sclerosis complex, Sturge–Weber etc.)</ce:para></ce:list-item><ce:list-item id="u3210"><ce:label>•</ce:label><ce:para id="p4605">Tumour</ce:para></ce:list-item><ce:list-item id="u3215"><ce:label>•</ce:label><ce:para id="p4610">Infection</ce:para></ce:list-item><ce:list-item id="u3220"><ce:label>•</ce:label><ce:para id="p4615">Trauma</ce:para></ce:list-item><ce:list-item id="u3225"><ce:label>•</ce:label><ce:para id="p4620">Angioma</ce:para></ce:list-item><ce:list-item id="u3230"><ce:label>•</ce:label><ce:para id="p4625">Perinatal insults</ce:para></ce:list-item><ce:list-item id="u3235"><ce:label>•</ce:label><ce:para id="p4630">Stroke etc.</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry align="left"><ce:bold>Epilepsies of unknown cause</ce:bold></entry></row><row role="thead2" rowsep="0"><entry align="left"><ce:bold>Conditions with epileptic seizures not needing long-term treatment</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1060"><ce:list-item id="u3240"><ce:label>•</ce:label><ce:para id="p4635">Benign neonatal seizures (BNS)</ce:para></ce:list-item><ce:list-item id="u3245"><ce:label>•</ce:label><ce:para id="p4640">Febrile seizures (FS)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0185" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9155" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0725" role="short">Image 32</ce:alt-text></ce:inline-figure> 25.33</ce:label><ce:alt-text id="atte0730" role="short">25.33</ce:alt-text><ce:textbox-head><ce:title id="tit0190">Common generalised epilepsy syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4650"><ce:display><ce:table frame="topbot" id="t0150"><ce:alt-text id="atte0735" role="short">Unlabelled table</ce:alt-text><tgroup cols="6"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><thead><row rowsep="1"><entry align="left">Syndrome</entry><entry align="left">Age of onset</entry><entry align="left">Type of seizure</entry><entry align="left">EEG features</entry><entry align="left">Treatment</entry><entry align="left">Prognosis</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Childhood absence epilepsy</ce:bold></entry><entry align="left">4–8 years</entry><entry align="left">Frequent brief absences</entry><entry align="left">3/sec spike and wave</entry><entry align="left"><ce:list id="ulist1065"><ce:list-item id="u3250"><ce:para id="p4655">Ethosuximide</ce:para></ce:list-item><ce:list-item id="u3255"><ce:para id="p4660">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u3260"><ce:para id="p4665">Levetiracetam</ce:para></ce:list-item></ce:list></entry><entry align="left">40% develop GTCS, 80% remit in adulthood</entry></row><row rowsep="1"><entry align="left"><ce:bold>Juvenile absence epilepsy</ce:bold></entry><entry align="left">10–15 years</entry><entry align="left">Less frequent absences than childhood absence</entry><entry align="left">Poly-spike and wave</entry><entry align="left"><ce:list id="ulist1070"><ce:list-item id="u3265"><ce:para id="p4670">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u3270"><ce:para id="p4675">Levetiracetam</ce:para></ce:list-item></ce:list></entry><entry align="left">80% develop GTCS, 80% seizure-free in adulthood</entry></row><row rowsep="1"><entry align="left"><ce:bold>Juvenile myoclonic epilepsy</ce:bold></entry><entry align="left">15–20 years</entry><entry align="left">GTCS, absences, morning myoclonus</entry><entry align="left">Poly-spike and wave, photosensitivity</entry><entry align="left"><ce:list id="ulist1075"><ce:list-item id="u3275"><ce:para id="p4680">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u3280"><ce:para id="p4685">Levetiracetam</ce:para></ce:list-item></ce:list></entry><entry align="left">90% remit with AEDs but relapse if AED withdrawn</entry></row><row><entry align="left"><ce:bold>GTCS on awakening</ce:bold></entry><entry align="left">10–25 years</entry><entry align="left">GTCS, sometimes myoclonus</entry><entry align="left">Spike and wave on waking and sleep onset</entry><entry align="left"><ce:list id="ulist1080"><ce:list-item id="u3285"><ce:para id="p4690">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u3290"><ce:para id="p4695">Levetiracetam</ce:para></ce:list-item></ce:list></entry><entry align="left">65% controlled with AEDs but relapse off treatment</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0250">(AED = antiepileptic drug; GTCS = generalised tonic–clonic seizure)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0190" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9160" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0740" role="short">Image 33</ce:alt-text></ce:inline-figure> 25.34</ce:label><ce:alt-text id="atte0745" role="short">25.34</ce:alt-text><ce:textbox-head><ce:title id="tit0195">Investigation of epilepsy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4710"><ce:display><ce:table frame="topbot" id="t0155"><ce:alt-text id="atte0750" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>From where is the epilepsy arising?</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1085"><ce:list-item id="u3295"><ce:label>•</ce:label><ce:para id="p4715">Standard EEG</ce:para></ce:list-item><ce:list-item id="u3300"><ce:label>•</ce:label><ce:para id="p4720">Sleep EEG</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1090"><ce:list-item id="u3305"><ce:label>•</ce:label><ce:para id="p4725">EEG with special electrodes (foramen ovale, subdural)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>What is the cause of the epilepsy?</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Structural lesion?</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1095"><ce:list-item id="u3310"><ce:label>•</ce:label><ce:para id="p4730">CT</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1100"><ce:list-item id="u3315"><ce:label>•</ce:label><ce:para id="p4735">MRI</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic disorder?</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1105"><ce:list-item id="u3320"><ce:label>•</ce:label><ce:para id="p4740">Urea and electrolytes</ce:para></ce:list-item><ce:list-item id="u3325"><ce:label>•</ce:label><ce:para id="p4745">Liver function tests</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1110"><ce:list-item id="u3330"><ce:label>•</ce:label><ce:para id="p4750">Blood glucose</ce:para></ce:list-item><ce:list-item id="u3335"><ce:label>•</ce:label><ce:para id="p4755">Serum calcium, magnesium</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory or infective disorder?</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1115"><ce:list-item id="u3340"><ce:label>•</ce:label><ce:para id="p4760">Full blood count, erythrocyte sedimentation rate, C-reactive protein</ce:para></ce:list-item><ce:list-item id="u3345"><ce:label>•</ce:label><ce:para id="p4765">Chest X-ray</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1120"><ce:list-item id="u3350"><ce:label>•</ce:label><ce:para id="p4770">Serology for syphilis, HIV, collagen disease</ce:para></ce:list-item><ce:list-item id="u3355"><ce:label>•</ce:label><ce:para id="p4775">CSF examination</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Are the attacks truly epileptic?</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1125"><ce:list-item id="u3360"><ce:label>•</ce:label><ce:para id="p4780">Ambulatory EEG</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1130"><ce:list-item id="u3365"><ce:label>•</ce:label><ce:para id="p4785">Videotelemetry</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0255">(CSF = cerebrospinal fluid; CT = computed tomography; EEG = electroencephalography; HIV = human immunodeficiency virus; MRI = magnetic resonance imaging)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0195" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9165" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0755" role="short">Image 34</ce:alt-text></ce:inline-figure> 25.35</ce:label><ce:alt-text id="atte0760" role="short">25.35</ce:alt-text><ce:textbox-head><ce:title id="tit0200">Indications for brain imaging in epilepsy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4805"><ce:list id="ulist1135"><ce:list-item id="u3370"><ce:label>•</ce:label><ce:para id="p4810">Epilepsy starting after the age of 16 years</ce:para></ce:list-item><ce:list-item id="u3375"><ce:label>•</ce:label><ce:para id="p4815">Seizures having focal features clinically</ce:para></ce:list-item><ce:list-item id="u3380"><ce:label>•</ce:label><ce:para id="p4820">Electroencephalogram showing a focal seizure source</ce:para></ce:list-item><ce:list-item id="u3385"><ce:label>•</ce:label><ce:para id="p4825">Control of seizures difficult or deteriorating</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0200" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9170" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000251/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0765" role="short">Image 35</ce:alt-text></ce:inline-figure> 25.36</ce:label><ce:alt-text id="atte0770" role="short">25.36</ce:alt-text><ce:textbox-head><ce:title id="tit0205">How to administer first aid for seizures</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4835"><ce:list id="ulist1140"><ce:list-item id="u3390"><ce:label>•</ce:label><ce:para id="p4840">Move the person away from danger (fire, water, machinery, furniture)</ce:para></ce:list-item><ce:list-item id="u3395"><ce:label>•</ce:label><ce:para id="p4845">After convulsions cease, turn the person into the ‘recovery’ position (semi-prone)</ce:para></ce:list-item><ce:list-item id="u3400"><ce:label>•</ce:label><ce:para id="p4850">Ensure the airway is clear but do <ce:bold>NOT</ce:bold> insert anything in the mouth (tongue-biting occurs at seizure onset and cannot be prevented by observers)</ce:para></ce:list-item><ce:list-item id="u3405"><ce:label>•</ce:label><ce:para id="p4855">If convulsions continue for more than 5 mins or recur without the person regaining consciousness, summon urgent medical attention</ce:para></ce:list-item><ce:list-item id="u3410"><ce:label>•</ce:label><ce:para id="p4860">Do not leave the person alone until fully recovered (drowsiness and delirium can persist for up to 1 hr)</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0205" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9175" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0775" role="short">Image 36</ce:alt-text></ce:inline-figure> 25.37</ce:label><ce:alt-text id="atte0780" role="short">25.37</ce:alt-text><ce:textbox-head><ce:title id="tit0210">Epilepsy: outcome after 20 years</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4865"><ce:list id="ulist1145"><ce:list-item id="u3415"><ce:label>•</ce:label><ce:para id="p4870">50% are seizure-free, without drugs, for the previous 5 years</ce:para></ce:list-item><ce:list-item id="u3420"><ce:label>•</ce:label><ce:para id="p4875">20% are seizure-free for the previous 5 years but continue to take medication</ce:para></ce:list-item><ce:list-item id="u3425"><ce:label>•</ce:label><ce:para id="p4880">30% continue to have seizures in spite of antiepileptic therapy</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0210" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9180" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0785" role="short">Image 37</ce:alt-text></ce:inline-figure> 25.38</ce:label><ce:alt-text id="atte0790" role="short">25.38</ce:alt-text><ce:textbox-head><ce:title id="tit0215">UK driving regulations</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4895"><ce:italic>The physician's prime duty is to ensure the patient is aware of the legal obligation to inform the driving authority</ce:italic></ce:para><ce:section id="s0825"><ce:section-title id="st0805">Private use</ce:section-title><ce:section id="s0830"><ce:section-title id="st0810">Single seizure</ce:section-title><ce:para id="p4900"><ce:list id="ulist1150"><ce:list-item id="u3430"><ce:label>•</ce:label><ce:para id="p4905">Cease driving for 6 months; a longer period may be required if risk of recurrence is high</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0835"><ce:section-title id="st0815">Epilepsy (i.e. more than one seizure over the age of 5 years)</ce:section-title><ce:para id="p4910"><ce:list id="ulist1155"><ce:list-item id="u3435"><ce:label>•</ce:label><ce:para id="p4915">Cease driving immediately</ce:para></ce:list-item><ce:list-item id="u3440"><ce:label>•</ce:label><ce:para id="p4920">Licence restored when patient is seizure-free for 1 year, <ce:italic>or</ce:italic> an initial sleep seizure is followed by exclusively sleep seizures for 1 year, <ce:italic>or</ce:italic> mixed awake and sleep seizures are followed by 3 years of exclusively sleep seizures</ce:para></ce:list-item><ce:list-item id="u3445"><ce:label>•</ce:label><ce:para id="p4925">Licence will require renewal every 3 years thereafter until patient is seizure-free for 10 years</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0840"><ce:section-title id="st0820">Withdrawal of antiepileptic drugs</ce:section-title><ce:para id="p4930"><ce:list id="ulist1160"><ce:list-item id="u3450"><ce:label>•</ce:label><ce:para id="p4935">Cease driving during withdrawal period and for 6 months thereafter</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0845"><ce:section-title id="st0825">Vocational drivers (heavy goods and public service vehicles)</ce:section-title><ce:para id="p4940"><ce:list id="ulist1165"><ce:list-item id="u3455"><ce:label>•</ce:label><ce:para id="p4945">No licence permitted if any seizure has occurred after the age of 5 years until patient is off medication and seizure-free for more than 10 years, and has no potentially epileptogenic brain lesion</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0215" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9185" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0795" role="short">Image 38</ce:alt-text></ce:inline-figure> 25.39</ce:label><ce:alt-text id="atte0800" role="short">25.39</ce:alt-text><ce:textbox-head><ce:title id="tit0220">Guidelines for antiepileptic drug therapy<ce:cross-ref id="crf0950" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0040">See Scottish Intercollegiate Guidelines Network SIGN 143 – Diagnosis and management of epilepsy in adults (May 2015).</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p4960"><ce:list id="ulist1170"><ce:list-item id="u3460"><ce:label>•</ce:label><ce:para id="p4965">Start with one first-line drug (see <ce:cross-ref id="crf0955" refid="b0220">Box 25.40</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u3465"><ce:label>•</ce:label><ce:para id="p4970">Start at a low dose; gradually increase dose until effective control of seizures is achieved or side-effects develop</ce:para></ce:list-item><ce:list-item id="u3470"><ce:label>•</ce:label><ce:para id="p4975">Optimise adherence (use minimum number of doses per day)</ce:para></ce:list-item><ce:list-item id="u3475"><ce:label>•</ce:label><ce:para id="p4980">If first drug fails (seizures continue or side-effects develop), start second first-line drug, followed if possible by gradual withdrawal of first</ce:para></ce:list-item><ce:list-item id="u3480"><ce:label>•</ce:label><ce:para id="p4985">If second drug fails (seizures continue or side-effects develop), start second-line drug in combination with the preferred baseline drug at maximum tolerated dose (beware interactions)</ce:para></ce:list-item><ce:list-item id="u3485"><ce:label>•</ce:label><ce:para id="p4990">If this combination fails (seizures continue or side-effects develop), replace second-line drug with alternative second-line drug</ce:para></ce:list-item><ce:list-item id="u3490"><ce:label>•</ce:label><ce:para id="p4995">If this combination fails, check adherence and reconsider diagnosis (Are events seizures? Occult lesion? Treatment adherence/alcohol/drugs confounding response?)</ce:para></ce:list-item><ce:list-item id="u3495"><ce:label>•</ce:label><ce:para id="p5000">Consider alternative, non-drug treatments (e.g. epilepsy surgery, vagal nerve stimulation)</ce:para></ce:list-item><ce:list-item id="u3500"><ce:label>•</ce:label><ce:para id="p5005">Use minimum number of drugs in combination at any one time</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0220" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9190" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0805" role="short">Image 39</ce:alt-text></ce:inline-figure> 25.40</ce:label><ce:alt-text id="atte0810" role="short">25.40</ce:alt-text><ce:textbox-head><ce:title id="tit0225">Guidelines for choice of antiepileptic drug<ce:cross-ref id="crf0965" refid="fn0015"><ce:sup loc="post">1</ce:sup></ce:cross-ref><ce:footnote id="fn0015"><ce:label>1</ce:label><ce:note-para id="np0045">See Scottish Intercollegiate Guidelines Network SIGN 143 – Diagnosis and management of epilepsy in adults (May 2015).</ce:note-para></ce:footnote><ce:footnote id="fn9000"><ce:label>2</ce:label><ce:note-para id="np9000">Genetic generalised epilepsies.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5010"><ce:display><ce:table frame="topbot" id="t0160"><ce:alt-text id="atte0815" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Epilepsy type</entry><entry align="left">First-line</entry><entry align="left">Second-line</entry><entry align="left">Third-line</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Focal onset and/or secondary GTCS</ce:bold></entry><entry align="left">Lamotrigine</entry><entry align="left"><ce:list id="ulist1175"><ce:list-item id="u3505"><ce:para id="p5015">Carbamazepine</ce:para></ce:list-item><ce:list-item id="u3510"><ce:para id="p5020">Levetiracetam</ce:para></ce:list-item><ce:list-item id="u3515"><ce:para id="p5025">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u3520"><ce:para id="p5030">Topiramate</ce:para></ce:list-item><ce:list-item id="u3525"><ce:para id="p5035">Zonisamide</ce:para></ce:list-item><ce:list-item id="u3530"><ce:para id="p5040">Lacosamide</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1180"><ce:list-item id="u3535"><ce:para id="p5045">Clobazam</ce:para></ce:list-item><ce:list-item id="u3540"><ce:para id="p5050">Gabapentin</ce:para></ce:list-item><ce:list-item id="u3545"><ce:para id="p5055">Oxcarbazepine</ce:para></ce:list-item><ce:list-item id="u3550"><ce:para id="p5060">Phenobarbital</ce:para></ce:list-item><ce:list-item id="u3555"><ce:para id="p5065">Phenytoin</ce:para></ce:list-item><ce:list-item id="u3560"><ce:para id="p5070">Pregabalin</ce:para></ce:list-item><ce:list-item id="u3565"><ce:para id="p5075">Primidone</ce:para></ce:list-item><ce:list-item id="u3570"><ce:para id="p5080">Tiagabine</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>GTCS</ce:bold><ce:cross-ref id="crf9000" refid="fn9000"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left"><ce:list id="ulist1185"><ce:list-item id="u3575"><ce:para id="p5085">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u3580"><ce:para id="p5090">Levetiracetam</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1190"><ce:list-item id="u3585"><ce:para id="p5095">Lamotrigine</ce:para></ce:list-item><ce:list-item id="u3590"><ce:para id="p5100">Topiramate</ce:para></ce:list-item><ce:list-item id="u3595"><ce:para id="p5105">Zonisamide</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1195"><ce:list-item id="u3600"><ce:para id="p5110">Carbamazepine</ce:para></ce:list-item><ce:list-item id="u3605"><ce:para id="p5115">Phenytoin</ce:para></ce:list-item><ce:list-item id="u3610"><ce:para id="p5120">Primidone</ce:para></ce:list-item><ce:list-item id="u3615"><ce:para id="p5125">Phenobarbital</ce:para></ce:list-item><ce:list-item id="u3620"><ce:para id="p5130">Acetazolamide</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Absence</ce:bold><ce:cross-ref id="crf9005" refid="fn9000"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">Ethosuximide</entry><entry align="left">Sodium valproate</entry><entry align="left"><ce:list id="ulist1200"><ce:list-item id="u3625"><ce:para id="p5135">Lamotrigine</ce:para></ce:list-item><ce:list-item id="u3630"><ce:para id="p5140">Clonazepam</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Myoclonic</ce:bold><ce:cross-ref id="crf9010" refid="fn9000"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">Sodium valproate</entry><entry align="left"><ce:list id="ulist1205"><ce:list-item id="u3635"><ce:para id="p5145">Levetiracetam</ce:para></ce:list-item><ce:list-item id="u3640"><ce:para id="p5150">Clonazepam</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1210"><ce:list-item id="u3645"><ce:para id="p5155">Lamotrigine</ce:para></ce:list-item><ce:list-item id="u3650"><ce:para id="p5160">Phenobarbital</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p5165"><ce:bold>N.B.</ce:bold> Use as few drugs as possible at the lowest possible dose.</ce:para><ce:para id="p5170">(GTCS = generalised tonic–clonic seizure)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0225" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9195" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000251/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0820" role="short">Image 40</ce:alt-text></ce:inline-figure> 25.41</ce:label><ce:alt-text id="atte0825" role="short">25.41</ce:alt-text><ce:textbox-head><ce:title id="tit0230">Epilepsy in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5210"><ce:list id="ulist1215"><ce:list-item id="u3655"><ce:label>•</ce:label><ce:para id="p5215"><ce:bold>Provision of pre-conception counselling is best practice</ce:bold>: start folic acid (5 mg daily for 2 months) before conception to reduce the risk of fetal malformations.</ce:para></ce:list-item><ce:list-item id="u3660"><ce:label>•</ce:label><ce:para id="p5220"><ce:bold>Fetal malformation</ce:bold>: risk is minimised if a single drug is used.<ce:list id="ulist1220"><ce:list-item id="u3665"><ce:para id="p5225">Carbamazepine and lamotrigine have the lowest incidence of major fetal malformations.</ce:para></ce:list-item><ce:list-item id="u3670"><ce:para id="p5230">The risk with sodium valproate is higher but should be carefully balanced against its benefits.</ce:para></ce:list-item><ce:list-item id="u3675"><ce:para id="p5235">Levetiracetam may be safe but avoid other newer drugs if possible.</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u3680"><ce:label>•</ce:label><ce:para id="p5240"><ce:bold>Learning difficulties in children</ce:bold>: IQ may be lower when children are exposed to valproate in utero, so its use should always be considered carefully.</ce:para></ce:list-item><ce:list-item id="u3685"><ce:label>•</ce:label><ce:para id="p5245"><ce:bold>Haemorrhagic disease of the newborn</ce:bold>: enzyme-inducing antiepileptic drugs increase risk. Give oral vitamin K (20 mg daily) to the mother during the last month of pregnancy and IM vitamin K (1 mg) to the infant at birth.</ce:para></ce:list-item><ce:list-item id="u3690"><ce:label>•</ce:label><ce:para id="p5250"><ce:bold>Increased frequency of seizures</ce:bold>: where breakthrough seizures occur, monitor antiepileptic drug levels and adjust the dose regimen accordingly.</ce:para></ce:list-item><ce:list-item id="u3695"><ce:label>•</ce:label><ce:para id="p5255"><ce:bold>Pharmacokinetic effects of pregnancy</ce:bold>: carbamazepine levels may fall in the third trimester. Lamotrigine and levetiracetam levels may fall early in pregnancy. Some advocate monitoring of levels.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0230" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9200" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000251/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0830" role="short">Image 41</ce:alt-text></ce:inline-figure> 25.42</ce:label><ce:alt-text id="atte0835" role="short">25.42</ce:alt-text><ce:textbox-head><ce:title id="tit0235">Epilepsy in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5280"><ce:list id="ulist1225"><ce:list-item id="u3700"><ce:label>•</ce:label><ce:para id="p5285"><ce:bold>Incidence and prevalence</ce:bold>: late-onset epilepsy is very common and the annual incidence in those over 60 years is rising.</ce:para></ce:list-item><ce:list-item id="u3705"><ce:label>•</ce:label><ce:para id="p5290"><ce:bold>Fits and faints</ce:bold>: the features that usually differentiate these may be less definitive than in younger patients.</ce:para></ce:list-item><ce:list-item id="u3710"><ce:label>•</ce:label><ce:para id="p5295"><ce:bold>Non-convulsive status epilepticus</ce:bold>: can present as delirium in the elderly.</ce:para></ce:list-item><ce:list-item id="u3715"><ce:label>•</ce:label><ce:para id="p5300"><ce:bold>Cerebrovascular disease</ce:bold>: the underlying cause of seizures in 30–50% of patients over the age of 50 years. A seizure may occur with an overt stroke or with occult vascular disease.</ce:para></ce:list-item><ce:list-item id="u3720"><ce:label>•</ce:label><ce:para id="p5305"><ce:bold>Antiepileptic drug regimens</ce:bold>: keep as simple as possible and take care to avoid interactions with other drugs being prescribed.</ce:para></ce:list-item><ce:list-item id="u3725"><ce:label>•</ce:label><ce:para id="p5310"><ce:bold>Carbamazepine-induced hyponatraemia</ce:bold>: increases significantly with age; this is particularly important in patients on diuretics or those with heart failure.</ce:para></ce:list-item><ce:list-item id="u3730"><ce:label>•</ce:label><ce:para id="p5315"><ce:bold>Withdrawal of antiepileptic therapy</ce:bold>: drug withdrawal should be attempted only where benefits exceed risk of harm from seizures.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0235" role="alt4"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9205" locator="icon04-9780702070280" xlink:href="pii:B9780702070280000251/icon04-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0840" role="short">Image 42</ce:alt-text></ce:inline-figure> 25.43</ce:label><ce:alt-text id="atte0845" role="short">25.43</ce:alt-text><ce:textbox-head><ce:title id="tit0240">Epilepsy in adolescence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5320"><ce:list id="ulist1230"><ce:list-item id="u3735"><ce:label>•</ce:label><ce:para id="p5325"><ce:bold>Effect on school/education</ce:bold>: seizures, antiepileptic drugs (AEDs) and psychological complications of epilepsy may hamper education. Fear may make some educational institutions unduly restrictive.</ce:para></ce:list-item><ce:list-item id="u3740"><ce:label>•</ce:label><ce:para id="p5330"><ce:bold>Effect on family relationships</ce:bold>: parents may adopt a protective role, which can lead to epilepsy (and AEDs) becoming a point of assertion and rebellion.</ce:para></ce:list-item><ce:list-item id="u3745"><ce:label>•</ce:label><ce:para id="p5335"><ce:bold>Effect on career choice</ce:bold>: epilepsy may exclude or restrict employment in the emergency services and armed forces.</ce:para></ce:list-item><ce:list-item id="u3750"><ce:label>•</ce:label><ce:para id="p5340"><ce:bold>Alcohol</ce:bold>: may affect sleep pattern; excess may be associated with poor AED adherence.</ce:para></ce:list-item><ce:list-item id="u3755"><ce:label>•</ce:label><ce:para id="p5345"><ce:bold>Illicit drugs</ce:bold>: may affect seizure threshold and be associated with poor AED adherence.</ce:para></ce:list-item><ce:list-item id="u3760"><ce:label>•</ce:label><ce:para id="p5350"><ce:bold>Sleep disturbance</ce:bold>: may be worsened by social activities and computer games.</ce:para></ce:list-item><ce:list-item id="u3765"><ce:label>•</ce:label><ce:para id="p5355"><ce:bold>Oral contraception</ce:bold>: interactions with AED can occur. Use may not always be disclosed to parents.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0240" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9210" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0850" role="short">Image 43</ce:alt-text></ce:inline-figure> 25.44</ce:label><ce:alt-text id="atte0855" role="short">25.44</ce:alt-text><ce:textbox-head><ce:title id="tit0245">Causes of hypersomnolence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5410"><ce:display><ce:table frame="topbot" id="t0165"><ce:alt-text id="atte0860" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Primary causes</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1235"><ce:list-item id="u3770"><ce:label>•</ce:label><ce:para id="p5415">Narcolepsy</ce:para></ce:list-item><ce:list-item id="u3775"><ce:label>•</ce:label><ce:para id="p5420">Idiopathic hypersomnolence</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1240"><ce:list-item id="u3780"><ce:label>•</ce:label><ce:para id="p5425">Brain injury</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Secondary causes (due to poor-quality sleep)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1245"><ce:list-item id="u3785"><ce:label>•</ce:label><ce:para id="p5430">Obstructive sleep apnoea</ce:para></ce:list-item><ce:list-item id="u3790"><ce:label>•</ce:label><ce:para id="p5435">Pain</ce:para></ce:list-item><ce:list-item id="u3795"><ce:label>•</ce:label><ce:para id="p5440">Restless legs/periodic limb movements of sleep</ce:para></ce:list-item><ce:list-item id="u3800"><ce:label>•</ce:label><ce:para id="p5445">Parkinsonism and other neurodegenerative diseases</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1250"><ce:list-item id="u3805"><ce:label>•</ce:label><ce:para id="p5450">Depression/anxiety</ce:para></ce:list-item><ce:list-item id="u3810"><ce:label>•</ce:label><ce:para id="p5455">Medication</ce:para></ce:list-item><ce:list-item id="u3815"><ce:label>•</ce:label><ce:para id="p5460">Environmental factors (noise, temperature etc.)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0245" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9215" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0865" role="short">Image 44</ce:alt-text></ce:inline-figure> 25.45</ce:label><ce:alt-text id="atte0870" role="short">25.45</ce:alt-text><ce:textbox-head><ce:title id="tit0250">Narcolepsy symptoms</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0935"><ce:section-title id="st0910">Sleep attacks</ce:section-title><ce:para id="p5470"><ce:list id="ulist1255"><ce:list-item id="u3820"><ce:label>•</ce:label><ce:para id="p5475">Brief, frequent and unlike normal somnolence</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0940"><ce:section-title id="st0915">Cataplexy</ce:section-title><ce:para id="p5480"><ce:list id="ulist1260"><ce:list-item id="u3825"><ce:label>•</ce:label><ce:para id="p5485">Sudden loss of muscle tone triggered by surprise, laughter, strong emotion etc.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0945"><ce:section-title id="st0920">Hypnagogic or hypnopompic hallucinations</ce:section-title><ce:para id="p5490"><ce:list id="ulist1265"><ce:list-item id="u3830"><ce:label>•</ce:label><ce:para id="p5495">Frightening hallucinations experienced during sleep onset or waking due to intrusion of REM sleep during wakefulness (can occur in normal people)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0950"><ce:section-title id="st0925">Sleep paralysis</ce:section-title><ce:para id="p5500"><ce:list id="ulist1270"><ce:list-item id="u3835"><ce:label>•</ce:label><ce:para id="p5505">Brief paralysis on waking (can occur in normal people)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0250" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9220" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0875" role="short">Image 45</ce:alt-text></ce:inline-figure> 25.46</ce:label><ce:alt-text id="atte0880" role="short">25.46</ce:alt-text><ce:textbox-head><ce:title id="tit0255">Diagnostic criteria for restless legs syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5530">A need to move the legs, usually accompanied or caused by uncomfortable, unpleasant sensations in the legs, with the following features:<ce:list id="ulist1275"><ce:list-item id="u3840"><ce:label>•</ce:label><ce:para id="p5535">only present or worse during periods of rest or inactivity such as lying or sitting</ce:para></ce:list-item><ce:list-item id="u3845"><ce:label>•</ce:label><ce:para id="p5540">partially or totally relieved by movement such as walking or stretching, at least as long as the activity continues</ce:para></ce:list-item><ce:list-item id="u3850"><ce:label>•</ce:label><ce:para id="p5545">generally worse or occurs only in the evening or night.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0255" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9225" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0885" role="short">Image 46</ce:alt-text></ce:inline-figure> 25.47</ce:label><ce:alt-text id="atte0890" role="short">25.47</ce:alt-text><ce:source>From Polman CH, Reingold SC, Branwell B, et al. Diagnostic criteria for multiple sclerosis. Ann Neurol 2011; 69:292–302.</ce:source><ce:textbox-head><ce:title id="tit0260">The Macdonald criteria for the diagnosis of multiple sclerosis (2011)<ce:cross-ref id="crf1050" refid="tn0040"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5580"><ce:display><ce:table frame="topbot" id="t0170"><ce:alt-text id="atte0895" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Clinical presentation<ce:cross-ref id="crf1055" refid="tn0045"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">Additional evidence required for diagnosis of MS</entry></row></thead><tbody><row rowsep="1"><entry align="left">Two or more attacks with <ce:italic>either</ce:italic> objective clinical evidence of at least 2 lesions<ce:br/><ce:italic>or</ce:italic><ce:br/>Objective clinical evidence of 1 attack with reasonable evidence (on clinical history) of at least 1 prior attack</entry><entry align="left">None</entry></row><row rowsep="1"><entry align="left">Two or more attacks with objective clinical evidence of 1 lesion</entry><entry align="left">Dissemination in ‘space’ demonstrated by magnetic resonance imaging (MRI)<ce:br/>≥ 1 lesion in at least 2 of the MS-typical regions<ce:cross-ref id="crf1060" refid="tn0050"><ce:sup loc="post">3</ce:sup></ce:cross-ref> (multiple lesions in different sites)<ce:br/><ce:italic>or</ce:italic><ce:br/>Await further clinical attack at different anatomical site</entry></row><row rowsep="1"><entry align="left">One attack with objective clinical evidence of ≥ 2 lesions</entry><entry align="left">Dissemination in ‘time’ demonstrated by evolving MRI showing combined enhancing (new) and non-enhancing (old) lesions<ce:br/><ce:italic>or</ce:italic><ce:br/>New T2 or enhancing lesion on repeat MRI<ce:br/><ce:italic>or</ce:italic><ce:br/>Await further (second) clinical attack at different anatomical site</entry></row><row rowsep="1"><entry align="left">One attack with clinical evidence of only 1 lesion (clinically isolated syndrome)</entry><entry align="left">Dissemination in ‘space’ demonstrated by ≥ 1 T2 lesion in at least 2 MS-typical regions<ce:br/><ce:italic>or</ce:italic><ce:br/>Dissemination in ‘time’, demonstrated by simultaneous enhancing and non-enhancing lesions<ce:br/><ce:italic>or</ce:italic><ce:br/>New T2 or enhancing lesions on repeat MRI<ce:br/><ce:italic>or</ce:italic><ce:br/>Await further (second) clinical attack</entry></row><row><entry align="left">Insidious neurological progression suggestive of MS</entry><entry align="left">1 year of progression plus 2 of the following:<ce:list id="ulist1280"><ce:list-item id="u3855"><ce:para id="p5585">Evidence for dissemination in space with ≥ 1 T2 lesions in MS-typical regions</ce:para></ce:list-item><ce:list-item id="u3860"><ce:para id="p5590">Evidence for dissemination in space based on ≥ 2 lesions in the spinal cord</ce:para></ce:list-item><ce:list-item id="u3865"><ce:para id="p5595">Positive cerebrospinal fluid (evidence of oligoclonal band and/or elevated immunoglobulin G index)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0040"><ce:label>1</ce:label><ce:note-para id="np0050">If the clinical presentation in the left-hand column is associated with the features in the right-hand column, the diagnosis is MS. If there is incomplete association, the diagnosis is ‘possible MS’.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0045"><ce:label>2</ce:label><ce:note-para id="np0055">Assumes other possible causes for central nervous system inflammation (e.g. sarcoidosis, systemic lupus erythematosus) have been excluded.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0050"><ce:label>3</ce:label><ce:note-para id="np0060">MS-typical regions = periventricular, juxtacortical, infratentorial, spinal cord.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0260" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9230" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0900" role="short">Image 47</ce:alt-text></ce:inline-figure> 25.48</ce:label><ce:alt-text id="atte0905" role="short">25.48</ce:alt-text><ce:textbox-head><ce:title id="tit0265">Clinical features of multiple sclerosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1005"><ce:section-title id="st0975">Common presentations of multiple sclerosis</ce:section-title><ce:para id="p5605"><ce:list id="ulist1285"><ce:list-item id="u3870"><ce:label>•</ce:label><ce:para id="p5610">Optic neuritis</ce:para></ce:list-item><ce:list-item id="u3875"><ce:label>•</ce:label><ce:para id="p5615">Relapsing/remitting sensory symptoms</ce:para></ce:list-item><ce:list-item id="u3880"><ce:label>•</ce:label><ce:para id="p5620">Subacute painless spinal cord lesion</ce:para></ce:list-item><ce:list-item id="u3885"><ce:label>•</ce:label><ce:para id="p5625">Acute brainstem syndrome</ce:para></ce:list-item><ce:list-item id="u3890"><ce:label>•</ce:label><ce:para id="p5630">Subacute loss of function of upper limb (dorsal column deficit)</ce:para></ce:list-item><ce:list-item id="u3895"><ce:label>•</ce:label><ce:para id="p5635">6th cranial nerve palsy</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1010"><ce:section-title id="st0980">Other symptoms and syndromes suggestive of central nervous system demyelination</ce:section-title><ce:para id="p5640"><ce:list id="ulist1290"><ce:list-item id="u3900"><ce:label>•</ce:label><ce:para id="p5645">Afferent pupillary defect and optic atrophy (previous optic neuritis)</ce:para></ce:list-item><ce:list-item id="u3905"><ce:label>•</ce:label><ce:para id="p5650">Lhermitte's symptom (tingling in spine or limbs on neck flexion)</ce:para></ce:list-item><ce:list-item id="u3910"><ce:label>•</ce:label><ce:para id="p5655">Progressive non-compressive paraparesis</ce:para></ce:list-item><ce:list-item id="u3915"><ce:label>•</ce:label><ce:para id="p5660">Partial Brown–Séquard syndrome (p. 1083)</ce:para></ce:list-item><ce:list-item id="u3920"><ce:label>•</ce:label><ce:para id="p5665">Internuclear ophthalmoplegia with ataxia</ce:para></ce:list-item><ce:list-item id="u3925"><ce:label>•</ce:label><ce:para id="p5670">Postural (‘rubral’, ‘Holmes’) tremor</ce:para></ce:list-item><ce:list-item id="u3930"><ce:label>•</ce:label><ce:para id="p5675">Trigeminal neuralgia (p. 1096) under the age of 50</ce:para></ce:list-item><ce:list-item id="u3935"><ce:label>•</ce:label><ce:para id="p5680">Recurrent facial palsy</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0265" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9235" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0910" role="short">Image 48</ce:alt-text></ce:inline-figure> 25.49</ce:label><ce:alt-text id="atte0915" role="short">25.49</ce:alt-text><ce:textbox-head><ce:title id="tit0270">Disease-modifying treatments in multiple sclerosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5715"><ce:display><ce:table frame="topbot" id="t0175"><ce:alt-text id="atte0920" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Treatment</entry><entry align="left">Route of administration/dosing</entry><entry align="left">Comment</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Moderate efficacy for less severe cases: average relapse rate reduction 30–50%</ce:bold></entry></row><row rowsep="0"><entry align="left">Interferon-beta</entry><entry align="left">Alternate-day or weekly intramuscular or subcutaneous injection</entry><entry align="left">In widespread use for reducing relapse rate</entry></row><row rowsep="0"><entry align="left">Glatiramer acetate</entry><entry align="left">Alternate-day subcutaneous injection</entry><entry align="left">Similar efficacy to interferon-beta</entry></row><row rowsep="0"><entry align="left">Teriflunomide</entry><entry align="left">Daily oral</entry><entry align="left"><ce:list id="ulist1295"><ce:list-item id="u3940"><ce:para id="p5720">May cause diarrhoea, alopecia, hepatotoxicity</ce:para></ce:list-item><ce:list-item id="u3945"><ce:para id="p5725">Highly teratogenic</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Dimethyl fumarate</entry><entry align="left">Daily oral</entry><entry align="left"><ce:list id="ulist1300"><ce:list-item id="u3950"><ce:para id="p5730">May cause flushing and gastrointestinal disturbance</ce:para></ce:list-item><ce:list-item id="u3955"><ce:para id="p5735">Risk of PML</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Fingolimod</entry><entry align="left">Daily oral</entry><entry align="left"><ce:list id="ulist1305"><ce:list-item id="u3960"><ce:para id="p5740">Superior efficacy to interferon-beta in randomised trials</ce:para></ce:list-item><ce:list-item id="u3965"><ce:para id="p5745">Cardiac conduction defects, especially with first dose</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>High efficacy for severe cases: average relapse rate reduction &#x003E; 50%</ce:bold></entry></row><row rowsep="0"><entry align="left">Alemtuzumab</entry><entry align="left">Intravenous infusion over two courses separated by 12 months; 5-day infusion initially, second course 3 days</entry><entry align="left">May precipitate autoimmune reactions, e.g. thyroid disease, ITP</entry></row><row><entry align="left">Natalizumab</entry><entry align="left">4-weekly intravenous infusion</entry><entry align="left"><ce:list id="ulist1310"><ce:list-item id="u3970"><ce:para id="p5750">Recently introduced; may be more effective than interferon-beta and glatiramer acetate</ce:para></ce:list-item><ce:list-item id="u3975"><ce:para id="p5755">Risk of PML</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0300">(ITP = idiopathic thrombocytopenic purpura; PML = progressive multifocal leucoencephalopathy)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0270" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9240" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0925" role="short">Image 49</ce:alt-text></ce:inline-figure> 25.50</ce:label><ce:alt-text id="atte0930" role="short">25.50</ce:alt-text><ce:textbox-head><ce:title id="tit0275">Treatment of complications in multiple sclerosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5775"><ce:display><ce:table frame="topbot" id="t0180"><ce:alt-text id="atte0935" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Spasticity</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1315"><ce:list-item id="u3980"><ce:label>•</ce:label><ce:para id="p5780">Physiotherapy</ce:para></ce:list-item><ce:list-item id="u3985"><ce:label>•</ce:label><ce:para id="p5785">Baclofen (usually oral)</ce:para></ce:list-item><ce:list-item id="u3990"><ce:label>•</ce:label><ce:para id="p5790">Dantrolene</ce:para></ce:list-item><ce:list-item id="u3995"><ce:label>•</ce:label><ce:para id="p5795">Gabapentin</ce:para></ce:list-item><ce:list-item id="u4000"><ce:label>•</ce:label><ce:para id="p5800">Sativex</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1320"><ce:list-item id="u4005"><ce:label>•</ce:label><ce:para id="p5805">Tizanidine</ce:para></ce:list-item><ce:list-item id="u4010"><ce:label>•</ce:label><ce:para id="p5810">Intrathecal baclofen</ce:para></ce:list-item><ce:list-item id="u4015"><ce:label>•</ce:label><ce:para id="p5815">Local (intramuscular) injection of botulinum toxin</ce:para></ce:list-item><ce:list-item id="u4020"><ce:label>•</ce:label><ce:para id="p5820">Chemical neuronectomy</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Dysaesthesia</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1325"><ce:list-item id="u4025"><ce:label>•</ce:label><ce:para id="p5825">Carbamazepine</ce:para></ce:list-item><ce:list-item id="u4030"><ce:label>•</ce:label><ce:para id="p5830">Gabapentin</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1330"><ce:list-item id="u4035"><ce:label>•</ce:label><ce:para id="p5835">Phenytoin</ce:para></ce:list-item><ce:list-item id="u4040"><ce:label>•</ce:label><ce:para id="p5840">Amitriptyline</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bladder symptoms</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1335"><ce:list-item id="u4045"><ce:label>•</ce:label><ce:para id="p5845">See <ce:cross-ref id="crf1100" refid="b0145">Box 25.25</ce:cross-ref> (p. 1094)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fatigue</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1340"><ce:list-item id="u4050"><ce:label>•</ce:label><ce:para id="p5850">Amantadine</ce:para></ce:list-item><ce:list-item id="u4055"><ce:label>•</ce:label><ce:para id="p5855">Modafinil</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1345"><ce:list-item id="u4060"><ce:label>•</ce:label><ce:para id="p5860">Amitriptyline</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Erectile dysfunction</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1350"><ce:list-item id="u4065"><ce:label>•</ce:label><ce:para id="p5865">Sildenafil 50–100 mg/day</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1355"><ce:list-item id="u4070"><ce:label>•</ce:label><ce:para id="p5870">Tadalafil</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0275" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9245" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000251/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0940" role="short">Image 50</ce:alt-text></ce:inline-figure> 25.51</ce:label><ce:alt-text id="atte0945" role="short">25.51</ce:alt-text><ce:textbox-head><ce:title id="tit0280">Multiple sclerosis in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5875"><ce:list id="ulist1360"><ce:list-item id="u4075"><ce:label>•</ce:label><ce:para id="p5880"><ce:bold>Counselling</ce:bold>: provision of pre-conception counselling is best practice.</ce:para></ce:list-item><ce:list-item id="u4080"><ce:label>•</ce:label><ce:para id="p5885"><ce:bold>Relapse risk</ce:bold>: endocrine effects on the immune system ensure that relapse risk drops during pregnancy.</ce:para></ce:list-item><ce:list-item id="u4085"><ce:label>•</ce:label><ce:para id="p5890"><ce:bold>Disease-modifying drugs</ce:bold>: risk of teratogenicity means that all disease-modifying drugs should ideally be stopped 6–8 weeks before conception and recommenced after breastfeeding has stopped.</ce:para></ce:list-item><ce:list-item id="u4090"><ce:label>•</ce:label><ce:para id="p5895"><ce:bold>Post-partum relapse rate</ce:bold>: rebound of immune system activity means that the highest risk of relapse is in the first year after delivery.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0280" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9250" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0950" role="short">Image 51</ce:alt-text></ce:inline-figure> 25.52</ce:label><ce:alt-text id="atte0955" role="short">25.52</ce:alt-text><ce:textbox-head><ce:title id="tit0285">Paraneoplastic disorders of the central nervous system</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5935"><ce:display><ce:table frame="topbot" id="t0185"><ce:alt-text id="atte0960" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Clinical presentation</entry><entry align="left">Associated tumour</entry><entry align="left">Antibodies demonstrated</entry></row></thead><tbody><row><entry morerows="3" rowsep="1" align="left"><ce:bold>Limbic encephalitis</ce:bold></entry><entry rowsep="0" align="left">SCLC</entry><entry rowsep="0" align="left">Anti-Hu, anti-CV2, PCA-2, anti-VGKC, anti-Ma1, anti-amphiphysin, anti-Ri, ANNA-3, anti-VGCC, anti-Zic4, anti-GluR1/2, anti-GABAR</entry></row><row rowsep="0"><entry align="left">Testicular, breast</entry><entry align="left">Anti-Ma2, anti-GluR1/2</entry></row><row rowsep="0"><entry align="left">Thymoma</entry><entry align="left">Anti-VGKC, anti-CV2, anti-GluR1/2</entry></row><row rowsep="1"><entry align="left">Ovarian/testicular teratoma</entry><entry align="left">Anti-NMDAR</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myelopathy</ce:bold></entry><entry align="left">SCLC, thymoma, others</entry><entry align="left">Anti-CV2, anti-amphiphysin, anti-aquaporin</entry></row><row rowsep="1"><entry align="left"><ce:bold>Motor neuron disease</ce:bold></entry><entry align="left">SCLC, others</entry><entry align="left">Anti-Hu</entry></row><row rowsep="1"><entry align="left"><ce:bold>Stiff person syndrome</ce:bold></entry><entry align="left">Breast, SCLC, thymoma, others</entry><entry align="left">Anti-amphiphysin, anti-Ri, anti-GAD, anti-GlyR</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Cerebellar degeneration</ce:bold></entry><entry rowsep="0" align="left">Breast, ovarian, others</entry><entry rowsep="0" align="left">Anti-Yo, anti-Ma1, anti-Ri</entry></row><row rowsep="0"><entry align="left">SCLC, others</entry><entry align="left">Anti-Hu, anti-CV2, PCA-2, ANNA-3, anti-amphiphysin, anti-VGCC, anti-Ri, anti-Zic4, anti-GAD</entry></row><row rowsep="1"><entry align="left">Lymphoma</entry><entry align="left">Anti-Tr, anti-mGluR1</entry></row><row rowsep="1"><entry align="left"><ce:bold>Multifocal encephalomyelitis</ce:bold></entry><entry align="left">SCLC, thymoma</entry><entry align="left">Anti-Hu, anti-CV2, anti-VGKC, anti-Ma1, anti-amphiphysin, anti-Ri, ANNA-3</entry></row><row><entry morerows="3" rowsep="1" align="left"><ce:bold>Opsoclonus–myoclonus</ce:bold></entry><entry rowsep="0" align="left">Breast, ovarian</entry><entry rowsep="0" align="left">Anti-Ri, anti-Yo, anti-amphiphysin</entry></row><row rowsep="0"><entry align="left">SCLC</entry><entry align="left">Anti Hu, anti-Ri, anti-CV2, anti-amphiphysin, anti-VGCC</entry></row><row rowsep="0"><entry align="left">Neuroblastoma</entry><entry align="left">Anti-Hu</entry></row><row rowsep="1"><entry align="left">Testicular</entry><entry align="left">Anti-Ma1/2, anti-CV2</entry></row><row rowsep="1"><entry align="left"><ce:bold>Extrapyramidal encephalitis</ce:bold></entry><entry align="left">SCLC, thymoma, testicular</entry><entry align="left">Anti-CV2, anti-Hu, anti-VGKC, anti-Ma</entry></row><row rowsep="1"><entry align="left"><ce:bold>Optic neuritis</ce:bold></entry><entry align="left">SCLC</entry><entry align="left">Anti-CV2, anti-aquaporin</entry></row><row><entry align="left"><ce:bold>Retinal degeneration</ce:bold></entry><entry align="left">SCLC</entry><entry align="left">Anti-recoverin</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0305">(ANNA = anti-neuronal nucleolar antibody; GABAR = GABA receptor; GAD = glutamic acid decarboxylase; GluR = glutamate receptor; GlyR = glycine receptor; NMDAR = <ce:italic>N</ce:italic>-methyl-<ce:small-caps>d</ce:small-caps>-aspartate receptor; PCA = Purkinje cell antibody; SCLC = small-cell lung cancer; VGCC = voltage-gated calcium channel; VGKC = voltage-gated potassium channel)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0285" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9255" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0965" role="short">Image 52</ce:alt-text></ce:inline-figure> 25.53</ce:label><ce:alt-text id="atte0970" role="short">25.53</ce:alt-text><ce:textbox-head><ce:title id="tit0290">Paraneoplastic disorders of the peripheral nervous system</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5940"><ce:display><ce:table frame="topbot" id="t0190"><ce:alt-text id="atte0975" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Clinical presentation</entry><entry align="left">Associated tumour</entry><entry align="left">Antibodies demonstrated</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Neuromyotonia</ce:bold></entry><entry align="left">Thymoma, SCLC, others</entry><entry align="left">Anti-VGKC</entry></row><row rowsep="1"><entry align="left"><ce:bold>Myasthenia gravis</ce:bold></entry><entry align="left">Thymoma</entry><entry align="left">Anti-Achr, anti-MuSK</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sensorimotor polyneuropathy</ce:bold></entry><entry align="left">Lymphoma, SCLC, others</entry><entry align="left">Anti-Hu, anti-CV2, ANNA-3, anti-Ma1, anti-amphiphysin</entry></row><row rowsep="1"><entry align="left"><ce:bold>Lambert–Eaton syndrome</ce:bold></entry><entry align="left">SCLC</entry><entry align="left">Anti-VGCC</entry></row><row rowsep="1"><entry align="left"><ce:bold>Motor neuropathy</ce:bold></entry><entry align="left">Lymphoma, SCLC, others</entry><entry align="left">Anti-Hu, anti-Yo, anti-CV2</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sensory neuropathy</ce:bold></entry><entry align="left">Lymphoma, SCLC, others</entry><entry align="left">Anti-Hu, anti-Yo, anti-CV2</entry></row><row><entry align="left"><ce:bold>Polymyositis/dermatomyositis</ce:bold></entry><entry align="left">Lung, breast</entry><entry align="left">Anti-Jo1</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0310">(MuSK = muscle-specific kinase; for other abbreviations, see <ce:cross-ref id="crf1125" refid="b0280">Box 25.52</ce:cross-ref>)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0290" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9260" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0980" role="short">Image 53</ce:alt-text></ce:inline-figure> 25.54</ce:label><ce:alt-text id="atte0985" role="short">25.54</ce:alt-text><ce:textbox-head><ce:title id="tit0295">Causes of parkinsonism</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p5975"><ce:display><ce:table frame="topbot" id="t0195"><ce:alt-text id="atte0990" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Idiopathic Parkinson's disease (at least 80% of parkinsonism)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cerebrovascular disease</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs and toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1365"><ce:list-item id="u4095"><ce:label>•</ce:label><ce:para id="p5980">Antipsychotic drugs (older and ‘atypical’)</ce:para></ce:list-item><ce:list-item id="u4100"><ce:label>•</ce:label><ce:para id="p5985">Metoclopramide, prochlorperazine</ce:para></ce:list-item><ce:list-item id="u4105"><ce:label>•</ce:label><ce:para id="p5990">Tetrabenazine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1370"><ce:list-item id="u4110"><ce:label>•</ce:label><ce:para id="p5995">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u4115"><ce:label>•</ce:label><ce:para id="p6000">Lithium</ce:para></ce:list-item><ce:list-item id="u4120"><ce:label>•</ce:label><ce:para id="p6005">Manganese</ce:para></ce:list-item><ce:list-item id="u4125"><ce:label>•</ce:label><ce:para id="p6010">MPTP</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Other degenerative diseases</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1375"><ce:list-item id="u4130"><ce:label>•</ce:label><ce:para id="p6015">Dementia with Lewy bodies</ce:para></ce:list-item><ce:list-item id="u4135"><ce:label>•</ce:label><ce:para id="p6020">Progressive supranuclear palsy</ce:para></ce:list-item><ce:list-item id="u4140"><ce:label>•</ce:label><ce:para id="p6025">Multiple system atrophy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1380"><ce:list-item id="u4145"><ce:label>•</ce:label><ce:para id="p6030">Corticobasal degeneration</ce:para></ce:list-item><ce:list-item id="u4150"><ce:label>•</ce:label><ce:para id="p6035">Alzheimer's disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1385"><ce:list-item id="u4155"><ce:label>•</ce:label><ce:para id="p6040">Huntington's disease</ce:para></ce:list-item><ce:list-item id="u4160"><ce:label>•</ce:label><ce:para id="p6045">Fragile X tremor ataxia syndrome</ce:para></ce:list-item><ce:list-item id="u4165"><ce:label>•</ce:label><ce:para id="p6050">Dopa-responsive dystonia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1390"><ce:list-item id="u4170"><ce:label>•</ce:label><ce:para id="p6055">Spinocerebellar ataxias (particularly SCA 3)</ce:para></ce:list-item><ce:list-item id="u4175"><ce:label>•</ce:label><ce:para id="p6060">Wilson's disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2"><entry namest="col1" nameend="col2" align="left"><ce:bold>Anoxic brain injury</ce:bold></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p6065">(MPTP = methyl-phenyl-tetrahydropyridine)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0295" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9265" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0995" role="short">Image 54</ce:alt-text></ce:inline-figure> 25.55</ce:label><ce:alt-text id="atte1000" role="short">25.55</ce:alt-text><ce:textbox-head><ce:title id="tit0300">Physical signs in Parkinson's disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6080"><ce:display><ce:table frame="topbot" id="t0200"><ce:alt-text id="atte1005" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>General</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1395"><ce:list-item id="u4180"><ce:label>•</ce:label><ce:para id="p6085">Expressionless face (hypomimia)</ce:para></ce:list-item><ce:list-item id="u4185"><ce:label>•</ce:label><ce:para id="p6090">Soft, rapid, indistinct speech (dysphonia)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1400"><ce:list-item id="u4190"><ce:label>•</ce:label><ce:para id="p6095">Flexed (stooped) posture</ce:para></ce:list-item><ce:list-item id="u4195"><ce:label>•</ce:label><ce:para id="p6100">Impaired postural reflexes</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gait</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1405"><ce:list-item id="u4200"><ce:label>•</ce:label><ce:para id="p6105">Slow to start walking (failure of gait ignition)</ce:para></ce:list-item><ce:list-item id="u4205"><ce:label>•</ce:label><ce:para id="p6110">Rapid, short stride length, tendency to shorten (festination)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1410"><ce:list-item id="u4210"><ce:label>•</ce:label><ce:para id="p6115">Reduction of arm swing</ce:para></ce:list-item><ce:list-item id="u4215"><ce:label>•</ce:label><ce:para id="p6120">Impaired balance on turning</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Tremor</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Resting (3–4 Hz, moderate amplitude): most common</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1415"><ce:list-item id="u4220"><ce:label>•</ce:label><ce:para id="p6125">Asymmetric, usually first in arm/hand (‘pill rolling’)</ce:para></ce:list-item><ce:list-item id="u4225"><ce:label>•</ce:label><ce:para id="p6130">May affect legs, jaw and chin but not head</ce:para></ce:list-item><ce:list-item id="u4230"><ce:label>•</ce:label><ce:para id="p6135">Intermittent, present at rest, often briefly abolished by movement of limb, exacerbated by walking</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Postural (6–8 Hz, moderate amplitude)</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1420"><ce:list-item id="u4235"><ce:label>•</ce:label><ce:para id="p6140">Present immediately on stretching out arms</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Re-emergent tremor (3–4 Hz, moderate amplitude)</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1425"><ce:list-item id="u4240"><ce:label>•</ce:label><ce:para id="p6145">Initially no tremor on stretching arms out, rest tremor re-emerges after a few seconds</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Rigidity</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1430"><ce:list-item id="u4245"><ce:label>•</ce:label><ce:para id="p6150">Cogwheel type, mostly upper limbs (due to tremor superimposed on rigidity)</ce:para></ce:list-item><ce:list-item id="u4250"><ce:label>•</ce:label><ce:para id="p6155">Lead pipe type</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Akinesia (fundamental feature)</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1435"><ce:list-item id="u4255"><ce:label>•</ce:label><ce:para id="p6160">Slowness of movement</ce:para></ce:list-item><ce:list-item id="u4260"><ce:label>•</ce:label><ce:para id="p6165">Fatiguing and decrease in size of repetitive movements</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Normal findings (if abnormal, consider other causes)</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1440"><ce:list-item id="u4265"><ce:label>•</ce:label><ce:para id="p6170">Power, deep tendon reflexes, plantar responses</ce:para></ce:list-item><ce:list-item id="u4270"><ce:label>•</ce:label><ce:para id="p6175">Eye movements</ce:para></ce:list-item><ce:list-item id="u4275"><ce:label>•</ce:label><ce:para id="p6180">Sensory and cerebellar examination</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0300" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9270" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1010" role="short">Image 55</ce:alt-text></ce:inline-figure> 25.56</ce:label><ce:alt-text id="atte1015" role="short">25.56</ce:alt-text><ce:textbox-head><ce:title id="tit0305">Dopamine agonists<ce:cross-ref id="crf1170" refid="fn0020">*</ce:cross-ref><ce:footnote id="fn0020"><ce:label>*</ce:label><ce:note-para id="np0065">Oral unless otherwise stated.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6230"><ce:display><ce:table frame="topbot" id="t0205"><ce:alt-text id="atte1020" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Ergot-derived</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1445"><ce:list-item id="u4280"><ce:label>•</ce:label><ce:para id="p6235">Bromocriptine</ce:para></ce:list-item><ce:list-item id="u4285"><ce:label>•</ce:label><ce:para id="p6240">Lisuride</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1450"><ce:list-item id="u4290"><ce:label>•</ce:label><ce:para id="p6245">Pergolide</ce:para></ce:list-item><ce:list-item id="u4295"><ce:label>•</ce:label><ce:para id="p6250">Cabergoline</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Non-ergot-derived</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1455"><ce:list-item id="u4300"><ce:label>•</ce:label><ce:para id="p6255">Ropinirole</ce:para></ce:list-item><ce:list-item id="u4305"><ce:label>•</ce:label><ce:para id="p6260">Pramipexole</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1460"><ce:list-item id="u4310"><ce:label>•</ce:label><ce:para id="p6265">Rotigotine (transdermal patch)</ce:para></ce:list-item><ce:list-item id="u4315"><ce:label>•</ce:label><ce:para id="p6270">Apomorphine (subcutaneous)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0305" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9275" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1025" role="short">Image 56</ce:alt-text></ce:inline-figure> 25.57</ce:label><ce:alt-text id="atte1030" role="short">25.57</ce:alt-text><ce:textbox-head><ce:title id="tit0310">Causes of acquired ataxia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6360"><ce:display><ce:table frame="topbot" id="t0210"><ce:alt-text id="atte1035" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Structural</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1465"><ce:list-item id="u4320"><ce:label>•</ce:label><ce:para id="p6365">Brain tumour</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1470"><ce:list-item id="u4325"><ce:label>•</ce:label><ce:para id="p6370">Brain abscess</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Toxic</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1475"><ce:list-item id="u4330"><ce:label>•</ce:label><ce:para id="p6375">Drugs: lithium, phenytoin, amiodarone, toluene, 5-fluorouracil, cytosine arabinoside</ce:para></ce:list-item><ce:list-item id="u4335"><ce:label>•</ce:label><ce:para id="p6380">Alcohol</ce:para></ce:list-item><ce:list-item id="u4340"><ce:label>•</ce:label><ce:para id="p6385">Heavy metals/chemicals: mercury, lead, thallium</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infection/post-infectious</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1480"><ce:list-item id="u4345"><ce:label>•</ce:label><ce:para id="p6390">HIV</ce:para></ce:list-item><ce:list-item id="u4350"><ce:label>•</ce:label><ce:para id="p6395">Varicella zoster</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1485"><ce:list-item id="u4355"><ce:label>•</ce:label><ce:para id="p6400">Whipple's disease</ce:para></ce:list-item><ce:list-item id="u4360"><ce:label>•</ce:label><ce:para id="p6405">Miller Fisher syndrome (p. 1140)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Degenerative</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1490"><ce:list-item id="u4365"><ce:label>•</ce:label><ce:para id="p6410">Multiple system atrophy</ce:para></ce:list-item><ce:list-item id="u4370"><ce:label>•</ce:label><ce:para id="p6415">Sporadic Creutzfeldt–Jakob disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1495"><ce:list-item id="u4375"><ce:label>•</ce:label><ce:para id="p6420">Idiopathic (or sporadic) late-onset cerebellar ataxia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory/immune-mediated</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1500"><ce:list-item id="u4380"><ce:label>•</ce:label><ce:para id="p6425">Multiple sclerosis</ce:para></ce:list-item><ce:list-item id="u4385"><ce:label>•</ce:label><ce:para id="p6430">Gluten ataxia (coeliac disease)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1505"><ce:list-item id="u4390"><ce:label>•</ce:label><ce:para id="p6435">Paraneoplastic ataxia</ce:para></ce:list-item><ce:list-item id="u4395"><ce:label>•</ce:label><ce:para id="p6440">Hashimoto encephalopathy</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1510"><ce:list-item id="u4400"><ce:label>•</ce:label><ce:para id="p6445">Vitamin B<ce:inf loc="post">1</ce:inf> or E deficiency</ce:para></ce:list-item><ce:list-item id="u4405"><ce:label>•</ce:label><ce:para id="p6450">Hypothyroidism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1515"><ce:list-item id="u4410"><ce:label>•</ce:label><ce:para id="p6455">Hypoparathyroidism</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Vascular</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1520"><ce:list-item id="u4415"><ce:label>•</ce:label><ce:para id="p6460">Stroke (ischaemic or haemorrhagic)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1525"><ce:list-item id="u4420"><ce:label>•</ce:label><ce:para id="p6465">Vascular malformations</ce:para></ce:list-item><ce:list-item id="u4425"><ce:label>•</ce:label><ce:para id="p6470">Superficial siderosis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0310" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9280" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1040" role="short">Image 57</ce:alt-text></ce:inline-figure> 25.58</ce:label><ce:alt-text id="atte1045" role="short">25.58</ce:alt-text><ce:textbox-head><ce:title id="tit0315">Inherited ataxias</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6475"><ce:display><ce:table frame="topbot" id="t0215"><ce:alt-text id="atte1050" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Inheritance pattern</entry><entry align="left">Age of onset</entry><entry align="left">Clinical features</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Autosomal dominant</ce:bold></entry></row><row rowsep="0"><entry align="left">Episodic ataxias</entry><entry align="left">Childhood and early adulthood</entry><entry align="left">Brief episodes of ataxia, sometimes induced by stress or startle. May develop progressive ataxia</entry></row><row rowsep="0"><entry align="left">Spinocerebellar ataxias (SCAs)</entry><entry align="left">Childhood to middle age</entry><entry align="left">Over 30 subtypes identified thus far. Progressive ataxia, sometimes associated with other features, including retinitis pigmentosa, pyramidal tract abnormalities, peripheral neuropathy and cognitive deficits</entry></row><row rowsep="1"><entry align="left">Dentato-rubro-pallidoluysian atrophy (DRPLA)</entry><entry align="left">Childhood to middle age</entry><entry align="left">Children present with myoclonic epilepsy and progressive ataxia. Adults have progressive ataxia with psychiatric features, dementia and choreoathetosis</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Autosomal recessive</ce:bold></entry></row><row rowsep="0"><entry align="left">Friedreich's ataxia</entry><entry align="left">Childhood/adolescence (late onset possible)</entry><entry align="left">Ataxia, nystagmus, dysarthria, spasticity, areflexia, proprioceptive impairment, diabetes mellitus, optic atrophy, cardiac abnormalities. Usually chair-bound</entry></row><row rowsep="0"><entry align="left">Ataxia telangiectasia</entry><entry align="left">Childhood</entry><entry align="left">Progressive ataxia, athetosis, telangiectasia on conjunctivae, impaired DNA repair, immune deficiency, tendency to malignancies</entry></row><row rowsep="0"><entry align="left">Abetalipoproteinaemia</entry><entry align="left">Childhood</entry><entry align="left">Steatorrhoea, sensorimotor neuropathy, retinitis pigmentosa, malabsorption of vitamins A, D, E and K</entry></row><row rowsep="0"><entry align="left">Hereditary ataxia with vitamin E deficiency</entry><entry align="left">&#x003C; 20 years</entry><entry align="left">Similar to Friedreich's ataxia, visual loss or retinitis pigmentosa, chorea</entry></row><row rowsep="1"><entry align="left">Others</entry><entry align="left">Usually young onset</entry><entry align="left">Numerous, with genes identified only in some</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>X-linked</ce:bold></entry></row><row rowsep="0"><entry align="left">Fragile X tremor ataxia syndrome</entry><entry align="left">&#x003E; 50 years</entry><entry align="left">Tremor, ataxia, parkinsonism, autonomic failure, cognitive impairment and dementia</entry></row><row rowsep="1"><entry align="left">Adrenoleukodystrophy</entry><entry align="left">Childhood to adult</entry><entry align="left">Impaired adrenal and cognitive function, sometimes spastic paraparesis</entry></row><row><entry align="left"><ce:bold>Mitochondrial disease</ce:bold></entry><entry align="left">Various</entry><entry align="left">Ataxia features in several mitochondrial diseases, including Kearns–Sayre syndrome, MELAS, MERRF, Leigh's syndrome (<ce:intra-ref id="ii0780" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0195">p. 49</ce:intra-ref>)</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0335">(MELAS = mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes; MERRF = myoclonic epilepsy with ragged red fibres)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0315" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9285" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1055" role="short">Image 58</ce:alt-text></ce:inline-figure> 25.59</ce:label><ce:alt-text id="atte1060" role="short">25.59</ce:alt-text><ce:textbox-head><ce:title id="tit0320">Drug-induced tremor (usually postural)<ce:cross-ref id="crf1200" refid="fn0025">*</ce:cross-ref><ce:footnote id="fn0025"><ce:label>*</ce:label><ce:note-para id="np0070">Drugs causing parkinsonism and associated tremor are listed in <ce:cross-ref id="crf1205" refid="b0290">Box 25.54</ce:cross-ref>.</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6490"><ce:display><ce:table frame="topbot" id="t0220"><ce:alt-text id="atte1065" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist1530"><ce:list-item id="u4430"><ce:label>•</ce:label><ce:para id="p6495">β-agonists (e.g. salbutamol)</ce:para></ce:list-item><ce:list-item id="u4435"><ce:label>•</ce:label><ce:para id="p6500">Theophylline</ce:para></ce:list-item><ce:list-item id="u4440"><ce:label>•</ce:label><ce:para id="p6505">Sodium valproate</ce:para></ce:list-item><ce:list-item id="u4445"><ce:label>•</ce:label><ce:para id="p6510">Thyroxine</ce:para></ce:list-item><ce:list-item id="u4450"><ce:label>•</ce:label><ce:para id="p6515">Lithium</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1535"><ce:list-item id="u4455"><ce:label>•</ce:label><ce:para id="p6520">Tricyclic antidepressants</ce:para></ce:list-item><ce:list-item id="u4460"><ce:label>•</ce:label><ce:para id="p6525">Recreational drugs (e.g. amphetamines)</ce:para></ce:list-item><ce:list-item id="u4465"><ce:label>•</ce:label><ce:para id="p6530">Alcohol</ce:para></ce:list-item><ce:list-item id="u4470"><ce:label>•</ce:label><ce:para id="p6535">Caffeine</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0320" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9290" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1070" role="short">Image 59</ce:alt-text></ce:inline-figure> 25.60</ce:label><ce:alt-text id="atte1075" role="short">25.60</ce:alt-text><ce:textbox-head><ce:title id="tit0325">Clinical features of motor neuron disease</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1260"><ce:section-title id="st1215">Onset</ce:section-title><ce:para id="p6565"><ce:list id="ulist1540"><ce:list-item id="u4475"><ce:label>•</ce:label><ce:para id="p6570">Usually after the age of 50 years</ce:para></ce:list-item><ce:list-item id="u4480"><ce:label>•</ce:label><ce:para id="p6575">Very uncommon before the age of 30 years</ce:para></ce:list-item><ce:list-item id="u4485"><ce:label>•</ce:label><ce:para id="p6580">Affects males more commonly than females</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1265"><ce:section-title id="st1220">Symptoms</ce:section-title><ce:para id="p6585"><ce:list id="ulist1545"><ce:list-item id="u4490"><ce:label>•</ce:label><ce:para id="p6590">Limb muscle weakness, cramps, occasionally fasciculation</ce:para></ce:list-item><ce:list-item id="u4495"><ce:label>•</ce:label><ce:para id="p6595">Disturbance of speech/swallowing (dysarthria/dysphagia)</ce:para></ce:list-item><ce:list-item id="u4500"><ce:label>•</ce:label><ce:para id="p6600">Cognitive and behavioural features common (similar to frontotemporal dementia)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1270"><ce:section-title id="st1225">Signs</ce:section-title><ce:para id="p6605"><ce:list id="ulist1550"><ce:list-item id="u4505"><ce:label>•</ce:label><ce:para id="p6610">Wasting and fasciculation of muscles</ce:para></ce:list-item><ce:list-item id="u4510"><ce:label>•</ce:label><ce:para id="p6615">Weakness of muscles of limbs, tongue, face and palate</ce:para></ce:list-item><ce:list-item id="u4515"><ce:label>•</ce:label><ce:para id="p6620">Pyramidal tract involvement, causing spasticity, exaggerated tendon reflexes, extensor plantar responses</ce:para></ce:list-item><ce:list-item id="u4520"><ce:label>•</ce:label><ce:para id="p6625">External ocular muscles and sphincters usually remain intact</ce:para></ce:list-item><ce:list-item id="u4525"><ce:label>•</ce:label><ce:para id="p6630">No objective sensory deficit</ce:para></ce:list-item><ce:list-item id="u4530"><ce:label>•</ce:label><ce:para id="p6635">Evidence of cognitive impairment with frontotemporal dominance</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1275"><ce:section-title id="st1230">Course</ce:section-title><ce:para id="p6640"><ce:list id="ulist1555"><ce:list-item id="u4535"><ce:label>•</ce:label><ce:para id="p6645">Symptoms often begin focally in one part and spread gradually but relentlessly to become widespread</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0325" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9295" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1080" role="short">Image 60</ce:alt-text></ce:inline-figure> 25.61</ce:label><ce:alt-text id="atte1085" role="short">25.61</ce:alt-text><ce:textbox-head><ce:title id="tit0330">Infections of the nervous system</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6675"><ce:display><ce:table frame="topbot" id="t0225"><ce:alt-text id="atte1090" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacterial infections</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1560"><ce:list-item id="u4540"><ce:label>•</ce:label><ce:para id="p6680">Meningitis</ce:para></ce:list-item><ce:list-item id="u4545"><ce:label>•</ce:label><ce:para id="p6685">Suppurative encephalitis</ce:para></ce:list-item><ce:list-item id="u4550"><ce:label>•</ce:label><ce:para id="p6690">Brain abscess</ce:para></ce:list-item><ce:list-item id="u4555"><ce:label>•</ce:label><ce:para id="p6695">Paravertebral (epidural) abscess</ce:para></ce:list-item><ce:list-item id="u4560"><ce:label>•</ce:label><ce:para id="p6700">Tuberculosis (<ce:intra-ref id="ii0795" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1030">p. 588</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1565"><ce:list-item id="u4565"><ce:label>•</ce:label><ce:para id="p6705">Neurosyphilis</ce:para></ce:list-item><ce:list-item id="u4570"><ce:label>•</ce:label><ce:para id="p6710">Leprosy (Hansen's disease) (peripheral nerves)<ce:cross-ref id="crf1225" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4575"><ce:label>•</ce:label><ce:para id="p6715">Diphtheria (peripheral nerves)<ce:cross-ref id="crf1230" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4580"><ce:label>•</ce:label><ce:para id="p6720">Tetanus (motor cells)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viral infections</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1570"><ce:list-item id="u4585"><ce:label>•</ce:label><ce:para id="p6725">Meningitis</ce:para></ce:list-item><ce:list-item id="u4590"><ce:label>•</ce:label><ce:para id="p6730">Encephalitis</ce:para></ce:list-item><ce:list-item id="u4595"><ce:label>•</ce:label><ce:para id="p6735">Transverse myelitis</ce:para></ce:list-item><ce:list-item id="u4600"><ce:label>•</ce:label><ce:para id="p6740">Progressive multifocal leucoencephalopathy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1575"><ce:list-item id="u4605"><ce:label>•</ce:label><ce:para id="p6745">Poliomyelitis</ce:para></ce:list-item><ce:list-item id="u4610"><ce:label>•</ce:label><ce:para id="p6750">Subacute sclerosing panencephalitis (late sequel)</ce:para></ce:list-item><ce:list-item id="u4615"><ce:label>•</ce:label><ce:para id="p6755">Rabies</ce:para></ce:list-item><ce:list-item id="u4620"><ce:label>•</ce:label><ce:para id="p6760">HIV infection (<ce:intra-ref id="ii0800" xlink:href="pii:B978-0-7020-7028-0.00012-3#c00012">Ch. 12</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Prion diseases</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1580"><ce:list-item id="u4625"><ce:label>•</ce:label><ce:para id="p6765">Creutzfeldt–Jakob disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1585"><ce:list-item id="u4630"><ce:label>•</ce:label><ce:para id="p6770">Kuru</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoal infections</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1590"><ce:list-item id="u4635"><ce:label>•</ce:label><ce:para id="p6775">Malaria<ce:cross-ref id="crf1235" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4640"><ce:label>•</ce:label><ce:para id="p6780">Toxoplasmosis (in immune-suppressed)<ce:cross-ref id="crf1240" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1595"><ce:list-item id="u4645"><ce:label>•</ce:label><ce:para id="p6785">Trypanosomiasis<ce:cross-ref id="crf1245" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4650"><ce:label>•</ce:label><ce:para id="p6790">Amoebic abscess<ce:cross-ref id="crf1250" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Helminthic infections</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1600"><ce:list-item id="u4655"><ce:label>•</ce:label><ce:para id="p6795">Schistosomiasis (spinal cord)<ce:cross-ref id="crf1255" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4660"><ce:label>•</ce:label><ce:para id="p6800">Cysticercosis<ce:cross-ref id="crf1260" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1605"><ce:list-item id="u4665"><ce:label>•</ce:label><ce:para id="p6805">Hydatid disease<ce:cross-ref id="crf1265" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4670"><ce:label>•</ce:label><ce:para id="p6810">Strongyloidiasis<ce:cross-ref id="crf1270" refid="tn0055">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fungal infections</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1610"><ce:list-item id="u4675"><ce:label>•</ce:label><ce:para id="p6815"><ce:italic>Candida</ce:italic> meningitis or brain abscess</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1615"><ce:list-item id="u4680"><ce:label>•</ce:label><ce:para id="p6820">Cryptococcal meningitis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0055"><ce:label>*</ce:label><ce:note-para id="np0075">These infections are discussed in <ce:intra-ref id="ii0805" xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011">Chapter 11</ce:intra-ref>.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0330" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9300" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1095" role="short">Image 61</ce:alt-text></ce:inline-figure> 25.62</ce:label><ce:alt-text id="atte1100" role="short">25.62</ce:alt-text><ce:textbox-head><ce:title id="tit0335">Causes of meningitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6830"><ce:display><ce:table frame="topbot" id="t0230"><ce:alt-text id="atte1105" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infective</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bacteria (see</ce:bold> <ce:cross-ref id="crf1285" refid="b0335"><ce:bold>Box 25.63</ce:bold></ce:cross-ref><ce:bold>)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Viruses</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1620"><ce:list-item id="u4685"><ce:label>•</ce:label><ce:para id="p6835">Enteroviruses (echo, Coxsackie, polio)</ce:para></ce:list-item><ce:list-item id="u4690"><ce:label>•</ce:label><ce:para id="p6840">Mumps</ce:para></ce:list-item><ce:list-item id="u4695"><ce:label>•</ce:label><ce:para id="p6845">Influenza</ce:para></ce:list-item><ce:list-item id="u4700"><ce:label>•</ce:label><ce:para id="p6850">Herpes simplex</ce:para></ce:list-item><ce:list-item id="u4705"><ce:label>•</ce:label><ce:para id="p6855">Varicella zoster</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1625"><ce:list-item id="u4710"><ce:label>•</ce:label><ce:para id="p6860">Epstein–Barr</ce:para></ce:list-item><ce:list-item id="u4715"><ce:label>•</ce:label><ce:para id="p6865">HIV</ce:para></ce:list-item><ce:list-item id="u4720"><ce:label>•</ce:label><ce:para id="p6870">Lymphocytic choriomeningitis</ce:para></ce:list-item><ce:list-item id="u4725"><ce:label>•</ce:label><ce:para id="p6875">Mollaret's meningitis (herpes simplex virus type 2)</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Protozoa and parasites</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1630"><ce:list-item id="u4730"><ce:label>•</ce:label><ce:para id="p6880">Cysticerci</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1635"><ce:list-item id="u4735"><ce:label>•</ce:label><ce:para id="p6885">Amoeba</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Fungi</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1640"><ce:list-item id="u4740"><ce:label>•</ce:label><ce:para id="p6890"><ce:italic>Cryptococcus neoformans</ce:italic></ce:para></ce:list-item><ce:list-item id="u4745"><ce:label>•</ce:label><ce:para id="p6895"><ce:italic>Candida</ce:italic></ce:para></ce:list-item><ce:list-item id="u4750"><ce:label>•</ce:label><ce:para id="p6900"><ce:italic>Histoplasma</ce:italic></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1645"><ce:list-item id="u4755"><ce:label>•</ce:label><ce:para id="p6905"><ce:italic>Blastomyces</ce:italic></ce:para></ce:list-item><ce:list-item id="u4760"><ce:label>•</ce:label><ce:para id="p6910"><ce:italic>Coccidioides</ce:italic></ce:para></ce:list-item><ce:list-item id="u4765"><ce:label>•</ce:label><ce:para id="p6915"><ce:italic>Sporothrix</ce:italic></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Non-infective (‘sterile’)</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Malignant disease</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1650"><ce:list-item id="u4770"><ce:label>•</ce:label><ce:para id="p6920">Breast cancer</ce:para></ce:list-item><ce:list-item id="u4775"><ce:label>•</ce:label><ce:para id="p6925">Bronchial cancer</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1655"><ce:list-item id="u4780"><ce:label>•</ce:label><ce:para id="p6930">Leukaemia</ce:para></ce:list-item><ce:list-item id="u4785"><ce:label>•</ce:label><ce:para id="p6935">Lymphoma</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory disease (may be recurrent)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist1660"><ce:list-item id="u4790"><ce:label>•</ce:label><ce:para id="p6940">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u4795"><ce:label>•</ce:label><ce:para id="p6945">Systemic lupus erythematosus</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1665"><ce:list-item id="u4800"><ce:label>•</ce:label><ce:para id="p6950">Behçet's disease</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0335" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9305" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1110" role="short">Image 62</ce:alt-text></ce:inline-figure> 25.63</ce:label><ce:alt-text id="atte1115" role="short">25.63</ce:alt-text><ce:textbox-head><ce:title id="tit0340">Bacterial causes of meningitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p6980"><ce:display><ce:table frame="topbot" id="t0235"><ce:alt-text id="atte1120" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Age of onset</entry><entry align="left">Common</entry><entry align="left">Less common</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Neonate</ce:bold></entry><entry align="left"><ce:list id="ulist1670"><ce:list-item id="u4805"><ce:para id="p6985">Gram-negative bacilli (<ce:italic>Escherichia coli</ce:italic>, <ce:italic>Proteus</ce:italic>)</ce:para></ce:list-item><ce:list-item id="u4810"><ce:para id="p6990">Group B streptococci</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:italic>Listeria monocytogenes</ce:italic></entry></row><row rowsep="1"><entry align="left"><ce:bold>Pre-school child</ce:bold></entry><entry align="left"><ce:list id="ulist1675"><ce:list-item id="u4815"><ce:para id="p6995"><ce:italic>Haemophilus influenzae</ce:italic></ce:para></ce:list-item><ce:list-item id="u4820"><ce:para id="p7000"><ce:italic>Neisseria meningitidis</ce:italic> (subtypes B, C, Y, W)</ce:para></ce:list-item><ce:list-item id="u4825"><ce:para id="p7005"><ce:italic>Streptococcus pneumoniae</ce:italic></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:italic>Mycobacterium tuberculosis</ce:italic></entry></row><row><entry align="left"><ce:bold>Older child and adult</ce:bold></entry><entry align="left"><ce:list id="ulist1680"><ce:list-item id="u4830"><ce:para id="p7010"><ce:italic>N. meningitidis</ce:italic> (subtypes B, C, Y, W)</ce:para></ce:list-item><ce:list-item id="u4835"><ce:para id="p7015"><ce:italic>Strep. pneumoniae</ce:italic></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1685"><ce:list-item id="u4840"><ce:para id="p7020"><ce:italic>L. monocytogenes</ce:italic></ce:para></ce:list-item><ce:list-item id="u4845"><ce:para id="p7025"><ce:italic>M. tuberculosis</ce:italic></ce:para></ce:list-item><ce:list-item id="u4850"><ce:para id="p7030"><ce:italic>Staphylococcus aureus (skull fracture)</ce:italic></ce:para></ce:list-item><ce:list-item id="u4855"><ce:para id="p7035"><ce:italic>H. influenzae</ce:italic></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0340" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9310" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1125" role="short">Image 63</ce:alt-text></ce:inline-figure> 25.64</ce:label><ce:alt-text id="atte1130" role="short">25.64</ce:alt-text><ce:textbox-head><ce:title id="tit0345">Complications of meningococcal sepsis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7050"><ce:display><ce:table frame="topbot" id="t0240"><ce:alt-text id="atte1135" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist1690"><ce:list-item id="u4860"><ce:label>•</ce:label><ce:para id="p7055">Meningitis</ce:para></ce:list-item><ce:list-item id="u4865"><ce:label>•</ce:label><ce:para id="p7060">Rash (morbilliform, petechial or purpuric)</ce:para></ce:list-item><ce:list-item id="u4870"><ce:label>•</ce:label><ce:para id="p7065">Shock</ce:para></ce:list-item><ce:list-item id="u4875"><ce:label>•</ce:label><ce:para id="p7070">Intravascular coagulation</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1695"><ce:list-item id="u4880"><ce:label>•</ce:label><ce:para id="p7075">Renal failure</ce:para></ce:list-item><ce:list-item id="u4885"><ce:label>•</ce:label><ce:para id="p7080">Peripheral gangrene</ce:para></ce:list-item><ce:list-item id="u4890"><ce:label>•</ce:label><ce:para id="p7085">Arthritis (septic or reactive)</ce:para></ce:list-item><ce:list-item id="u4895"><ce:label>•</ce:label><ce:para id="p7090">Pericarditis (septic or reactive)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0345" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9315" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1140" role="short">Image 64</ce:alt-text></ce:inline-figure> 25.65</ce:label><ce:alt-text id="atte1145" role="short">25.65</ce:alt-text><ce:textbox-head><ce:title id="tit0350">Treatment of pyogenic meningitis of unknown cause</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1350"><ce:label>1</ce:label><ce:section-title id="st1305">Adults aged 18–50 years with or without a typical meningococcal rash</ce:section-title><ce:para id="p7105"><ce:list id="ulist1700"><ce:list-item id="u4900"><ce:label>•</ce:label><ce:para id="p7110">Cefotaxime 2 g IV 4 times daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u4905"><ce:label>•</ce:label><ce:para id="p7115">Ceftriaxone 2 g IV twice daily</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1355"><ce:label>2</ce:label><ce:section-title id="st1310">Patients in whom penicillin-resistant pneumococcal infection is suspected, or in areas with a significant incidence of penicillin resistance in the community</ce:section-title><ce:para id="p7120">As for (1) but add:<ce:list id="ulist1705"><ce:list-item id="u4910"><ce:label>•</ce:label><ce:para id="p7125">Vancomycin 1 g IV twice daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u4915"><ce:label>•</ce:label><ce:para id="p7130">Rifampicin 600 mg IV twice daily</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1360"><ce:label>3</ce:label><ce:section-title id="st1315">Adults aged <ce:italic>&#x003E;</ce:italic> 50 years and those in whom <ce:italic>Listeria monocytogenes</ce:italic> infection is suspected (brainstem signs, immunosuppression, diabetic, alcoholic)</ce:section-title><ce:para id="p7135">As for (1) but add:<ce:list id="ulist1710"><ce:list-item id="u4920"><ce:label>•</ce:label><ce:para id="p7140">Ampicillin 2 g IV 6 times daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u4925"><ce:label>•</ce:label><ce:para id="p7145">Co-trimoxazole 60–120 mg/kg daily in four divided doses</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1365"><ce:label>4</ce:label><ce:section-title id="st1320">Patients with a clear history of anaphylaxis to <ce:italic>β</ce:italic>-lactams</ce:section-title><ce:para id="p7150"><ce:list id="ulist1715"><ce:list-item id="u4930"><ce:label>•</ce:label><ce:para id="p7155">Chloramphenicol 25 mg/kg IV 4 times daily <ce:italic>plus</ce:italic></ce:para></ce:list-item><ce:list-item id="u4935"><ce:label>•</ce:label><ce:para id="p7160">Vancomycin 1 g IV twice daily</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1370"><ce:label>5</ce:label><ce:section-title id="st1325">Adjunctive treatment (see text)</ce:section-title><ce:para id="p7165"><ce:list id="ulist1720"><ce:list-item id="u4940"><ce:label>•</ce:label><ce:para id="p7170">Dexamethasone 0.15 mg/kg 4 times daily for 2–4 days</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0350" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9320" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1150" role="short">Image 65</ce:alt-text></ce:inline-figure> 25.66</ce:label><ce:alt-text id="atte1155" role="short">25.66</ce:alt-text><ce:textbox-head><ce:title id="tit0355">Chemotherapy of bacterial meningitis when the cause is known</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7175"><ce:display><ce:table frame="topbot" id="t0245"><ce:alt-text id="atte1160" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Pathogen</entry><entry align="left">Regimen of choice</entry><entry align="left">Alternative agents</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Neisseria meningitidis</ce:italic></ce:bold></entry><entry align="left">Benzylpenicillin 2.4 g IV 6 times daily for 5–7 days</entry><entry align="left"><ce:list id="ulist1725"><ce:list-item id="u4945"><ce:para id="p7180">Cefuroxime, ampicillin</ce:para></ce:list-item><ce:list-item id="u4950"><ce:para id="p7185">Chloramphenicol<ce:cross-ref id="crf1320" refid="tn0060">*</ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Streptococcus pneumoniae</ce:italic></ce:bold> (sensitive to β-lactams, MIC &#x003C; 1 mg/L)</entry><entry align="left"><ce:list id="ulist1730"><ce:list-item id="u4955"><ce:para id="p7190">Cefotaxime 2 g IV 4 times daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u4960"><ce:para id="p7195">Ceftriaxone 2 g IV twice daily for 10–14 days</ce:para></ce:list-item></ce:list></entry><entry align="left">Chloramphenicol<ce:cross-ref id="crf1325" refid="tn0060">*</ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Strep. pneumoniae</ce:italic></ce:bold> (resistant to β-lactams)</entry><entry align="left"><ce:list id="ulist1735"><ce:list-item id="u4965"><ce:para id="p7200">As for sensitive strains but add:</ce:para></ce:list-item><ce:list-item id="u4970"><ce:para id="p7205">Vancomycin 1 g IV twice daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u4975"><ce:para id="p7210">Rifampicin 600 mg IV twice daily</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1740"><ce:list-item id="u4980"><ce:para id="p7215">Vancomycin plus rifampicin<ce:cross-ref id="crf1330" refid="tn0060">*</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u4985"><ce:para id="p7220">Moxifloxacin</ce:para></ce:list-item><ce:list-item id="u4990"><ce:para id="p7225">Gatifloxacin</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Haemophilus influenzae</ce:italic></ce:bold></entry><entry align="left"><ce:list id="ulist1745"><ce:list-item id="u4995"><ce:para id="p7230">Cefotaxime 2 g IV 4 times daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u5000"><ce:para id="p7235">Ceftriaxone 2 g IV twice daily for 10–14 days</ce:para></ce:list-item></ce:list></entry><entry align="left">Chloramphenicol<ce:cross-ref id="crf1335" refid="tn0060">*</ce:cross-ref></entry></row><row rowsep="1"><entry align="left"><ce:bold><ce:italic>Listeria monocytogenes</ce:italic></ce:bold></entry><entry align="left"><ce:list id="ulist1750"><ce:list-item id="u5005"><ce:para id="p7240">Ampicillin 2 g IV 6 times daily <ce:italic>plus</ce:italic></ce:para></ce:list-item><ce:list-item id="u5010"><ce:para id="p7245">Gentamicin 5 mg/kg IV daily</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1755"><ce:list-item id="u5015"><ce:para id="p7250">Ampicillin 2 g IV 4-hourly <ce:italic>plus</ce:italic></ce:para></ce:list-item><ce:list-item id="u5020"><ce:para id="p7255">Co-trimoxazole 60–120 mg/kg daily in four divided doses</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold><ce:italic>Streptococcus suis</ce:italic></ce:bold></entry><entry align="left"><ce:list id="ulist1760"><ce:list-item id="u5025"><ce:para id="p7260">Cefotaxime 2 g IV 4 times daily <ce:italic>or</ce:italic></ce:para></ce:list-item><ce:list-item id="u5030"><ce:para id="p7265">Ceftriaxone 2 g IV twice daily for 10–14 days</ce:para></ce:list-item></ce:list></entry><entry align="left">Chloramphenicol<ce:cross-ref id="crf1340" refid="tn0060">*</ce:cross-ref></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0355">(MIC = minimum inhibitory concentration)</ce:simple-para></ce:legend><ce:table-footnote id="tn0060"><ce:label>*</ce:label><ce:note-para id="np0080">For patients with a history of anaphylaxis to β-lactam antibiotics.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0355" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9325" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1165" role="short">Image 66</ce:alt-text></ce:inline-figure> 25.67</ce:label><ce:alt-text id="atte1170" role="short">25.67</ce:alt-text><ce:textbox-head><ce:title id="tit0360">Chemoprophylaxis following meningococcal exposure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1380"><ce:section-title id="st1335">Close contacts warranting chemoprophylaxis</ce:section-title><ce:para id="p7280"><ce:list id="ulist1765"><ce:list-item id="u5035"><ce:label>•</ce:label><ce:para id="p7285">Household contacts (including persons who ate or slept in the same dwelling as the patient during the 7 days prior to disease onset)</ce:para></ce:list-item><ce:list-item id="u5040"><ce:label>•</ce:label><ce:para id="p7290">Child-care and nursery-school contacts</ce:para></ce:list-item><ce:list-item id="u5045"><ce:label>•</ce:label><ce:para id="p7295">Persons having contact with patient's oral secretions during the 7 days prior to disease onset:<ce:list id="ulist1770"><ce:list-item id="u5050"><ce:para id="p7300">Kissing</ce:para></ce:list-item><ce:list-item id="u5055"><ce:para id="p7305">Sharing of toothbrushes</ce:para></ce:list-item><ce:list-item id="u5060"><ce:para id="p7310">Sharing of eating utensils</ce:para></ce:list-item><ce:list-item id="u5065"><ce:para id="p7315">Mouth-to-mouth resuscitation</ce:para></ce:list-item><ce:list-item id="u5070"><ce:para id="p7320">Unprotected contact during endotracheal intubation</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u5075"><ce:label>•</ce:label><ce:para id="p7325">Aircraft contacts for persons seated next to the patient for &#x003E; 8 hrs</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1385"><ce:section-title id="st1340">Persons at low risk in whom chemoprophylaxis is not recommended</ce:section-title><ce:para id="p7330"><ce:list id="ulist1775"><ce:list-item id="u5080"><ce:label>•</ce:label><ce:para id="p7335">Casual contact (e.g. at school or work) without direct exposure to patient's oral secretions</ce:para></ce:list-item><ce:list-item id="u5085"><ce:label>•</ce:label><ce:para id="p7340">Indirect contact only (contact with a high-risk contact and not a case)</ce:para></ce:list-item><ce:list-item id="u5090"><ce:label>•</ce:label><ce:para id="p7345">Health-care worker without direct exposure to patient's oral secretions</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0360" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9330" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1175" role="short">Image 67</ce:alt-text></ce:inline-figure> 25.68</ce:label><ce:alt-text id="atte1180" role="short">25.68</ce:alt-text><ce:textbox-head><ce:title id="tit0365">Clinical features and staging of tuberculous meningitis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7365"><ce:display><ce:table frame="topbot" id="t0250"><ce:alt-text id="atte1185" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Symptoms</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1780"><ce:list-item id="u5095"><ce:label>•</ce:label><ce:para id="p7370">Headache</ce:para></ce:list-item><ce:list-item id="u5100"><ce:label>•</ce:label><ce:para id="p7375">Vomiting</ce:para></ce:list-item><ce:list-item id="u5105"><ce:label>•</ce:label><ce:para id="p7380">Low-grade fever</ce:para></ce:list-item><ce:list-item id="u5110"><ce:label>•</ce:label><ce:para id="p7385">Lassitude</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1785"><ce:list-item id="u5115"><ce:label>•</ce:label><ce:para id="p7390">Depression</ce:para></ce:list-item><ce:list-item id="u5120"><ce:label>•</ce:label><ce:para id="p10250">Delirium</ce:para></ce:list-item><ce:list-item id="u5125"><ce:label>•</ce:label><ce:para id="p7400">Behaviour changes</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Signs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist1790"><ce:list-item id="u5130"><ce:label>•</ce:label><ce:para id="p7405">Meningism (may be absent)</ce:para></ce:list-item><ce:list-item id="u5135"><ce:label>•</ce:label><ce:para id="p7410">Oculomotor palsies</ce:para></ce:list-item><ce:list-item id="u5140"><ce:label>•</ce:label><ce:para id="p7415">Papilloedema</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1795"><ce:list-item id="u5145"><ce:label>•</ce:label><ce:para id="p7420">Depression of conscious level</ce:para></ce:list-item><ce:list-item id="u5150"><ce:label>•</ce:label><ce:para id="p7425">Focal hemisphere signs</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Staging of severity</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist1800"><ce:list-item id="u5155"><ce:label>•</ce:label><ce:para id="p7430">Stage I (early): non-specific symptoms and signs without alteration of consciousness</ce:para></ce:list-item><ce:list-item id="u5160"><ce:label>•</ce:label><ce:para id="p7435">Stage II (intermediate): altered consciousness without coma or delirium <ce:italic>plus</ce:italic> minor focal neurological signs</ce:para></ce:list-item><ce:list-item id="u5165"><ce:label>•</ce:label><ce:para id="p7440">Stage III (advanced): stupor or coma, severe neurological deficits, seizures or abnormal movements</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0365" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9470" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1190" role="short">Image 68</ce:alt-text></ce:inline-figure> 25.69</ce:label><ce:alt-text id="atte1195" role="short">25.69</ce:alt-text><ce:textbox-head><ce:title id="tit9000">Antibiotic treatment of cerebral abscess</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p10255"><ce:display><ce:table frame="topbot" id="t9000"><ce:alt-text id="atte1200" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Likely source of infection</entry><entry align="left">Typical site(s) of abscess</entry><entry align="left">Likely target organisms</entry><entry align="left">Appropriate antibiotic treatment<ce:cross-ref id="crf9020" refid="tn9000">*</ce:cross-ref></entry></row></thead><tbody><row rowsep="1"><entry align="left">Paranasal and sphenoid sinuses, dental infection</entry><entry align="left">Frontal lobe, cerebellum</entry><entry align="left">Streptococci, <ce:italic>Haemophilus</ce:italic> spp., <ce:italic>Enterobacterales</ce:italic>, <ce:italic>Fusarium</ce:italic> spp., other anaerobes</entry><entry align="left">Ceftriaxone 2 g IV 12-hourly <ce:italic>and</ce:italic> metronidazole 500 mg IV 8-hourly.<ce:br/>MRSA positive add vancomycin IV</entry></row><row rowsep="1"><entry align="left">Middle ear, mastoid sinuses</entry><entry align="left">Temporal lobe, cerebellum</entry><entry align="left">As above plus <ce:italic>Pseudomonas aeruginosa</ce:italic></entry><entry align="left">Ceftazidime<ce:cross-ref id="crf9025" refid="tn9005">**</ce:cross-ref> 2 g IV 8-hourly <ce:italic>and</ce:italic> metronidazole 500 mg IV 8-hourly.<ce:br/>MRSA positive add vancomycin IV</entry></row><row rowsep="1"><entry align="left">Penetrating trauma</entry><entry align="left">Any site</entry><entry align="left"><ce:italic>Staph. aureus</ce:italic> (including MRSA), streptococci, <ce:italic>Enterobacterales, Pseudomonas aeruginosa</ce:italic></entry><entry align="left">Ceftazidime 2 g IV 8-hourly <ce:italic>and</ce:italic> metronidazole 500 mg IV 8-hourly <ce:italic>and</ce:italic> vancomycin IV</entry></row><row rowsep="1"><entry align="left">Post-operative</entry><entry align="left">Any site</entry><entry align="left"><ce:italic>Staph. aureus</ce:italic> (including MRSA), coagulase-negative staphylococci, streptococci, <ce:italic>Cutibacterium acnes</ce:italic>, <ce:italic>Enterobacterales</ce:italic>, <ce:italic>Pseudomonas aeruginosa</ce:italic></entry><entry align="left">Ceftazidime 2 g IV 8-hourly <ce:italic>and</ce:italic> metronidazole 500 mg IV 8-hourly <ce:italic>and</ce:italic> vancomycin IV</entry></row><row rowsep="1"><entry align="left">Unknown source</entry><entry align="left">Any site</entry><entry align="left">As above plus non-bacterial organisms<ce:cross-ref id="crf9030" refid="tn9010">***</ce:cross-ref></entry><entry align="left">Ceftazidime 2 g IV 8-hourly <ce:italic>and</ce:italic> metronidazole 500 mg IV 8-hourly <ce:italic>and</ce:italic> vancomycin IV</entry></row><row><entry align="left">Haematogenous spread</entry><entry align="left">Any site</entry><entry align="left">Depends on source e.g. infective endocarditis (streptococci), septic thrombophlebitis (<ce:italic>Staph. aureus including MRSA</ce:italic>), intra-abdominal infection (<ce:italic>Enterobacterales</ce:italic>, anaerobes) etc.</entry><entry align="left">Depends on source and likely causative organism(s) from that source. Initial empiric therapy: ceftriaxone 2 g IV 12-hourly <ce:italic>and</ce:italic> metronidazole 500 mg IV 8-hourly <ce:italic>and</ce:italic> vancomycin IV</entry></row></tbody></tgroup><ce:table-footnote id="tn9000"><ce:label>*</ce:label><ce:note-para id="np9005">Antibiotic choice should be determined by the likely organisms, local antibiotic resistance patterns, local guidelines and the patient's microbiological and antibiotic history. There are no universally accepted antibiotic guidelines for cerebral abscess and these recommendations will not cover all the possible pathogens.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn9005"><ce:label>**</ce:label><ce:note-para id="np9010">Meropenem 2 g IV 8-hourly may be substituted.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn9010"><ce:label>***</ce:label><ce:note-para id="np9015">Because of the wide spectrum of organisms that can cause cerebral abscesses establishing the causative organism is critical.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0370" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9340" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1205" role="short">Image 69</ce:alt-text></ce:inline-figure> 25.70</ce:label><ce:alt-text id="atte1210" role="short">25.70</ce:alt-text><ce:textbox-head><ce:title id="tit0375">Clinical and pathological features of neurosyphilis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p7770"><ce:display><ce:table frame="topbot" id="t0260"><ce:alt-text id="atte1215" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Type and interval from primary infection</entry><entry align="left">Pathology</entry><entry align="left">Clinical features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Meningovascular</ce:bold> (5 years)*</entry><entry align="left"><ce:list id="ulist1850"><ce:list-item id="u5275"><ce:para id="p7775">Endarteritis obliterans</ce:para></ce:list-item><ce:list-item id="u5280"><ce:para id="p7780">Meningeal exudate</ce:para></ce:list-item><ce:list-item id="u5285"><ce:para id="p7785">Granuloma (gumma)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1855"><ce:list-item id="u5290"><ce:para id="p7790">Stroke</ce:para></ce:list-item><ce:list-item id="u5295"><ce:para id="p7795">Cranial nerve palsies</ce:para></ce:list-item><ce:list-item id="u5300"><ce:para id="p7800">Seizures/mass lesion</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>General paralysis of the insane</ce:bold> (5–15 years)*</entry><entry align="left"><ce:list id="ulist1860"><ce:list-item id="u5305"><ce:para id="p7805">Degeneration in cerebral cortex/cerebral atrophy</ce:para></ce:list-item><ce:list-item id="u5310"><ce:para id="p7810">Thickened meninges</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1865"><ce:list-item id="u5315"><ce:para id="p7815">Dementia</ce:para></ce:list-item><ce:list-item id="u5320"><ce:para id="p7820">Tremor</ce:para></ce:list-item><ce:list-item id="u5325"><ce:para id="p7825">Bilateral upper motor signs</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Tabes dorsalis</ce:bold> (5–20 years)*</entry><entry align="left"><ce:list id="ulist1870"><ce:list-item id="u5330"><ce:para id="p7830">Degeneration of sensory neurons</ce:para></ce:list-item><ce:list-item id="u5335"><ce:para id="p7835">Wasting of dorsal columns</ce:para></ce:list-item><ce:list-item id="u5340"><ce:para id="p7840">Optic atrophy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1875"><ce:list-item id="u5345"><ce:para id="p7845">Lightning pains</ce:para></ce:list-item><ce:list-item id="u5350"><ce:para id="p7850">Sensory ataxia</ce:para></ce:list-item><ce:list-item id="u5355"><ce:para id="p7855">Visual failure</ce:para></ce:list-item><ce:list-item id="u5360"><ce:para id="p7860">Abdominal crises</ce:para></ce:list-item><ce:list-item id="u5365"><ce:para id="p7865">Incontinence</ce:para></ce:list-item><ce:list-item id="u5370"><ce:para id="p7870">Trophic changes</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Any of the above</ce:bold></entry><entry align="left"/><entry align="left">Argyll Robertson pupils (p. 1092)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0375" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9345" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1220" role="short">Image 70</ce:alt-text></ce:inline-figure> 25.71</ce:label><ce:alt-text id="atte1225" role="short">25.71</ce:alt-text><ce:textbox-head><ce:title id="tit0380">Treatment of tetanus</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1630"><ce:section-title id="st1585">Neutralise absorbed toxin</ce:section-title><ce:para id="p7925"><ce:list id="ulist1880"><ce:list-item id="u5375"><ce:label>•</ce:label><ce:para id="p7930">Give IV injection of 3000 IU of human tetanus antitoxin</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1635"><ce:section-title id="st1590">Prevent further toxin production</ce:section-title><ce:para id="p7935"><ce:list id="ulist1885"><ce:list-item id="u5380"><ce:label>•</ce:label><ce:para id="p7940">Débride wound</ce:para></ce:list-item><ce:list-item id="u5385"><ce:label>•</ce:label><ce:para id="p7945">Give benzylpenicillin 600 mg IV 4 times daily (metronidazole if patient is allergic to penicillin)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1640"><ce:section-title id="st1595">Control spasms</ce:section-title><ce:para id="p7950"><ce:list id="ulist1890"><ce:list-item id="u5390"><ce:label>•</ce:label><ce:para id="p7955">Nurse in a quiet room</ce:para></ce:list-item><ce:list-item id="u5395"><ce:label>•</ce:label><ce:para id="p7960">Avoid unnecessary stimuli</ce:para></ce:list-item><ce:list-item id="u5400"><ce:label>•</ce:label><ce:para id="p7965">Give IV diazepam</ce:para></ce:list-item><ce:list-item id="u5405"><ce:label>•</ce:label><ce:para id="p7970">If spasms continue, paralyse patient and ventilate</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1645"><ce:section-title id="st1600">General measures</ce:section-title><ce:para id="p7975"><ce:list id="ulist1895"><ce:list-item id="u5410"><ce:label>•</ce:label><ce:para id="p7980">Maintain hydration and nutrition</ce:para></ce:list-item><ce:list-item id="u5415"><ce:label>•</ce:label><ce:para id="p7985">Treat secondary infections</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0380" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9350" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1230" role="short">Image 71</ce:alt-text></ce:inline-figure> 25.72</ce:label><ce:alt-text id="atte1235" role="short">25.72</ce:alt-text><ce:textbox-head><ce:title id="tit0385">US Centers for Disease Control (CDC) definition of botulism</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1660"><ce:section-title id="st1615">Three main syndromes</ce:section-title><ce:para id="p8010"><ce:list id="ulist1900"><ce:list-item id="u5420"><ce:label>•</ce:label><ce:para id="p8015">Infantile</ce:para></ce:list-item><ce:list-item id="u5425"><ce:label>•</ce:label><ce:para id="p8020">Food-borne</ce:para></ce:list-item><ce:list-item id="u5430"><ce:label>•</ce:label><ce:para id="p8025">Wound infection</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1665"><ce:section-title id="st1620">Clinical features</ce:section-title><ce:para id="p8030"><ce:list id="ulist1905"><ce:list-item id="u5435"><ce:label>•</ce:label><ce:para id="p8035">Absence of fever</ce:para></ce:list-item><ce:list-item id="u5440"><ce:label>•</ce:label><ce:para id="p8040">Symmetrical neurological deficits</ce:para></ce:list-item><ce:list-item id="u5445"><ce:label>•</ce:label><ce:para id="p8045">Patient remains responsive</ce:para></ce:list-item><ce:list-item id="u5450"><ce:label>•</ce:label><ce:para id="p8050">Normal or slow heart rate and normal blood pressure</ce:para></ce:list-item><ce:list-item id="u5455"><ce:label>•</ce:label><ce:para id="p8055">No sensory deficits with the exception of blurred vision</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0385" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9355" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1240" role="short">Image 72</ce:alt-text></ce:inline-figure> 25.73</ce:label><ce:alt-text id="atte1245" role="short">25.73</ce:alt-text><ce:textbox-head><ce:title id="tit0390">Prion diseases affecting humans</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p8075"><ce:display><ce:table frame="topbot" id="t0265"><ce:alt-text id="atte1250" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Mechanism</entry></row></thead><tbody><row rowsep="0"><entry align="left"><ce:bold>Creutzfeldt–Jakob disease</ce:bold></entry><entry align="left"/></row><row rowsep="0"><entry align="left">Sporadic</entry><entry align="left">Unknown: spontaneous PrP<ce:sup loc="post">C</ce:sup> to PrP<ce:sup loc="post">SC</ce:sup> conversion or somatic mutation</entry></row><row rowsep="0"><entry align="left">Familial</entry><entry align="left">Genetic: mutations in the <ce:italic>PrP</ce:italic> gene</entry></row><row rowsep="1"><entry align="left">Variant</entry><entry align="left">Dietary ingestion: infection from bovine spongiform encephalopathy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gerstmann–Sträussler–Scheinker disease</ce:bold></entry><entry align="left">Genetic: mutations in the <ce:italic>PrP</ce:italic> gene</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fatal familial insomnia</ce:bold></entry><entry align="left">Genetic: mutations in the <ce:italic>PrP</ce:italic> gene</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sporadic fatal insomnia</ce:bold></entry><entry align="left">Genetic: spontaneous PrP<ce:sup loc="post">C</ce:sup> to PrP<ce:sup loc="post">SC</ce:sup> conversion or somatic mutation</entry></row><row><entry align="left"><ce:bold>Kuru</ce:bold></entry><entry align="left">Dietary: ingestion of affected human brain</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0390" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9360" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1255" role="short">Image 73</ce:alt-text></ce:inline-figure> 25.74</ce:label><ce:alt-text id="atte1260" role="short">25.74</ce:alt-text><ce:textbox-head><ce:title id="tit0395">Common causes of raised intracranial pressure</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1690"><ce:section-title id="st1645">Mass lesions</ce:section-title><ce:para id="p8100"><ce:list id="ulist1910"><ce:list-item id="u5460"><ce:label>•</ce:label><ce:para id="p8105">Intracranial haemorrhage (traumatic or spontaneous):<ce:list id="ulist1915"><ce:list-item id="u5465"><ce:para id="p8110">Extradural haematoma</ce:para></ce:list-item><ce:list-item id="u5470"><ce:para id="p8115">Subdural haematoma</ce:para></ce:list-item><ce:list-item id="u5475"><ce:para id="p8120">Intracerebral haemorrhage</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u5480"><ce:label>•</ce:label><ce:para id="p8125">Cerebral tumour (particularly posterior fossa lesions or high-grade gliomas: see <ce:cross-ref id="crf1430" refid="b0400">Box 25.76</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u5485"><ce:label>•</ce:label><ce:para id="p8130">Infective:<ce:list id="ulist1920"><ce:list-item id="u5490"><ce:para id="p8135">Cerebral abscess</ce:para></ce:list-item><ce:list-item id="u5495"><ce:para id="p8140">Tuberculoma</ce:para></ce:list-item><ce:list-item id="u5500"><ce:para id="p8145">Cysticercosis (<ce:intra-ref id="ii0940" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2750">p. 298</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u5505"><ce:para id="p8150">Hydatid cyst (<ce:intra-ref id="ii0945" xlink:href="pii:B978-0-7020-7028-0.00011-1#p7825">p. 299</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u5510"><ce:label>•</ce:label><ce:para id="p8155">Colloid cyst (in ventricles)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1695"><ce:section-title id="st1650">Disturbance of cerebrospinal fluid circulation</ce:section-title><ce:para id="p8160"><ce:list id="ulist1925"><ce:list-item id="u5515"><ce:label>•</ce:label><ce:para id="p8165">Obstructive (non-communicating) hydrocephalus: obstruction within ventricular system</ce:para></ce:list-item><ce:list-item id="u5520"><ce:label>•</ce:label><ce:para id="p8170">Communicating hydrocephalus: site of obstruction outside ventricular system</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1700"><ce:section-title id="st1655">Obstruction to venous sinuses</ce:section-title><ce:para id="p8175"><ce:list id="ulist1930"><ce:list-item id="u5525"><ce:label>•</ce:label><ce:para id="p8180">Cerebral venous thrombosis</ce:para></ce:list-item><ce:list-item id="u5530"><ce:label>•</ce:label><ce:para id="p8185">Trauma (depressed fractures overlying sinuses)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1705"><ce:section-title id="st1660">Diffuse brain oedema or swelling</ce:section-title><ce:para id="p8190"><ce:list id="ulist1935"><ce:list-item id="u5535"><ce:label>•</ce:label><ce:para id="p8195">Meningo-encephalitis</ce:para></ce:list-item><ce:list-item id="u5540"><ce:label>•</ce:label><ce:para id="p8200">Trauma (diffuse head injury, near-drowning)</ce:para></ce:list-item><ce:list-item id="u5545"><ce:label>•</ce:label><ce:para id="p8205">Subarachnoid haemorrhage</ce:para></ce:list-item><ce:list-item id="u5550"><ce:label>•</ce:label><ce:para id="p8210">Metabolic (e.g. water intoxication)</ce:para></ce:list-item><ce:list-item id="u5555"><ce:label>•</ce:label><ce:para id="p8215">Idiopathic intracranial hypertension</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0395" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9365" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1265" role="short">Image 74</ce:alt-text></ce:inline-figure> 25.75</ce:label><ce:alt-text id="atte1270" role="short">25.75</ce:alt-text><ce:textbox-head><ce:title id="tit0400">Clinical features of intracranial mass lesions</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p8230"><ce:display><ce:table frame="topbot" id="t0270"><ce:alt-text id="atte1275" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Presentation</entry><entry align="left">Features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Seizures</ce:bold></entry><entry align="left">Focal onset ± generalised spread</entry></row><row rowsep="1"><entry align="left"><ce:bold>Focal symptoms</ce:bold></entry><entry align="left"><ce:list id="ulist1940"><ce:list-item id="u5560"><ce:para id="p8235">Progressive loss of function</ce:para></ce:list-item><ce:list-item id="u5565"><ce:para id="p8240">Weakness</ce:para></ce:list-item><ce:list-item id="u5570"><ce:para id="p8245">Numbness</ce:para></ce:list-item><ce:list-item id="u5575"><ce:para id="p8250">Dysphasia</ce:para></ce:list-item><ce:list-item id="u5580"><ce:para id="p8255">Cranial neuropathy</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>False localising signs</ce:bold></entry><entry align="left"><ce:list id="ulist1945"><ce:list-item id="u5585"><ce:para id="p8260">Unilateral/bilateral 6th nerve palsies</ce:para></ce:list-item><ce:list-item id="u5590"><ce:para id="p8265">Contralateral 3rd nerve (usually pupil first)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Raised intracranial pressure</ce:bold> (usually aggressive tumours causing vasogenic oedema or obstructive hydrocephalus)</entry><entry align="left"><ce:list id="ulist1950"><ce:list-item id="u5595"><ce:para id="p8270">Headache worse on lying/straining</ce:para></ce:list-item><ce:list-item id="u5600"><ce:para id="p8275">Vomiting</ce:para></ce:list-item><ce:list-item id="u5605"><ce:para id="p8280">Diplopia (6th nerve involvement)</ce:para></ce:list-item><ce:list-item id="u5610"><ce:para id="p8285">Papilloedema</ce:para></ce:list-item><ce:list-item id="u5615"><ce:para id="p8290">Bradycardia, raised blood pressure</ce:para></ce:list-item><ce:list-item id="u5620"><ce:para id="p8295">Impaired conscious level</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Stroke/TIA-like symptoms</ce:bold></entry><entry align="left"><ce:list id="ulist1955"><ce:list-item id="u5625"><ce:para id="p8300">Acute haemorrhage into tumour</ce:para></ce:list-item><ce:list-item id="u5630"><ce:para id="p8305">Paroxysmal ‘tumour attacks’</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Cognitive/behavioural change</ce:bold></entry><entry align="left">Usually frontal mass lesions</entry></row><row rowsep="1"><entry align="left"><ce:bold>Endocrine abnormalities</ce:bold></entry><entry align="left">Pituitary tumours</entry></row><row><entry align="left"><ce:bold>Incidental finding</ce:bold></entry><entry align="left">Asymptomatic but identified on imaging (meningiomas commonly)</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0390">(TIA = transient ischaemic attack)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0400" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9370" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1280" role="short">Image 75</ce:alt-text></ce:inline-figure> 25.76</ce:label><ce:alt-text id="atte1285" role="short">25.76</ce:alt-text><ce:textbox-head><ce:title id="tit0405">Primary brain tumours</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p8330"><ce:display><ce:table frame="topbot" id="t0275"><ce:alt-text id="atte1290" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Histological type</entry><entry align="left">Common site</entry><entry align="left">Age</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Malignant</ce:bold></entry></row><row rowsep="0"><entry align="left">Glioma (astrocytoma)</entry><entry align="left"><ce:list id="ulist1960"><ce:list-item id="u5635"><ce:para id="p8335">Cerebral hemisphere</ce:para></ce:list-item><ce:list-item id="u5640"><ce:para id="p8340">Cerebellum</ce:para></ce:list-item><ce:list-item id="u5645"><ce:para id="p8345">Brainstem</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1965"><ce:list-item id="u5650"><ce:para id="p8350">Adulthood</ce:para></ce:list-item><ce:list-item id="u5655"><ce:para id="p8355">Childhood/adulthood</ce:para></ce:list-item><ce:list-item id="u5660"><ce:para id="p8360">Childhood/young adulthood</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Oligodendroglioma</entry><entry align="left">Cerebral hemisphere</entry><entry align="left">Adulthood</entry></row><row rowsep="0"><entry align="left">Medulloblastoma</entry><entry align="left">Posterior fossa</entry><entry align="left">Childhood</entry></row><row rowsep="0"><entry align="left">Ependymoma</entry><entry align="left">Posterior fossa</entry><entry align="left">Childhood/adolescence</entry></row><row rowsep="1"><entry align="left">Cerebral lymphoma</entry><entry align="left">Cerebral hemisphere</entry><entry align="left">Adulthood</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Benign</ce:bold></entry></row><row rowsep="0"><entry align="left">Meningioma</entry><entry align="left"><ce:list id="ulist1970"><ce:list-item id="u5665"><ce:para id="p8365">Cortical dura</ce:para></ce:list-item><ce:list-item id="u5670"><ce:para id="p8370">Parasagittal</ce:para></ce:list-item><ce:list-item id="u5675"><ce:para id="p8375">Sphenoid ridge</ce:para></ce:list-item><ce:list-item id="u5680"><ce:para id="p8380">Suprasellar</ce:para></ce:list-item><ce:list-item id="u5685"><ce:para id="p8385">Olfactory groove</ce:para></ce:list-item></ce:list></entry><entry align="left">Adulthood (often incidental finding)</entry></row><row rowsep="0"><entry align="left">Neurofibroma</entry><entry align="left">Acoustic neuroma</entry><entry align="left">Adulthood</entry></row><row rowsep="0"><entry align="left">Craniopharyngioma</entry><entry align="left">Suprasellar</entry><entry align="left">Childhood/adolescence</entry></row><row rowsep="0"><entry align="left">Pituitary adenoma</entry><entry align="left">Pituitary fossa</entry><entry align="left">Adulthood</entry></row><row rowsep="0"><entry align="left">Colloid cyst</entry><entry align="left">Third ventricle</entry><entry align="left">Any age</entry></row><row><entry align="left">Pineal tumours</entry><entry align="left">Quadrigeminal cistern</entry><entry align="left"><ce:list id="ulist1975"><ce:list-item id="u5690"><ce:para id="p8390">Childhood (teratomas)</ce:para></ce:list-item><ce:list-item id="u5695"><ce:para id="p8395">Young adulthood (germ cell)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0405" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9375" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1295" role="short">Image 76</ce:alt-text></ce:inline-figure> 25.77</ce:label><ce:alt-text id="atte1300" role="short">25.77</ce:alt-text><ce:textbox-head><ce:title id="tit0410">Neurofibromatosis types 1 and 2: clinical features</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p8500"><ce:display><ce:table frame="topbot" id="t0280"><ce:alt-text id="atte1305" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Neurofibromatosis 1</entry><entry align="left">Neurofibromatosis 2</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Skin</ce:bold></entry></row><row rowsep="1"><entry align="left"><ce:list id="ulist1980"><ce:list-item id="u5700"><ce:para id="p8505">Cutaneous/subcutaneous neurofibromas</ce:para></ce:list-item><ce:list-item id="u5705"><ce:para id="p8510">Angiomas</ce:para></ce:list-item><ce:list-item id="u5710"><ce:para id="p8515">Café au lait patches (&#x003E; 6)</ce:para></ce:list-item><ce:list-item id="u5715"><ce:para id="p8520">Axillary/groin freckling</ce:para></ce:list-item><ce:list-item id="u5720"><ce:para id="p8525">Hypopigmented patches</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1985"><ce:list-item id="u5725"><ce:para id="p8530">Much less commonly affected than in NF1</ce:para></ce:list-item><ce:list-item id="u5730"><ce:para id="p8535">Café au lait patches (usually &#x003C; 6)</ce:para></ce:list-item><ce:list-item id="u5735"><ce:para id="p8540">Cutaneous schwannomas: plaque lesions</ce:para></ce:list-item><ce:list-item id="u5740"><ce:para id="p8545">Subcutaneous schwannomas</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Eyes</ce:bold></entry></row><row rowsep="1"><entry align="left"><ce:list id="ulist1990"><ce:list-item id="u5745"><ce:para id="p8550">Lisch nodules (iris fibromas)</ce:para></ce:list-item><ce:list-item id="u5750"><ce:para id="p8555">Glaucoma</ce:para></ce:list-item><ce:list-item id="u5755"><ce:para id="p8560">Congenital ptosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist1995"><ce:list-item id="u5760"><ce:para id="p8565">Cataracts</ce:para></ce:list-item><ce:list-item id="u5765"><ce:para id="p8570">Retinal hamartoma</ce:para></ce:list-item><ce:list-item id="u5770"><ce:para id="p8575">Optic nerve meningioma</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Nervous system</ce:bold></entry></row><row rowsep="1"><entry align="left"><ce:list id="ulist2000"><ce:list-item id="u5775"><ce:para id="p8580">Plexiform neurofibromas</ce:para></ce:list-item><ce:list-item id="u5780"><ce:para id="p8585">Malignant peripheral nerve sheath tumours</ce:para></ce:list-item><ce:list-item id="u5785"><ce:para id="p8590">Aqueduct stenosis</ce:para></ce:list-item><ce:list-item id="u5790"><ce:para id="p8595">Slight tonsillar descent</ce:para></ce:list-item><ce:list-item id="u5795"><ce:para id="p8600">Cognitive impairment</ce:para></ce:list-item><ce:list-item id="u5800"><ce:para id="p8605">Epilepsy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2005"><ce:list-item id="u5805"><ce:para id="p8610">Vestibular schwannomas</ce:para></ce:list-item><ce:list-item id="u5810"><ce:para id="p8615">Cranial nerve schwannomas (not 1 and 2)</ce:para></ce:list-item><ce:list-item id="u5815"><ce:para id="p8620">Spinal schwannomas</ce:para></ce:list-item><ce:list-item id="u5820"><ce:para id="p8625">Peripheral nerve schwannomas</ce:para></ce:list-item><ce:list-item id="u5825"><ce:para id="p8630">Cranial meningiomas</ce:para></ce:list-item><ce:list-item id="u5830"><ce:para id="p8635">Spinal meningiomas</ce:para></ce:list-item><ce:list-item id="u5835"><ce:para id="p8640">Spinal/brainstem ependymomas</ce:para></ce:list-item><ce:list-item id="u5840"><ce:para id="p8645">Spinal/cranial astrocytoma</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Bone</ce:bold></entry></row><row rowsep="1"><entry align="left"><ce:list id="ulist2010"><ce:list-item id="u5845"><ce:para id="p8650">Scoliosis</ce:para></ce:list-item><ce:list-item id="u5850"><ce:para id="p8655">Osteoporosis</ce:para></ce:list-item><ce:list-item id="u5855"><ce:para id="p8660">Pseudoarthrosis</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Cardiorespiratory systems</ce:bold></entry></row><row rowsep="1"><entry align="left"><ce:list id="ulist2015"><ce:list-item id="u5860"><ce:para id="p8665">Pulmonary stenosis</ce:para></ce:list-item><ce:list-item id="u5865"><ce:para id="p8670">Hypertension</ce:para></ce:list-item><ce:list-item id="u5870"><ce:para id="p8675">Renal artery stenosis</ce:para></ce:list-item><ce:list-item id="u5875"><ce:para id="p8680">Compression from neurofibroma causing restrictive lung defect</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Gastrointestinal system</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist2020"><ce:list-item id="u5880"><ce:para id="p8685">Gastrointestinal stromal tumour (GIST)</ce:para></ce:list-item><ce:list-item id="u5885"><ce:para id="p8690">Duodenal/ampullary neuro-endocrine tumour</ce:para></ce:list-item></ce:list></entry><entry align="left"/></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0410" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9380" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1310" role="short">Image 77</ce:alt-text></ce:inline-figure> 25.78</ce:label><ce:alt-text id="atte1315" role="short">25.78</ce:alt-text><ce:textbox-head><ce:title id="tit0415">Causes of hydrocephalus</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p8710"><ce:display><ce:table frame="topbot" id="t0285"><ce:alt-text id="atte1320" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Congenital malformations</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2025"><ce:list-item id="u5890"><ce:label>•</ce:label><ce:para id="p8715">Aqueduct stenosis</ce:para></ce:list-item><ce:list-item id="u5895"><ce:label>•</ce:label><ce:para id="p8720">Chiari malformations</ce:para></ce:list-item><ce:list-item id="u5900"><ce:label>•</ce:label><ce:para id="p8725">Dandy–Walker syndrome</ce:para></ce:list-item><ce:list-item id="u5905"><ce:label>•</ce:label><ce:para id="p8730">Benign intracranial cysts</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2030"><ce:list-item id="u5910"><ce:label>•</ce:label><ce:para id="p8735">Vein of Galen aneurysms</ce:para></ce:list-item><ce:list-item id="u5915"><ce:label>•</ce:label><ce:para id="p8740">Congenital central nervous system infections</ce:para></ce:list-item><ce:list-item id="u5920"><ce:label>•</ce:label><ce:para id="p8745">Craniofacial anomalies</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Acquired causes</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist2035"><ce:list-item id="u5925"><ce:label>•</ce:label><ce:para id="p8750">Mass lesions (especially those in the posterior fossa)</ce:para></ce:list-item><ce:list-item id="u5930"><ce:label>•</ce:label><ce:para id="p8755">Tumour</ce:para></ce:list-item><ce:list-item id="u5935"><ce:label>•</ce:label><ce:para id="p8760">Colloid cyst of third ventricle</ce:para></ce:list-item><ce:list-item id="u5940"><ce:label>•</ce:label><ce:para id="p8765">Abscess</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2040"><ce:list-item id="u5945"><ce:label>•</ce:label><ce:para id="p8770">Haematoma</ce:para></ce:list-item><ce:list-item id="u5950"><ce:label>•</ce:label><ce:para id="p8775">Absorption blockages due to:<ce:list id="ulist2045"><ce:list-item id="u5955"><ce:para id="p8780">Inflammation (e.g. meningitis, sarcoidosis)</ce:para></ce:list-item><ce:list-item id="u5960"><ce:para id="p8785">Intracranial haemorrhage</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0415" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9385" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1325" role="short">Image 78</ce:alt-text></ce:inline-figure> 25.79</ce:label><ce:alt-text id="atte1330" role="short">25.79</ce:alt-text><ce:textbox-head><ce:title id="tit0420">Causes of spinal cord compression</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p8965"><ce:display><ce:table frame="topbot" id="t0290"><ce:alt-text id="atte1335" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Site</entry><entry align="left">Frequency</entry><entry align="left">Causes</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Vertebral</ce:bold></entry><entry align="left">80%</entry><entry align="left"><ce:list id="ulist2050"><ce:list-item id="u5965"><ce:para id="p8970">Trauma (extradural)</ce:para></ce:list-item><ce:list-item id="u5970"><ce:para id="p8975">Intervertebral disc prolapse</ce:para></ce:list-item><ce:list-item id="u5975"><ce:para id="p8980">Metastatic carcinoma (e.g. breast, prostate, bronchus)</ce:para></ce:list-item><ce:list-item id="u5980"><ce:para id="p8985">Myeloma</ce:para></ce:list-item><ce:list-item id="u5985"><ce:para id="p8990">Tuberculosis</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Meninges (intradural, extramedullary)</ce:bold></entry><entry align="left">15%</entry><entry align="left"><ce:list id="ulist2055"><ce:list-item id="u5990"><ce:para id="p8995">Tumours (e.g. meningioma, neurofibroma, ependymoma, metastasis, lymphoma, leukaemia)</ce:para></ce:list-item><ce:list-item id="u5995"><ce:para id="p9000">Epidural abscess</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Spinal cord (intradural, intramedullary)</ce:bold></entry><entry align="left">5%</entry><entry align="left">Tumours (e.g. glioma, ependymoma, metastasis)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0420" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9390" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1340" role="short">Image 79</ce:alt-text></ce:inline-figure> 25.80</ce:label><ce:alt-text id="atte1345" role="short">25.80</ce:alt-text><ce:textbox-head><ce:title id="tit0425">Symptoms of spinal cord compression</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s1980"><ce:section-title id="st1915">Pain</ce:section-title><ce:para id="p9010"><ce:list id="ulist2060"><ce:list-item id="u6000"><ce:label>•</ce:label><ce:para id="p9015">Localised over the spine or in a root distribution, which may be aggravated by coughing, sneezing or straining</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1985"><ce:section-title id="st1920">Sensory</ce:section-title><ce:para id="p9020"><ce:list id="ulist2065"><ce:list-item id="u6005"><ce:label>•</ce:label><ce:para id="p9025">Paraesthesia, numbness or cold sensations, especially in the lower limbs, which spread proximally, often to a level on the trunk</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1990"><ce:section-title id="st1925">Motor</ce:section-title><ce:para id="p9030"><ce:list id="ulist2070"><ce:list-item id="u6010"><ce:label>•</ce:label><ce:para id="p9035">Weakness, heaviness or stiffness of the limbs, most commonly the legs</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s1995"><ce:section-title id="st1930">Sphincters</ce:section-title><ce:para id="p9040"><ce:list id="ulist2075"><ce:list-item id="u6015"><ce:label>•</ce:label><ce:para id="p9045">Urgency or hesitancy of micturition, leading eventually to urinary retention</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0425" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9395" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1350" role="short">Image 80</ce:alt-text></ce:inline-figure> 25.81</ce:label><ce:alt-text id="atte1355" role="short">25.81</ce:alt-text><ce:textbox-head><ce:title id="tit0430">Signs of spinal cord compression</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2000"><ce:section-title id="st1935">Cervical, above C5</ce:section-title><ce:para id="p9055"><ce:list id="ulist2080"><ce:list-item id="u6020"><ce:label>•</ce:label><ce:para id="p9060">Upper motor neuron signs and sensory loss in all four limbs</ce:para></ce:list-item><ce:list-item id="u6025"><ce:label>•</ce:label><ce:para id="p9065">Diaphragm weakness (phrenic nerve)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2005"><ce:section-title id="st1940">Cervical, C5–T1</ce:section-title><ce:para id="p9070"><ce:list id="ulist2085"><ce:list-item id="u6030"><ce:label>•</ce:label><ce:para id="p9075">Lower motor neuron signs and segmental sensory loss in the arms; upper motor neuron signs in the legs</ce:para></ce:list-item><ce:list-item id="u6035"><ce:label>•</ce:label><ce:para id="p9080">Respiratory (intercostal) muscle weakness</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2010"><ce:section-title id="st1945">Thoracic cord</ce:section-title><ce:para id="p9085"><ce:list id="ulist2090"><ce:list-item id="u6040"><ce:label>•</ce:label><ce:para id="p9090">Spastic paraplegia with a sensory level on the trunk</ce:para></ce:list-item><ce:list-item id="u6045"><ce:label>•</ce:label><ce:para id="p9095">Weakness of legs, sacral loss of sensation and extensor plantar responses</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2015"><ce:section-title id="st1950">Cauda equina</ce:section-title><ce:para id="p9100"><ce:list id="ulist2095"><ce:list-item id="u6050"><ce:label>•</ce:label><ce:para id="p9105">Spinal cord ends approximately at the T12/L1 spinal level and spinal lesions below this level can cause lower motor neuron signs only by affecting the cauda equina</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0430" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9400" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000251/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1360" role="short">Image 81</ce:alt-text></ce:inline-figure> 25.82</ce:label><ce:alt-text id="atte1365" role="short">25.82</ce:alt-text><ce:textbox-head><ce:title id="tit0435">Investigation of acute spinal cord syndrome</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9120"><ce:display><ce:table frame="topbot" id="t0295"><ce:alt-text id="atte1370" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row><entry align="left"><ce:list id="ulist2100"><ce:list-item id="u6055"><ce:label>•</ce:label><ce:para id="p9125">Magnetic resonance imaging of spine or myelography</ce:para></ce:list-item><ce:list-item id="u6060"><ce:label>•</ce:label><ce:para id="p9130">Plain X-rays of spine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2105"><ce:list-item id="u6065"><ce:label>•</ce:label><ce:para id="p9135">Chest X-ray</ce:para></ce:list-item><ce:list-item id="u6070"><ce:label>•</ce:label><ce:para id="p9140">Cerebrospinal fluid</ce:para></ce:list-item><ce:list-item id="u6075"><ce:label>•</ce:label><ce:para id="p9145">Serum vitamin B<ce:inf loc="post">12</ce:inf></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0435" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9405" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1375" role="short">Image 82</ce:alt-text></ce:inline-figure> 25.83</ce:label><ce:alt-text id="atte1380" role="short">25.83</ce:alt-text><ce:textbox-head><ce:title id="tit0440">Intrinsic diseases of the spinal cord</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9165"><ce:display><ce:table frame="topbot" id="t0300"><ce:alt-text id="atte1385" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Type of disorder</entry><entry align="left">Condition</entry><entry align="left">Clinical features</entry></row></thead><tbody><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Congenital</ce:bold></entry><entry rowsep="0" align="left">Diastematomyelia (spina bifida)</entry><entry rowsep="0" align="left"><ce:list id="ulist2110"><ce:list-item id="u6080"><ce:para id="p9170">Features variably present at birth and deteriorate thereafter</ce:para></ce:list-item><ce:list-item id="u6085"><ce:para id="p9175">LMN features, deformity and sensory loss of legs</ce:para></ce:list-item><ce:list-item id="u6090"><ce:para id="p9180">Impaired sphincter function</ce:para></ce:list-item><ce:list-item id="u6095"><ce:para id="p9185">Hairy patch or pit over low back</ce:para></ce:list-item><ce:list-item id="u6100"><ce:para id="p9190">Incidence reduced by increased maternal intake of folic acid during pregnancy</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Hereditary spastic paraplegia</entry><entry align="left"><ce:list id="ulist2115"><ce:list-item id="u6105"><ce:para id="p9195">Onset usually in adult life</ce:para></ce:list-item><ce:list-item id="u6110"><ce:para id="p9200">Autosomal dominant inheritance usual</ce:para></ce:list-item><ce:list-item id="u6115"><ce:para id="p9205">Slowly progressive UMN features affecting legs &#x003E; arms</ce:para></ce:list-item><ce:list-item id="u6120"><ce:para id="p9210">Little or no sensory loss</ce:para></ce:list-item></ce:list></entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Infective/inflammatory</ce:bold></entry><entry rowsep="0" align="left">Transverse myelitis due to viruses (HZV), schistosomiasis, HIV, MS, sarcoidosis</entry><entry rowsep="0" align="left"><ce:list id="ulist2120"><ce:list-item id="u6125"><ce:para id="p9215">Weakness and sensory loss, often with pain, developing over hours to days</ce:para></ce:list-item><ce:list-item id="u6130"><ce:para id="p9220">UMN features below lesion</ce:para></ce:list-item><ce:list-item id="u6135"><ce:para id="p9225">Impaired sphincter function</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Paraneoplastic</entry><entry align="left">May predate tumour diagnosis</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Vascular</ce:bold></entry><entry rowsep="0" align="left">Anterior spinal artery infarct due to atherosclerosis, aortic dissection, embolus</entry><entry rowsep="0" align="left"><ce:list id="ulist2125"><ce:list-item id="o9000"><ce:para id="p10245">Abrupt onset</ce:para></ce:list-item><ce:list-item id="u6140"><ce:para id="p9230">Anterior horn cell loss (LMN) at level of lesion</ce:para></ce:list-item><ce:list-item id="u6145"><ce:para id="p9235">UMN features below it</ce:para></ce:list-item><ce:list-item id="u6150"><ce:para id="p9240">Spinothalamic sensory loss below lesion but dorsal column sensation spared</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Spinal AVM/dural fistula</entry><entry align="left"><ce:list id="ulist2130"><ce:list-item id="u6155"><ce:para id="p9245">Onset variable (acute to slowly progressive)</ce:para></ce:list-item><ce:list-item id="u6160"><ce:para id="p9250">Variable LMN, UMN, sensory and sphincter disturbance</ce:para></ce:list-item><ce:list-item id="u6165"><ce:para id="p9255">Symptoms and signs often not well localised to site of AVM</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Neoplastic</ce:bold></entry><entry align="left">Glioma, ependymoma</entry><entry align="left"><ce:list id="ulist2135"><ce:list-item id="u6170"><ce:para id="p9260">Weakness and sensory loss often with pain, developing over months to years</ce:para></ce:list-item><ce:list-item id="u6175"><ce:para id="p9265">UMN features below lesion in cord; additional LMN features in conus</ce:para></ce:list-item><ce:list-item id="u6180"><ce:para id="p9270">Impaired sphincter function</ce:para></ce:list-item></ce:list></entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Metabolic</ce:bold></entry><entry rowsep="0" align="left">Vitamin B<ce:inf loc="post">12</ce:inf> deficiency (subacute combined degeneration)</entry><entry rowsep="0" align="left"><ce:list id="ulist2140"><ce:list-item id="u6185"><ce:para id="p9275">Progressive spastic paraparesis with proprioception loss</ce:para></ce:list-item><ce:list-item id="u6190"><ce:para id="p9280">Absent reflexes due to peripheral neuropathy</ce:para></ce:list-item><ce:list-item id="u6195"><ce:para id="p9285">± Optic nerve and cerebral involvement (<ce:intra-ref id="ii1005" xlink:href="pii:B978-0-7020-7028-0.00019-6#s0500">p. 715</ce:intra-ref>)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left">Copper deficiency</entry><entry align="left">Excess dietary zinc</entry></row><row rowsep="1"><entry align="left">Nitrous oxide toxicity</entry><entry align="left">Modifies vitamin B<ce:inf loc="post">12</ce:inf> metabolism</entry></row><row><entry morerows="1" align="left"><ce:bold>Degenerative</ce:bold></entry><entry rowsep="0" align="left">Motor neuron disease</entry><entry rowsep="0" align="left"><ce:list id="ulist2145"><ce:list-item id="u6200"><ce:para id="p9290">Relentlessly progressive LMN and UMN features, associated bulbar weakness</ce:para></ce:list-item><ce:list-item id="u6205"><ce:para id="p9295">No sensory involvement (p. 1116)</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left">Syringomyelia</entry><entry align="left"><ce:list id="ulist2150"><ce:list-item id="u6210"><ce:para id="p9300">Gradual onset over months or years, pain in cervical segments</ce:para></ce:list-item><ce:list-item id="u6215"><ce:para id="p9305">Anterior horn cell loss (LMN) at level of lesion, UMN features below it</ce:para></ce:list-item><ce:list-item id="u6220"><ce:para id="p9310">Suspended spinothalamic sensory loss at level of lesion, dorsal columns preserved (see <ce:cross-ref id="crf1600" refid="f0120">Figs 25.18F</ce:cross-ref> (p. 1084) and <ce:cross-ref id="crf1605" refid="f0285">25.51</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0490">(AVM = arteriovenous malformation; HIV = human immunodeficiency virus; HZV = herpes zoster virus; LMN = lower motor neuron; MS = multiple sclerosis; UMN = upper motor neuron)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0440" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9410" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1390" role="short">Image 83</ce:alt-text></ce:inline-figure> 25.84</ce:label><ce:alt-text id="atte1395" role="short">25.84</ce:alt-text><ce:textbox-head><ce:title id="tit0445">Causes of polyneuropathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9325"><ce:display><ce:table frame="topbot" id="t0305"><ce:alt-text id="atte1400" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Genetic</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist2155"><ce:list-item id="u6225"><ce:label>•</ce:label><ce:para id="p9330">Charcot–Marie–Tooth disease (CMT)</ce:para></ce:list-item><ce:list-item id="u6230"><ce:label>•</ce:label><ce:para id="p9335">Hereditary neuropathy with liability to pressure palsies (HNPP)</ce:para></ce:list-item><ce:list-item id="u6235"><ce:label>•</ce:label><ce:para id="p9340">Hereditary sensory ± autonomic neuropathies (HSN, HSAN)</ce:para></ce:list-item><ce:list-item id="u6240"><ce:label>•</ce:label><ce:para id="p9345">Familial amyloid polyneuropathy</ce:para></ce:list-item><ce:list-item id="u6245"><ce:label>•</ce:label><ce:para id="p9350">Hereditary neuralgic amyotrophy</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Drugs</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2160"><ce:list-item id="u6250"><ce:label>•</ce:label><ce:para id="p9355">Amiodarone</ce:para></ce:list-item><ce:list-item id="u6255"><ce:label>•</ce:label><ce:para id="p9360">Antibiotics (dapsone, isoniazid, metronidazole, ethambutol)</ce:para></ce:list-item><ce:list-item id="u6260"><ce:label>•</ce:label><ce:para id="p9365">Antiretrovirals</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2165"><ce:list-item id="u6265"><ce:label>•</ce:label><ce:para id="p9370">Chemotherapy (cisplatin, vincristine, thalidomide)</ce:para></ce:list-item><ce:list-item id="u6270"><ce:label>•</ce:label><ce:para id="p9375">Phenytoin</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Toxins</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2170"><ce:list-item id="u6275"><ce:label>•</ce:label><ce:para id="p9380">Alcohol</ce:para></ce:list-item><ce:list-item id="u6280"><ce:label>•</ce:label><ce:para id="p9385">Nitrous oxide (recreational use)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2175"><ce:list-item id="u6285"><ce:label>•</ce:label><ce:para id="p9390">Rarely: lead, arsenic, mercury, organophosphates, solvents</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Vitamin deficiencies</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2180"><ce:list-item id="u6290"><ce:label>•</ce:label><ce:para id="p9395">Thiamin</ce:para></ce:list-item><ce:list-item id="u6295"><ce:label>•</ce:label><ce:para id="p9400">Pyridoxine</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2185"><ce:list-item id="u6300"><ce:label>•</ce:label><ce:para id="p9405">Vitamin B<ce:inf loc="post">12</ce:inf></ce:para></ce:list-item><ce:list-item id="u6305"><ce:label>•</ce:label><ce:para id="p9410">Vitamin E</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Infections</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2190"><ce:list-item id="u6310"><ce:label>•</ce:label><ce:para id="p9415">HIV</ce:para></ce:list-item><ce:list-item id="u6315"><ce:label>•</ce:label><ce:para id="p9420">Leprosy</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2195"><ce:list-item id="u6320"><ce:label>•</ce:label><ce:para id="p9425">Brucellosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Inflammatory</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist2200"><ce:list-item id="u6325"><ce:label>•</ce:label><ce:para id="p9430">Guillain–Barré syndrome</ce:para></ce:list-item><ce:list-item id="u6330"><ce:label>•</ce:label><ce:para id="p9435">Chronic inflammatory demyelinating polyradiculoneuropathy</ce:para></ce:list-item><ce:list-item id="u6335"><ce:label>•</ce:label><ce:para id="p9440">Vasculitis (polyarteritis nodosa, granulomatosis with polyangiitis (also known as Wegener's granulomatosis), rheumatoid arthritis, systemic lupus erythematosus)</ce:para></ce:list-item><ce:list-item id="u6340"><ce:label>•</ce:label><ce:para id="p9445">Paraneoplastic (antibody-mediated)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Systemic medical conditions</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2205"><ce:list-item id="u6345"><ce:label>•</ce:label><ce:para id="p9450">Diabetes</ce:para></ce:list-item><ce:list-item id="u6350"><ce:label>•</ce:label><ce:para id="p9455">Renal failure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2210"><ce:list-item id="u6355"><ce:label>•</ce:label><ce:para id="p9460">Sarcoidosis</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Malignant disease</ce:bold></entry></row><row rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist2215"><ce:list-item id="u6360"><ce:label>•</ce:label><ce:para id="p9465">Infiltration</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Others</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist2220"><ce:list-item id="u6365"><ce:label>•</ce:label><ce:para id="p9470">Paraproteinaemias</ce:para></ce:list-item><ce:list-item id="u6370"><ce:label>•</ce:label><ce:para id="p9475">Amyloidosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2225"><ce:list-item id="u6375"><ce:label>•</ce:label><ce:para id="p9480">Critical illness polyneuropathy/myopathy</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0445" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9415" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1405" role="short">Image 84</ce:alt-text></ce:inline-figure> 25.85</ce:label><ce:alt-text id="atte1410" role="short">25.85</ce:alt-text><ce:textbox-head><ce:title id="tit0450">Common causes of axonal and demyelinating chronic polyneuropathies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9490"><ce:display><ce:table frame="topbot" id="t0310"><ce:alt-text id="atte1415" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Axonal</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2230"><ce:list-item id="u6380"><ce:label>•</ce:label><ce:para id="p9495">Diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u6385"><ce:label>•</ce:label><ce:para id="p9500">Alcohol</ce:para></ce:list-item><ce:list-item id="u6390"><ce:label>•</ce:label><ce:para id="p9505">Uraemia</ce:para></ce:list-item><ce:list-item id="u6395"><ce:label>•</ce:label><ce:para id="p9510">Cirrhosis</ce:para></ce:list-item><ce:list-item id="u6400"><ce:label>•</ce:label><ce:para id="p9515">Amyloid</ce:para></ce:list-item><ce:list-item id="u6405"><ce:label>•</ce:label><ce:para id="p9520">Myxoedema</ce:para></ce:list-item><ce:list-item id="u6410"><ce:label>•</ce:label><ce:para id="p9525">Acromegaly</ce:para></ce:list-item><ce:list-item id="u6415"><ce:label>•</ce:label><ce:para id="p9530">Paraneoplasm</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2235"><ce:list-item id="u6420"><ce:label>•</ce:label><ce:para id="p9535">Drugs and toxins (see <ce:cross-ref id="crf1645" refid="b0440">Box 25.84</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u6425"><ce:label>•</ce:label><ce:para id="p9540">Deficiency states (see <ce:cross-ref id="crf1650" refid="b0440">Box 25.84</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u6430"><ce:label>•</ce:label><ce:para id="p9545">Hereditary factors</ce:para></ce:list-item><ce:list-item id="u6435"><ce:label>•</ce:label><ce:para id="p9550">Infection (see <ce:cross-ref id="crf1655" refid="b0440">Box 25.84</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u6440"><ce:label>•</ce:label><ce:para id="p9555">Idiopathic factors</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Demyelinating</ce:bold></entry></row><row><entry namest="col1" nameend="col2" align="left"><ce:list id="ulist2240"><ce:list-item id="u6445"><ce:label>•</ce:label><ce:para id="p9560">Chronic inflammatory demyelinating polyradiculoneuropathy</ce:para></ce:list-item><ce:list-item id="u6450"><ce:label>•</ce:label><ce:para id="p9565">Multifocal motor neuropathy</ce:para></ce:list-item><ce:list-item id="u6455"><ce:label>•</ce:label><ce:para id="p9570">Paraprotein-associated demyelinating neuropathy</ce:para></ce:list-item><ce:list-item id="u6460"><ce:label>•</ce:label><ce:para id="p9575">Charcot–Marie–Tooth disease type I and type X</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0450" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9420" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1420" role="short">Image 85</ce:alt-text></ce:inline-figure> 25.86</ce:label><ce:alt-text id="atte1425" role="short">25.86</ce:alt-text><ce:textbox-head><ce:title id="tit0455">Investigation of peripheral neuropathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9590"><ce:display><ce:table frame="topbot" id="t0315"><ce:alt-text id="atte1430" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Initial tests</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist2245"><ce:list-item id="u6465"><ce:label>•</ce:label><ce:para id="p9595">Glucose (fasting)</ce:para></ce:list-item><ce:list-item id="u6470"><ce:label>•</ce:label><ce:para id="p9600">Erythrocyte sedimentation rate, C-reactive protein</ce:para></ce:list-item><ce:list-item id="u6475"><ce:label>•</ce:label><ce:para id="p9605">Full blood count</ce:para></ce:list-item><ce:list-item id="u6480"><ce:label>•</ce:label><ce:para id="p9610">Urea and electrolytes</ce:para></ce:list-item><ce:list-item id="u6485"><ce:label>•</ce:label><ce:para id="p9615">Liver function tests</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2250"><ce:list-item id="u6490"><ce:label>•</ce:label><ce:para id="p9620">Serum protein electrophoresis</ce:para></ce:list-item><ce:list-item id="u6495"><ce:label>•</ce:label><ce:para id="p9625">Vitamin B<ce:inf loc="post">12</ce:inf>, folate</ce:para></ce:list-item><ce:list-item id="u6500"><ce:label>•</ce:label><ce:para id="p9630">ANA, ANCA</ce:para></ce:list-item><ce:list-item id="u6505"><ce:label>•</ce:label><ce:para id="p9635">Chest X-ray</ce:para></ce:list-item><ce:list-item id="u6510"><ce:label>•</ce:label><ce:para id="p9640">HIV testing</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>If initial tests are negative</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist2255"><ce:list-item id="u6515"><ce:label>•</ce:label><ce:para id="p9645">Nerve conduction studies</ce:para></ce:list-item><ce:list-item id="u6520"><ce:label>•</ce:label><ce:para id="p9650">Vitamins E and A</ce:para></ce:list-item><ce:list-item id="u6525"><ce:label>•</ce:label><ce:para id="p9655">Genetic testing (see <ce:cross-ref id="crf1665" refid="b0440">Box 25.84</ce:cross-ref>)</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2260"><ce:list-item id="u6530"><ce:label>•</ce:label><ce:para id="p9660">Lyme serology (<ce:intra-ref id="ii1050" xlink:href="pii:B978-0-7020-7028-0.00011-1#u2930">p. 256</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u6535"><ce:label>•</ce:label><ce:para id="p9665">Serum angiotensin-converting enzyme</ce:para></ce:list-item><ce:list-item id="u6540"><ce:label>•</ce:label><ce:para id="p9670">Serum amyloid</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para><ce:para id="p9675">(ANCA = antineutrophil cytoplasmic antibody; ANA = antineutrophil antibody)</ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0455" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9425" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1435" role="short">Image 86</ce:alt-text></ce:inline-figure> 25.87</ce:label><ce:alt-text id="atte1440" role="short">25.87</ce:alt-text><ce:textbox-head><ce:title id="tit0460">Symptoms and signs in common entrapment neuropathies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9685"><ce:display><ce:table frame="topbot" id="t0320"><ce:alt-text id="atte1445" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Nerve</entry><entry align="left">Symptoms</entry><entry align="left">Muscle weakness/muscle-wasting</entry><entry align="left">Area of sensory loss</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Median</ce:bold> (at wrist) (carpal tunnel syndrome)</entry><entry align="left">Pain and paraesthesia on palmar aspect of hands and fingers, waking patient from sleep. Pain may extend to arm and shoulder</entry><entry align="left">Abductor pollicis brevis</entry><entry align="left">Lateral palm and thumb, index, middle and lateral half fourth finger</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ulnar</ce:bold> (at elbow)</entry><entry align="left">Paraesthesia on medial border of hand, wasting and weakness of hand muscles</entry><entry align="left">All small hand muscles, excluding abductor pollicis brevis</entry><entry align="left">Medial palm and little finger, and medial half fourth finger</entry></row><row rowsep="1"><entry align="left"><ce:bold>Radial</ce:bold></entry><entry align="left">Weakness of extension of wrist and fingers, often precipitated by sleeping in abnormal posture, e.g. arm over back of chair</entry><entry align="left">Wrist and finger extensors, supinator</entry><entry align="left">Dorsum of thumb</entry></row><row rowsep="1"><entry align="left"><ce:bold>Common peroneal</ce:bold></entry><entry align="left">Foot drop, trauma to head of fibula</entry><entry align="left">Dorsiflexion and eversion of foot</entry><entry align="left">Nil or dorsum of foot</entry></row><row><entry align="left"><ce:bold>Lateral cutaneous nerve of the thigh</ce:bold> (meralgia paraesthetica)</entry><entry align="left">Tingling and dysaesthesia on lateral border of thigh</entry><entry align="left">Nil</entry><entry align="left">Lateral border of thigh</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0460" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9430" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1450" role="short">Image 87</ce:alt-text></ce:inline-figure> 25.88</ce:label><ce:alt-text id="atte1455" role="short">25.88</ce:alt-text><ce:textbox-head><ce:title id="tit0465">Causes of multifocal mononeuropathy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2075"><ce:section-title id="st2000">Axonal (defined on nerve conduction studies)</ce:section-title><ce:para id="p9695"><ce:list id="ulist2265"><ce:list-item id="u6545"><ce:label>•</ce:label><ce:para id="p9700">Vasculitis (systemic or non-systemic)</ce:para></ce:list-item><ce:list-item id="u6550"><ce:label>•</ce:label><ce:para id="p9705">Diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u6555"><ce:label>•</ce:label><ce:para id="p9710">Sarcoidosis</ce:para></ce:list-item><ce:list-item id="u6560"><ce:label>•</ce:label><ce:para id="p9715">Infection (HIV, hepatitis C, Lyme disease, leprosy, diphtheria)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2080"><ce:section-title id="st2005">Focal demyelination with/without conduction block</ce:section-title><ce:para id="p9720"><ce:list id="ulist2270"><ce:list-item id="u6565"><ce:label>•</ce:label><ce:para id="p9725">Multifocal motor neuropathy</ce:para></ce:list-item><ce:list-item id="u6570"><ce:label>•</ce:label><ce:para id="p9730">Multiple compression neuropathies (usually in association with underlying disease, such as diabetes or alcoholism)</ce:para></ce:list-item><ce:list-item id="u6575"><ce:label>•</ce:label><ce:para id="p9735">Multifocal acquired demyelinating sensory and motor neuropathy (MADSAM)</ce:para></ce:list-item><ce:list-item id="u6580"><ce:label>•</ce:label><ce:para id="p9740">Hereditary neuropathy with a predisposition to pressure palsy (autosomal dominant, peripheral myelin protein 22 gene)</ce:para></ce:list-item><ce:list-item id="u6585"><ce:label>•</ce:label><ce:para id="p9745">Lymphoma</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0465" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9435" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1460" role="short">Image 88</ce:alt-text></ce:inline-figure> 25.89</ce:label><ce:alt-text id="atte1465" role="short">25.89</ce:alt-text><ce:textbox-head><ce:title id="tit0470">Physical signs in brachial plexus lesions</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9800"><ce:display><ce:table frame="topbot" id="t0325"><ce:alt-text id="atte1470" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Site</entry><entry align="left">Affected muscles</entry><entry align="left">Sensory loss</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Upper plexus</ce:bold> (Erb–Duchenne)</entry><entry align="left">Biceps, deltoid, spinati, rhomboids, brachioradialis (triceps, serratus anterior)</entry><entry align="left">Patch over deltoid</entry></row><row rowsep="1"><entry align="left"><ce:bold>Lower plexus</ce:bold> (Déjerine–Klumpke)</entry><entry align="left">All small hand muscles, claw hand (ulnar wrist flexors)</entry><entry align="left">Ulnar border of hand/forearm</entry></row><row><entry align="left"><ce:bold>Thoracic outlet syndrome</ce:bold></entry><entry align="left">Small hand muscles, ulnar forearm</entry><entry align="left">Ulnar border of hand/forearm/upper arm</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0470" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9440" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1475" role="short">Image 89</ce:alt-text></ce:inline-figure> 25.90</ce:label><ce:alt-text id="atte1480" role="short">25.90</ce:alt-text><ce:textbox-head><ce:title id="tit0475">Immunological treatment of myasthenia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s2180"><ce:section-title id="st2095">Acute treatments</ce:section-title><ce:section id="s2185"><ce:section-title id="st2100">Intravenous immunoglobulin</ce:section-title><ce:para id="p9870"><ce:list id="ulist2275"><ce:list-item id="u6590"><ce:label>•</ce:label><ce:para id="p9875">Lowers production of antibodies and rapidly reduces weakness</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2190"><ce:section-title id="st2105">Plasma exchange</ce:section-title><ce:para id="p9880"><ce:list id="ulist2280"><ce:list-item id="u6595"><ce:label>•</ce:label><ce:para id="p9885">Removing antibody from the blood may produce marked improvement; this is usually brief, so is normally reserved for myasthenic crisis or for pre-operative preparation</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s2195"><ce:section-title id="st2110">Long-term treatments</ce:section-title><ce:section id="s2200"><ce:section-title id="st2115">Glucocorticoid treatment</ce:section-title><ce:para id="p9890"><ce:list id="ulist2285"><ce:list-item id="u6600"><ce:label>•</ce:label><ce:para id="p9895">Improvement is commonly preceded by marked exacerbation of myasthenic symptoms, so treatment should be initiated in hospital</ce:para></ce:list-item><ce:list-item id="u6605"><ce:label>•</ce:label><ce:para id="p9900">Usually necessary to continue treatment for months or years, risking adverse effects</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2205"><ce:section-title id="st2120">Pharmacological immunosuppression treatment</ce:section-title><ce:para id="p9905"><ce:list id="ulist2290"><ce:list-item id="u6610"><ce:label>•</ce:label><ce:para id="p9910">Azathioprine 2.5 mg/kg daily reduces the necessary dosage of glucocorticoids and may allow their withdrawal. Effect on clinical features may be delayed for months</ce:para></ce:list-item><ce:list-item id="u6615"><ce:label>•</ce:label><ce:para id="p9915">Mycophenolate mofetil: less commonly used</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s2210"><ce:section-title id="st2125">Thymectomy</ce:section-title><ce:para id="p9920"><ce:list id="ulist2295"><ce:list-item id="u6620"><ce:label>•</ce:label><ce:para id="p9925">Should be considered in any antibody-positive patient under 45 years with symptoms not confined to extraocular muscles, unless the disease has been established for more than 7 years</ce:para></ce:list-item><ce:list-item id="u6625"><ce:label>•</ce:label><ce:para id="p9930">Likely to be required for thymoma</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0475" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9445" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1485" role="short">Image 90</ce:alt-text></ce:inline-figure> 25.91</ce:label><ce:alt-text id="atte1490" role="short">25.91</ce:alt-text><ce:textbox-head><ce:title id="tit0480">The muscular dystrophies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p9950"><ce:display><ce:table frame="topbot" id="t0330"><ce:alt-text id="atte1495" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Genetics</entry><entry align="left">Age of onset</entry><entry align="left">Muscles affected</entry><entry align="left">Other features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Myotonic dystrophy (DM1)</ce:bold></entry><entry align="left">Autosomal dominant; expanded triplet repeat chromosome 19q</entry><entry align="left">Any</entry><entry align="left">Face (including ptosis), sternomastoids, distal limb, generalised later</entry><entry align="left">Myotonia, cognitive impairment, cardiac conduction abnormalities, lens opacities, frontal balding, hypogonadism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Proximal myotonic myopathy (PROMM; DM2)</ce:bold></entry><entry align="left">Autosomal dominant; quadruplet repeat expansion in <ce:italic>Zn finger protein 9</ce:italic> gene chromosome 3q</entry><entry align="left">8–50 years</entry><entry align="left">Proximal, especially thigh, sometimes muscle hypertrophy</entry><entry align="left"><ce:list id="ulist2300"><ce:list-item id="u6630"><ce:para id="p9955">As for DM1 but cognition not affected</ce:para></ce:list-item><ce:list-item id="u6635"><ce:para id="p9960">Muscle pain</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Duchenne</ce:bold></entry><entry align="left">X-linked; deletions in <ce:italic>dystrophin</ce:italic> gene Xp21</entry><entry align="left">&#x003C; 5 years</entry><entry align="left">Proximal and limb girdle</entry><entry align="left">Cardiomyopathy and respiratory failure</entry></row><row rowsep="1"><entry align="left"><ce:bold>Becker</ce:bold></entry><entry align="left">X-linked; deletions in <ce:italic>dystrophin</ce:italic> gene Xp21</entry><entry align="left">Childhood/early adulthood</entry><entry align="left">Proximal and limb girdle</entry><entry align="left">Cardiomyopathy common but respiratory failure uncommon</entry></row><row rowsep="1"><entry align="left"><ce:bold>Limb girdle</ce:bold></entry><entry align="left">Many mutations on different chromosomes</entry><entry align="left">Childhood/early adulthood</entry><entry align="left">Limb girdle</entry><entry align="left">Very variable depending on genetic subtype, some involve cardiac and respiratory systems</entry></row><row rowsep="1"><entry align="left"><ce:bold>Facioscapulohumeral (FSH)</ce:bold></entry><entry align="left">Autosomal dominant; tandem repeat deletion chromosome 4q35</entry><entry align="left">7–30 years</entry><entry align="left">Face and upper limb girdle, distal lower limb weakness</entry><entry align="left"><ce:list id="ulist2305"><ce:list-item id="u6640"><ce:para id="p9965">Pain in shoulder girdle common, deafness</ce:para></ce:list-item><ce:list-item id="u6645"><ce:para id="p9970">Cardiorespiratory involvement rare</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Oculopharyngeal</ce:bold></entry><entry align="left">Autosomal dominant and recessive; triplet repeat expansion in <ce:italic>PABP2</ce:italic> gene chromosome 14q</entry><entry align="left">30–60 years</entry><entry align="left">Ptosis, external ophthalmoplegia, dysphagia, tongue weakness</entry><entry align="left">Mild lower limb weakness</entry></row><row><entry align="left"><ce:bold>Emery–Dreifuss</ce:bold></entry><entry align="left">X-linked recessive; mutations in <ce:italic>emerin</ce:italic> gene</entry><entry align="left">4–5 years</entry><entry align="left">Humero-peroneal, proximal limb girdle later</entry><entry align="left"><ce:list id="ulist2310"><ce:list-item id="u6650"><ce:para id="p9975">Contractures develop early</ce:para></ce:list-item><ce:list-item id="u6655"><ce:para id="p9980">Cardiac involvement leads to sudden death</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0480" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9450" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1500" role="short">Image 91</ce:alt-text></ce:inline-figure> 25.92</ce:label><ce:alt-text id="atte1505" role="short">25.92</ce:alt-text><ce:textbox-head><ce:title id="tit0485">Inherited disorders of muscle metabolism</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p10005"><ce:display><ce:table frame="topbot" id="t0335"><ce:alt-text id="atte1510" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Clinical features</entry><entry align="left">Diagnosis</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Carbohydrate (glycogen) metabolism</ce:bold></entry></row><row rowsep="0"><entry align="left">Myophosphorylase deficiency (McArdle's disease): autosomal recessive</entry><entry align="left">Exercise-induced myalgia, stiffness, weakness (with ‘second wind’ phenomenon), myoglobinuria</entry><entry align="left"><ce:list id="ulist2315"><ce:list-item id="u6660"><ce:para id="p10010">Creatine kinase (CK) elevated</ce:para></ce:list-item><ce:list-item id="u6665"><ce:para id="p10015">Muscle biopsy</ce:para></ce:list-item><ce:list-item id="u6670"><ce:para id="p10020">Enzyme assay</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Acid maltase deficiency (Pompe's disease): autosomal recessive</entry><entry align="left"><ce:list id="ulist2320"><ce:list-item id="u6675"><ce:para id="p10025">Infantile form: death within 2 years</ce:para></ce:list-item><ce:list-item id="u6680"><ce:para id="p10030">Childhood: death in twenties or thirties</ce:para></ce:list-item><ce:list-item id="u6685"><ce:para id="p10035">Adult: progressive proximal myopathy with respiratory failure</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2325"><ce:list-item id="u6690"><ce:para id="p10040">CK elevated</ce:para></ce:list-item><ce:list-item id="u6695"><ce:para id="p10045">Blood lymphocyte analysis for glycogen granules</ce:para></ce:list-item><ce:list-item id="u6700"><ce:para id="p10050">Muscle biopsy</ce:para></ce:list-item><ce:list-item id="u6705"><ce:para id="p10055">Enzyme assay</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col3" align="left"><ce:bold>Lipid metabolism (β-oxidation)</ce:bold></entry></row><row><entry align="left">Carnitine-palmitoyl transferase (CPT) deficiency</entry><entry align="left">Myalgia <ce:italic>after</ce:italic> exercise, myoglobinuria, weakness</entry><entry align="left"><ce:list id="ulist2330"><ce:list-item id="u6710"><ce:para id="p10060">CK normal between attacks</ce:para></ce:list-item><ce:list-item id="u6715"><ce:para id="p10065">Urinary organic acids</ce:para></ce:list-item><ce:list-item id="u6720"><ce:para id="p10070">Enzyme assays</ce:para></ce:list-item><ce:list-item id="u6725"><ce:para id="p10075">Muscle biopsy</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0485" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9455" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1515" role="short">Image 92</ce:alt-text></ce:inline-figure> 25.93</ce:label><ce:alt-text id="atte1520" role="short">25.93</ce:alt-text><ce:textbox-head><ce:title id="tit0490">Mitochondrial syndromes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p10095"><ce:display><ce:table frame="topbot" id="t0340"><ce:alt-text id="atte1525" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Syndrome</entry><entry align="left">Clinical features</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Myoclonic epilepsy with ragged red fibres (MERRF)</ce:bold></entry><entry align="left">Myoclonic epilepsy, cerebellar ataxia, dementia, sensorineural deafness ± peripheral neuropathy, optic atrophy and multiple lipomas</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS)</ce:bold></entry><entry align="left">Episodic encephalopathy, stroke-like episodes often preceded by migraine-like headache, nausea and vomiting</entry></row><row rowsep="1"><entry align="left"><ce:bold>Chronic progressive external ophthalmoplegia (CPEO)</ce:bold></entry><entry align="left">Progressive ptosis and external oculomotor palsy, proximal myopathy ± deafness, ataxia and cardiac conduction defects</entry></row><row rowsep="1"><entry align="left"><ce:bold>Kearns–Sayre syndrome</ce:bold></entry><entry align="left">Like CPEO but early age of onset (&#x003C; 20 years), heart block, pigmentary retinopathy</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)</ce:bold></entry><entry align="left">Progressive ptosis, external oculomotor palsy, gastrointestinal dysmotility (often pseudo-obstruction), diffuse leucoencephalopathy, thin body habitus, peripheral neuropathy and myopathy</entry></row><row><entry align="left"><ce:bold>Neuropathy, ataxia and retinitis pigmentosa (NARP)</ce:bold></entry><entry align="left">Weakness, ataxia and progressive loss of vision, along with dementia, seizures and proximal weakness</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0490" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9460" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000251/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1530" role="short">Image 93</ce:alt-text></ce:inline-figure> 25.94</ce:label><ce:alt-text id="atte1535" role="short">25.94</ce:alt-text><ce:textbox-head><ce:title id="tit0495">Muscle channelopathies</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p10110"><ce:display><ce:table frame="topbot" id="t0345"><ce:alt-text id="atte1540" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Channel</entry><entry align="left">Muscle disease</entry><entry align="left">Gene and inheritance</entry><entry align="left">Clinical features</entry></row></thead><tbody><row><entry morerows="3" rowsep="1" align="left"><ce:bold>Sodium</ce:bold></entry><entry rowsep="0" align="left">Paramyotonia congenita</entry><entry rowsep="0" align="left"><ce:list id="ulist2335"><ce:list-item id="u6730"><ce:para id="p10115"><ce:italic>SCN4A</ce:italic> (17q35)</ce:para></ce:list-item><ce:list-item id="u6735"><ce:para id="p10120">Autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry rowsep="0" align="left">Cold-evoked myotonia with episodic weakness provoked by exercise and cold</entry></row><row rowsep="0"><entry align="left">Potassium-aggravated myotonia</entry><entry align="left"><ce:italic>SCN4A</ce:italic></entry><entry align="left">Pure myotonia without weakness provoked by potassium</entry></row><row rowsep="0"><entry align="left">Hyperkalaemic periodic paralysis</entry><entry align="left"><ce:list id="ulist2340"><ce:list-item id="u6740"><ce:para id="p10125"><ce:italic>SCN4A</ce:italic></ce:para></ce:list-item><ce:list-item id="u6745"><ce:para id="p10130">Autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2345"><ce:list-item id="u6750"><ce:para id="p10135">Brief (mins to hours), frequent episodes of weakness provoked by rest, cold, potassium, fasting, pregnancy, stress</ce:para></ce:list-item><ce:list-item id="u6755"><ce:para id="p10140">Less common than hypokalaemic periodic paralysis</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Hypokalaemic periodic paralysis</entry><entry align="left"><ce:list id="ulist2350"><ce:list-item id="u6760"><ce:para id="p10145"><ce:italic>SCN4A</ce:italic></ce:para></ce:list-item><ce:list-item id="u6765"><ce:para id="p10150">Autosomal dominant (one-third new mutations)</ce:para></ce:list-item></ce:list></entry><entry align="left">Longer (hours to days) episodic weakness triggered by rest, carbohydrate loading, cold</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Chloride</ce:bold></entry><entry rowsep="0" align="left">Myotonia congenita:</entry><entry rowsep="0" align="left"/><entry rowsep="0" align="left"/></row><row rowsep="0"><entry align="left"><ce:hsp sp="1"/>Thomsen's disease</entry><entry align="left"><ce:list id="ulist2355"><ce:list-item id="u6770"><ce:para id="p10155"><ce:italic>CLCN1</ce:italic></ce:para></ce:list-item><ce:list-item id="u6775"><ce:para id="p10160">Autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry align="left">Myotonia usually mild, little weakness</entry></row><row rowsep="1"><entry align="left"><ce:hsp sp="1"/>Becker's disease</entry><entry align="left"><ce:list id="ulist2360"><ce:list-item id="u6780"><ce:para id="p10165"><ce:italic>CLCN1</ce:italic></ce:para></ce:list-item><ce:list-item id="u6785"><ce:para id="p10170">Autosomal recessive</ce:para></ce:list-item></ce:list></entry><entry align="left">Myotonia often severe, transient weakness</entry></row><row><entry morerows="1" rowsep="1" align="left"><ce:bold>Calcium</ce:bold></entry><entry rowsep="0" align="left">Hypokalaemic periodic paralysis</entry><entry rowsep="0" align="left"><ce:list id="ulist2365"><ce:list-item id="u6790"><ce:para id="p10175"><ce:italic>CACNA1S</ce:italic></ce:para></ce:list-item><ce:list-item id="u6795"><ce:para id="p10180">Autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry rowsep="0" align="left">Episodic weakness triggered by carbohydrate meal</entry></row><row rowsep="1"><entry align="left">Malignant hyperthermia</entry><entry align="left"><ce:list id="ulist2370"><ce:list-item id="u6800"><ce:para id="p10185"><ce:italic>CACNA1S</ce:italic>, <ce:italic>CACNL2A</ce:italic></ce:para></ce:list-item><ce:list-item id="u6805"><ce:para id="p10190">Autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry align="left">Hyperpyrexia due to excess muscle activity, precipitated by drugs, usually anaesthetic agents; most common cause of death during general anaesthetic</entry></row><row rowsep="1"><entry align="left"><ce:bold>Potassium</ce:bold></entry><entry align="left">Andersen–Tawil syndrome</entry><entry align="left"><ce:list id="ulist2375"><ce:list-item id="u6810"><ce:para id="p10195"><ce:italic>KCNJ2</ce:italic></ce:para></ce:list-item><ce:list-item id="u6815"><ce:para id="p10200">Autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry align="left">Similar to hypokalaemic periodic paralysis, associated with cardiac and non-myopathic features (skeletal and facial)</entry></row><row><entry align="left"><ce:bold>Ryanodine receptor</ce:bold></entry><entry align="left"><ce:list id="ulist2380"><ce:list-item id="u6820"><ce:para id="p10205">Malignant hyperthermia</ce:para></ce:list-item><ce:list-item id="u6825"><ce:para id="p10210">Central core and multicore disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2385"><ce:list-item id="u6830"><ce:para id="p10215"><ce:italic>RYR1</ce:italic> (19q13)</ce:para></ce:list-item><ce:list-item id="u6835"><ce:para id="p10220"><ce:italic>RYR1</ce:italic></ce:para></ce:list-item><ce:list-item id="u6840"><ce:para id="p10225">Mostly autosomal dominant</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist2390"><ce:list-item id="u6845"><ce:para id="p10230">As malignant hyperthermia above</ce:para></ce:list-item><ce:list-item id="u6850"><ce:para id="p10235">Present in infancy with mild progressive weakness</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>25</ce:label><ce:title id="tit0010">Neurology</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000251-84b60ed91ccf96b4d0e7904d48897523" id="au0010"><ce:given-name>JP</ce:given-name><ce:surname>Leach</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B9780702070280000251-239fa03842f5a829dc8536a6b36d2f38" id="au0015"><ce:given-name>RJ</ce:given-name><ce:surname>Davenport</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination of the nervous system</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>1062</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Functional anatomy and physiology</ce:bold> <ce:cross-ref id="crf0015" refid="s0015"><ce:bold>1064</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0020"><ce:para id="p0020">Functional anatomy of the nervous system <ce:cross-ref id="crf0020" refid="s0035">1065</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025">Localising lesions in the central nervous system <ce:cross-ref id="crf0025" refid="s0130">1071</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0030"><ce:para id="p0030"><ce:bold>Investigation of neurological disease</ce:bold> <ce:cross-ref id="crf0030" refid="s0135"><ce:bold>1072</ce:bold></ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0035"><ce:para id="p0035">Neuroimaging <ce:cross-ref id="crf0035" refid="s0140">1072</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0040"><ce:para id="p0040">Neurophysiological testing <ce:cross-ref id="crf0040" refid="s0160">1074</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045"><ce:bold>Presenting problems in neurological disease</ce:bold> <ce:cross-ref id="crf0045" refid="s0215"><ce:bold>1078</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0050"><ce:para id="p0050">Headache and facial pain <ce:cross-ref id="crf0050" refid="s0245">1080</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0055"><ce:para id="p0055">Dizziness, blackouts and ‘funny turns’ <ce:cross-ref id="crf0055" refid="s0260">1080</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Status epilepticus <ce:cross-ref id="crf0060" refid="s0265">1080</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0065"><ce:para id="p0065">Coma <ce:cross-ref id="crf0065" refid="s0295">1080</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">Delirium <ce:cross-ref id="crf0070" refid="s0300">1080</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075">Amnesia <ce:cross-ref id="crf0075" refid="s0305">1080</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0080"><ce:para id="p0080">Weakness <ce:cross-ref id="crf0080" refid="s0320">1081</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0085"><ce:para id="p0085">Sensory disturbance <ce:cross-ref id="crf0085" refid="s0335">1083</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0090"><ce:para id="p0090">Abnormal movements <ce:cross-ref id="crf0090" refid="s0375">1084</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Abnormal perception <ce:cross-ref id="crf0095" refid="s0420">1086</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100">Altered balance and vertigo <ce:cross-ref id="crf0100" refid="s0425">1086</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0105"><ce:para id="p0105">Abnormal gait <ce:cross-ref id="crf0105" refid="s0435">1086</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Abnormal speech and language <ce:cross-ref id="crf0110" refid="s0480">1087</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0115"><ce:para id="p0115">Disturbance of smell <ce:cross-ref id="crf0115" refid="s0500">1088</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0120"><ce:para id="p0120">Visual disturbance and ocular abnormalities <ce:cross-ref id="crf0120" refid="s0505">1088</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125">Hearing disturbance <ce:cross-ref id="crf0125" refid="s0550">1093</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130">Bulbar symptoms – dysphagia and dysarthria <ce:cross-ref id="crf0130" refid="s0555">1093</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0135"><ce:para id="p0135">Bladder, bowel and sexual disturbance <ce:cross-ref id="crf0135" refid="s0560">1093</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140">Personality change <ce:cross-ref id="crf0140" refid="s0580">1094</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0145"><ce:para id="p0145">Sleep disturbance <ce:cross-ref id="crf0145" refid="s0585">1094</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0150"><ce:para id="p0150">Psychiatric disorders <ce:cross-ref id="crf0150" refid="s0590">1094</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155"><ce:bold>Functional symptoms</ce:bold> <ce:cross-ref id="crf0155" refid="s0595"><ce:bold>1094</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0160"><ce:para id="p0160"><ce:bold>Headache syndromes</ce:bold> <ce:cross-ref id="crf0160" refid="s0600"><ce:bold>1095</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165"><ce:bold>Epilepsy</ce:bold> <ce:cross-ref id="crf0165" refid="s0705"><ce:bold>1097</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0170"><ce:para id="p0170"><ce:bold>Vestibular disorders</ce:bold> <ce:cross-ref id="crf0170" refid="s0895"><ce:bold>1104</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0175"><ce:para id="p0175"><ce:bold>Disorders of sleep</ce:bold> <ce:cross-ref id="crf0175" refid="s0920"><ce:bold>1105</ce:bold></ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0180"><ce:para id="p0180">Excessive daytime sleepiness (hypersomnolence) <ce:cross-ref id="crf0180" refid="s0925">1105</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0185"><ce:para id="p0185">Parasomnias <ce:cross-ref id="crf0185" refid="s0955">1105</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0190"><ce:para id="p0190"><ce:bold>Neuro-inflammatory diseases</ce:bold> <ce:cross-ref id="crf0190" refid="s0980"><ce:bold>1106</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0195"><ce:para id="p0195"><ce:bold>Paraneoplastic neurological disorders</ce:bold> <ce:cross-ref id="crf0195" refid="s1070"><ce:bold>1110</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0200"><ce:para id="p0200"><ce:bold>Neurodegenerative diseases</ce:bold> <ce:cross-ref id="crf0200" refid="s1095"><ce:bold>1111</ce:bold></ce:cross-ref><ce:list id="ulist0035"><ce:list-item id="u0205"><ce:para id="p0205">Movement disorders <ce:cross-ref id="crf0205" refid="s1100">1112</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0210"><ce:para id="p0210">Ataxias <ce:cross-ref id="crf0210" refid="s1220">1115</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0215"><ce:para id="p0215">Tremor disorders <ce:cross-ref id="crf0215" refid="s1225">1115</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0220"><ce:para id="p0220">Dystonia <ce:cross-ref id="crf0220" refid="s1235">1116</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0225"><ce:para id="p0225">Hemifacial spasm <ce:cross-ref id="crf0225" refid="s1240">1116</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0230"><ce:para id="p0230">Motor neuron disease <ce:cross-ref id="crf0230" refid="s1245">1116</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0235"><ce:para id="p0235">Spinal muscular atrophy <ce:cross-ref id="crf0235" refid="s1290">1117</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0240"><ce:para id="p0240"><ce:bold>Infections of the nervous system</ce:bold> <ce:cross-ref id="crf0240" refid="s1295"><ce:bold>1117</ce:bold></ce:cross-ref><ce:list id="ulist0040"><ce:list-item id="u0245"><ce:para id="p0245">Meningitis <ce:cross-ref id="crf0245" refid="s1300">1118</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0250"><ce:para id="p0250">Parenchymal viral infections <ce:cross-ref id="crf0250" refid="s1420">1121</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0255"><ce:para id="p0255">Parenchymal bacterial infections <ce:cross-ref id="crf0255" refid="s1540">1124</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0260"><ce:para id="p0260">Diseases caused by bacterial toxins <ce:cross-ref id="crf0260" refid="s1600">1125</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0265"><ce:para id="p0265">Prion diseases <ce:cross-ref id="crf0265" refid="s1670">1127</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0270"><ce:para id="p0270"><ce:bold>Intracranial mass lesions and raised intracranial pressure</ce:bold> <ce:cross-ref id="crf0270" refid="s1685"><ce:bold>1127</ce:bold></ce:cross-ref><ce:list id="ulist0045"><ce:list-item id="u0275"><ce:para id="p0275">Raised intracranial pressure <ce:cross-ref id="crf0275" refid="s1710">1128</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0280"><ce:para id="p0280">Brain tumours <ce:cross-ref id="crf0280" refid="s1730">1129</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0285"><ce:para id="p0285">Paraneoplastic neurological disease <ce:cross-ref id="crf0285" refid="s1800">1132</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0290"><ce:para id="p0290">Hydrocephalus <ce:cross-ref id="crf0290" refid="s1805">1132</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0295"><ce:para id="p0295">Idiopathic intracranial hypertension <ce:cross-ref id="crf0295" refid="s1820">1133</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0300"><ce:para id="p0300">Head injury <ce:cross-ref id="crf0300" refid="s1845">1133</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0305"><ce:para id="p0305"><ce:bold>Disorders of cerebellar function</ce:bold> <ce:cross-ref id="crf0305" refid="s1850"><ce:bold>1134</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0310"><ce:para id="p0310"><ce:bold>Disorders of the spine and spinal cord</ce:bold> <ce:cross-ref id="crf0310" refid="s1855"><ce:bold>1134</ce:bold></ce:cross-ref><ce:list id="ulist0050"><ce:list-item id="u0315"><ce:para id="p0315">Cervical spondylosis <ce:cross-ref id="crf0315" refid="s1860">1134</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0320"><ce:para id="p0320">Lumbar spondylosis <ce:cross-ref id="crf0320" refid="s1910">1135</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0325"><ce:para id="p0325">Spinal cord compression <ce:cross-ref id="crf0325" refid="s1965">1136</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0330"><ce:para id="p0330">Intrinsic diseases of the spinal cord <ce:cross-ref id="crf0330" refid="s2030">1137</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0335"><ce:para id="p0335"><ce:bold>Diseases of peripheral nerves</ce:bold> <ce:cross-ref id="crf0335" refid="s2035"><ce:bold>1138</ce:bold></ce:cross-ref><ce:list id="ulist0055"><ce:list-item id="u0340"><ce:para id="p0340">Entrapment neuropathy <ce:cross-ref id="crf0340" refid="s2065">1139</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0345"><ce:para id="p0345">Multifocal neuropathy <ce:cross-ref id="crf0345" refid="s2070">1140</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0350"><ce:para id="p0350">Polyneuropathy <ce:cross-ref id="crf0350" refid="s2085">1140</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0355"><ce:para id="p0355">Guillain–Barré syndrome <ce:cross-ref id="crf0355" refid="s2090">1140</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0360"><ce:para id="p0360">Chronic polyneuropathy <ce:cross-ref id="crf0360" refid="s2115">1140</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0365"><ce:para id="p0365">Brachial plexopathy <ce:cross-ref id="crf0365" refid="s2130">1141</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0370"><ce:para id="p0370">Lumbosacral plexopathy <ce:cross-ref id="crf0370" refid="s2135">1141</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0375"><ce:para id="p0375">Spinal root lesions <ce:cross-ref id="crf0375" refid="s2140">1141</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0380"><ce:para id="p0380"><ce:bold>Diseases of the neuromuscular junction</ce:bold> <ce:cross-ref id="crf0380" refid="s2145"><ce:bold>1141</ce:bold></ce:cross-ref><ce:list id="ulist0060"><ce:list-item id="u0385"><ce:para id="p0385">Myasthenia gravis <ce:cross-ref id="crf0385" refid="s2150">1141</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0390"><ce:para id="p0390">Lambert–Eaton myasthenic syndrome <ce:cross-ref id="crf0390" refid="s2215">1143</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0395"><ce:para id="p0395"><ce:bold>Diseases of muscle</ce:bold> <ce:cross-ref id="crf0395" refid="s2220"><ce:bold>1143</ce:bold></ce:cross-ref><ce:list id="ulist0065"><ce:list-item id="u0400"><ce:para id="p0400">Muscular dystrophies <ce:cross-ref id="crf0400" refid="s2225">1143</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0405"><ce:para id="p0405">Inherited metabolic myopathies <ce:cross-ref id="crf0405" refid="s2250">1144</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0410"><ce:para id="p0410">Acquired myopathies <ce:cross-ref id="crf0410" refid="s2265">1144</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination of the nervous system</ce:section-title><ce:para id="p0415"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte1545" role="short">Unlabelled image</ce:alt-text><ce:source>Insets (winging of scapula, 12th nerve palsy, wasting of thenar eminence) Courtesy of Dr R.E. Cull, Western General Hospital, Edinburgh.</ce:source><ce:link id="ln0010" locator="u025-001-9780702070280" xlink:href="pii:B9780702070280000251/u025-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:textbox id="b0010" role="alt7"><ce:label>1</ce:label><ce:alt-text id="atte1550" role="short">1</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Examination of gait and posture</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0420"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte1555" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Procedure</entry><entry align="left">Abnormality</entry><entry align="left">Disease</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Rising from chair</ce:bold></entry><entry align="left">Difficulty rising</entry><entry align="left">Proximal muscle weakness or joint disorders</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gait initiation</ce:bold></entry><entry align="left">Difficulty starting to walk, frozen</entry><entry align="left">Cerebrovascular disease or parkinsonism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Posture</ce:bold></entry><entry align="left">Stooped</entry><entry align="left">Parkinsonism</entry></row><row rowsep="1"><entry align="left"><ce:bold>Retropulsion/anteropulsion</ce:bold></entry><entry align="left">Postural instability</entry><entry align="left">Parkinsonism</entry></row><row><entry morerows="2" rowsep="1" align="left"><ce:bold>Arms during walking</ce:bold></entry><entry rowsep="0" align="left">Reduced arm swing</entry><entry rowsep="0" align="left">Parkinsonism or upper motor neuron lesion</entry></row><row rowsep="0"><entry align="left">Enhanced tremor</entry><entry align="left">Parkinsonism</entry></row><row rowsep="1"><entry align="left">Dystonic posturing</entry><entry align="left">Dystonia</entry></row><row><entry morerows="5" align="left"><ce:bold>Gait pattern</ce:bold></entry><entry rowsep="0" align="left">Circumduction (stiff leg moves outwards in ‘circular’ manner)</entry><entry rowsep="0" align="left">Hemiparesis, typically after stroke</entry></row><row rowsep="0"><entry align="left">‘Slapping’, high-stepping due to foot drop</entry><entry align="left">L5 radiculopathy or common peroneal nerve lesion</entry></row><row rowsep="0"><entry align="left">Narrow-based, short strides, freezing in doorways</entry><entry align="left">Parkinsonism</entry></row><row rowsep="0"><entry align="left">Stiff-legged, scissors gait</entry><entry align="left">Spastic paraparesis (multiple sclerosis, vascular disease, spinal cord lesions)</entry></row><row rowsep="0"><entry align="left">Wide-based, unsteady, unable to perform tandem gait</entry><entry align="left">Cerebellar lesion</entry></row><row><entry align="left">Waddling gait</entry><entry align="left">Myopathies with proximal weakness</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0015" role="alt7"><ce:label>4</ce:label><ce:alt-text id="atte1560" role="short">4</ce:alt-text><ce:textbox-head><ce:title id="tit0020">Examination of cranial nerves</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0425"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte1565" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Nerve</entry><entry align="left">Name</entry><entry align="left">Tests</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>I</ce:bold></entry><entry align="left">Olfactory</entry><entry align="left">Ask patient about sense of smell (examine only if change is reported)</entry></row><row rowsep="1"><entry align="left"><ce:bold>II</ce:bold></entry><entry align="left">Optic</entry><entry align="left"><ce:list id="ulist0070"><ce:list-item id="u0415"><ce:para id="p0430">Visual acuity and colour vision</ce:para></ce:list-item><ce:list-item id="u0420"><ce:para id="p0435">Visual fields</ce:para></ce:list-item><ce:list-item id="u0425"><ce:para id="p0440">Pupillary responses</ce:para></ce:list-item><ce:list-item id="u0430"><ce:para id="p0445">Ophthalmoscopy</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>III</ce:bold></entry><entry align="left">Oculomotor</entry><entry align="left"><ce:list id="ulist0075"><ce:list-item id="u0435"><ce:para id="p0450">Eyelids (ptosis)</ce:para></ce:list-item><ce:list-item id="u0440"><ce:para id="p0455">Pupil size, symmetry, reactions</ce:para></ce:list-item><ce:list-item id="u0445"><ce:para id="p0460">Eye movements</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>IV</ce:bold></entry><entry align="left">Trochlear</entry><entry align="left"><ce:list id="ulist0080"><ce:list-item id="u0450"><ce:para id="p0465">Eye movements (superior oblique muscle)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>V</ce:bold></entry><entry align="left">Trigeminal</entry><entry align="left"><ce:list id="ulist0085"><ce:list-item id="u0455"><ce:para id="p0470">Facial sensation</ce:para></ce:list-item><ce:list-item id="u0460"><ce:para id="p0475">Corneal reflex</ce:para></ce:list-item><ce:list-item id="u0465"><ce:para id="p0480">Muscles of mastication</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>VI</ce:bold></entry><entry align="left">Abducens</entry><entry align="left">Eye movements (lateral rectus muscle)</entry></row><row rowsep="1"><entry align="left"><ce:bold>VII</ce:bold></entry><entry align="left">Facial</entry><entry align="left">Facial symmetry and movements</entry></row><row rowsep="1"><entry align="left"><ce:bold>VIII</ce:bold></entry><entry align="left">Vestibulocochlear</entry><entry align="left"><ce:list id="ulist0090"><ce:list-item id="u0470"><ce:para id="p0485">Otoscopy</ce:para></ce:list-item><ce:list-item id="u0475"><ce:para id="p0490">Hearing</ce:para></ce:list-item><ce:list-item id="u0480"><ce:para id="p0495">Tuning fork tests (Rinne and Weber)</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>IX</ce:bold></entry><entry align="left">Glossopharyngeal</entry><entry align="left">Swallowing</entry></row><row rowsep="1"><entry align="left"><ce:bold>X</ce:bold></entry><entry align="left">Vagus</entry><entry align="left"><ce:list id="ulist0095"><ce:list-item id="u0485"><ce:para id="p0500">Palatal elevation (uvula deviates to side opposite lesion)</ce:para></ce:list-item><ce:list-item id="u0490"><ce:para id="p0505">Swallowing</ce:para></ce:list-item><ce:list-item id="u0495"><ce:para id="p0510">Cough (bovine)</ce:para></ce:list-item><ce:list-item id="u0500"><ce:para id="p0515">Speech</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>XI</ce:bold></entry><entry align="left">Accessory</entry><entry align="left"><ce:list id="ulist0100"><ce:list-item id="u0505"><ce:para id="p0520">Look for wasting of trapezius/sternocleidomastoid</ce:para></ce:list-item><ce:list-item id="u0510"><ce:para id="p0525">Elevation of shoulders</ce:para></ce:list-item><ce:list-item id="u0515"><ce:para id="p0530">Turning head to right and left</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>XII</ce:bold></entry><entry align="left">Hypoglossal</entry><entry align="left"><ce:list id="ulist0105"><ce:list-item id="u0520"><ce:para id="p0535">Look for wasting/fasciculation</ce:para></ce:list-item><ce:list-item id="u0525"><ce:para id="p0540">Tongue protrusion (deviates to side of lesion)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display><ce:display><ce:textbox id="b0020" role="alt7"><ce:label>6</ce:label><ce:alt-text id="atte1570" role="short">6</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Root values of tendon reflexes</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0545"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte1575" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Reflex</entry><entry align="left">Root value</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Arm</ce:bold></entry></row><row rowsep="0"><entry align="left">Biceps jerk</entry><entry align="left">C5</entry></row><row rowsep="0"><entry align="left">Supinator jerk</entry><entry align="left">C6</entry></row><row rowsep="0"><entry align="left">Triceps jerk</entry><entry align="left">C7</entry></row><row rowsep="1"><entry align="left">Finger jerk</entry><entry align="left">C8</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Leg</ce:bold></entry></row><row rowsep="0"><entry align="left">Knee jerk</entry><entry align="left">L3/L4</entry></row><row><entry align="left">Ankle jerk</entry><entry align="left">S1</entry></row></tbody></tgroup></ce:table></ce:display><ce:display><ce:figure id="f0015"><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Motor and sensory homunculi.</ce:simple-para><ce:simple-para id="sp0015" role="caption">The motor and sensory homunculi illustrate the cortical areas serving each anatomical area within the pre-central (motor) and post-central (sensory) gyri.</ce:simple-para></ce:caption><ce:alt-text id="atte1580" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0015" locator="u025-002-9780702070280" xlink:href="pii:B9780702070280000251/u025-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display>The complexity of the brain differentiates us from other species, and its interactions with the spinal cord and peripheral nerves combine to allow us to perceive and react to the external world while maintaining a stable internal environment. The cerebral cortex provides a platform for processing information and forming a response, and in doing so, both forms and is affected by our personality and mental state.</ce:para><ce:para id="p0550">Neurology has for too long been misperceived as a specialty in which intricate clinical examination and numerous investigations are required to diagnose obscure and untreatable conditions. In fact, nervous system disorders are common, accounting for around 10% of the UK's general practice consultations, 20% of acute medical admissions, and most chronic physical disability. The development of specific, effective treatments has made accurate diagnosis essential. Neurological management requires knowledge of a range of common conditions, which can then be applied to individual patients after careful history-taking, with lesser contributions arising from targeted examination and considered investigation.</ce:para><ce:para id="p0555">Pathological and anatomical localisation of symptoms and signs is important, but skill can be required to identify those <ce:italic>not</ce:italic> associated with neurological disease, differentiating patients requiring investigation and treatment from those who need reassurance.</ce:para><ce:para id="p0560">Initially, it is important to exclude conditions that constitute neurological emergencies (<ce:cross-ref id="crf0415" refid="b0025">Box 25.1</ce:cross-ref><ce:float-anchor refid="b0025"/>). If the presentation is not an emergency, time can be taken to reach a diagnosis. The history should provide a hypothesis for the site and nature of the potential pathology, which a focused examination may refine, and direct appropriate further investigations. An informed discussion with the patient and family regarding diagnosis, management and prognosis may then take place.</ce:para><ce:para id="p0605">As stroke has become a specific subspecialty in many centres, it is described in a separate chapter, although it is clearly a neurological condition. This chapter should be read with it, to help clarify how the presentation, diagnosis and management of stroke present their own challenges.</ce:para></ce:section><ce:section id="s0015"><ce:section-title id="st0015">Functional anatomy and physiology</ce:section-title><ce:section id="s0020"><ce:section id="s0025"><ce:section-title id="st0020">Cells of the nervous system</ce:section-title><ce:para id="p0610">The nervous system comprises billions of specialised cells, forming a spectacular network of connections, each human brain having almost as many connections as there are grains of sand in the whole world. In addition to neurons, there are three types of glial cells. Astrocytes form the structural framework for neurons and control their biochemical environment, their foot processes adjoining small blood vessels and forming the blood–brain barrier (<ce:cross-ref id="crf0420" refid="f0020">Fig. 25.1</ce:cross-ref><ce:float-anchor refid="f0020"/>). Oligodendrocytes are responsible for the formation and maintenance of the myelin sheath, which surrounds axons and is essential for maintaining the speed and consistency of action potential propagation along axons. Peripheral nerves have axons invested in myelin made by oligodendrocytes (Schwann cells). Microglial cells derive from monocytes/macrophages and play a role in fighting infection and removing damaged cells. Ependymal cells line the cerebral ventricles.</ce:para></ce:section><ce:section id="s0030"><ce:section-title id="st0025">Generation and transmission of the nervous impulse</ce:section-title><ce:para id="p0615">The role of the central nervous system (CNS) is to generate outputs in response to external stimuli and changes in internal conditions. The CNS has to maintain a delicate balance between responsivity to external stimuli and remaining stoic enough to remain stable in a rapidly changing environment. Each neuron receives input by synaptic transmission from dendrites (branched projections of other neurons), which sum to produce output in the form of an action potential that is then conducted along the axon, resulting in synaptic transmission to other neurons or, in the motor system, to muscle cells. Summation of the inputs causes net changes in the target neuron's electrochemical gradient, which, if large enough, will trigger an action potential. Communication between cells is by synaptic transmission that involves the release of neurotransmitters to interact with structures on the target cell's surface, including ion channels and other cell surface receptors (<ce:cross-ref id="crf0425" refid="f0025">Fig. 25.2</ce:cross-ref><ce:float-anchor refid="f0025"/>). At least 20 different neurotransmitters are known to act at different sites in the nervous system, most of which are potentially amenable to pharmacological manipulation.</ce:para><ce:para id="p0620">Each neuronal cell body may receive synaptic input from thousands of other neurons. The synapsing neuron terminals are also subject to feedback regulation via receptor sites on the pre-synaptic membrane, modifying the release of transmitter across the synaptic cleft. In addition to such acute effects, some neurotransmitters produce long-term modulation of metabolic function or gene expression. This effect probably underlies more complex processes such as long-term memory.</ce:para></ce:section></ce:section><ce:section id="s0035"><ce:section-title id="st0030">Functional anatomy of the nervous system</ce:section-title><ce:para id="p0625">Major components of the nervous system and their inter-relationships are depicted in <ce:cross-ref id="crf0430" refid="f0030">Figure 25.3</ce:cross-ref><ce:float-anchor refid="f0030"/>.</ce:para><ce:section id="s0040"><ce:section-title id="st0035">Cerebral hemispheres</ce:section-title><ce:para id="p0630">The cerebral hemispheres coordinate the highest level of nervous function, the anterior half dealing with executive (‘doing’) functions and the posterior half constructing a perception of the environment. Each cerebral hemisphere has four functionally specialised lobes (<ce:cross-ref id="crf0440" refid="b0030">Box 25.2</ce:cross-ref><ce:float-anchor refid="b0030"/> and <ce:cross-ref id="crf0435" refid="f0035">Fig. 25.4</ce:cross-ref><ce:float-anchor refid="f0035"/>), with some functions being distributed asymmetrically (‘lateralised’), to produce cerebral dominance for functions such as motor control, speech or memory. Cerebral dominance aligns limb dominance with language function: in right-handed individuals the left hemisphere is almost always dominant, while around half of left-handers have a dominant right hemisphere.</ce:para><ce:para id="p0930">Frontal lobes are concerned with executive function, movement, behaviour and planning. As well as the primary and supplementary motor cortex, there are specialised areas for control of eye movements, speech (Broca's area) and micturition.</ce:para><ce:para id="p0935">The parietal lobes integrate sensory perception. The primary sensory cortex lies in the post-central gyrus of the parietal lobe. Much of the remainder is devoted to ‘association’ cortex, which processes and interprets input from the various sensory modalities. The supramarginal and angular gyri of the dominant parietal lobe form part of the language area (p. 1088). Close to these are regions dealing with numerical function. The non-dominant parietal lobe is concerned with spatial awareness and orientation.</ce:para><ce:para id="p0940">The temporal lobes contain the primary auditory cortex and primary vestibular cortex. On the inner medial sides lie the olfactory and parahippocampal cortices, which are involved in memory function. The temporal lobes also link intimately to the limbic system, including the hippocampus and the amygdala, which are involved in memory and emotional processing. The dominant temporal lobe also participates in language functions, particularly verbal comprehension (Wernicke's area). Musical processing occurs across both temporal lobes, rhythm on the dominant side and melody/pitch on the non-dominant.</ce:para><ce:para id="p0945">The occipital lobes are responsible for visual interpretation. The contralateral visual hemifield is represented in each primary visual cortex, with surrounding areas processing specific visual submodalities such as colour, movement or depth, and the analysis of more complex visual patterns such as faces.</ce:para><ce:para id="p0950">Deep to the grey matter in the cortices, and the white matter (composed of neuronal axons), are collections of cells known as the basal ganglia that are concerned with motor control; the thalamus, which is responsible for the level of attention to sensory perception; the limbic system, concerned with emotion and memory; and the hypothalamus, responsible for homeostasis, such as temperature and appetite control. The cerebral ventricles contain cerebrospinal fluid (CSF), which cushions the brain during cranial movement.</ce:para><ce:para id="p0955">CSF is formed in the lateral ventricles and protects and nourishes the CNS. CSF flows from third to fourth ventricles and through foramina in the brainstem to dissipate over the surface of the CNS, eventually being reabsorbed into the cerebral venous system (see <ce:cross-ref id="crf0480" refid="f0250">Fig. 25.44</ce:cross-ref>, p. 1132).</ce:para></ce:section><ce:section id="s0045"><ce:section-title id="st0040">The brainstem</ce:section-title><ce:para id="p0960">In addition to containing all the sensory and motor pathways entering and leaving the hemispheres, the brainstem houses the nuclei and projections of most cranial nerves, as well as other important collections of neurons in the reticular formation (<ce:cross-ref id="crf0485" refid="f0040">Fig. 25.5</ce:cross-ref><ce:float-anchor refid="f0040"/>). Cranial nerve nuclei provide motor control to muscles of the head (including face and eyes) and coordinate sensory input from the special sense organs and the face, nose, mouth, larynx and pharynx. They also relay autonomic messages, including pupillary, salivary and lacrimal functions. The reticular formation is mainly involved in control of conjugate eye movements, the maintenance of balance and arousal, and cardiorespiratory control.</ce:para></ce:section><ce:section id="s0050"><ce:section-title id="st0045">The spinal cord</ce:section-title><ce:para id="p0965">The spinal cord is the route for virtually all communication between the extracranial structures and the CNS. Afferent and efferent fibres are grouped in discrete bundles but collections of cells in the grey matter are responsible for lower-order motor reflexes and the primary processing of sensory information.</ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0050">Sensory peripheral nervous system</ce:section-title><ce:para id="p0970">The sensory cell bodies of peripheral nerves are situated just outside the spinal cord, in the dorsal root ganglia in the spinal exit foramina, while the distal ends of their neurons utilise various specialised endings for the conversion of external stimuli into action potentials. Sensory nerves consist of a combination of large, fast, myelinated axons (which carry information about joint position sense and commands to muscles) and smaller, slower, unmyelinated axons (which carry information about pain and temperature, as well as autonomic function).</ce:para></ce:section><ce:section id="s0060"><ce:section-title id="st0055">Motor peripheral nervous system</ce:section-title><ce:para id="p0975">The anterior horns of the spinal cord comprise cell bodies of the lower motor neurons. To increase conduction speed, peripheral motor nerve axons are wrapped in myelin produced by Schwann cells. Motor neurons release acetylcholine across the neuromuscular junction, which changes the muscle end-plate potential and initiates muscle contraction.</ce:para></ce:section><ce:section id="s0065"><ce:section-title id="st0060">The autonomic system</ce:section-title><ce:para id="p0980">The autonomic system regulates the cardiovascular and respiratory systems, the smooth muscle of the gastrointestinal tract, and many exocrine and endocrine glands throughout the body. The autonomic system is controlled centrally by diffuse modulatory systems in the brainstem, limbic system, hypothalamus and frontal lobes, which are concerned with arousal and background behavioural responses to threat. Autonomic output divides functionally and pharmacologically into two divisions: the parasympathetic and sympathetic systems.</ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0065">The motor system</ce:section-title><ce:para id="p0985">A programme of movement formulated by the pre-motor cortex is converted into a series of excitatory and inhibitory signals in the motor cortex that are transmitted to the spinal cord in the pyramidal tract (<ce:cross-ref id="crf0490" refid="f0045">Fig. 25.6</ce:cross-ref><ce:float-anchor refid="f0045"/>). This passes through the internal capsule and the ventral brainstem before crossing (decussating) in the medulla to enter the lateral columns of the spinal cord. The pyramidal tract ‘upper motor neurons’ synapse with the anterior horn cells of the spinal cord grey matter, which form the lower motor neurons.</ce:para><ce:para id="p0990">Any movement necessitates changes in posture and muscle tone, sometimes in quite separate muscle groups to those involved in the actual movement. The motor system consists of a hierarchy of controls that maintain body posture and muscle tone, on which any movement is superimposed. In the grey matter of the spinal cord, the lowest order of the motor hierarchy controls reflex responses to stretch. Muscle spindles sense lengthening of the muscle; they provide the afferent side of the stretch reflex and initiate a monosynaptic reflex leading to protective or reactive muscle contraction. Inputs from the brainstem are largely inhibitory. Polysynaptic connections in the spinal cord grey matter control more complex reflex actions of flexion and extension of the limbs that form the basic building blocks of coordinated actions, but complete control requires input from the extrapyramidal system and the cerebellum.</ce:para><ce:section id="s0075"><ce:section-title id="st0070">Lower motor neurons</ce:section-title><ce:para id="p0995">Lower motor neurons in the anterior horn of the spinal cord innervate a group of muscle fibres termed a ‘motor unit’. Loss of lower motor neurons causes loss of contraction within this unit, resulting in weakness and reduced muscle tone. Subsequently, denervated muscle fibres atrophy, causing muscle wasting, and depolarise spontaneously, causing ‘fibrillations’. Except in the tongue, these are usually perceptible only on electromyography (EMG; p. 1076). With the passage of time, neighbouring intact neurons sprout to provide re-innervation, but the neuromuscular junctions of the enlarged motor units are unstable and depolarise spontaneously, causing fasciculations (large enough to be visible). Fasciculations therefore imply chronic denervation with partial re-innervation.</ce:para></ce:section><ce:section id="s0080"><ce:section-title id="st0075">Upper motor neurons</ce:section-title><ce:para id="p1000">Upper motor neurons have both inhibitory and excitatory influence on the function of lower motor neurons in the anterior horn. Lesions affecting the upper motor neuron result in increased tone, most evident in the strongest muscle groups (i.e. the extensors of the lower limbs and the flexors of the upper limbs). The weakness of upper motor neuron lesions is conversely more pronounced in the opposing muscle groups. Loss of inhibition will also lead to brisk reflexes and enhanced reflex patterns of movement, such as flexion withdrawal to noxious stimuli and spasms of extension. The increased tone is more apparent during rapid stretching (‘spastic catch’) but may quickly give way with sustained tension (the ‘clasp-knife’ phenomenon). More primitive reflexes are also released, manifest as extensor plantar responses. Spasticity may not be present until some weeks after the onset of an upper motor neuron lesion.</ce:para></ce:section></ce:section><ce:section id="s0085"><ce:section-title id="st0080">The extrapyramidal system</ce:section-title><ce:para id="p1005">Circuits between the basal ganglia and the motor cortex constitute the extrapyramidal system, which controls muscle tone, body posture and the initiation of movement (see <ce:cross-ref id="crf0495" refid="f0045">Fig. 25.6</ce:cross-ref>). Lesions of the extrapyramidal system produce an increase in tone that, unlike spasticity, is continuous throughout the range of movement at any speed of stretch (‘lead pipe’ rigidity). Involuntary movements are also a feature of extrapyramidal lesions (p. 1084), and tremor in combination with rigidity produces typical ‘cogwheel’ rigidity. Extrapyramidal lesions also cause slowed and clumsy movements (bradykinesia), which characteristically reduce in size with repetition, as well as postural instability, which can precipitate falls.</ce:para></ce:section><ce:section id="s0090"><ce:section-title id="st0085">The cerebellum</ce:section-title><ce:para id="p1010">The cerebellum fine-tunes and coordinates movement initiated by the motor cortex, including articulation of speech. It also participates in the planning and learning of skilled movements through reciprocal connections with the thalamus and cortex. A lesion in a cerebellar hemisphere causes lack of coordination on the same side of the body. Cerebellar dysfunction impairs the smoothness of eye movements, causing nystagmus, and renders speech dysarthric. In the limbs, the initial movement is normal, but as the target is approached, the accuracy of the movement deteriorates, producing an ‘intention tremor’. The distances of targets are misjudged (dysmetria), resulting in ‘past-pointing’. The ability to produce rapid, accurate, regularly alternating movements is also impaired (dysdiadochokinesis). The central vermis of the cerebellum is concerned with the coordination of gait and posture. Disorders of this area therefore produce a characteristic ataxic gait (see below).</ce:para></ce:section><ce:section id="s0095"><ce:section-title id="st0090">Vision</ce:section-title><ce:para id="p1015">The neurological organisation of visual pathways is shown in <ce:cross-ref id="crf0500" refid="f0050">Figure 25.7</ce:cross-ref><ce:float-anchor refid="f0050"/>. Fibres from ganglion cells in the retina pass to the optic disc and then backwards through the lamina cribrosa to the optic nerve. Nasal optic nerve fibres (subserving the temporal visual field) cross at the chiasm but temporal fibres do not. Hence, fibres in each optic tract and further posteriorly carry representation of contralateral visual space. From the lateral geniculate nucleus, lower fibres pass through the temporal lobes on their way to the primary visual area in the occipital cortex, while the upper fibres pass through the parietal lobe.</ce:para><ce:para id="p1020">Normally, the eyes move conjugately (in the same direction at the same speed), though horizontal convergence allows fusion of images at different distances. The control of eye movements begins in the cerebral hemispheres, particularly within the frontal eye fields, and the pathway then descends to the brainstem with input from the visual cortex, superior colliculus and cerebellum. Horizontal and vertical gaze centres in the pons and mid-brain, respectively, coordinate output to the ocular motor nerve nuclei (3, 4 and 6), which are connected to each other by the medial longitudinal fasciculus (MLF) (<ce:cross-ref id="crf0505" refid="f0055">Fig. 25.8</ce:cross-ref><ce:float-anchor refid="f0055"/>). The MLF is particularly important in coordinating horizontal movements of the eyes. The resulting signals to extraocular muscles are supplied by the oculomotor (3rd), trochlear (4th) and abducens (6th) cranial nerves.</ce:para><ce:para id="p1025">The pupillary size is determined by a combination of parasympathetic and sympathetic activity. Parasympathetic fibres originate in the Edinger–Westphal subnucleus of the 3rd nerve, and pass with the 3rd nerve to synapse in the ciliary ganglion before supplying the constrictor pupillae of the iris. Sympathetic fibres originate in the hypothalamus, pass down the brainstem and cervical spinal cord to emerge at T1, return up to the eye in association with the internal carotid artery, and supply the dilator pupillae.</ce:para></ce:section><ce:section id="s0100"><ce:section-title id="st0095">Speech</ce:section-title><ce:para id="p1030">Much of the cerebral cortex is involved in the process of forming and interpreting communicating sounds, especially in the dominant hemisphere (see <ce:cross-ref id="crf0510" refid="b0030">Box 25.2</ce:cross-ref>). Decoding of speech sounds (phonemes) is carried out in the upper part of the posterior temporal lobe. The attribution of meaning, as well as the formulation of the language required for the expression of ideas and concepts, occurs predominantly in the lower parts of the anterior parietal lobe (the angular and supramarginal gyri). The temporal speech comprehension region is called Wernicke's area (<ce:cross-ref id="crf0515" refid="f0060">Fig. 25.9</ce:cross-ref><ce:float-anchor refid="f0060"/>). Other parts of the temporal lobe contribute to verbal memory, where lexicons of meaningful words are ‘stored’. Parts of the non-dominant parietal lobe appear to contribute to non-verbal aspects of language in recognising meaningful intonation patterns (prosody).</ce:para><ce:para id="p1035">The frontal language area is in the posterior end of the dominant inferior frontal gyrus known as Broca's area. This receives input from the temporal and parietal lobes via the arcuate fasciculus. The motor commands generated in Broca's area pass to the cranial nerve nuclei in the pons and medulla, as well as to the anterior horn cells in the spinal cord. Nerve impulses to the lips, tongue, palate, pharynx, larynx and respiratory muscles result in the series of ordered sounds comprising speech. The cerebellum also plays an important role in coordinating speech, and lesions of the cerebellum lead to dysarthria, where the problem lies in motor articulation of speech.</ce:para></ce:section><ce:section id="s0105"><ce:section-title id="st0100">The somatosensory system</ce:section-title><ce:para id="p1040">The body surface can be described by dermatomes, each dermatome being an area of skin in which sensory nerves derive from a single spinal nerve root (<ce:cross-ref id="crf0520" refid="f0065">Fig. 25.10</ce:cross-ref><ce:float-anchor refid="f0065"/>). Sensory information ascends in two anatomically discrete systems (<ce:cross-ref id="crf0525" refid="f0070">Fig. 25.11</ce:cross-ref><ce:float-anchor refid="f0070"/>). Fibres from proprioceptive organs and those mediating specific sensation (including vibration) enter the spinal cord at the posterior horn and pass without synapsing into the ipsilateral posterior columns. In contrast, fibres conveying pain and temperature sensory information (nociceptive neurons) synapse with second-order neurons that cross the midline in the spinal cord before ascending in the contralateral anterolateral spinothalamic tract to the brainstem.</ce:para><ce:para id="p1045">The second-order neurons of the dorsal column sensory system cross the midline in the upper medulla to ascend through the brainstem. Here they lie just medial to the (already crossed) spinothalamic pathway. Brainstem lesions can therefore cause sensory loss affecting all modalities on the contralateral side of the body. Distribution of facial sensory loss due to brainstem lesions arises from the anatomy of the trigeminal fibres within the brainstem. Fibres from the back of the face (near the ears) descend within the brainstem to the upper part of the spinal cord before synapsing, the second-order neurons crossing the midline and then ascending with the spinothalamic fibres. Fibres conveying sensation from more anterior areas of the face descend a shorter distance in the brainstem. Thus, sensory loss in the face from low brainstem lesions is in a ‘balaclava helmet’ distribution, as the longer descending trigeminal fibres are affected. Both dorsal column and spinothalamic tracts end in the thalamus, relaying from there to the parietal cortex.</ce:para><ce:section id="s0110"><ce:section-title id="st0105">Pain</ce:section-title><ce:para id="p1050">Pain is a complex perception that is only partly related to activity in nociceptor neurons (<ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00034-2#s0010">p. 1338</ce:intra-ref> and <ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00034-2#f0015">Fig. 34.2</ce:intra-ref>). Higher up, chronic and severe pain interacts extensively with mood and can exacerbate or be exacerbated by mood disorder, including depression and anxiety. Modification of psychological and psychiatric sequelae is a vital part of pain management (<ce:intra-ref id="ii0075" xlink:href="pii:B978-0-7020-7028-0.00034-2#s0085">p. 1343</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0115"><ce:section-title id="st0110">Sphincter control</ce:section-title><ce:para id="p1055">The sympathetic supply to the bladder arises from roots T11–L2 to synapse in the inferior hypogastric plexus, while the parasympathetic supply leaves from S2–4. In addition, a somatic supply to the external (voluntary) sphincter arises from S2–4, travelling via the pudendal nerves.</ce:para><ce:para id="p1060">Storage of urine is maintained by inhibiting parasympathetic activity and thus relaxing the detrusor muscle of the bladder wall. Continence is also helped by simultaneous sympathetic- and somatic-mediated tonic contraction of the urethral sphincters. Voiding in adults is usually carried out under conscious control, which triggers relaxation of tonic inhibition on the pontine micturition centre from higher centres, leading to relaxation of the pelvic floor muscles and external and internal urethral sphincters, along with parasympathetic-mediated detrusor contraction.</ce:para></ce:section></ce:section><ce:section id="s0120"><ce:section-title id="st0115">Personality and mood</ce:section-title><ce:para id="p1065">The physiology and pathology of mood disorders are discussed elsewhere (<ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00028-7#c00028">Ch. 28</ce:intra-ref>) but it is important to remember that any process affecting brain function may influence mood and affect. Conversely, mood disorder may have a significant effect on perception and function. It can be difficult to disentangle whether psychological and psychiatric changes are the cause or the effect of any neurological symptoms.</ce:para></ce:section><ce:section id="s0125"><ce:section-title id="st0120">Sleep</ce:section-title><ce:para id="p1070">The function of sleep is unknown but it is required for health. Sleep is controlled by the reticular activating system in the upper brainstem and diencephalon. It is composed of different stages that can be visualised on electroencephalography (EEG). As drowsiness occurs, normal EEG background alpha rhythm disappears and activity becomes dominated by deepening slow-wave activity. As sleep deepens and dreaming begins, the limbs become flaccid, movements are ‘blocked’ and EEG signs of rapid eye movements (REM) are superimposed on the slow wave. REM sleep persists for a short spell before another slow-wave spell starts, the cycle repeating several times throughout the night. REM phases lengthen as sleep progresses. REM sleep seems to be the most important part of the sleep cycle for refreshing cognitive processes, and REM sleep deprivation causes tiredness, irritability and impaired judgement.</ce:para></ce:section></ce:section><ce:section id="s0130"><ce:section-title id="st0125">Localising lesions in the central nervous system</ce:section-title><ce:para id="p1075">After taking a history and examining the patient, the clinician should have an idea of the nature and site of any pathology (see <ce:cross-ref id="crf0530" refid="b0065">Box 25.10</ce:cross-ref>). Given the intricate anatomy of the brainstem, this section will dwell on the possible localisation in more detail (see <ce:cross-ref id="crf0535" refid="f0040">Fig. 25.5</ce:cross-ref>).</ce:para><ce:para id="p1080">Brainstem lesions typically present with symptoms due to cranial nerve, cerebellar and upper motor neuron dysfunction and are most commonly caused by vascular disease. Since the anatomy of the brainstem is very precisely organised, it is usually possible to localise the site of a lesion on the basis of careful history and examination in order to determine exactly which tracts/nuclei are affected, usually invoking the fewest number of lesions.</ce:para><ce:para id="p1085">For example, in a patient presenting with sudden onset of upper motor neuron features affecting the right face, arm and leg in association with a left 3rd nerve palsy, the lesion will be in the left cerebral peduncle in the brainstem and the pathology is likely to have been a discrete stroke, as the onset was sudden. This combination of symptoms and signs is known as Weber's syndrome, and is one of several well-described brainstem syndromes, which are listed in <ce:cross-ref id="crf0540" refid="b0035">Box 25.3</ce:cross-ref><ce:float-anchor refid="b0035"/>. The effects of individual cranial nerve deficits are discussed in the sections on eye movements (p. 1088) and on facial weakness, sensory loss in brainstem lesions, dysphonia and dysarthria, and bulbar symptoms (pp. 1082, 1083, 1087 and 1093).</ce:para></ce:section></ce:section><ce:section id="s0135"><ce:section-title id="st0130">Investigation of neurological disease</ce:section-title><ce:para id="p1190">Experienced clinicians make most neurological diagnoses on history alone, with a lesser contribution from examination and investigation. As investigations become more complex and more easily available, it is tempting to adopt a ‘scan first, think later’ approach to neurological symptoms. The frequency of ‘false-positive’ results, the wide range of normality, and the negative implications for patients (unnecessary expense, inconvenience, discomfort and worry) necessitate a more thoughtful approach. Investigation may include assessment of structure (imaging) and function (neurophysiology). Neurophysiological testing has become so complex that in some countries it constitutes a separate specialty focusing on electroencephalography, evoked potentials, nerve conduction studies and electromyography.</ce:para><ce:section id="s0140"><ce:section-title id="st0135">Neuroimaging</ce:section-title><ce:para id="p1195">Neurological imaging has traditionally allowed only assessment of structure but advances are allowing much more sophistication. Imaging modalities can use X-rays (plain X-rays, computed tomography (CT), CT angiography, myelography and angiography), magnetic resonance (MR imaging (MRI), MR angiography (MRA)), ultrasound (Doppler imaging of blood vessels) and nuclear medicine techniques (single photon emission computed tomography (SPECT) and positron emission tomography (PET)). The uses and limitations of each of these are shown in <ce:cross-ref id="crf0545" refid="b0040">Box 25.4</ce:cross-ref><ce:float-anchor refid="b0040"/>. Different sequences for analysing MRI signals can provide helpful information for characterising tissues and pathologies (<ce:cross-ref id="crf0550" refid="b0045">Box 25.5</ce:cross-ref><ce:float-anchor refid="b0045"/>).</ce:para><ce:para id="p1425">Specialist MR techniques, such as functional MRI (fMRI), MR spectroscopy or diffusion tensor imaging (DTI), can be used to assess brain metabolism and chemical compositions. This may be dynamic and can provide ‘maps’ of cortical function to help plan lesionectomy and epilepsy surgery. Similarly, MR spectroscopy can outline the chemical composition of specific regions, providing notions of whether lesions are ischaemic, neoplastic or inflammatory.</ce:para><ce:para id="p1430">Some degenerative neurological conditions cause functional rather than structural abnormalities that make metabolic and neurochemical assessment increasingly useful. PET scanning can display glucose metabolism in dementia and epilepsy. SPECT scanning uses the lipid-soluble properties of radioactive tracers to mark cerebral blood flow at the time of injection to help in investigating seizures. Dopaminergic pathway tracers can assess the integrity of the nigrostriatal pathway in patients with possible parkinsonism.</ce:para><ce:section id="s0145"><ce:section-title id="st0140">Head and orbit</ce:section-title><ce:para id="p1435">Plain skull X-rays now have a very limited role in neurological disease. CT or MRI is needed for intracranial imaging. CT is good for demonstrating bone and calcification well. It will also detect abnormalities of the brain and ventricles, such as atrophy, tumours, cysts, abscesses, vascular lesions and hydrocephalus. Diagnostic yield may be improved by the use of intravenous contrast and thinner slicing but CT is not optimal for lesions of meninges, cranial nerves or subtle parenchymal changes.</ce:para><ce:para id="p1440">MRI resolution is unaffected by bone and so is more useful in posterior fossa disease. Its sensitivity for cortical and white matter changes makes it the modality of choice in inflammatory conditions such as multiple sclerosis and in the investigation of epilepsy. Different MRI techniques can selectively suppress signal from fluid or fat, for example, and so increase sensitivity for more subtle pathologies.</ce:para><ce:para id="p1445">Examples of brain imaged by the various techniques are shown in <ce:cross-ref id="crf0555" refid="f0090">Figure 25.12</ce:cross-ref><ce:float-anchor refid="f0090"/>.</ce:para></ce:section><ce:section id="s0150"><ce:section-title id="st0145">Cervical, thoracic and lumbar spine</ce:section-title><ce:para id="p1450">X-rays are useful for imaging bony structures and can show destruction or damage to vertebrae, for example, but will provide no information about non-bony tissues, such as intervertebral discs, spinal cord and nerve roots. They have some usefulness in dynamic imaging, e.g. flexion/extension of the spine, in the assessment of instability. MRI has transformed spinal investigation, as it can give information not only about vertebrae and intervertebral discs but also about their effects on the spinal cord and nerve roots. Myelography (usually with CT) is an invasive technique requiring injection of contrast into the lumbar theca. While outlining the nerve roots and spinal cord provides some detail about abnormal structure, the accuracy and availability of MRI have reduced the need for it. Myelography may still be used where MRI is unavailable, contraindicated, or precluded by a patient's claustrophobia. Examples of the cervical spine imaged by plain X-rays, myelography and MRI are shown in <ce:cross-ref id="crf0560" refid="f0095">Figure 25.13</ce:cross-ref><ce:float-anchor refid="f0095"/>.</ce:para></ce:section><ce:section id="s0155"><ce:section-title id="st0150">Blood vessels</ce:section-title><ce:para id="p1455">Imaging of the extra- and intracranial blood vessels and disturbance of arterial or venous blood flow is described on <ce:intra-ref id="ii0110" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0320">page 1161</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s0160"><ce:section-title id="st0155">Neurophysiological testing</ce:section-title><ce:section id="s0165"><ce:section-title id="st0160">Electroencephalography</ce:section-title><ce:para id="p1460">The electroencephalogram (EEG) detects electrical activity arising in the cerebral cortex via electrodes placed on the scalp to record the amplitude and frequency of the resulting waveforms. With closed eyes, the normal background activity is 8–13 Hz (known as alpha rhythm), most prominent occipitally and suppressed on eye opening. Other frequency bands seen over different parts of the brain in different circumstances are beta (faster than 13/sec), theta (4–8/sec) and delta (slower than 4/sec). Normal EEG patterns evolve with age and alertness; lower frequencies predominate in the very young and during sleep.</ce:para><ce:para id="p1465">In recent years, digital technology has allowed longer, cleaner EEG recordings that can be analysed in a number of ways and recorded alongside contemporaneous video of any clinical ‘event’. Meanwhile, the development of intracranial recording allows more sensitive monitoring via surgically placed electrodes in and around lesions to help increase the efficacy and safety of epilepsy surgery.</ce:para><ce:para id="p1470">Abnormal EEGs result from a number of conditions. Examples include an increase in fast frequencies (beta) seen with sedating drugs such as benzodiazepines, or marked focal slowing noted over a structural lesion such as a tumour or an infarct. Improved quality and accessibility of imaging have made EEG redundant in lesion localisation, except in the specialist investigation of epilepsy (p. 1100). EEG remains useful in progressive and continuous disorders such as reduced consciousness (<ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0425">p. 194</ce:intra-ref>), encephalitis (p. 1121), and certain dementias such as Creutzfeldt–Jakob disease (p. 1127).</ce:para><ce:para id="p1475">Since sleep induces marked changes in cerebral activity, EEG can be useful in diagnosis of sleep disturbances. In paroxysmal disorders such as epilepsy, EEG is at its most useful when it captures activity during one of the events in question. Over 50% of patients with epilepsy have a normal ‘routine’ EEG but, conversely, the presence of epileptiform features does not of itself make a diagnosis. Up to 5% of some normal populations may demonstrate epileptiform discharges on EEG, preventing its use as a screening test for epilepsy, most notably in younger patients with a family history of epilepsy. In view of this, the EEG should not be used where epilepsy is merely ‘possible’.</ce:para><ce:para id="p1480">Therefore the EEG in epilepsy is predominantly used for classification and prognostication, but in some patients can help localise the seat of epileptiform discharges when surgery is being considered. During a seizure, high-voltage disturbances of background activity (‘discharges’) are often noted. These may be generalised, as in the 3 Hz ‘spike and wave’ of childhood absence epilepsy, or more focal, as in localisation-related epilepsies (<ce:cross-ref id="crf0565" refid="f0100">Fig. 25.14</ce:cross-ref><ce:float-anchor refid="f0100"/>). Techniques such as hyperventilation or photic stimulation can be used to increase the yield of epileptiform changes, particularly in the generalised epilepsy syndromes. While some argue that it is possible to detect ‘spikes’ and ‘sharp waves’ to lend support to a clinical diagnosis, these are non-specific and therefore not diagnostic, and can lead an unwary clinician to err in ascribing other symptoms to epilepsy.</ce:para></ce:section><ce:section id="s0170"><ce:section-title id="st0165">Nerve conduction studies</ce:section-title><ce:para id="p1485">Electrical stimulation of a nerve causes an impulse to travel both efferently and afferently along the underlying axons. Nerve conduction studies (NCS) make use of this, recording action potentials as they pass along peripheral nerves and (with motor nerves) as they pass into the muscle belly. Digital recording has enhanced sensitivity and reproducibility of these tiny potentials. By measuring the time taken to traverse a known distance, it is possible to calculate nerve conduction velocities (NCVs). Healthy nerves at room temperature will conduct at a speed of 40–50 m/sec. If the recorded potential is smaller than expected, this provides evidence of a reduction in the overall number of functioning axons. Significant slowing of conduction velocity, in contrast, suggests impaired conduction due to peripheral nerve demyelination. Such changes in NCS may be diffuse (as in a hereditary demyelinating peripheral neuropathy, p. 1138), focal (as in pressure palsies, p. 1139) or multifocal (e.g. Guillain–Barré syndrome, p. 1140; mononeuritis multiplex, p. 1140). The information gained can allow the disease responsible for peripheral nerve dysfunction to be better deduced (see <ce:cross-ref id="crf0570" refid="b0440">Box 25.84</ce:cross-ref>, p. 1139).</ce:para><ce:para id="p1490">Stimulation of motor nerves allows for the recording of compound muscle action potentials (CMAPs) over muscles (<ce:cross-ref id="crf0575" refid="f0105">Fig. 25.15</ce:cross-ref><ce:float-anchor refid="f0105"/>). These are around 500 times larger than sensory nerve potentials, typically around 1–20 millivolts. Since a proportion of stimulated impulses in motor nerves will ‘reflect’ back from the anterior horn cell body (forming the ‘F’ wave), it is also possible to obtain some information about the condition of nerve roots.</ce:para><ce:para id="p1495">Repetitive nerve stimulation (RNS) at 3–15/sec provides consistent CMAPs in healthy muscle. In myasthenia gravis (p. 1141), however, where there is partial blockage of acetylcholine receptors, there is a diagnostic fall (decrement) in CMAP amplitude. In contrast, an increasing CMAP with high-frequency RNS is seen in Lambert–Eaton myasthenic syndrome (p. 1143).</ce:para></ce:section><ce:section id="s0175"><ce:section-title id="st0170">Electromyography</ce:section-title><ce:para id="p1500">Electromyography (EMG) is usually performed alongside NCS and involves needle recording of muscle electrical potential during rest and contraction. At rest, muscle is electrically silent but loss of nerve supply causes muscle membrane to become unstable, manifest as fibrillations, positive sharp waves (‘spontaneous activity’) or fasciculations. Motor unit action potentials are recorded during muscle contraction. Axonal loss or destruction will result in fewer motor units. Resultant sprouting of remaining units will lead to increasing size of each individual unit on EMG. Myopathy, in contrast, causes muscle fibre splitting, which results in a large number of smaller units on EMG. Other abnormal activity, such as myotonic discharges, may signify abnormal ion channel conduction, as in myotonic dystrophy or myotonia congenita.</ce:para><ce:para id="p1505">Specialised single-fibre electromyography (SFEMG) can be used to investigate neuromuscular junction transmission. Measuring ‘jitter’ and ‘blocking’ can identify the effect of antibodies in reducing the action of acetylcholine on the receptor.</ce:para></ce:section><ce:section id="s0180"><ce:section-title id="st0175">Evoked potentials</ce:section-title><ce:para id="p1510">The cortical response to visual, auditory or electrical stimulation can be measured on an EEG as an evoked potential (EP). If a stimulus is provided – e.g. to the eye, the tiny EEG response can be discerned when averaging 100–1000 repeated stimuli. Assessing the latency (the time delay) and amplitude can give information about the integrity of the relevant pathway. MRI now provides more information about CNS pathways, thus reducing reliance on EPs. In practice, visual evoked potentials (VEPs) are most commonly used to help differentiate CNS demyelination from small-vessel white-matter changes (<ce:cross-ref id="crf0580" refid="f0110">Fig. 25.16</ce:cross-ref><ce:float-anchor refid="f0110"/>).</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0180">Magnetic stimulation</ce:section-title><ce:para id="p1515">Central conduction times can also be measured using electromagnetic induction of action potentials in the cortex or spinal cord by the local application of specialised coils. Again, MRI has made this technique largely redundant, other than for research.</ce:para></ce:section><ce:section id="s0190"><ce:section-title id="st0185">Routine blood tests</ce:section-title><ce:para id="p1520">Many systemic conditions that can affect the nervous system can be identified by simple blood tests. Nutritional deficiencies, metabolic disturbances, inflammatory conditions or infections may all present or be associated with neurological symptoms, and basic blood tests (full blood count, erythrocyte sedimentation rate, C-reactive protein, biochemical screening) may provide clues. Specific blood tests will be highlighted in the relevant subsections of this chapter. Human immunodeficiency virus (HIV) infection is increasingly recognised as a cause of neurological disease and the clinician should have a low threshold for checking this.</ce:para></ce:section><ce:section id="s0195"><ce:section-title id="st0190">Immunological tests</ce:section-title><ce:para id="p1525">Recent developments have seen a host of new immune-mediated conditions emerge in clinical neurology, with antibody targets ranging from muscle and neuromuscular junction disturbance (causing weakness and muscle pain) to specific neuronal ion channels (causing cognitive decline, epilepsy and psychiatric changes). The 21st century has seen the identification of many causative antibodies (see <ce:cross-ref id="crf0585" refid="b0280">Boxes 25.52</ce:cross-ref> and <ce:cross-ref id="crf0590" refid="b0285">25.53</ce:cross-ref>, p. 1111) and it is likely that further conditions will turn out to have an immune basis.</ce:para></ce:section><ce:section id="s0200"><ce:section-title id="st0195">Genetic testing</ce:section-title><ce:para id="p1530">This evolving field represents a huge untapped area for neurological exploration, particularly with the development of genome-wide association study (GWAS) and whole-genome sequencing. Relevant subsections will detail the increasing numbers of inherited neurological conditions that can now be diagnosed by DNA analysis (<ce:intra-ref id="ii0175" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0265">p. 56</ce:intra-ref>). These include diseases caused by increased numbers of trinucleotide repeats, such as Huntington's disease (p. 1114); myotonic dystrophy (p. 1143); and some types of spinocerebellar ataxia (p. 1115). Mitochondrial DNA can also be sequenced to diagnose relevant disorders (p. 1144).</ce:para></ce:section><ce:section id="s0205"><ce:section-title id="st0200">Lumbar puncture</ce:section-title><ce:para id="p1535">Lumbar puncture (LP) is the technique used to obtain both a CSF sample and an indirect measure of intracranial pressure. After local anaesthetic injection, a needle is inserted between lumbar spinous processes (usually between L3 and L4) through the dura and into the spinal canal. Intracranial pressure can be deduced (if patients are lying on their side) and CSF removed for analysis. CSF pressure measurement is important in the diagnosis and monitoring of idiopathic intracranial hypertension (p. 1133). In this condition, the LP itself is therapeutic.</ce:para><ce:para id="p1540">CSF is normally clear and colourless, and the tests that are usually performed include a naked eye examination of the CSF and centrifugation to determine the colour of the supernatant (yellow, or xanthochromic, some hours after subarachnoid haemorrhage; <ce:intra-ref id="ii0205" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0285">p. 1160</ce:intra-ref>). Measurement of absorption of specific light wavelengths helps quantify the amount of haem metabolites in CSF. Routine analysis involves a cell count, as well as glucose and protein concentrations.</ce:para><ce:para id="p1545">CSF assessment is important in investigating infections (meningitis or encephalitis), subarachnoid haemorrhage and inflammatory conditions (multiple sclerosis, sarcoidosis and cerebral lupus). Normal values and abnormalities found in specific conditions are shown in <ce:cross-ref id="crf0595" refid="b0050">Box 25.6</ce:cross-ref><ce:float-anchor refid="b0050"/>.</ce:para><ce:para id="p1565">More sophisticated analysis allows measurement of antibody formation solely within the CNS (oligoclonal bands), genetic analysis (e.g. polymerase chain reaction (PCR) for herpes simplex or tuberculosis), immunological tests (paraneoplastic antibodies) and cytology (to detect malignant cells).</ce:para><ce:para id="p1570">If there is a cranial space-occupying lesion causing raised intracranial pressure, LP presents a theoretical risk of downward shift of intracerebral contents, a potentially fatal process known as coning (p. 1128). Consequently, LP is contraindicated if there is any clinical suggestion of raised intracranial pressure (papilloedema), depressed level of consciousness, or focal neurological signs suggesting a cerebral lesion, until imaging (by CT or MRI) has excluded a space-occupying lesion or hydrocephalus. When there is a risk of local haemorrhage (thrombocytopenia, disseminated intravascular coagulation or anticoagulant treatment), then caution should be exercised or specific measures should be taken. LP can be safely performed in patients on antiplatelet drugs or low-dose heparin, but may be unsafe in patients who are fully anticoagulated due to the increased risk of epidural haematoma.</ce:para><ce:para id="p1575">About 30% of LPs are followed by a postural headache, due to reduced CSF pressure. The frequency of headache can be reduced by using smaller or atraumatic needles. Rarer complications involve transient radicular pain, and pain over the lumbar region during the procedure. Aseptic technique renders secondary infections such as meningitis extremely rare.</ce:para></ce:section><ce:section id="s0210"><ce:section-title id="st0205">Biopsy</ce:section-title><ce:para id="p1580">Biopsies of nervous tissue (peripheral nerve, muscle, meninges or brain) are occasionally required for diagnosis.</ce:para><ce:para id="p1585">Nerve biopsy can help in the investigation of peripheral neuropathy. Usually, a distal sensory nerve (sural or radial) is targeted. Histological examination can help identify underlying causes, such as vasculitides or infiltrative disorders like amyloid. Nerve biopsy should not be undertaken lightly since there is an appreciable morbidity; it should be reserved for cases where the diagnosis is in doubt after routine investigations and where it will influence management.</ce:para><ce:para id="p1590">Muscle biopsy is performed more frequently and is indicated for the differentiation of myositis and myopathies. These conditions can usually be distinguished by histological examination, and enzyme histochemistry can be useful when mitochondrial diseases and storage diseases are suspected. The quadriceps muscle is most commonly biopsied but other muscles may also be sampled if they are involved clinically. Although pain and infection can follow the procedure, these are less of a problem than after nerve biopsy.</ce:para><ce:para id="p1595">Brain biopsy is required when imaging fails to clarify the nature of intracerebral lesions, e.g. in unexplained degenerative diseases such as unusual cases of dementia and in patients with brain tumours. Most biopsies are performed stereotactically through a burr hole in the skull, which lowers complication rates. Nevertheless, haemorrhage, infection and death still occur and brain biopsy should be considered only if a diagnosis is otherwise elusive.</ce:para><ce:para id="p1600">Biopsy of other organs can be useful in the diagnosis of systemic disorders presenting as neurological problems, such as tonsillar biopsy (diagnosis of prion diseases), or rectal or fat biopsy (for assessment of amyloid).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0215"><ce:section-title id="st0210">Presenting problems in neurological disease</ce:section-title><ce:para id="p1605">While history is important in all medical specialties, it is especially key in neurology, where many neurological diagnoses have no confirmatory test. History-taking allows doctor and patient to get to know one another; many neurological diseases follow chronic paths and this may be the first of many such consultations. It also allows the clinician to obtain information about the patient's affect, cognition and psychiatric state.</ce:para><ce:para id="p1610">History-taking is a highly active process. While there are generic templates (<ce:cross-ref id="crf0600" refid="b0055">Box 25.7</ce:cross-ref><ce:float-anchor refid="b0055"/>), each individual story will follow its own course, and diagnostic considerations during the history will guide further questioning.</ce:para><ce:para id="p1735">It is important to be clear about what patients mean by certain words. They may find it difficult to describe symptoms: for instance, weakness may be called ‘numbness’, while there are many possible interpretations of ‘dizziness’. These must be clarified; even in emergency situations, a clear, accurate history is the foundation of any management plan. While the story should come primarily from the patient, input from eye-witnesses and family members is crucial if the patient is unable to provide details or if there has been loss of consciousness. This need for corroboration and clarification means the telephone is as important as any investigation.</ce:para><ce:para id="p1740">The aim of the history is to address two key issues: where is the lesion and what is the lesion (<ce:cross-ref id="crf0605" refid="b0060">Box 25.8</ce:cross-ref><ce:float-anchor refid="b0060"/>)? These should remain uppermost in the doctor's mind while the history is being elicited. Some common combinations of symptoms may suggest particular locations for a lesion (<ce:cross-ref id="crf0610" refid="b0065">Box 25.10</ce:cross-ref><ce:float-anchor refid="b0065"/>). Enquiry about handedness is important; lateralisation of the dominant hand helps designate the dominant hemisphere, which in turn may help to localise any pathologies, or to plan rehabilitation or treatment strategies in asymmetrical disorders such as stroke or Parkinson's disease.<ce:display><ce:textbox id="b0070" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln9465" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000251/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte1585" role="short">Image 94</ce:alt-text></ce:inline-figure> 25.9</ce:label><ce:alt-text id="atte1590" role="short">25.9</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Neurological examination in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1905"><ce:list id="ulist0360"><ce:list-item id="u1425"><ce:label>•</ce:label><ce:para id="p1910"><ce:bold>Pupils</ce:bold>: tend to be smaller, making fundoscopy more difficult.</ce:para></ce:list-item><ce:list-item id="u1430"><ce:label>•</ce:label><ce:para id="p1915"><ce:bold>Limb tone</ce:bold>: more difficult to assess because of poor relaxation and concomitant joint disease.</ce:para></ce:list-item><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p1920"><ce:bold>Ankle reflexes</ce:bold>: may be absent.</ce:para></ce:list-item><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p1925"><ce:bold>Gait assessment</ce:bold>: more difficult because of concurrent musculoskeletal disease and pre-existing neurological deficits.</ce:para></ce:list-item><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p1930"><ce:bold>Sensory testing</ce:bold>: especially difficult when there is cognitive impairment.</ce:para></ce:list-item><ce:list-item id="u1450"><ce:label>•</ce:label><ce:para id="p1935"><ce:bold>Vibration sense</ce:bold>: may be reduced distally in the legs.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:display></ce:para><ce:para id="p1940">Epidemiology must be borne in mind. How likely is it that this particular patient has any specific condition under consideration? For example, a 20-year-old with right-sided headache and tenderness will not have temporal arteritis, but this is an important possibility if such symptoms present in a 78-year-old female.</ce:para><ce:para id="p1945">Determining the evolution, speed of onset and progression of a disease is important (<ce:cross-ref id="crf0615" refid="b0075">Box 25.11</ce:cross-ref><ce:float-anchor refid="b0075"/>). For example, if right-hand weakness occurred overnight, it would suggest a stroke in an older person or an acute entrapment neuropathy in a younger one. Evolution over several days, however, might make demyelination (multiple sclerosis) a possible diagnosis, or perhaps a subdural haematoma if the weakness was preceded by a head injury in an older person taking warfarin. Progression over weeks might bring an intracranial mass lesion or motor neuron disease into the differential. Slow progression over a year or so, with difficulty in using the hand, could suggest a degenerative process such as Parkinson's disease. The impact on day-to-day activities, such as walking, climbing stairs and carrying out fine hand movements, should also be established in order to gauge the level of associated disability.</ce:para><ce:para id="p1990">Estimates of the frequency and duration of specific events are essential when taking details of a paroxysmal disorder such as migraine and epilepsy. Vague terms such as ‘a lot’ or ‘sometimes’ are unhelpful, and it can assist the patient if choices are given to estimate numbers, such as once a day, week or month.</ce:para><ce:para id="p1995">Many neurological symptoms are not explained by disease. Describing these as ‘functional’ is less pejorative and more acceptable to patients than ‘psychogenic’ or ‘hysterical’. Functional symptoms require considerable experience in diagnosis and are frequently missed (p. 1094).</ce:para><ce:section id="s0245"><ce:section-title id="st0240">Headache and facial pain</ce:section-title><ce:para id="p2000">Most headaches are chronic disorders but acute presentation of headaches is an important aspect of emergency medical care. Headache may be divided into primary (benign) or secondary, and most patients, whether presenting in clinic or as emergencies, have primary syndromes (see <ce:intra-ref id="ii0225" xlink:href="pii:B978-0-7020-7028-0.00010-X#b0060">Box 10.10</ce:intra-ref>, <ce:intra-ref id="ii0230" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0155">p. 184</ce:intra-ref>). The emergency clinical assessment of headaches is dealt with on <ce:intra-ref id="ii0235" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0195">page 185</ce:intra-ref>.</ce:para><ce:section id="s0250"><ce:section-title id="st0245">Ocular pain</ce:section-title><ce:para id="p2005">Assuming that ocular disease (such as acute glaucoma) has been excluded, ocular pain may be due to trigeminal autonomic cephalalgias (TACs) or, rarely, inflammatory or infiltrative lesions at the apex of the orbit or the cavernous sinus, when 3rd, 4th, 5th or 6th cranial nerve involvement is usually evident. Ocular pain and headache are also discussed on <ce:intra-ref id="ii0240" xlink:href="pii:B978-0-7020-7028-0.00027-5#s0215">page 1170</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0255"><ce:section-title id="st0250">Facial pain</ce:section-title><ce:para id="p2010">Pain in the face can be due to dental or temporomandibular joint problems. Acute sinusitis is usually apparent from other features of sinus congestion/infection and may cause localised pain over the affected sinus, but is almost never the explanation for persistent facial pain or headache.</ce:para><ce:para id="p2015">Facial pain is not uncommon in migraine but some syndromes can present solely with facial pain. The most common neurological causes of facial pain are trigeminal neuralgia, herpes zoster (shingles) and post-herpetic neuralgia, all characterised by their extreme severity. In trigeminal neuralgia, the patient describes bouts of brief (seconds), lancinating pain (‘electric shocks’), most frequently felt in the second and third divisions of the nerve and often triggered by talking or chewing. Facial shingles most commonly affects the first (ophthalmic) division of the trigeminal nerve, and pain usually precedes the rash. Post-herpetic neuralgia may follow, typically a continuous burning pain throughout the affected territory, with marked sensitivity to light touch (allodynia) and resistance to treatment. Destructive lesions of the trigeminal nerve usually cause numbness rather than pain.</ce:para><ce:para id="p2020">Persistent idiopathic facial pain is most frequently seen in middle-aged women, who report persistent pain, with no abnormal signs or investigations, and is similar to other forms of idiopathic chronic pain.</ce:para></ce:section></ce:section><ce:section id="s0260"><ce:section-title id="st0255">Dizziness, blackouts and ‘funny turns’</ce:section-title><ce:para id="p2025">Acute onset of dizziness or blackouts will present to the acute medical department. In neurological practice, it is common to deal with patients presenting with a history of multiple events. While detailed questioning will be dealt with in the relevant section (<ce:intra-ref id="ii0245" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0115">p. 181</ce:intra-ref>), the neurologist will have to tease out the pattern of each of the different attack types experienced by the patient to be able to form a treatment and investigation plan, one of the challenges of clinical neurology.</ce:para></ce:section><ce:section id="s0265"><ce:section-title id="st0260">Status epilepticus</ce:section-title><ce:para id="p2030">Status epilepticus is seizure activity not resolving spontaneously, or recurrent seizure with no recovery of consciousness in between. Persisting seizure activity has a recognised mortality and is a medical emergency.</ce:para><ce:para id="p2035">Diagnosis is usually clinical and can be made on the basis of the description of prolonged rigidity and/or clonic movements with loss of awareness. As seizure activity becomes prolonged, movements may become more subtle. Cyanosis, pyrexia, acidosis and sweating may occur, and complications include aspiration, hypotension, cardiac arrhythmias and renal or hepatic failure.</ce:para><ce:para id="p2040">In patients with pre-existing epilepsy, the most likely cause is a fall in antiepileptic drug levels. In de novo status epilepticus, it is essential to exclude precipitants such as infection (meningitis, encephalitis), neoplasia and metabolic derangement (hypoglycaemia, hyponatraemia or hypocalcaemia). Treatment and investigation are outlined in <ce:cross-ref id="crf0620" refid="b0080">Box 25.12</ce:cross-ref><ce:float-anchor refid="b0080"/>.</ce:para></ce:section><ce:section id="s0295"><ce:section-title id="st0290">Coma</ce:section-title><ce:para id="p2180">Coma and loss of consciousness usually present to the acute medical admissions department (<ce:intra-ref id="ii0250" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0425">p. 194</ce:intra-ref>). Clarification of cause and prognosis may require specialist neurological input.</ce:para></ce:section><ce:section id="s0300"><ce:section-title id="st0295">Delirium</ce:section-title><ce:para id="p2185">Delirium describes cortical dysfunction and replaces the older term ‘acute confusional state’. It has a range of primary causes, and given its role in precipitating acute admission, it is covered in detail on <ce:intra-ref id="ii0255" xlink:href="pii:B978-0-7020-7028-0.00010-X#p0845">page 183</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0305"><ce:section-title id="st0300">Amnesia</ce:section-title><ce:para id="p2190">Memory disturbance is a common symptom. In the absence of significant functional impairment (e.g. inability to work, dyspraxias, loss of daily function), many patients will prove to have benign memory dysfunction related to age, mood or psychiatric disorders. The increasing publicity given to dementia, combined with a natural fear of losing one's mind, has led to an increase in patients presenting with memory loss but many will have benign symptoms. Investigation and treatment of the dementias are discussed elsewhere (<ce:intra-ref id="ii0260" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0480">p. 1191</ce:intra-ref>).</ce:para><ce:para id="p2195">Temporary loss of memory may be due to a transient delirium related to infection, the post-ictal period after seizure, or transient global amnesia. These are usually distinguished on the basis of the history. Transient amnesia resulting directly from a seizure (transient epileptic amnesia) is a rare result of temporal lobe epilepsy.</ce:para><ce:section id="s0310"><ce:section-title id="st0305">Transient global amnesia</ce:section-title><ce:para id="p2200">Transient global amnesia (TGA) predominantly affects middle-aged people, with an abrupt, discrete loss of anterograde memory function lasting up to a few hours. During the episode, patients are unable to record new memories, resulting in repetitive questioning, the hallmark of this condition. Consciousness is preserved and patients may perform even complex motor acts normally. During the attack there is retrograde amnesia for the events of the past few days, weeks or years. After 4–6 hours, memory function and behaviour return to normal but the patient has persistent, complete amnesia for the duration of the attack itself. There are no seizure markers and, unlike epileptic amnesia, transient global amnesia recurs in only around 10–20% of cases. A vascular aetiology is unlikely (TGA is not a risk factor for subsequent vascular disease) and amnesia may be due to a benign process similar to migraine, occurring in the hippocampus. TGA causes no physical signs and, provided there is a typical history (which requires a witness), no investigation is necessary and patients may be reassured.</ce:para></ce:section><ce:section id="s0315"><ce:section-title id="st0310">Persistent amnesia</ce:section-title><ce:para id="p2205">Serious neurological disease must be excluded in patients with persistent memory disturbance, although many will prove to have benign symptoms. Symptoms corroborated by relatives or colleagues are likely to be more significant than those noted by the patient only. Where poor concentration is at the heart of cognitive deterioration, it is more likely to be due to an underlying mood disorder.</ce:para><ce:para id="p2210">It is important to assess the timing of onset and to establish which aspects of memory are affected. Complaints of getting lost or of losing complex abilities are more pathological than word-finding difficulties. Disturbance of episodic or working memory (previously called ‘short-term memory’) must be distinguished from semantic memory (memory for concept-based knowledge unrelated to specific experiences). Episodic memory is selectively impaired in Korsakoff's syndrome (often secondary to alcohol) or bilateral temporal lobe damage. It can also be seen in conjunction with other types of dementia. Progressive deterioration over months suggests an underlying dementia, and a full medical assessment must be performed to detect any underlying medical problem.</ce:para><ce:para id="p2215">It is important to identify and treat depression (<ce:intra-ref id="ii0265" xlink:href="pii:B978-0-7020-7028-0.00028-7#p0640">p. 1185</ce:intra-ref>) in patients with memory loss. Depression may present as a ‘pseudo-dementia’, with concentration and memory impairment as dominant features, and this is often reversible with antidepressant medication. Any patient with dementia (particularly of Alzheimer's type) may develop depression in the early stages of their illness, however. Specific causes of progressive dementia, with their investigation and treatment, are described elsewhere (<ce:intra-ref id="ii0270" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0480">p. 1191</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0320"><ce:section-title id="st0315">Weakness</ce:section-title><ce:para id="p2220">The assessment of weakness requires the application of basic anatomy, physiology and some pathology to the interpretation of the history and clinical findings. Points to consider are shown on <ce:cross-ref id="crf0635" refid="f0115">Figure 25.17</ce:cross-ref><ce:float-anchor refid="f0115"/> and in <ce:cross-ref id="crf0625" refid="b0085">Boxes 25.13</ce:cross-ref><ce:float-anchor refid="b0085"/> and <ce:cross-ref id="crf0630" refid="b0090">25.14</ce:cross-ref><ce:float-anchor refid="b0090"/>. The pattern and evolution of weakness and the clinical signs provide clues to the site and nature of the lesion.</ce:para><ce:para id="p2245">It is important to establish whether the patient has loss of power rather than reduced sensation or generalised fatigue. Pain may restrict movement and thus mimic weakness. Paradoxically, sensory neglect (p. 1083) may leave patients unaware of severe weakness.</ce:para><ce:para id="p2250">Patients with parkinsonism may complain of weakness; extrapyramidal signs of rigidity (cogwheel or lead pipe) and bradykinesia should be evident, and a resting tremor (usually asymmetrical) may provide a further clue (p. 1112). Simple observation of the patient walking into the consulting room may be diagnostic, and is as important as formal strength testing. Movement restricted by pain should be apparent, and other features (contractures, wasting, fasciculations, abnormal movements/postures) all provide diagnostic clues.</ce:para><ce:para id="p2255">Weakness is a common symptom arising without an underlying degenerative or destructive cause (functional symptom). Functional weakness does not conform to typical organic patterns, and the signs in <ce:cross-ref id="crf0640" refid="b0085">Box 25.13</ce:cross-ref> are absent. Clinical examination is often variable (e.g. the patient can walk but appears to have no leg movement when assessed on the couch), and strength may appear to ‘give way’, with the patient able to achieve full power for brief bursts, which does not occur in disease. Hoover's sign is useful to confirm functional weakness, and relies on eliciting the normal phenomenon of simultaneous hip extension when the contralateral hip flexes. In functional weakness, hip extension weakness may be seen; this then returns to full strength when contralateral hip flexion is tested. This sign may be demonstrated to the patient in a non-confrontational manner, to show that the potential limb power is intact.</ce:para><ce:section id="s0325"><ce:section-title id="st0320">Facial weakness</ce:section-title><ce:section id="s0330"><ce:section-title id="st0325">Facial nerve palsy (Bell's palsy)</ce:section-title><ce:para id="p2260">One of the most common causes of facial weakness is Bell's palsy, a lower motor neuron lesion of the 7th (facial) nerve, affecting all ages and both sexes. It is more common following upper respiratory tract infections, during pregnancy, and in patients with diabetes, immunosuppression and hypertension.</ce:para><ce:para id="p2265">The lesion is within the facial canal. Symptoms usually develop subacutely over a few hours, with pain around the ear preceding the unilateral facial weakness. Patients often describe the face as ‘numb’ but there is no objective sensory loss (except to taste, if the chorda tympani is involved). Hyperacusis may occur if the nerve to stapedius is involved and impairment of parasympathetic fibres may cause diminished salivation and tear secretion. Examination reveals an ipsilateral lower motor neuron facial nerve palsy (no sparing of forehead muscles). Vesicles in the ear or on the palate may indicate primary herpes zoster infection (<ce:intra-ref id="ii0285" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0615">p. 239</ce:intra-ref>). A clinical search for signs of other causes of lower motor neuron facial nerve weakness, such as parotid or scalp lesions, trauma or skull base lesions, is justified.</ce:para><ce:para id="p2270">Glucocorticoids improve recovery rates if started within 72 hours of onset but antiviral drugs are not effective. Artificial tears applied regularly prevent corneal drying, and taping the eye shut overnight helps prevent exposure keratitis and corneal abrasion. Patients unable to close the eye should be referred urgently to an ophthalmologist. About 80% of patients recover spontaneously within 12 weeks. Plastic surgery may be considered for the minority left with facial disfigurement after 12 months. Recurrence is unusual and should prompt further investigation. Aberrant re-innervation may occur during recovery, producing unwanted facial movements, such as eye closure when the mouth is moved (synkinesis) or ‘crocodile tears’ (tearing during salivation).</ce:para><ce:para id="p2275">Unlike Bell's palsy, lesions with an upper motor neuron origin may spare the upper face. Cortical lesions may cause a facial weakness either in isolation or with associated hemiparesis and speech difficulties.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0335"><ce:section-title id="st0330">Sensory disturbance</ce:section-title><ce:para id="p2280">Sensory symptoms are common and frequently benign. Patients often find sensory symptoms difficult to describe and sensory examination is difficult for both doctor and patient. While neurological disease can cause sensory symptoms, systemic disorders can also be responsible. Tingling in both hands and around the mouth can occur as the result of hyperventilation (<ce:intra-ref id="ii0290" xlink:href="pii:B978-0-7020-7028-0.00017-2#p0805">p. 558</ce:intra-ref>) or hypocalcaemia (<ce:intra-ref id="ii0295" xlink:href="pii:B978-0-7020-7028-0.00018-4#p2880">p. 662</ce:intra-ref>). When there is dysfunction of the relevant cerebral cortex, the patient's perception of the wholeness or actual presence of the relevant part of the body may be distorted.</ce:para><ce:section id="s0340"><ce:section-title id="st0335">Numbness and paraesthesia</ce:section-title><ce:para id="p2285">The history may give the best clues to localisation and pathology. Certain common patterns are recognised: in migraine, the aura may consist of spreading tingling or paraesthesia, followed by numbness evolving over 20–30 minutes over one half of the body, often splitting the tongue. Sensory loss caused by a stroke or transient ischaemic attack (TIA) occurs much more rapidly and is typically negative (numbness) rather than positive (tingling). Rarely, unpleasant paraesthesia of sensory epilepsy spreads within seconds. The sensory alteration of inflammatory spinal cord lesions often ascends from one or both lower limbs to a distinct level on the trunk over hours to days. Psychogenic sensory change can occur as a manifestation of anxiety or as part of a conversion disorder (<ce:intra-ref id="ii0300" xlink:href="pii:B978-0-7020-7028-0.00028-7#s1025">p. 1202</ce:intra-ref>). In such cases, the distribution usually neither conforms to a known anatomical pattern nor fits with any organic disease. Care must be taken in diagnosing non-organic sensory problems; a careful history and examination will ensure there is no other objective neurological deficit.</ce:para><ce:para id="p2290">Sensory neurological examination needs to be undertaken and interpreted with care because the findings depend, by definition, on subjective reports. The reported distribution of sensory loss can be useful, however, when combined with the coexisting deficits of motor and/or cranial nerve function (<ce:cross-ref id="crf0645" refid="f0120">Fig. 25.18</ce:cross-ref><ce:float-anchor refid="f0120"/>).</ce:para><ce:section id="s0345"><ce:section-title id="st0340">Sensory loss in peripheral nerve lesions</ce:section-title><ce:para id="p2295">Here the symptoms are usually of sensory loss and paraesthesia. Single nerve lesions cause disturbance in the sensory distribution of the nerve, whereas in diffuse neuropathies the longest neurons are affected first, giving a characteristic ‘glove and stocking’ distribution. If smaller nerve fibres are preferentially affected (e.g. in diabetic neuropathy), temperature and pin-prick (pain) are reduced, whilst vibration sense and proprioception (modalities served by the larger, well-myelinated, sensory nerves) may be relatively spared. In contrast, vibration and proprioception are particularly affected if the neuropathy is demyelinating in character (p. 1138), producing symptoms of tightness and swelling with impairment of proprioception and vibration sensation.</ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0345">Sensory loss in nerve root lesions</ce:section-title><ce:para id="p2300">These typically present with pain as a prominent feature, either within the spine or in the limb plexuses. Pain is often felt in the myotome rather than the dermatome. The nerve root involved may be deduced from the dermatomal pattern of sensory loss (p. 1071), although overlap may lead to this being smaller than expected.</ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0350">Sensory loss in spinal cord lesions</ce:section-title><ce:para id="p2305">Transverse lesions of the spinal cord produce loss of all sensory modalities below that segmental level, although the clinical level may only be manifest 2–3 segments lower than the anatomical site of the lesion. Very often, there is a band of paraesthesia or hyperaesthesia at the top of the area of sensory loss. Clinical examination may reveal dissociated sensory loss, i.e. different patterns in the spinothalamic and dorsal columnar pathways. If the transverse lesion is vascular due to anterior spinal artery thrombosis, the spinothalamic pathways may be affected while the posterior one-third of the spinal cord (the dorsal column modalities) may be spared.</ce:para><ce:para id="p2310">Lesions damaging one side of the spinal cord will produce loss of spinothalamic modalities (pain and temperature) on the opposite side, and of dorsal column modalities (joint position and vibration sense) on the same side of the body – the Brown–Séquard syndrome (p. 1084).</ce:para><ce:para id="p2315">Lesions in the centre of the spinal cord (such as syringomyelia: see <ce:cross-ref id="crf0650" refid="b0435">Box 25.83</ce:cross-ref> and <ce:cross-ref id="crf0655" refid="f0285">Fig. 25.51</ce:cross-ref>, pp. 1138 and 1139) spare the dorsal columns but involve the spinothalamic fibres crossing the cord from both sides over the length of the lesion. There is no sensory loss in segments above and below the lesion; this is described as ‘suspended’ sensory loss. There is sometimes reflex loss at the level of the lesion if afferent fibres of the reflex arc are affected.</ce:para><ce:para id="p2320">An isolated lesion of the dorsal columns is not uncommon in multiple sclerosis. This produces a characteristic unpleasant, tight feeling over the limb(s) involved and, while there is no loss of pin-prick or temperature sensation, the associated loss of proprioception may severely limit function of the affected limb(s).</ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0355">Sensory loss in brainstem lesions</ce:section-title><ce:para id="p2325">Lesions in the brainstem can be associated with sensory loss but the distribution depends on the site of the lesion. A lesion limited to the trigeminal nucleus or its sensory projections will cause ipsilateral facial sensory disturbance. For example, pain resembling trigeminal neuralgia can be seen in patients with multiple sclerosis. The anatomy of the trigeminal connections means that lesions in the medulla or spinal cord can give rise to ‘balaclava’ patterns of sensory loss (p. 1070). Sensory pathways running up from the spinal cord can also be damaged in the brainstem, resulting in simultaneous sensory loss in arm(s) and/or leg(s).</ce:para></ce:section><ce:section id="s0365"><ce:section-title id="st0360">Sensory loss in hemispheric lesions</ce:section-title><ce:para id="p2330">The temporal, parietal and occipital lobes receive sensory information regarding the various modalities of touch, vision, hearing and balance (see <ce:cross-ref id="crf0660" refid="b0030">Box 25.2</ce:cross-ref>, p. 1066). The initial points of entry into the cortex are the respective primary cortical areas (see <ce:cross-ref id="crf0665" refid="f0035">Fig. 25.4</ce:cross-ref>, p. 1067). Damage to any of these primary areas will result in reduction or loss of the ability to perceive that particular modality: ‘negative’ symptomatology. Abnormal excitation of these areas can result in a false perception (‘positive’ symptoms), the most common of which is migrainous visual aura (flashing lights or teichopsia).</ce:para><ce:para id="p2335">Cortical lesions are more likely to cause a mixed motor and sensory loss. Substantial lesions of the parietal cortex (as in large strokes) can cause severe loss of proprioception and may even abolish conscious awareness of the existence of the affected limb(s), known as neglect; this can be difficult to distinguish from paralysis. Pathways are so tightly packed in the thalamus that even small lacunar strokes can cause isolated contralateral hemisensory loss.</ce:para></ce:section></ce:section><ce:section id="s0370"><ce:section-title id="st0365">Neuropathic pain</ce:section-title><ce:para id="p2340">Neuropathic pain is a positive neurological symptom caused by dysfunction of the pain perception apparatus, in contrast to nociceptive pain, which is secondary to pathological processes such as inflammation. Neuropathic pain has distinctive features and typically provokes a very unpleasant, persistent, burning sensation. There is often increased sensitivity to touch, so that light brushing of the affected area causes exquisite pain (allodynia). Painful stimuli are felt as though they arise from a larger area than that touched, and spontaneous bursts of pain may also occur. Pain may be elicited by other modalities (allodynia) and is considerably affected by emotional influences. The most common causes of neuropathic pain are diabetic neuropathies, trigeminal and post-herpetic neuralgias, and trauma to a peripheral nerve. Treatment of these syndromes can be difficult. Drugs that modulate various parts of the nociceptive system, such as gabapentin, carbamazepine or tricyclic antidepressants, may help. Localised treatment (topical treatment or nerve blocks) sometimes succeeds but may increase the sensory deficit and worsen the situation. Electrical stimulation has occasionally proved successful. For further information, see <ce:intra-ref id="ii0340" xlink:href="pii:B978-0-7020-7028-0.00034-2#s0160">page 1347</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s0375"><ce:section-title id="st0370">Abnormal movements</ce:section-title><ce:para id="p2345">Disorders of movement lead to either extra, unwanted movement (hyperkinetic disorders) or too little movement (hypokinetic disorders) (<ce:cross-ref id="crf0670" refid="b0095">Box 25.15</ce:cross-ref><ce:float-anchor refid="b0095"/>). In either case, the lesion often localises to the basal ganglia, although some tremors are related to cerebellar or brainstem disturbance. Functional movement disorders are common and may mimic all of the organic syndromes below. The most important hypokinetic disorder is Parkinson's disease (p. 1112). Parkinsonism is a clinical description of a collection of symptoms, including tremor, bradykinesia and rigidity. While the history is always important, observation is clearly vital; much of the skill in diagnosing movement disorders lies in pattern recognition. Once it is established whether the problem is hypo- or hyperkinetic, the next task is to categorise the movements further, accepting that there is often overlap. Videoing the movements (with the patient's consent), so that they can be shown to a movement disorder expert, may provide a quick diagnosis in cases of uncertainty.</ce:para><ce:section id="s0380"><ce:section-title id="st0375">Tremor</ce:section-title><ce:para id="p2480">Tremor is caused by alternating agonist/antagonist muscle contractions and produces a rhythmical oscillation of the body part affected. In the assessment of tremor, the position, body part affected, frequency and amplitude should be considered, as these provide diagnostic clues (<ce:cross-ref id="crf0685" refid="b0100">Box 25.16</ce:cross-ref><ce:float-anchor refid="b0100"/>).</ce:para></ce:section><ce:section id="s0385"><ce:section-title id="st0380">Other hyperkinetic syndromes</ce:section-title><ce:para id="p2510">Non-rhythmic involuntary movements include chorea, athetosis, ballism, dystonia, myoclonus and tics. They are categorised by clinical appearance, and coexistence and overlap are common, such as in choreoathetosis.</ce:para><ce:section id="s0390"><ce:section-title id="st0385">Chorea</ce:section-title><ce:para id="p2515">Chorea refers to jerky, brief, purposeless involuntary movements, appearing fidgety and affecting different areas. They suggest disease in the caudate nucleus (as in Huntington's disease, p. 1114) and are a common complication of levodopa treatment for Parkinson's disease. Other causes are shown in <ce:cross-ref id="crf0690" refid="b0105">Box 25.17</ce:cross-ref><ce:float-anchor refid="b0105"/>.</ce:para></ce:section><ce:section id="s0395"><ce:section-title id="st0390">Athetosis</ce:section-title><ce:para id="p2620">Slower, writhing movement of the limbs are often combined with chorea and have similar causes.</ce:para></ce:section><ce:section id="s0400"><ce:section-title id="st0395">Ballism</ce:section-title><ce:para id="p2625">This more dramatic form of chorea causes often violent flinging movements of one limb (monoballism) or one side of the body (hemiballism). The lesion localises to the contralateral subthalamic nucleus and the most common cause is stroke.</ce:para></ce:section><ce:section id="s0405"><ce:section-title id="st0400">Dystonia</ce:section-title><ce:para id="p2630">Sustained involuntary muscle contraction causes abnormal postures or movement. It may be generalised (usually in childhood-onset genetic syndromes) or, more commonly, focal/segmental (such as in torticollis, when the head is twisted repeatedly to one side). Some dystonias occur only with specific tasks, such as writer's cramp or other occupational ‘cramps’. Dystonic tremor is associated, and is asymmetrical and of large amplitude.</ce:para></ce:section><ce:section id="s0410"><ce:section-title id="st0405">Myoclonus</ce:section-title><ce:para id="p2635">Myoclonus consists of brief, isolated, random jerks of muscle groups. This is physiological at the onset of sleep (hypnic jerks). Similarly, a myoclonic jerk is a component of the normal startle response, which may be exaggerated in some rare (mostly genetic) disorders. Myoclonus may occur in disorders of the cerebral cortex, such as some forms of epilepsy. Alternatively, myoclonus can arise from subcortical structures or, more rarely, from segments of the spinal cord.</ce:para></ce:section><ce:section id="s0415"><ce:section-title id="st0410">Tics</ce:section-title><ce:para id="p2640">Tics are stereotyped repetitive movements, such as blinking, winking, head shaking or shoulder shrugging. Unlike dyskinesias, the patient may be able to suppress them, although only for a short time. Isolated tics are common in childhood and usually disappear. Tourette's syndrome is defined by the presence of multiple motor and vocal tics that may evolve over time; it is frequently associated with psychiatric disease, including obsessive compulsions, depression, self-harm or attention deficit disorder. Tics may also occur in Huntington's and Wilson's diseases, or after streptococcal infection.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0420"><ce:section-title id="st0415">Abnormal perception</ce:section-title><ce:para id="p2645">The parietal lobes are involved in the higher processing and integration of primary sensory information. This takes place in areas referred to as ‘association’ cortex, damage to which gives rise to sensory (including visual) inattention, disorders of spatial perception, and disruption of spatially orientated behaviour, leading to apraxia. Apraxia is the inability to perform complex, organised activity in the presence of normal basic motor, sensory and cerebellar function (after weakness, numbness and ataxia have been excluded as causes). Examples of complex motor activities include dressing, using cutlery and geographical orientation. Other abnormalities that can result from damage to the association cortex involve difficulty reading (dyslexia) or writing (dysgraphia), or the inability to recognise familiar objects (agnosia). The results of damage to particular lobes of the brain are given in <ce:cross-ref id="crf0695" refid="b0030">Box 25.2</ce:cross-ref> (p. 1066).</ce:para></ce:section><ce:section id="s0425"><ce:section-title id="st0420">Altered balance and vertigo</ce:section-title><ce:para id="p2650">Balance is a complicated dynamic process that requires ongoing modification of both axial and limb muscles to compensate for the effects of gravity and alterations in body position and load (and hence centre of gravity) in order to prevent a person from falling. This requires input from a variety of sensory modalities (visual, vestibular and proprioceptive), processing by the cerebellum and brainstem, and output via a number of descending pathways (e.g. vestibulospinal, rubrospinal and reticulospinal tracts).</ce:para><ce:para id="p2655">Disorders of balance can therefore arise from any part of this process. Disordered input (loss of vision, vestibular disorders or lack of joint position sense), processing (damage to vestibular nuclei or cerebellum) or motor function (spinal cord lesions, leg weakness of any cause) can all impair balance. The patient may complain of different symptoms, depending on the location of the lesion. For example, loss of joint position sense or cerebellar function may result in a sensation of unsteadiness, while damage to the vestibular nuclei or labyrinth may result in an illusion of movement, such as vertigo (see below). A careful history is vital. Since vision can often compensate for lack of joint position sense, patients with peripheral neuropathies or dorsal column loss will often find their problem more noticeable in the dark.</ce:para><ce:para id="p2660">Examination of such patients may yield physical signs that again depend on the site of the lesion. Sensory abnormalities may be manifest as altered visual acuities or visual fields, possibly with abnormalities on fundoscopy, altered eye movements (including nystagmus, p. 1090), impaired vestibular function (p. 1104) or lack of joint position sense. Disturbance of cerebellar function may be manifest as nystagmus, dysarthria or ataxia, or difficulty with gait (unsteadiness or inability to perform tandem gait; see below). Leg weakness, if present, will be detectable on examination of the limbs.</ce:para><ce:section id="s0430"><ce:section-title id="st0425">Vertigo</ce:section-title><ce:para id="p2665">Vertigo is defined as an abnormal perception of movement of the environment or self, and occurs because of conflicting visual, proprioceptive and vestibular information about a person's position in space. Vertigo commonly arises from imbalance of vestibular input and is within the experience of most people, since this is the ‘dizziness’ that occurs after someone has spun round vigorously and then stops. Bilateral labyrinthine dysfunction often causes some unsteadiness. Labyrinthine vertigo usually lasts days at a time, though it may recur, while vertigo arising from central (brainstem) disorders is often persistent and accompanied by other brainstem signs. Benign paroxysmal positional vertigo (p. 1104) lasts a few seconds on head movement. A careful history will reveal the likely cause in most patients.</ce:para></ce:section></ce:section><ce:section id="s0435"><ce:section-title id="st0430">Abnormal gait</ce:section-title><ce:para id="p2670">Many neurological disorders can affect gait. Observing patients as they walk into the consulting room can be very informative, although formal examination is also important. Neurogenic gait disorders need to be distinguished from those due to skeletal abnormalities, usually characterised by pain producing an antalgic gait, or limp. Gait alteration incompatible with any anatomical or physiological deficit may be due to functional disorders.</ce:para><ce:section id="s0440"><ce:section id="s0445"><ce:section-title id="st0435">Pyramidal gait</ce:section-title><ce:para id="p2675">Upper motor neuron lesions cause characteristic extension of the affected leg. The resultant tendency for the toes to strike the ground on walking requires the leg to swing outwards at the hip (circumduction). Nevertheless, a shoe on the affected side worn down at the toes may provide evidence of this type of gait. In hemiplegia, the asymmetry between affected and normal sides is obvious on walking, but in paraparesis both lower limbs swing slowly from the hips in extension and are dragged stiffly over the ground – described as ‘walking in mud’.</ce:para></ce:section><ce:section id="s0450"><ce:section-title id="st0440">Foot drop</ce:section-title><ce:para id="p2680">In normal walking, the heel is the first part of the foot to hit the ground. A lower motor neuron lesion affecting the leg will cause weakness of ankle dorsiflexion, resulting in a less controlled descent of the foot, which makes a slapping noise as it hits the ground. In severe cases, the foot will have to be lifted higher at the knee to allow room for the inadequately dorsiflexed foot to swing through, resulting in a high-stepping gait.</ce:para></ce:section><ce:section id="s0455"><ce:section-title id="st0445">Myopathic gait</ce:section-title><ce:para id="p2685">During walking, alternating transfer of the body's weight through each leg requires adequate hip abduction. In proximal muscle weakness, usually caused by muscle disease, the hips are not properly fixed by these muscles and trunk movements are exaggerated, producing a rolling or waddling gait.</ce:para></ce:section><ce:section id="s0460"><ce:section-title id="st0450">Ataxic gait</ce:section-title><ce:para id="p2690">An ataxic gait can result from lesions in the cerebellum, vestibular apparatus or peripheral nerves. Patients with lesions of the central portion of the cerebellum (the vermis) walk with a characteristic broad-based gait ‘as if drunk’ (cerebellar function is particularly sensitive to alcohol). Patients with acute vestibular disturbances walk similarly but the accompanying vertigo is characteristic. Inability to walk heel to toe may be the only sign of less severe cerebellar dysfunction.</ce:para><ce:para id="p2695">Proprioceptive defects can also cause an ataxic gait. The impairment of joint position sense makes walking unreliable, especially in poor light. The feet tend to be placed on the ground with greater emphasis, presumably to enhance proprioceptive input, resulting in a ‘stamping’ gait.</ce:para></ce:section><ce:section id="s0465"><ce:section-title id="st0455">Apraxic gait</ce:section-title><ce:para id="p2700">In an apraxic gait, power, cerebellar function and proprioception are normal on examination of the legs. The patient may be able to carry out complex motor tasks (e.g. bicycling motion) while recumbent and yet cannot formulate the motor act of walking. In this higher cerebral dysfunction, the feet appear stuck to the floor and the patient cannot walk. Gait apraxia is a sign of diffuse bilateral hemisphere disease (such as normal pressure hydrocephalus) or diffuse frontal lobe disease.</ce:para></ce:section><ce:section id="s0470"><ce:section-title id="st0460">Marche à petits pas</ce:section-title><ce:para id="p2705">This gait is characterised by small, slow steps and marked instability. It differs from the festination found in Parkinson's disease (see below), in that it lacks increasing pace and freezing. The usual cause is small-vessel cerebrovascular disease and there may be accompanying bilateral upper motor neuron signs.</ce:para></ce:section><ce:section id="s0475"><ce:section-title id="st0465">Extrapyramidal gait</ce:section-title><ce:para id="p2710">The rigidity and bradykinesia of basal ganglia dysfunction (p. 1112) lead to a stooped posture and characteristic gait difficulties, with problems initiating walking and controlling the pace of the gait. Patients may become stuck while trying to start walking or when walking through doorways (‘freezing’). The centre of gravity will be moved forwards to aid propulsion, which, with poor axial control, can lead to an accelerating pace of shuffling and difficulty stopping. This produces the festinant gait: initial stuttering steps that quickly increase in frequency while decreasing in length.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0480"><ce:section-title id="st0470">Abnormal speech and language</ce:section-title><ce:para id="p2715">Speech disturbance may be isolated to disruption of sound output (dysarthria) or may involve language disturbance (dysphasia). Dysphonia (reduction in the sound/volume) is usually due to mechanical laryngeal disruption, whereas dysarthria is more typically neurological in origin. Dysphasia is always neurological and localises to the dominant cerebral hemisphere (usually left, regardless of handedness). Combinations of speech and swallowing problems are explained below (p. 1093).</ce:para><ce:section id="s0485"><ce:section-title id="st0475">Dysphonia</ce:section-title><ce:para id="p2720">Dysphonia describes hoarse or whispered speech. The most common cause is laryngitis, but dysphonia can also result from a lesion of the 10th cranial nerve or disease of the vocal cords, including laryngeal dystonia. Parkinsonism may cause hypophonia with marked reduction in speech volume, often in association with dysarthria, making speech difficult to understand.</ce:para></ce:section><ce:section id="s0490"><ce:section-title id="st0480">Dysarthria</ce:section-title><ce:para id="p2725">Dysarthria is characterised by poorly articulated or slurred speech and can occur in association with lesions of the cerebellum, brainstem and lower cranial nerves, as well as in myasthenia or myopathic disease. Language function is not affected. The quality of the speech tends to differ, depending on the cause, but it can be very difficult to distinguish the different types clinically (<ce:cross-ref id="crf0700" refid="b0110">Box 25.18</ce:cross-ref><ce:float-anchor refid="b0110"/>). Dysarthria is discussed further in the section on bulbar symptoms (p. 1093).</ce:para></ce:section><ce:section id="s0495"><ce:section-title id="st0485">Dysphasia</ce:section-title><ce:para id="p2755">Dysphasia (or aphasia) is a disorder of the language content of speech. It can occur with lesions over a wide area of the dominant hemisphere (<ce:cross-ref id="crf0705" refid="f0125">Fig. 25.19</ce:cross-ref><ce:float-anchor refid="f0125"/>). Dysphasia may be categorised according to whether the speech output is fluent or non-fluent. Fluent aphasias, also called receptive aphasias, are impairments related mostly to the input or reception of language, with difficulties either in auditory verbal comprehension or in the repetition of words, phrases or sentences spoken by others. Speech is easy and fluent but there are difficulties related to the output of language as well, such as paraphasia (either substitution of similar-sounding non-words, or incorrect words) and neologisms (non-existent words). Examples include Wernicke's aphasia (which localises to the superior posterior temporal lobe), transcortical sensory aphasia, conduction aphasia and anomic aphasia.</ce:para><ce:para id="p2760">Non-fluent aphasias, also called expressive aphasias, are difficulties in articulating, but in most cases there is relatively good auditory verbal comprehension. Examples include Broca's aphasia (associated with pathologies in the inferior frontal region), transcortical motor aphasia and global aphasia.</ce:para><ce:para id="p2765">‘Pure’ aphasias are selective impairments in reading, writing or the recognition of words. These disorders may be quite selective. For example, a person is able to read but not write, or is able to write but not read. Examples include pure alexia, agraphia and pure word deafness.</ce:para><ce:para id="p2770">Dysphasia (a focal symptom) is frequently misinterpreted as disorientation (which is non-focal) and it is important always to consider dysphasia as an alternative explanation for the apparently ‘confused’ patient. Dysphasia can be misheard/misspelt as dysphagia, and for this reason some prefer to use ‘aphasia’ to avoid confusion.</ce:para></ce:section></ce:section><ce:section id="s0500"><ce:section-title id="st0490">Disturbance of smell</ce:section-title><ce:para id="p2775">Symptomatic olfactory loss is most commonly due to local causes (nasal obstruction) but may follow head injury. Hyposmia may predate motor symptoms in Parkinson's disease by many years, although it is rarely noticed by the patient. Frontal lobe lesions are a rare cause. Positive olfactory symptoms may arise in Alzheimer's disease or epilepsy.</ce:para></ce:section><ce:section id="s0505"><ce:section-title id="st0495">Visual disturbance and ocular abnormalities</ce:section-title><ce:para id="p2780">Disturbances of vision may be due to primary ocular disease or to disorders of the central connections and visual cortex. Visual symptoms are usually negative (loss of vision) but sometimes positive, most commonly in migraine. Eye movements may be disturbed, giving rise to double vision (diplopia) or blurred vision. Loss of vision is also discussed on <ce:intra-ref id="ii0400" xlink:href="pii:B978-0-7020-7028-0.00027-5#s0215">page 1170</ce:intra-ref>.</ce:para><ce:section id="s0510"><ce:section-title id="st0500">Visual loss</ce:section-title><ce:para id="p2785">Visual loss can occur as the result of lesions in any areas between the retina and the visual cortex. Patterns of visual field loss are explained by the anatomy of the visual pathways (see <ce:cross-ref id="crf0710" refid="f0050">Fig. 25.7</ce:cross-ref>, p. 1069). Associated clinical manifestations are described in <ce:cross-ref id="crf0715" refid="b0115">Box 25.19</ce:cross-ref><ce:float-anchor refid="b0115"/>. Visual symptoms affecting one eye only are due to lesions anterior to the optic chiasm.</ce:para><ce:para id="p3015">Transient visual loss is quite common and sudden-onset visual loss lasting less than 15 minutes is likely to have a vascular origin. It may be difficult to know whether the visual loss was monocular (carotid circulation) or binocular (vertebrobasilar circulation), and it is important to ask if the patient tried closing each eye in turn to see whether the symptom affected one eye or both. Visual field testing is an important part of the examination, either at the bedside or formally with perimetry. Field defects become more symmetrical (congruous), the closer the lesion comes to the visual cortex.</ce:para><ce:para id="p3020">Migrainous visual symptoms are very common and, when associated with typical headache and other migraine features, rarely pose a diagnostic challenge. They may occur in isolation, however, making distinction from TIA difficult, but TIAs typically cause negative (blindness) symptoms, whereas migraine causes positive phenomena (see below). TIAs often last for a shorter time (a few minutes), compared to the 10–60-minute duration of migraine aura, and have an abrupt onset and end, unlike the gradual evolution of a migraine aura.</ce:para></ce:section><ce:section id="s0515"><ce:section-title id="st0505">Positive visual phenomena</ce:section-title><ce:para id="p3025">The most common cause is migraine; patients may describe silvery zigzag lines (fortification spectra) or flashing coloured lights (teichopsia), usually preceding the headache. Simple flashes of light (phosphenes) may indicate damage to the retina (e.g. detachment) or to the primary visual cortex. Formed visual hallucinations may be caused by drugs or may be due to epilepsy or ‘release phenomena’ in a blind visual field (Charles Bonnet syndrome).</ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0510">Double vision</ce:section-title><ce:para id="p3030">Diplopia arises from misalignment of the eyes, meaning that the image is not projected to the same points on the two retinas. At its most subtle it may be reported as blurred rather than double vision. Monocular diplopia indicates ocular disease, while binocular diplopia suggests a neurological cause. Closing either eye in turn will abort binocular diplopia. Once the presence of binocular diplopia is confirmed, it should be established whether the diplopia is maximal in any particular direction of gaze, whether the images are separated horizontally or vertically, and whether there are any associated symptoms or signs, such as ptosis or pupillary disturbance.</ce:para><ce:para id="p3035">Binocular diplopia may result from central disorders or from disturbance of the ocular motor nerves, muscles or the neuromuscular junction (see <ce:cross-ref id="crf0720" refid="f0055">Fig. 25.8</ce:cross-ref>, p. 1070). The pattern of double vision, along with any associated features, usually allows the clinician to infer which nerves/muscles are affected, while the mode of onset and other features (e.g. fatigability in myasthenia) provide further clues to the cause.</ce:para><ce:para id="p3040">The causes of ocular motor nerve palsies are listed in <ce:cross-ref id="crf0725" refid="b0120">Box 25.20</ce:cross-ref><ce:float-anchor refid="b0120"/>. Examination findings are illustrated in <ce:cross-ref id="crf0730" refid="f0130">Figure 25.20</ce:cross-ref><ce:float-anchor refid="f0130"/>.</ce:para></ce:section><ce:section id="s0525"><ce:section-title id="st0515">Nystagmus</ce:section-title><ce:para id="p3200">Nystagmus describes a repetitive to-and-fro movement of the eyes. In central lesions, the slow drifts are the primary abnormal movement, each followed by fast (corrective) phases. Nystagmus occurs because the control systems of the eyes are defective, causing them to drift off target; corrections then become necessary to return fixation to the object of interest, causing nystagmus. The direction of the fast phase is usually designated as the direction of the nystagmus because it is easier to see. Nystagmus may be horizontal, vertical or torsional, and usually involves both eyes synchronously. It may be a physiological phenomenon in response to sustained vestibular stimulation or movement of the visual world (optokinetic nystagmus). There are many causes of pathological nystagmus, the most common sites of lesions being the vestibular system, brainstem and cerebellum.</ce:para><ce:para id="p3205">The brainstem and the cerebellum are involved in maintaining eccentric positions of gaze. Lesions will therefore allow the eyes to drift back in towards primary position, producing nystagmus with fast component beats in the direction of gaze (gaze-evoked nystagmus). This is the most common type of ‘central’ nystagmus; it is most commonly bidirectional and not usually accompanied by vertigo. Other signs of brainstem dysfunction may be evident. Brainstem disease may also cause vertical nystagmus.</ce:para><ce:para id="p3210">Unilateral cerebellar lesions may result in gaze-evoked nystagmus when looking in the direction of the lesion, where the fast phases are directed towards the side of the lesion. Cerebellar hemisphere lesions also cause ‘ocular dysmetria’, an overshoot of target-directed, fast eye movements (saccades) resembling ‘past-pointing’ in limbs.</ce:para><ce:para id="p3215">In vestibular lesions, damage to one of the horizontal canals or its connections will allow the tonic output from the healthy contralateral side to cause the eyes to drift towards the side of the lesion. This elicits recurrent compensatory fast movements away from the side of the lesion, manifest as unidirectional horizontal nystagmus. Vertical and torsional components can be seen with damage to other parts of the vestibular apparatus. The nystagmus of peripheral labyrinthine lesions is accompanied by vertigo and usually by nausea, vomiting and unsteadiness, but as the CNS habituates, the nystagmus disappears (fatigues) quite quickly. Central vestibular nystagmus is more persistent.</ce:para><ce:para id="p3220">Nystagmus also occurs as a consequence of drug toxicity and nutritional deficiency (e.g. thiamin). The severity is variable, and it may or may not result in visual degradation, though it may be associated with a sensation of movement of the visual world (oscillopsia). Nystagmus may occur as a congenital phenomenon, in which case both phases are equal and ‘pendular’, rather than having alternating fast and slow components.</ce:para></ce:section><ce:section id="s0530"><ce:section-title id="st0520">Ptosis</ce:section-title><ce:para id="p3225">Various disorders may cause drooping of the eyelids (ptosis) and these are listed in <ce:cross-ref id="crf0735" refid="b0125">Box 25.21</ce:cross-ref><ce:float-anchor refid="b0125"/> and shown on <ce:cross-ref id="crf0750" refid="f0135">Figure 25.21</ce:cross-ref><ce:float-anchor refid="f0135"/>.</ce:para></ce:section><ce:section id="s0535"><ce:section-title id="st0525">Abnormal pupillary responses</ce:section-title><ce:para id="p3360">Abnormal pupillary responses may arise from lesions at several points between the retina and brainstem. Lesions of the oculomotor nerve, ciliary ganglion and sympathetic supply produce characteristic ipsilateral disorders of pupillary function. ‘Afferent’ defects result from damage to an optic nerve, impairing the direct response of a pupil to light, although leaving the consensual response from stimulation of the normal eye intact. Structural damage to the iris itself can also result in pupillary abnormalities. Causes are given in <ce:cross-ref id="crf0755" refid="b0130">Box 25.22</ce:cross-ref><ce:float-anchor refid="b0130"/>. An example is shown in <ce:cross-ref id="crf0775" refid="f0140">Figure 25.22</ce:cross-ref><ce:float-anchor refid="f0140"/>.</ce:para></ce:section><ce:section id="s0540"><ce:section-title id="st0530">Papilloedema</ce:section-title><ce:para id="p3460">There are several causes of swelling of the optic disc but the term ‘papilloedema’ is reserved for swelling secondary to raised intracranial pressure, when obstructed axoplasmic flow from retinal ganglion cells results in swollen nerve fibres, which in turn cause capillary and venous congestion, producing papilloedema. The earliest sign is the cessation of venous pulsation seen at the disc, progression causing the disc margins to become red (hyperaemic). Disc margins become indistinct and haemorrhages may occur in the retina (<ce:cross-ref id="crf0780" refid="f0145">Fig. 25.23</ce:cross-ref><ce:float-anchor refid="f0145"/>). Lack of papilloedema never excludes raised intracranial pressure. Other causes of optic disc swelling are listed in <ce:cross-ref id="crf0785" refid="b0135">Box 25.23</ce:cross-ref><ce:float-anchor refid="b0135"/>. Some normal variations of disc appearance (e.g. optic nerve drusen, <ce:intra-ref id="ii0420" xlink:href="pii:B978-0-7020-7028-0.00027-5#s0465">p. 1178</ce:intra-ref>) can mimic disc swelling. Optic disc swelling is also discussed on <ce:intra-ref id="ii0425" xlink:href="pii:B978-0-7020-7028-0.00027-5#p0960">page 1171</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0545"><ce:section-title id="st0535">Optic atrophy</ce:section-title><ce:para id="p3550">Loss of nerve fibres causes the optic disc to appear pale, as the choroid becomes visible (<ce:cross-ref id="crf0790" refid="f0150">Fig. 25.24</ce:cross-ref><ce:float-anchor refid="f0150"/>). A pale disc (optic atrophy) follows optic nerve damage; causes include previous optic neuritis or ischaemic damage, long-standing papilloedema, optic nerve compression, trauma and degenerative conditions (e.g. Friedreich's ataxia, p. 1116).</ce:para></ce:section></ce:section><ce:section id="s0550"><ce:section-title id="st0540">Hearing disturbance</ce:section-title><ce:para id="p3555">Each cochlear organ has bilateral cortical representation, so unilateral hearing loss is a result of peripheral organ damage. Bilateral hearing dysfunction is usual and is most commonly due to age-related degeneration or noise damage, although infection and drugs (particularly diuretics and aminoglycoside antibiotics) can be a primary cause. Prominent deafness may suggest a mitochondrial disorder (see <ce:cross-ref id="crf0795" refid="b0485">Box 25.93</ce:cross-ref>, p. 1144).</ce:para></ce:section><ce:section id="s0555"><ce:section-title id="st0545">Bulbar symptoms – dysphagia and dysarthria</ce:section-title><ce:para id="p3560">Swallowing is a complex activity involving the coordinated action of lips, tongue, soft palate, pharynx and larynx, which are innervated by cranial nerves 7, 9, 10, 11 and 12. Structural causes of dysphagia are considered on <ce:intra-ref id="ii0440" xlink:href="pii:B978-0-7020-7028-0.00021-4#s0335">page 778</ce:intra-ref>. Neurological mechanisms are vulnerable to damage at different points, resulting in dysphagia that is usually accompanied by dysarthria. Tempo is again crucial: acute onset of dysphagia may occur as a result of brainstem stroke or a rapidly developing neuropathy, such as Guillain–Barré syndrome or diphtheria. Intermittent fatigable muscle weakness (including dysphagia) would suggest myasthenia gravis. Dysphagia developing over weeks or months may be seen in motor neuron disease, basal meningitis and inflammatory brainstem disease. More slowly developing dysphagia suggests a myopathy or possibly a brainstem or skull-base tumour.</ce:para><ce:para id="p3565">Pathologies affecting lower cranial nerves (9, 10, 11 and 12) frequently manifest bilaterally, producing dysphagia and dysarthria. The term ‘bulbar palsy’ is used to describe lower motor neuron lesions, either within the medulla or outside the brainstem. The tongue may be wasted and fasciculating, and palatal movement is reduced.</ce:para><ce:para id="p3570">Upper motor neuron innervation of swallowing is bilateral, so persistent dysphagia is unusual with a unilateral upper motor lesion (the exception being in the acute stages of, for example, a hemispheric stroke). Widespread lesions above the medulla will cause upper motor neuron bulbar paralysis, known as ‘pseudobulbar palsy’. Here the tongue is small and contracted, and moves slowly; the jaw jerk is brisk, and there may be associated emotional variability. Causes of these are shown in <ce:cross-ref id="crf0800" refid="b0140">Box 25.24</ce:cross-ref><ce:float-anchor refid="b0140"/>.</ce:para></ce:section><ce:section id="s0560"><ce:section-title id="st0550">Bladder, bowel and sexual disturbance</ce:section-title><ce:para id="p3635">While isolated disturbances of bladder, bowel and sexual function are rarely the sole presenting features of neurological disease, they are common complications of many chronic disorders such as multiple sclerosis, stroke and dementia, and are frequently found post head injury. Abnormalities in these functions considerably reduce quality of life for patients. Incontinence and its management are discussed elsewhere (<ce:intra-ref id="ii0480" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0300">pp. 397</ce:intra-ref>, <ce:intra-ref id="ii0485" xlink:href="pii:B978-0-7020-7028-0.00021-4#s2105">835</ce:intra-ref> and <ce:intra-ref id="ii0490" xlink:href="pii:B978-0-7020-7028-0.00032-9#p0680">1309</ce:intra-ref>).</ce:para><ce:section id="s0565"><ce:section-title id="st0555">Bladder dysfunction</ce:section-title><ce:para id="p3640">The anatomy and physiology involved in controlling bladder functions are discussed on <ce:intra-ref id="ii0495" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0045">page 386</ce:intra-ref> but it is worth emphasising the role of the pontine micturition centre, which is itself under higher control via inputs from the pre-frontal cortex, mid-brain and hypothalamus.</ce:para><ce:para id="p3645">In the absence of conscious control (e.g. in coma or dementia), distension of the bladder to near capacity evokes reflex detrusor contraction (analogous to the muscle stretch reflex), and reciprocal changes in sympathetic activation and relaxation of the distal sphincter result in coordinated bladder emptying.</ce:para><ce:para id="p3650">Damage to the lower motor neuron pathways (the pelvic and pudendal nerves) produces a flaccid bladder and sphincter with overflow incontinence, often accompanied by loss of pudendal sensation. Such damage may be due to disease of the conus medullaris or sacral nerve roots, either within the dura (as in inflammatory or carcinomatous meningitis) or as they pass through the sacrum (trauma or malignancy), or due to damage to the nerves themselves in the pelvis (infection, haematoma, trauma or malignancy).</ce:para><ce:para id="p3655">Damage to the pons or spinal cord results in an ‘upper motor neuron’ pattern of bladder dysfunction due to uncontrolled over-activity of the parasympathetic supply. The bladder is small and highly sensitive to being stretched. This results in frequency, urgency and urge incontinence. Loss of the coordinating control of the pontine micturition centre will also result in the phenomenon of detrusor–sphincter dyssynergia, in which detrusor contraction and sphincter relaxation are not coordinated; the spastic bladder will often try to empty against a closed sphincter. This manifests as both urgency and an inability to pass urine, which is distressing and painful. The resultant incomplete bladder emptying predisposes to urinary infection, and the prolonged high intravesical pressure may result in obstructive uropathy and renal failure; post-micturition bladder ultrasound may confirm incomplete bladder emptying. More severe lesions of the spinal cord, as in spinal cord compression or trauma, can result in painless urinary retention as bladder sensation, normally carried in the lateral spinothalamic tracts, will be disrupted.</ce:para><ce:para id="p3660">Damage to the frontal lobes gives rise to loss of awareness of bladder fullness and consequent incontinence. Coexisting cognitive impairment may result in inappropriate micturition. These features may be seen in hydrocephalus, frontal tumours, dementia and bifrontal subdural haematomas.</ce:para><ce:para id="p3665">When a patient presents with bladder symptoms, it is important to localise the lesion on the basis of history and examination, remembering that most bladder problems are not neurological unless there are overt neurological signs. Clinical features and management are summarised in <ce:cross-ref id="crf0810" refid="b0145">Box 25.25</ce:cross-ref><ce:float-anchor refid="b0145"/>.</ce:para></ce:section><ce:section id="s0570"><ce:section-title id="st0560">Rectal dysfunction</ce:section-title><ce:para id="p3785">The rectum has an excitatory cholinergic input from the parasympathetic sacral outflow, and inhibitory sympathetic supply similar to the bladder. Continence depends largely on skeletal muscle contraction in the puborectalis and pelvic floor muscles supplied by the pudendal nerves, as well as the internal and external anal sphincters. Damage to the autonomic components usually causes constipation (a common early symptom in Parkinson's disease) but diabetic neuropathy can be associated with diarrhoea. Lesions affecting the conus medullaris, the somatic S2–4 roots and the pudendal nerves may cause faecal incontinence.</ce:para></ce:section><ce:section id="s0575"><ce:section-title id="st0565">Erectile failure and ejaculatory failure</ce:section-title><ce:para id="p3790">These related functions are under autonomic control via the pelvic nerves (parasympathetic, S2–4) and hypogastric nerves (sympathetic, L1–2). Descending influences from the cerebrum are important for erection but it can occur as a reflex phenomenon in response to genital stimulation. Erection is largely parasympathetic and may be impaired by a number of drugs, including anticholinergic, antihypertensive and antidepressant agents. Sympathetic activity is important for ejaculation and may be inhibited by α-adrenoceptor antagonists (α-blockers). For further information on erectile dysfunction, see <ce:intra-ref id="ii0500" xlink:href="pii:B978-0-7020-7028-0.00015-9#p4005">page 440</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s0580"><ce:section-title id="st0570">Personality change</ce:section-title><ce:para id="p3795">While this is often due to psychiatric illness, neurological conditions that alter the function of the frontal lobes can cause personality change and mood disorder (see <ce:cross-ref id="crf0815" refid="b0030">Box 25.2</ce:cross-ref>, p. 1066). Personality change due to a frontal lobe disorder may occur as the result of structural damage due to stroke, trauma, tumour or hydrocephalus. The nature of any change may help localise the lesion.</ce:para><ce:para id="p3800">Patients with mesial frontal lesions become increasingly withdrawn, unresponsive and mute (abulic), often in association with urinary incontinence, gait apraxia and an increase in tone known as gegenhalten, in which the patient varies the resistance to movement in proportion to the force exerted by the examiner.</ce:para><ce:para id="p3805">Patients with lesions of the dorsolateral pre-frontal cortex develop a dysexecutive syndrome, which involves difficulties with speech, motor planning and organisation. Those with orbitofrontal lesions of the frontal lobes, in contrast, become disinhibited, displaying grandiosity or irresponsible behaviour. Memory is substantially intact but frontal release signs may emerge, such as a grasp reflex, palmomental response or pout. Proximity to the olfactory bulb and tracts means that inferior frontal lobe tumours may be associated with anosmia.</ce:para><ce:para id="p3810">Disturbance to the cortical areas responsible for speech or memory can result in changes that may be interpreted as changes in personality.</ce:para></ce:section><ce:section id="s0585"><ce:section-title id="st0575">Sleep disturbance</ce:section-title><ce:para id="p3815">Disturbances of sleep are common and are not usually due to neurological disease. Patients may complain of insomnia (difficulty sleeping), excessive daytime sleepiness, disturbed behaviour during night-time sleep, parasomnia (sleep walking and talking, or night terrors) or disturbing subjective experiences during sleep and/or its onset (nightmares, hypnagogic hallucinations, sleep paralysis). A careful history (from bed partner as well as patient) usually allows specific causes of sleep disturbance to be identified and these are discussed in more detail on page 1105.</ce:para></ce:section><ce:section id="s0590"><ce:section-title id="st0580">Psychiatric disorders</ce:section-title><ce:para id="p3820">Psychiatric disorders are described in <ce:intra-ref id="ii0515" xlink:href="pii:B978-0-7020-7028-0.00028-7#c00028">Chapter 28</ce:intra-ref> but may cause or result from neurological problems. Care is needed in their identification, as effective management will help the underlying neurological illness.</ce:para></ce:section></ce:section><ce:section id="s0595"><ce:section-title id="st0585">Functional symptoms</ce:section-title><ce:para id="p3825">Many patients presenting with neurological symptoms do not have a defined neurological disease and are best described as having functional symptoms (<ce:intra-ref id="ii0520" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0370">p. 1187</ce:intra-ref>). Some of these are psychogenic (or conversion) disorders. Such patients often have symptoms affecting multiple systems and an impressively long list of consultations and negative tests from other medical specialties when they present. Considering the possibility of a functional origin may save the patient some further anxiety and further investigation (which will be unnecessary, expensive, possibly invasive, and inconvenient).</ce:para><ce:para id="p3830">Weakness and sensory change predominate among patients with functional neurological disorders but pain or loss of consciousness can also occur. Associated symptoms, such as tiredness, lethargy, poor concentration, bowel upset (irritable bowel syndrome) and gynaecological complaints, are common. A functional cause should always be considered, as it can allow for more rapid diagnosis and minimise investigation. Some clinical features may hint at a functional origin for symptoms (<ce:cross-ref id="crf0820" refid="b0150">Box 25.26</ce:cross-ref><ce:float-anchor refid="b0150"/>). It is the clinician's (rewarding, albeit sometimes challenging) job to elicit the context of the patient's symptoms in a sensitive and non-judgemental manner. Whatever the cause of the illness, it is important to acknowledge that mood and sleep disturbance will exacerbate neurological symptoms, thus increasing disability. The best practitioners have the skill to carry the patient with them when describing the patterns of behaviour contributing to worsening symptoms.</ce:para><ce:para id="p3880">Assessment to detect an underlying or exacerbating mood disorder is vital in all patients, ensuring that depression and anxiety are managed to minimise their secondary effects on neurological symptoms.</ce:para></ce:section><ce:section id="s0600"><ce:section-title id="st0590">Headache syndromes</ce:section-title><ce:para id="p3885">Acute management of headache is dealt with on <ce:intra-ref id="ii0530" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0155">page 184</ce:intra-ref> but management of chronic, complex, or refractory headaches may require specialist input. Headaches may be classified as primary or secondary, depending on the underlying cause (see <ce:intra-ref id="ii0535" xlink:href="pii:B978-0-7020-7028-0.00010-X#b0060">Box 10.10</ce:intra-ref>, <ce:intra-ref id="ii0540" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0155">p. 184</ce:intra-ref>). Secondary headache may be due to structural, infective, inflammatory or vascular conditions, discussed later in this chapter. Primary headache syndromes are described here.</ce:para><ce:section id="s0605"><ce:section id="s0610"><ce:section-title id="st0595">Tension-type headache</ce:section-title><ce:para id="p3890">This is the most common type of headache and is experienced to some degree by the majority of the population.</ce:para><ce:section id="s0615"><ce:section-title id="st0600">Pathophysiology</ce:section-title><ce:para id="p3895">Tension-type headache is incompletely understood, and some consider that it is simply a milder version of migraine; certainly, the original notion that it is due primarily to muscle tension (hence the unsatisfactory name) has long since been dismissed. Anxiety about the headache itself may lead to continuation of symptoms, and patients may become convinced of a serious underlying condition.</ce:para></ce:section><ce:section id="s0620"><ce:section-title id="st0605">Clinical features</ce:section-title><ce:para id="p3900">The pain of tension headache is characterised as ‘dull’, ‘tight’ or like a ‘pressure’, and there may be a sensation of a band round the head or pressure at the vertex. It is of constant character and generalised, but often radiates forwards from the occipital region. It may be episodic or persistent, although the severity may vary, and there is no associated vomiting or photophobia. Tension-type headache is rarely disabling and patients appear well. The pain often progresses throughout the day. Tenderness may be present over the skull vault or in the occiput but is easily distinguished from the triggered pains of trigeminal neuralgia and the exquisite tenderness of temporal arteritis. Analgesics may be taken with chronic regularity, despite little effect, and may perpetuate the symptoms (see ‘<ce:cross-ref id="crf0825" refid="s0650">Medication overuse headache</ce:cross-ref>’ below).</ce:para></ce:section><ce:section id="s0625"><ce:section-title id="st0610">Management</ce:section-title><ce:para id="p3905">Most benefit is derived from a careful assessment, followed by discussion of likely precipitants and reassurance that the prognosis is good. The concept of medication overuse headache needs careful explanation. An important therapeutic step is to allow patients to realise that their problem has been taken seriously and rigorously assessed. Physiotherapy (with muscle relaxation and stress management) may help and low-dose amitriptyline can provide benefit. Investigation is rarely required. The reassurance value of brain imaging needs careful assessment: the pick-up rate of structural abnormalities is exceedingly low, and significantly outweighed by the likelihood of identifying an incidental and irrelevant finding (e.g. an arachnoid cyst, Chiari I malformation or vascular abnormality). The value of such ‘reassurance’ is usually over-estimated by doctors and patients alike.</ce:para></ce:section></ce:section><ce:section id="s0630"><ce:section-title id="st0615">Migraine</ce:section-title><ce:para id="p3910">Migraine usually appears before middle age, or occasionally in later life; it affects about 20% of females and 6% of males at some point in life. Migraine is usually readily identifiable from the history, although unusual variants can cause uncertainty.</ce:para><ce:section id="s0635"><ce:section-title id="st0620">Pathophysiology</ce:section-title><ce:para id="p3915">The cause of migraine is unknown but there is increasing evidence that the aura (see below) is due to dysfunction of ion channels causing a spreading front of cortical depolarisation (excitation) followed by hyperpolarisation (depression of activity). This process (the ‘spreading depression of Leão’) spreads over the cortex at a rate of about 3 mm/min, corresponding to the aura's symptomatic spread. The headache phase is associated with vasodilatation of extracranial vessels and may be relayed by hypothalamic activity. Activation of the trigeminovascular system is probably important. A genetic contribution is implied by the frequently positive family history, and similar phenomena occurring in disorders such as CADASIL (<ce:intra-ref id="ii9000" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1770">p. 1052</ce:intra-ref>) or mitochondrial disease (p. 1144). The female preponderance and the frequency of migraine attacks at certain points in the menstrual cycle also suggest hormonal influences. Oestrogen-containing oral contraception sometimes exacerbates migraine and increases the very small risk of stroke in patients who suffer from migraine with aura. Doctors and patients often over-estimate the role of dietary precipitants such as cheese, chocolate or red wine. When psychological factors contribute, the migraine attack often occurs after a period of stress, being more likely on Friday evening at the end of the working week or at the beginning of a holiday.</ce:para></ce:section><ce:section id="s0640"><ce:section-title id="st0625">Clinical features</ce:section-title><ce:para id="p3920">Some patients report a prodrome of malaise, irritability or behavioural change for some hours or days. Around 20% of patients experience an aura and are said to have migraine with aura (previously known as classical migraine). The aura may manifest as almost any neurological symptom but is most often visual, consisting of fortification spectra, which are usually positive phenomena such as shimmering, silvery zigzag lines marching across the visual fields for up to 40 minutes, sometimes leaving a trail of temporary visual field loss (scotoma). Sensory symptoms characteristically spreading over 20–30 minutes, from one part of the body to another, are more common than motor ones, and language function can be affected, leading to similarities with TIA/stroke. Isolated aura may occur (i.e. the neurological symptoms are not followed by headache).</ce:para><ce:para id="p3925">The 80% of patients with characteristic headache but no ‘aura’ are said to have migraine without aura (previously called ‘common’ migraine).</ce:para><ce:para id="p3930">Migraine headache is usually severe and throbbing, with photophobia, phonophobia and vomiting lasting from 4 to 72 hours. Movement makes the pain worse and patients prefer to lie in a quiet, dark room.</ce:para><ce:para id="p3935">In a small number of patients the aura may persist, leaving more permanent neurological disturbance. This persistent migrainous aura may occur with or without evidence of brain infarction.</ce:para></ce:section><ce:section id="s0645"><ce:section-title id="st0630">Management</ce:section-title><ce:para id="p3940">Avoidance of identified triggers or exacerbating factors (such as the combined contraceptive pill) may prevent attacks. Treatment of an acute attack consists of simple analgesia with aspirin, paracetamol or non-steroidal anti-inflammatory agents. Nausea may require an antiemetic such as metoclopramide or domperidone. Severe attacks can be aborted by one of the ‘triptans’ (e.g. sumatriptan), which are potent 5-hydroxytryptamine (5-HT, serotonin) agonists. These can be administered via the oral, subcutaneous or nasal route. Caution is needed with ergotamine preparations because they may lead to dependence. Overuse of any analgesia, including triptans, may contribute to medication overuse headache.</ce:para><ce:para id="p3945">If attacks are frequent (more than two per month), prophylaxis should be considered. Many drugs can be chosen but the most frequently used are vasoactive drugs (β-blockers), antidepressants (amitriptyline, dosulepin) and antiepileptic drugs (valproate, topiramate). Women with aura should avoid oestrogen treatment for either oral contraception or hormone replacement, although the increased risk of ischaemic stroke is minimal.</ce:para></ce:section></ce:section><ce:section id="s0650"><ce:section-title id="st0635">Medication overuse headache</ce:section-title><ce:para id="p3950">With increasing availability of over-the-counter medication, headache syndromes perpetuated by analgesia intake are becoming much more common. Medication overuse headache (MOH) can complicate any headache syndrome but is especially common with migraine and chronic tension-type headache. The most frequent culprits are compound analgesics (particularly codeine and other opiate-containing preparations) and triptans, and MOH is usually associated with use on more than 10–15 days per month.</ce:para><ce:para id="p3955">Management is by withdrawal of the responsible analgesics. Patients should be warned that the initial effect will be to exacerbate the headache, and migraine prophylactics may be helpful in reducing the rebound headaches. Relapse rates are high, and patients often need help and support in withdrawing from analgesia; a careful explanation of this paradoxical concept is vital.</ce:para></ce:section><ce:section id="s0655"><ce:section-title id="st0640">Cluster headache</ce:section-title><ce:para id="p3960">Cluster headaches (also known as migrainous neuralgia) are much less common than migraine. Unusually for headache syndromes, there is a significant male predominance and onset is usually in the third decade.</ce:para><ce:section id="s0660"><ce:section-title id="st0645">Pathophysiology</ce:section-title><ce:para id="p3965">The cause is unknown but this type of headache differs from migraine in many ways, suggesting a different pathophysiological basis. Although uncommon, it is the most common of the trigeminal autonomic cephalalgia syndromes. Functional imaging studies have suggested abnormal hypothalamic activity. Patients are more often smokers with a higher than average alcohol consumption.</ce:para></ce:section><ce:section id="s0665"><ce:section-title id="st0650">Clinical features</ce:section-title><ce:para id="p3970">Cluster headache is strikingly periodic, featuring runs of identical headaches beginning at the same time for weeks at a stretch (the ‘cluster’). Patients may experience either one or several attacks within a 24-hour period, and typically are awoken from sleep by symptoms (‘alarm clock headache’). Cluster headache causes severe, unilateral periorbital pain with autonomic features, such as ipsilateral tearing, nasal congestion and conjunctival injection (occasionally with the other features of a Horner's syndrome). The pain, though severe, is characteristically brief (30–90 minutes). In contrast to the behaviour of those with migraine, patients are highly agitated during the headache phase. The cluster period is typically a few weeks, followed by remission for months to years, but a small proportion do not experience remission.</ce:para></ce:section><ce:section id="s0670"><ce:section-title id="st0655">Management</ce:section-title><ce:para id="p3975">Acute attacks can usually be halted by subcutaneous injections of sumatriptan or inhalation of 100% oxygen. The brevity of the attack probably prevents other migraine therapies from being effective. Migraine prophylaxis is often ineffective too but attacks can be prevented in some patients by verapamil, sodium valproate, or short courses of oral glucocorticoids. Patients with severe debilitating clusters can be helped with lithium therapy, although this requires monitoring (<ce:intra-ref id="ii0550" xlink:href="pii:B978-0-7020-7028-0.00028-7#p2385">p. 1200</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0675"><ce:section-title id="st0660">Trigeminal neuralgia</ce:section-title><ce:para id="p3980">This is characterised by unilateral lancinating facial pain, most commonly involving the second and/or third divisions of the trigeminal nerve territory, usually in patients over the age of 50 years.</ce:para><ce:section id="s0680"><ce:section-title id="st0665">Pathophysiology</ce:section-title><ce:para id="p3985">For most, trigeminal neuralgia remains an idiopathic condition but there is a suggestion that it may be due to an irritative lesion involving the trigeminal root zone, in some cases an aberrant loop of artery. Other compressive lesions, usually benign, are occasionally found. Trigeminal neuralgia associated with multiple sclerosis may result from a plaque of demyelination in the brainstem.</ce:para></ce:section><ce:section id="s0685"><ce:section-title id="st0670">Clinical features</ce:section-title><ce:para id="p3990">The pain is repetitive, severe and very brief (seconds or less). It may be triggered by touch, a cold wind or eating. Physical signs are usually absent, although the spasms may make the patient wince and sit silently (tic douloureux). There is a tendency for the condition to remit and relapse over many years. Rarely, there may be combined features of trigeminal neuralgia and cluster headache (‘cluster–tic’).</ce:para></ce:section><ce:section id="s0690"><ce:section-title id="st0675">Management</ce:section-title><ce:para id="p3995">The pain often responds to carbamazepine. It is wise to start with a low dose and increase gradually, according to effect. In patients who cannot tolerate carbamazepine, oxcarbazepine, gabapentin, pregabalin, amitriptyline or glucocorticoids may be effective alternatives, but if medication is ineffective or poorly tolerated, surgical treatment should be considered. Decompression of the vascular loop encroaching on the trigeminal root is said to have a 90% success rate. Otherwise, localised injection of alcohol or phenol into a peripheral branch of the nerve may be effective.</ce:para></ce:section></ce:section><ce:section id="s0695"><ce:section-title id="st0680">Headaches associated with specific activities</ce:section-title><ce:para id="p4000">These usually affect men in their thirties and forties. Patients develop a sudden, severe headache with exertion, including sexual activity. There is usually no vomiting or neck stiffness, and the headache lasts less than 10–15 minutes, though a less severe dullness may persist for some hours. Subarachnoid haemorrhage needs to be excluded by CT and/or CSF examination (see <ce:intra-ref id="ii0555" xlink:href="pii:B978-0-7020-7028-0.00026-3#f0085">Fig. 26.14</ce:intra-ref>, <ce:intra-ref id="ii0560" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0330">p. 1162</ce:intra-ref>) after a first event. The pathogenesis of these headaches is unknown. Although frightening, attacks are usually brief and patients may need only reassurance and simple analgesia for the residual headache. The syndrome may recur, and prevention may be necessary with propranolol or indometacin.</ce:para></ce:section><ce:section id="s0700"><ce:section-title id="st0685">Other headache syndromes</ce:section-title><ce:para id="p4005">A number of rare headache syndromes produce pains about the eye similar to cluster headaches (<ce:cross-ref id="crf0830" refid="b0155">Box 25.27</ce:cross-ref><ce:float-anchor refid="b0155"/>). These include chronic paroxysmal hemicrania and SUNCT (short-lasting unilateral neuralgiform headaches with conjunctival injection and tearing). The recognition of these syndromes is useful because they often respond to specific treatments such as indometacin.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0705"><ce:section-title id="st0690">Epilepsy</ce:section-title><ce:para id="p4015">A seizure can be defined as the occurrence of signs and/or symptoms due to abnormal, excessive or synchronous neuronal activity in the brain. The lifetime risk of an isolated seizure is about 5%, although incidence is highest at the extremes of age. Epilepsy is the tendency to have unprovoked seizures. While the prevalence of active epilepsy in European countries is about 0.5%, the figure in developing countries may be higher because of parasitic illnesses such as cysticercosis (<ce:intra-ref id="ii0565" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2750">p. 298</ce:intra-ref>). A recent change in definition allows the diagnosis of epilepsy to be made after a single seizure with a high risk of recurrence (e.g. a single seizure in the presence of a cortical lesion). Such changes may lead to an observed increase in epilepsy incidence.</ce:para><ce:para id="p4020">Historical terms such as ‘grand mal’ (implying tonic–clonic seizures) and ‘petit mal’ (intended originally to mean ‘absence seizures’ but commonly misused to describe ‘anything other than grand mal’) have been superseded. Subsequent revisions, including terms such as ‘complex partial’ and ‘simple partial’, have been imprecise and carry little information about underlying pathology, treatment or prognosis. The modern equivalents for these terms will be given below, but it is preferable to adhere to the 2010 iteration of the International League Against Epilepsy's classification (<ce:cross-ref id="crf0840" refid="b0160">Box 25.28</ce:cross-ref><ce:float-anchor refid="b0160"/>).</ce:para><ce:section id="s0710"><ce:section id="s0715"><ce:section-title id="st0695">Pathophysiology</ce:section-title><ce:para id="p4145">To function normally, the brain must maintain a continual balance between excitation and inhibition, remaining responsive to the environment while avoiding continued unrestrained spontaneous activity. The inhibitory transmitter gamma-aminobutyric acid (GABA) is particularly important, acting on ion channels to enhance chloride inflow and reducing the chances of action potential formation. Excitatory amino acids (glutamate and aspartate) allow influx of sodium and calcium, producing the opposite effect. It is likely that many seizures result from an imbalance between this excitation and inhibition. Intracellular recordings during seizures demonstrate a paroxysmal depolarisation shift in neuronal membrane potential, an upshift in internal potential predisposing to recurrent action potentials. In vivo, epileptic cortex shows repetitive discharges involving large groups of neurons.</ce:para><ce:section id="s0720"><ce:section-title id="st0700">Focal epilepsy</ce:section-title><ce:para id="p4150">Seizures may be related to a localised disturbance in the cortex, becoming manifest in the first instance as focal seizures. Any disturbance of cortical architecture and function can precipitate this, whether focal infection, tumour, hamartoma or trauma-related scarring. If focal seizures remain localised, the symptoms experienced depend on which cortical area is affected. If areas in the temporal lobes become involved, then awareness of the environment becomes impaired but without associated tonic–clonic movements. When both hemispheres become involved, the seizure becomes generalised (<ce:cross-ref id="crf0845" refid="f0155">Fig. 25.25</ce:cross-ref><ce:float-anchor refid="f0155"/>).</ce:para></ce:section><ce:section id="s0725"><ce:section-title id="st0705">Generalised epilepsies</ce:section-title><ce:para id="p4155">The new terminology is genetic generalised epilepsies (GGEs) (previously idiopathic generalised epilepsies) to reflect their likely cause. These seizures are generalised at onset, abnormal activity probably originating in the central mechanisms controlling cortical activation (<ce:cross-ref id="crf0850" refid="f0155">Fig. 25.25</ce:cross-ref>) and spreading rapidly. This group constitutes around 30% of all epilepsy and is likely to reflect widespread disturbance of structure or function. GGEs almost always become apparent before the age of 35.</ce:para><ce:para id="p4160">Seizure activity is usually apparent on EEG as spike and wave discharges (see <ce:cross-ref id="crf0855" refid="f0100">Fig. 25.14</ce:cross-ref>, p. 1075). Other generalised seizures may involve merely brief loss of awareness (absence seizures), single jerks (myoclonus) or loss of tone (atonic seizures), as detailed in <ce:cross-ref id="crf0860" refid="b0160">Box 25.28</ce:cross-ref>.</ce:para></ce:section></ce:section><ce:section id="s0730"><ce:section-title id="st0710">Clinical features</ce:section-title><ce:section id="s0735"><ce:section-title id="st0715">Seizure type and epilepsy type</ce:section-title><ce:para id="p4165">Patients can experience more than one type of seizure attack, and it is important to document each attack type and the patient's age at its onset, along with its frequency, duration and typical features. Any triggers should be identified (<ce:cross-ref id="crf0865" refid="b0165">Box 25.29</ce:cross-ref><ce:float-anchor refid="b0165"/>). The type of seizure, other clinical features and investigations can then be used to determine the epilepsy syndrome, as discussed below. Where there is doubt about the type, this is best stated and a full classification should be deferred until the evolution of the clinical features clarifies the picture.</ce:para><ce:para id="p4215">To classify seizure type, the clinician should ask firstly whether there is a focal onset, and secondly whether the seizures conform to one of the recognised patterns (see <ce:cross-ref id="crf0870" refid="b0160">Box 25.28</ce:cross-ref>). Epilepsy that starts in patients beyond their mid-thirties will almost invariably reflect a focal cerebral event. Where activity remains focal, the classification will be obvious. With generalised tonic–clonic seizures, a focal onset will be heralded by positive neurological symptoms and signs corresponding to the normal function of that area. Occipital onset causes visual changes (lights and blobs of colour), temporal lobe onset causes false recognition (déjà vu), sensory strip involvement causes sensory alteration (burning, tingling), and motor strip involvement causes jerking.</ce:para><ce:para id="p4220">Alternatively, patients report a previous local cortical insult, and it may be reasonably (but not invariably) inferred that this is the seat of epileptogenesis.</ce:para><ce:section id="s0740"><ce:section-title id="st0720">Focal seizures</ce:section-title><ce:para id="p4225">The classification of focal seizures is shown in <ce:cross-ref id="crf0875" refid="b0160">Box 25.28</ce:cross-ref>. They are caused by localised cortical activity with retained awareness. The localisation of such symptoms is described above. A spreading pattern of seizure may occur, the abnormal sensation spreading much faster (in seconds) than a migrainous focal sensory attack.</ce:para><ce:para id="p4230">Awareness may become impaired if spread occurs to the temporal lobes (previously ‘complex partial seizure’). Patients stop and stare blankly, often blinking repetitively, making smacking movements of their lips or displaying other automatisms, such as picking at their clothes. After a few minutes consciousness returns but the patient may be muddled and feel drowsy for a period of up to an hour. The age of onset, preceding aura, longer duration and post-ictal symptoms usually make these easy to differentiate from childhood absence seizures (see below).</ce:para><ce:para id="p4235">Seizures arising from the anterior parts of the frontal lobe may produce bizarre behaviour patterns, including limb posturing, sleep walking or even frenetic, ill-directed motor activity with incoherent screaming. Video EEG may be necessary to differentiate these from psychogenic attacks (which are more common) but abruptness of onset, stereotyped nature, relative brevity and nocturnal preponderance may indicate a frontal origin. Causes of focal seizures are given in <ce:cross-ref id="crf0880" refid="b0170">Box 25.30</ce:cross-ref><ce:float-anchor refid="b0170"/>.</ce:para></ce:section><ce:section id="s0745"><ce:section-title id="st0725">Generalised seizures</ce:section-title><ce:section id="s0750"><ce:section-title id="st0730">Tonic–clonic seizures</ce:section-title><ce:para id="p4365">An initial ‘aura’ may be experienced by the patient, depending on the cortical area from which the seizure originates (as above). The patient then becomes rigid (tonic) and unconscious, falling heavily if standing (‘like a log’) and risking facial injury. During this phase, breathing stops and central cyanosis may occur. As cortical discharges reduce in frequency, jerking (clonic) movements emerge for 2 minutes at most. Afterwards, there is a flaccid state of deep coma, which can persist for some minutes, and on regaining awareness the patient may be confused, disorientated and/or amnesic. During the attack, urinary incontinence and tongue-biting may occur. A severely bitten, bleeding tongue after an attack of loss of consciousness is pathognomonic of a generalised seizure but less marked lingual injury can occur in syncope. Subsequently, the patient usually feels unwell and sleepy, with headache and myalgia. Witnesses are usually frightened by the event, often believe the person to be dying, and may struggle to give a clear account of the episode. Some may not describe the tonic or clonic phase and may not mention cyanosis or tongue-biting. In less typical episodes, post-ictal delirium, or sequelae such as headache or myalgia, may be the main pointers to the diagnosis. Causes of generalised tonic–clonic seizures are listed in <ce:cross-ref id="crf0885" refid="b0175">Box 25.31</ce:cross-ref><ce:float-anchor refid="b0175"/>.</ce:para></ce:section><ce:section id="s0755"><ce:section-title id="st0735">Absence seizures</ce:section-title><ce:para id="p4495">Absence seizures (previously ‘petit mal’) always start in childhood. The attacks are rarely mistaken for focal seizures because of their brevity. They can occur so frequently (20–30 times a day) that they are mistaken for daydreaming or poor concentration in school.</ce:para></ce:section><ce:section id="s0760"><ce:section-title id="st0740">Myoclonic seizures</ce:section-title><ce:para id="p4500">These are typically brief, jerking movements, predominating in the arms. In epilepsy, they are more marked in the morning or on awakening from sleep, and tend to be provoked by fatigue, alcohol, or sleep deprivation.</ce:para></ce:section><ce:section id="s0765"><ce:section-title id="st0745">Atonic seizures</ce:section-title><ce:para id="p4505">These are seizures involving brief loss of muscle tone, usually resulting in heavy falls with or without loss of consciousness. They occur only in the context of epilepsy syndromes that involve other forms of seizure.</ce:para></ce:section><ce:section id="s0770"><ce:section-title id="st0750">Tonic seizures</ce:section-title><ce:para id="p4510">These are associated with a generalised increase in tone and an associated loss of awareness. They are usually seen as part of an epilepsy syndrome and are unlikely to be isolated.</ce:para></ce:section><ce:section id="s0775"><ce:section-title id="st0755">Clonic seizures</ce:section-title><ce:para id="p4515">Clonic seizures are similar to tonic–clonic seizures. The clinical manifestations are similar but there is no preceding tonic phase.</ce:para></ce:section></ce:section><ce:section id="s0780"><ce:section-title id="st0760">Seizures of uncertain generalised or focal nature</ce:section-title><ce:section id="s0785"><ce:section-title id="st0765">Epileptic spasms</ce:section-title><ce:para id="p4520">While these are highlighted in the classification system, they are unusual in adult practice and occur mainly in infancy. They signify widespread cortical disturbance and take the form of marked contractions of the axial musculature, lasting a fraction of a second but recurring in clusters of 5–50, often on awakening.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0790"><ce:section-title id="st0770">Epilepsy syndromes</ce:section-title><ce:para id="p4525">Many patients with epilepsy fall into specific patterns, depending on seizure type(s), age of onset and treatment responsiveness: the so-called electroclinical syndromes (<ce:cross-ref id="crf0895" refid="b0180">Box 25.32</ce:cross-ref><ce:float-anchor refid="b0180"/>). It is anticipated that genetic testing will ultimately demonstrate similarities in molecular pathophysiology.</ce:para><ce:para id="p4645"><ce:cross-ref id="crf0900" refid="b0185">Box 25.33</ce:cross-ref><ce:float-anchor refid="b0185"/> highlights the more common epilepsy syndromes, which are largely of early onset and are sensitive to sleep deprivation, hyperventilation, alcohol and photic stimulation. Epilepsies that do not fit into any of these diagnostic categories can be delineated firstly on the basis of the presence or absence of a known structural or metabolic condition (presumed cause), and then on the basis of the primary mode of seizure onset (generalised versus focal).</ce:para></ce:section><ce:section id="s0795"><ce:section-title id="st0775">Investigations</ce:section-title><ce:section id="s0800"><ce:section-title id="st0780">Single seizure</ce:section-title><ce:para id="p4700">All patients with transient loss of consciousness should have a 12-lead ECG. Where seizure is suspected or definite, patients should have cranial imaging with either MRI or CT, although the yield is low unless focal signs are present. EEG may help to assess prognosis once a firm diagnosis has been made. The recurrence rate after a first seizure is approximately 40% and most recurrent attacks occur within a month or two of the first. Further seizures are less likely if an identified trigger can be avoided (see <ce:cross-ref id="crf0905" refid="b0165">Box 25.29</ce:cross-ref>).</ce:para><ce:para id="p4705">Other investigations for infective, toxic and metabolic causes (<ce:cross-ref id="crf0910" refid="b0190">Box 25.34</ce:cross-ref><ce:float-anchor refid="b0190"/>) may be appropriate. An EEG performed immediately after a seizure may be more helpful in showing focal features than if performed after a delay.</ce:para></ce:section><ce:section id="s0805"><ce:section-title id="st0785">Epilepsy</ce:section-title><ce:para id="p4790">The same investigations are required in a patient with epilepsy (<ce:cross-ref id="crf0915" refid="b0190">Box 25.34</ce:cross-ref>). The EEG may help to establish the type of epilepsy and guide therapy. Investigations should be revisited if the epilepsy is intractable to treatment.</ce:para><ce:para id="p4795">Inter-ictal EEG is abnormal in only about 50% of patients with recurrent seizures, so it cannot be used to exclude epilepsy. The sensitivity can be increased to about 85% by prolonging recording time and including a period of natural or drug-induced sleep, but this does not replace a well-taken history. Ambulatory EEG recording or video EEG monitoring may help with differentiation of epilepsy from other disorders if attacks are sufficiently frequent.</ce:para><ce:para id="p4800">Indications for imaging are summarised in <ce:cross-ref id="crf0920" refid="b0195">Box 25.35</ce:cross-ref><ce:float-anchor refid="b0195"/>. Imaging cannot establish a diagnosis of epilepsy but identifies any structural cause. It is not required if a confident diagnosis of a recognised GGE syndrome (e.g. juvenile myoclonic epilepsy) is made. While CT excludes a major structural cause of epilepsy, MRI is required to demonstrate subtle changes such as hippocampal sclerosis, which may direct or inform surgical intervention.</ce:para></ce:section></ce:section><ce:section id="s0810"><ce:section-title id="st0790">Management</ce:section-title><ce:para id="p4830">It is important to explain the nature and cause of seizures to patients and their relatives, and to instruct relatives in the first aid management of seizures (<ce:cross-ref id="crf0925" refid="b0200">Box 25.36</ce:cross-ref><ce:float-anchor refid="b0200"/>). Many people with epilepsy feel stigmatised and may become unnecessarily isolated from work and social life. It is important to emphasise that epilepsy is a common disorder that affects 0.5–1% of the population, and that full control of seizures can be expected in approximately 70% of patients (<ce:cross-ref id="crf0930" refid="b0205">Box 25.37</ce:cross-ref><ce:float-anchor refid="b0205"/>).</ce:para><ce:section id="s0815"><ce:section-title id="st0795">Immediate care</ce:section-title><ce:para id="p4885">Little can or needs to be done for a person during a convulsive seizure except for first aid and common-sense manœuvres to limit damage or secondary complications (see <ce:cross-ref id="crf0935" refid="b0200">Box 25.36</ce:cross-ref>). Advice should be given that on no account should anything be inserted into the patient's mouth. The management of status epilepticus is described on page 1080.</ce:para></ce:section><ce:section id="s0820"><ce:section-title id="st0800">Lifestyle advice</ce:section-title><ce:para id="p4890">Patients should be advised to avoid activities where they might place themselves or others at risk if they have a seizure. This applies at work, at home and at leisure. At home, only shallow baths (or showers) should be taken. Prolonged cycle journeys should be discouraged until reasonable freedom from seizures has been achieved. Activities involving prolonged proximity to water (swimming, fishing or boating) should always be carried out in the company of someone who is aware of the risks and the potential need for rescue measures. Driving regulations vary between countries and the patient should be made aware of these (<ce:cross-ref id="crf0940" refid="b0210">Box 25.38</ce:cross-ref><ce:float-anchor refid="b0210"/>). Certain occupations, such as firefighter or airline pilot, are not open to those with a previous or active diagnosis of epilepsy; further information is available from epilepsy support organisations.</ce:para><ce:para id="p4950">The risk of harm from epilepsy should be discussed around the time of diagnosis. This should be done with care and sensitivity, and with the aim of motivating the patient to adapt habits and lifestyle to optimise epilepsy control and minimise risks of serious complications.</ce:para></ce:section><ce:section id="s0850"><ce:section-title id="st0830">Antiepileptic drugs</ce:section-title><ce:para id="p4955">Antiepileptic drugs (AEDs) should be considered where risk of seizure recurrence is high. A diagnosis of two or more seizures is justification enough but a prolonged inter-seizure interval may deter some patients and physicians. Treatment decisions should always be shared with the patient, to enhance adherence. A wide range of drugs is available. These agents either increase inhibitory neurotransmission in the brain or alter neuronal sodium channels to prevent abnormally rapid transmission of impulses. In the majority of patients, full control is achieved with a single drug. Dose regimens should be kept as simple as possible. Guidelines are listed in <ce:cross-ref id="crf0945" refid="b0215">Box 25.39</ce:cross-ref><ce:float-anchor refid="b0215"/>. For focal epilepsies, one large study suggests that lamotrigine is the best-tolerated monotherapy, which, alongside its favourable adverse-effect profile and relative lack of pharmacokinetic interactions, makes it a good first-line drug, although caution must be exercised with oral contraceptive use. Unclassified or genetic generalised epilepsies respond best to valproate, although pregnancy-related problems mean that valproate should not be used in women of reproductive age unless the benefits outweigh the risks. The initial choice should be an established first-line drug (<ce:cross-ref id="crf0960" refid="b0220">Box 25.40</ce:cross-ref><ce:float-anchor refid="b0220"/>), with more recently introduced drugs as second choice.</ce:para></ce:section><ce:section id="s0855"><ce:section-title id="st0835">Monitoring therapy</ce:section-title><ce:para id="p5175">Some practitioners confuse epilepsy care with serum level monitoring. The newer drugs have much more predictable pharmacokinetics than the older ones and the only indication for measuring serum levels is if there is doubt about adherence. Blood levels need to be interpreted carefully and dose changes made to treat the patient rather than to bring a serum level into the ‘therapeutic range’. Some centres advocate serum level monitoring during pregnancy (notably with lamotrigine) but the evidence of benefit for this is not strong.</ce:para></ce:section><ce:section id="s0860"><ce:section-title id="st0840">Epilepsy surgery</ce:section-title><ce:para id="p5180">Some patients with drug-resistant epilepsy benefit from surgical resection of epileptogenic brain tissue. Less invasive treatments, including vagal nerve stimulation or deep brain stimulation, may also be helpful in some patients. All those who continue to experience seizures despite appropriate drug treatment should be considered for surgical treatment. Planning such interventions requires intensive specialist assessment and investigation to identify the site of seizure onset and the dispensability of any target areas for resection, i.e. whether the area of brain involved is necessary for a critical function such as vision or motor function.</ce:para></ce:section><ce:section id="s0865"><ce:section-title id="st0845">Withdrawing antiepileptic therapy</ce:section-title><ce:para id="p5185">Withdrawal of medication may be considered after a patient has been seizure-free for more than 2 years. Childhood-onset epilepsy, particularly classical absence seizures, carries the best prognosis for successful drug withdrawal. Other epilepsy syndromes, such as juvenile myoclonic epilepsy, have a marked tendency to recur after drug withdrawal.</ce:para><ce:para id="p5190">Focal epilepsies that begin in adult life are also likely to recur, especially if there is an identified structural lesion. Overall, the recurrence rate after drug withdrawal depends on the individual's epilepsy history. An individualised estimate may be gained from the SIGN guideline tables (see ‘<ce:cross-ref id="crf0970" refid="st2180">Further information</ce:cross-ref>’, p. 1146).</ce:para><ce:para id="p5195">Patients should be advised of the risks of recurrence, to allow them to decide whether or not they wish to withdraw. If undertaken, withdrawal should be done slowly, reducing the drug dose gradually over weeks or months. Withdrawal may necessitate precautions around driving or occupation (see <ce:cross-ref id="crf0975" refid="b0210">Box 25.38</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0870"><ce:section-title id="st0850">Contraception</ce:section-title><ce:para id="p5200">Some AEDs induce hepatic enzymes that metabolise synthetic hormones, increasing the risk of contraceptive failure. This is most marked with carbamazepine, phenytoin and barbiturates, but clinically significant effects can be seen with lamotrigine and topiramate. If the AED cannot be changed, this can be overcome by giving higher-dose preparations of the oral contraceptive. Sodium valproate and levetiracetam have no interaction with hormonal contraception.</ce:para></ce:section><ce:section id="s0875"><ce:section-title id="st0855">Pregnancy and reproduction</ce:section-title><ce:para id="p5205">Epilepsy presents specific management problems during pregnancy (<ce:cross-ref id="crf0980" refid="b0225">Box 25.41</ce:cross-ref><ce:float-anchor refid="b0225"/>). There is usually concern about teratogenesis associated with AEDs. It is important to recognise proportionate risks: background risk of severe fetal malformation in the general population is around 2–3%, while the AED most associated with teratogenesis is sodium valproate, which, at high dose, increases the risk to around 6–7%. Long-term observational studies show that most of the commonly used AEDs can be given safely in pregnancy.</ce:para><ce:para id="p5260">Pre-conception treatment with folic acid (5 mg daily), along with use of the smallest effective doses of as few AEDs as possible, may reduce the risk of fetal abnormalities. The risks of abrupt AED withdrawal to the mother should be stressed.</ce:para><ce:para id="p5265">Seizures may become more frequent during pregnancy, particularly if pharmacokinetic changes decrease serum levels of AEDs (see <ce:cross-ref id="crf0985" refid="b0225">Box 25.41</ce:cross-ref>).</ce:para><ce:para id="p5270">Menstrual irregularities and reduced fertility are more common in women with epilepsy, and are also increased by sodium valproate. Patients with epilepsy are at greater risk of osteoporosis, apparently independently of the drug used. Some centres advocate vitamin D supplementation in any patient with epilepsy but the higher female risk of osteoporosis makes this most important in women. Oral contraception can interact with individual AEDs (<ce:cross-ref id="crf0990" refid="b0225">Box 25.41</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s0880"><ce:section-title id="st0860">Prognosis</ce:section-title><ce:para id="p5275">The outcome of newly diagnosed epilepsy is generally good. Overall, generalised epilepsies and generalised seizures are more readily controlled than focal seizures. The presence of a structural lesion reduces the chances of freedom from seizures. The overall prognosis for epilepsy is shown in <ce:cross-ref id="crf0995" refid="b0205">Box 25.37</ce:cross-ref>. The particular problems that epilepsy poses in the elderly and in adolescents are summarised in <ce:cross-ref id="crf1000" refid="b0230">Boxes 25.42</ce:cross-ref><ce:float-anchor refid="b0230"/> and <ce:cross-ref id="crf1005" refid="b0235">25.43</ce:cross-ref><ce:float-anchor refid="b0235"/>, respectively.</ce:para></ce:section><ce:section id="s0885"><ce:section-title id="st0865">Status epilepticus</ce:section-title><ce:para id="p5360">Presentation and management are described on page 1080. While generalised status epilepticus is most easily recognised, non-convulsive status may be less dramatic and less easily diagnosed. It may cause only altered awareness, delirium or wandering with automatisms. In an intensive care unit setting, EEG monitoring is essential to ensure that diagnosis and treatment are optimised.</ce:para></ce:section><ce:section id="s0890"><ce:section-title id="st0870">Non-epileptic attack disorder (‘dissociative attacks’)</ce:section-title><ce:para id="p5365">The difficulty with nomenclature is discussed on page 1097. Patients may present with attacks that resemble epileptic seizures but are caused by psychological phenomena and have no abnormal EEG discharges. Such attacks may be very prolonged, sometimes mimicking status epilepticus. Epileptic and non-epileptic attacks may coexist and time and effort are needed to clarify the relative contribution of each, allowing more accurate and comprehensive treatment.</ce:para><ce:para id="p5370">Non-epileptic attack disorder (NEAD) may be accompanied by dramatic flailing of the limbs and arching of the back, with side-to-side head movements and vocalising. Cyanosis and severe biting of the tongue are rare but incontinence can occur. Distress and crying are common following non-epileptic attacks. The distinction between epileptic attacks originating in the frontal lobes and non-epileptic attacks may be especially difficult, and may require videotelemetry with prolonged EEG recordings. Non-epileptic attacks are three times more common in women than in men and have been linked with a history of past or ongoing life trauma. They are not necessarily associated with formal psychiatric illness. Patients and carers may need reassurance that hospital admission is not required for every attack. Prevention requires psychotherapeutic interventions rather than drug therapy (<ce:intra-ref id="ii0665" xlink:href="pii:B978-0-7020-7028-0.00028-7#s1025">p. 1202</ce:intra-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s0895"><ce:section-title id="st0875">Vestibular disorders</ce:section-title><ce:para id="p5375">Vertigo is the typical symptom caused by vestibular dysfunction, and most patients with vertigo have acute vestibular failure, benign paroxysmal positional vertigo or Ménière's disease. Central (brain) causes of vertigo are rare by comparison, with the exception of migraine (p. 1095).</ce:para><ce:section id="s0900"><ce:section id="s0905"><ce:section-title id="st0880">Acute vestibular failure</ce:section-title><ce:para id="p5380">Although commonly called ‘labyrinthitis’ or ‘vestibular neuronitis’, acute vestibular failure is a more accurate term, as most cases are idiopathic. It usually presents as isolated severe vertigo with vomiting and unsteadiness. It begins abruptly, often on waking, and many patients are initially bed-bound. The vertigo settles within a few days, though head movement may continue to provoke transient symptoms (positional vertigo) for some time. During the acute attack, nystagmus (p. 1090) will be present for a few days.</ce:para><ce:para id="p5385">Cinnarizine, prochlorperazine or betahistine provide symptomatic relief but should not be used long-term, as this may delay recovery. A small proportion of patients fail to recover fully and complain of ongoing imbalance and dysequilibrium rather than vertigo; vestibular rehabilitation by a physiotherapist may help.</ce:para></ce:section><ce:section id="s0910"><ce:section-title id="st0885">Benign paroxysmal positional vertigo</ce:section-title><ce:para id="p5390">Benign paroxysmal positional vertigo (BPPV) is due to the presence of otolithic debris from the saccule or utricle affecting the free flow of endolymph in the semicircular canals (cupulolithiasis). It may follow minor head injury but typically is spontaneous. The history is diagnostic, with transient (seconds) vertigo precipitated by movement (typically, rolling over in bed or getting into or out of bed). Although it is benign, and usually self-limiting after weeks or months, patients are often alarmed by the symptoms. The diagnosis can be confirmed by the ‘Hallpike manœuvre’ to demonstrate positional nystagmus (<ce:cross-ref id="crf1010" refid="f0160">Fig. 25.26</ce:cross-ref><ce:float-anchor refid="f0160"/>). Treatment comprises explanation and reassurance, along with positioning procedures designed to return otolithic debris from the semicircular canal to saccule or utricle (such as the Epley manœuvre) and/or to re-educate the brain to cope with the inappropriate signals from the labyrinth (such as Cawthorne–Cooksey exercises: see ‘<ce:cross-ref id="crf1015" refid="st2180">Further information</ce:cross-ref>’, p. 1146).</ce:para></ce:section><ce:section id="s0915"><ce:section-title id="st0890">Ménière's disease</ce:section-title><ce:para id="p5395">This is due to an abnormality of the endolymph that causes episodes of vertigo accompanied by tinnitus and fullness in the ear, each attack typically lasting a few hours. Over the years, patients may develop progressive deafness (typically low-tone on audiometry). Examination is typically normal in between attacks. The diagnosis is clinical, supported by abnormal audiometry. Ménière's disease is idiopathic but a similar syndrome may be caused by middle ear trauma or infection. Imaging may be indicated to exclude other focal brainstem or cerebellopontine angle pathology but will be normal in Ménière's disease. Management includes a low-salt diet, vestibular sedatives for acute attacks (e.g. cinnarizine or prochlorperazine), and occasionally surgery to increase endolymphatic drainage from the vestibular system. Migraine may also cause episodic vertigo, and can be confused with Ménière's disease, although usually other migrainous features will appear in the history.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0920"><ce:section-title id="st0895">Disorders of sleep</ce:section-title><ce:para id="p5400">Sleep disturbances include too much sleep (hypersomnolence or excessive daytime sleepiness), insufficient or poor-quality sleep (insomnia), and abnormal behaviour during sleep (parasomnias). Insomnia is usually caused by psychological or psychiatric disorders, shift work and other environmental causes, pain and so on, and will not be discussed further. Many symptoms and disorders may affect sleep and sleep quality (e.g. pain, depression/anxiety, parkinsonism).</ce:para><ce:section id="s0925"><ce:section-title id="st0900">Excessive daytime sleepiness (hypersomnolence)</ce:section-title><ce:para id="p5405">There are primary and secondary causes (<ce:cross-ref id="crf1020" refid="b0240">Box 25.44</ce:cross-ref><ce:float-anchor refid="b0240"/>). The most common causes are impaired sleep due to lifestyle issues or sleep-disordered breathing (<ce:intra-ref id="ii0685" xlink:href="pii:B978-0-7020-7028-0.00017-2#p7030">p. 622</ce:intra-ref>). Sleepiness may be measured using the Epworth Sleepiness Score (see <ce:intra-ref id="ii0690" xlink:href="pii:B978-0-7020-7028-0.00017-2#b0435">Box 17.86</ce:intra-ref>, <ce:intra-ref id="ii0695" xlink:href="pii:B978-0-7020-7028-0.00017-2#s2020">p. 623</ce:intra-ref>). Most causes will be identified by a detailed history from the patient and their bed partner, and a 2-week sleep diary.</ce:para><ce:section id="s0930"><ce:section-title id="st0905">Narcolepsy</ce:section-title><ce:para id="p5465">This has a prevalence of about 1 in 2000, with peak onset in adolescence and early middle age. The key symptom is sudden, irresistible ‘sleep attacks’, often in inappropriate circumstances such as while eating or talking. Other characteristic features help distinguish this from excessive daytime sleepiness (<ce:cross-ref id="crf1025" refid="b0245">Box 25.45</ce:cross-ref><ce:float-anchor refid="b0245"/>). Symptoms may be due to loss of hypocretin-secreting hypothalamic neurons. Diagnosis requires sleep study with sleep latency testing (demonstrating rapid onset of REM sleep). Narcolepsy may respond to stimulants such as modafinil but more severe cases may require sodium oxybate, dexamfetamine, methylphenidate or selective serotonin reuptake inhibitor (SSRIs). Cataplexy can be debilitating and can respond to sodium oxybate or to antidepressants, such as clomipramine or venlafaxine.</ce:para></ce:section></ce:section><ce:section id="s0955"><ce:section-title id="st0930">Parasomnias</ce:section-title><ce:para id="p5510">Parasomnias are abnormal motor behaviours that occur around sleep. They may arise in either REM or non-REM sleep, with characteristic features and timing. Non-REM parasomnias tend to occur early in sleep. Parasomnias should be distinguished from other motor disturbances (such as periodic limb movements, hypnic jerks or sleep talking) and sleep-onset epileptic seizures (p. 1101). History from a sleeping partner or other witness is essential.</ce:para><ce:section id="s0960"><ce:section-title id="st0935">Non-REM parasomnias</ce:section-title><ce:para id="p5515">These are due to incomplete arousal from non-REM sleep and manifest as night terrors, sleep walking and confusional arousals (sleep drunkenness). They typically occur within an hour or two of sleep onset, and are common in children and usually of no pathological significance. Rarely, they persist into adulthood and may become increasingly complex, including dressing, moving objects, eating, drinking or even acts of violence. Patients have little or no recollection of the episodes, even though they appear ‘awake’. The episodes may be triggered by alcohol or unfamiliar sleeping situations, and can be familial. Treatment is usually not required but clonazepam can be used.</ce:para></ce:section><ce:section id="s0965"><ce:section-title id="st0940">REM sleep behaviour disorder</ce:section-title><ce:para id="p5520">In REM sleep behaviour disorder (RBD), patients ‘act out’ their dreams during REM sleep, due to failure of the usual muscle atonia. Sleep partners provide typical histories of patients ‘fighting’ or ‘struggling’ in their sleep, sometimes causing injury to themselves or to their partner. They are easily roused from this state, with recollection of their dream, unlike in non-REM states. RBD is more common in men and may be an early symptom of neurodegenerative diseases such as alpha synucleinopathies (p. 1111), perhaps preceding more typical symptoms of these conditions by years. Polysomnography will confirm absence of atonia during REM sleep. Clonazepam is the most successful treatment.</ce:para></ce:section><ce:section id="s0970"><ce:section-title id="st0945">Restless legs syndrome</ce:section-title><ce:para id="p5525">Restless legs syndrome (RLS) is common, with a prevalence of up to 10%, but many patients never seek medical attention. It is characterised by unpleasant leg (rarely, arm) sensations that are eased by movement (motor restlessness); the diagnosis is clinical (<ce:cross-ref id="crf1030" refid="b0250">Box 25.46</ce:cross-ref><ce:float-anchor refid="b0250"/>). It has a strong familial tendency and can present with daytime somnolence due to poor sleep. It is usually idiopathic but may be associated with iron deficiency, pregnancy, peripheral neuropathy, Parkinson's disease or uraemia. It should be distinguished from akathisia, the daytime motor restlessness that is an adverse effect of antipsychotic drugs. Treatment, if required, is with dopaminergic drugs (dopamine agonists or levodopa, p. 1113) or benzodiazepines.</ce:para></ce:section><ce:section id="s0975"><ce:section-title id="st0950">Periodic limb movements in sleep</ce:section-title><ce:para id="p5550">Unlike RLS, periodic limb movements in sleep (PLMS) only occur during sleep and cause repetitive flexion movements of the limbs, usually in the early (non-REM) stages of sleep. Although patients are unaware of the symptoms, they may disrupt sleep quality and often disturb partners. The pathological significance of PLMS is uncertain and it often occurs in normal health. There is an overlap with RLS. Treatment is most successful with clonazepam or dopaminergic drugs.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0980"><ce:section-title id="st0955">Neuro-inflammatory diseases</ce:section-title><ce:section id="s0985"><ce:section id="s0990"><ce:section-title id="st0960">Multiple sclerosis</ce:section-title><ce:para id="p5555">Multiple sclerosis (MS) is an important cause of long-term disability in adults, especially in the UK, where the prevalence is approximately 120 per 100 000. The annual incidence is around 7 per 100 000, while the lifetime risk of developing MS is about 1 in 400. The incidence of MS is higher in Northern Europeans and the disease is about twice as common in females.</ce:para><ce:section id="s0995"><ce:section-title id="st0965">Pathophysiology</ce:section-title><ce:para id="p5560">There is evidence that both genetic and environmental factors play a causative role. The prevalence of MS is low near the equator and increases in the temperate zones of both hemispheres. People retain the risk of developing the disease in the zone in which they grew up, indicating that environmental exposures during growth and development are important. Prevalence also correlates with environmental factors, such as sunlight exposure, vitamin D (a controversial association) and exposure to Epstein–Barr virus (EBV), although causative mechanisms remain unclear. Genetic factors are also relevant; the risk of familial occurrence in MS is 15%, with highest risk in first-degree relatives (age-adjusted risk 4–5% for siblings and 2–3% for parents or offspring). Monozygotic twins have a concordance rate of 30%. The genes that predispose to MS are incompletely defined but inheritance appears to be polygenic, with influences from genes for human leucocyte antigen (HLA) typing, interleukin receptors, <ce:italic>CLEC16A</ce:italic> (C-type lectin domain family 16 member A) and <ce:italic>CD226</ce:italic> genes. An immune hypothesis is supported by increased levels of activated T lymphocytes in the CSF and increased immunoglobulin synthesis within the CNS.</ce:para><ce:para id="p5565">Initial CNS inflammation in MS involves entry of activated T lymphocytes across the blood–brain barrier. These recognise myelin-derived antigens on the surface of the nervous system's antigen-presenting cells, the microglia, and undergo clonal proliferation. The resulting inflammatory cascade releases cytokines and initiates destruction of the oligodendrocyte–myelin unit by macrophages. Histologically, the resultant lesion is a plaque of inflammatory demyelination, most commonly in the periventricular regions of the brain, the optic nerves and the subpial regions of the spinal cord (<ce:cross-ref id="crf1035" refid="f0165">Fig. 25.27</ce:cross-ref><ce:float-anchor refid="f0165"/>). This begins as a circumscribed area of disintegration of the myelin sheath, accompanied by infiltration by activated lymphocytes and macrophages, often with conspicuous perivascular inflammation. After the acute attack, gliosis follows, leaving a shrunken scar.</ce:para><ce:para id="p5570">Much of the initial acute clinical deficit is caused by the effect of inflammatory cytokines on transmission of the nervous impulse rather than structural disruption of myelin, and may explain the rapid recovery of some deficits and probably the acute benefit from glucocorticoids. In the long term, accumulating myelin loss reduces the efficiency of impulse propagation or causes complete conduction block, contributing to sustained impairment of CNS functions. Inflammatory mediators released during the acute attack (particularly nitric oxide) probably also initiate axonal damage, which is a feature of the latter stages of the disease. In established MS there is progressive axonal loss, probably due to the successive damage from acute attacks and the subsequent loss of neurotrophic factors from oligodendrocytes. This axonal loss may account for the phase of the disease characterised by progressive and persistent disability (<ce:cross-ref id="crf1040" refid="f0170">Fig. 25.28</ce:cross-ref><ce:float-anchor refid="f0170"/>).</ce:para></ce:section><ce:section id="s1000"><ce:section-title id="st0970">Clinical features</ce:section-title><ce:para id="p5575">The diagnosis of MS requires the demonstration of otherwise unexplained CNS lesions separated in time and space (<ce:cross-ref id="crf1045" refid="b0255">Box 25.47</ce:cross-ref><ce:float-anchor refid="b0255"/>); traditionally, this meant two or more clinical relapses affecting different parts of the nervous system, and the first ever episode was labelled ‘clinically isolated syndrome’ (CIS). Recent changes to diagnostic criteria mean that MS may be diagnosed after an isolated episode (i.e. at the CIS stage), provided that certain criteria are met (<ce:cross-ref id="crf1065" refid="b0255">Box 25.47</ce:cross-ref>) The peak age of onset of MS is the fourth decade; onset before puberty or after the age of 60 years is rare. Symptoms and signs of MS usually evolve over days or weeks, resolving over weeks or months. Rarely, a more rapid stroke-like presentation may occur. About 85–90% of patients have an initial relapsing and remitting clinical course with variable intervening recovery, although the majority will eventually enter a secondary progressive phase. Most of the rest follow a slowly progressive clinical course (so-called primary progressive MS), while rare patients have a fulminant variety leading to early death (see <ce:cross-ref id="crf1070" refid="f0170">Fig. 25.28</ce:cross-ref>). Frequent relapses with incomplete recovery indicate a poor prognosis. Some milder cases have an interval of years or even decades between attacks, while in others (particularly if optic neuritis is the initial manifestation) there is no recurrence of disease.</ce:para><ce:para id="p5600">There are a number of clinical symptoms and syndromes suggestive of MS, occurring either at presentation or during the course of the illness (<ce:cross-ref id="crf1075" refid="b0260">Box 25.48</ce:cross-ref><ce:float-anchor refid="b0260"/>). The physical signs observed in MS are determined by the anatomical site of demyelination. Combined spinal cord and brainstem signs are common, although evidence of previous optic neuritis may be found in the form of an afferent pupillary deficit. Significant intellectual impairment appears only late in the disease, when loss of frontal lobe functions and impairment of memory are common.</ce:para><ce:para id="p5685">The prognosis for patients with MS is difficult to predict with confidence, especially early in the disease. Those with relapsing and remitting MS experience, on average, 1–2 relapses every 2 years, although this may decline with time. Approximately 5% of patients die within 5 years of disease onset, and slightly more have very good long-term outcome with little or no disability. Prognosis is good for patients with optic neuritis and only sensory relapses. Overall, about one-third of patients are disabled to the point of needing help with walking after 10 years, and this proportion rises to about half after 15 years. It would appear likely (though this is as yet unproven) that disease-modifying drugs will have an effect on long-term disability.</ce:para></ce:section><ce:section id="s1015"><ce:section-title id="st0985">Investigations</ce:section-title><ce:para id="p5690">There is no single diagnostic test that is definitive for MS and the results of investigation need to be combined with the clinical picture in order to make a diagnosis; MRI is the most important investigation (<ce:cross-ref id="crf1080" refid="f0175">Fig. 25.29</ce:cross-ref><ce:float-anchor refid="f0175"/>). MS mimics should be excluded (see below). Following the first clinical event (CIS), investigations may help prognosis by confirming the disseminated nature of the disease. MRI is the most sensitive technique for imaging lesions in brain and spinal cord (<ce:cross-ref id="crf1085" refid="f0180">Fig. 25.30</ce:cross-ref><ce:float-anchor refid="f0180"/>) and for excluding other causes that have provoked the neurological deficit. However, the MRI appearances in MS may be confused with those of small-vessel disease or cerebral vasculitis, and these diagnoses should be considered and excluded. Evoked potentials (visual, auditory or somatosensory) may detect clinically silent lesions but are rarely used nowadays with the advent of MRI.</ce:para><ce:para id="p5695">The CSF may show a lymphocytic pleocytosis in the acute phase and unique (i.e. absent from the serum) oligoclonal bands of IgG in 70–90% of patients between attacks. Oligoclonal bands are not specific for MS and denote only intrathecal inflammation, provided they are unique for the CSF. These can appear in other disorders, which should be excluded by examination and investigation. It is important to exclude other potentially treatable conditions, such as infection, vitamin B<ce:inf loc="post">12</ce:inf> deficiency and spinal cord compression.</ce:para></ce:section><ce:section id="s1020"><ce:section-title id="st0990">Management</ce:section-title><ce:para id="p5700">The management of MS involves four different strands: treatment of the acute episode, prevention of future relapses, treatment of complications, and management of the patient's disability.</ce:para><ce:section id="s1025"><ce:section-title id="st0995">The acute episode</ce:section-title><ce:para id="p5705">In a disabling exacerbation of MS, pulses of high-dose glucocorticoid, given either intravenously or orally over 3–5 days, will shorten the duration of the acute episode. Prolonged administration of glucocorticoids does not alter the long-term outcome and is associated with severe adverse effects; it should therefore be avoided. Pulses of glucocorticoids can be given up to three times in a year but use should be restricted to those individuals with significant function-threatening deficits. Prophylaxis to prevent glucocorticoid-induced osteoporosis (<ce:intra-ref id="ii0725" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1635">p. 1045</ce:intra-ref>) should be considered in patients requiring multiple courses of glucocorticoids.</ce:para></ce:section><ce:section id="s1030"><ce:section-title id="st1000">Disease-modifying treatment</ce:section-title><ce:para id="p5710">Until the 1990s, there were no effective disease-modifying treatments (DMTs) for MS; azathioprine showed some promise but this was offset by adverse effects and the drug was rarely used. The introduction of, initially, beta-interferons and glatiramer acetate paved the way for a new and exciting era of DMTs, which is still evolving. All reduce annual relapse rates and the number and size of lesions on MRI, and some may reduce disability. They are not indicated for treatment of early or pre-clinical MS. These drugs – available orally, as regular subcutaneous injections or as pulsed intravenous treatments – may be divided into two groups (<ce:cross-ref id="crf1090" refid="b0265">Box 25.49</ce:cross-ref><ce:float-anchor refid="b0265"/>). All DMTs have strict licensing criteria and are associated with a range of adverse effects, some occasionally fatal, especially the more effective drugs. Careful selection and counselling of patients are necessary and these drugs should be supervised by teams experienced in their use, as recommended in national guidelines.</ce:para><ce:para id="p5760">Clinical trials suggest that DMT options for primary and secondary progressive MS will be available in coming years. Clinical trials involving stem cells are ongoing.</ce:para><ce:para id="p5765">Special diets, including gluten-free regimens or linoleic acid supplements, and hyperbaric oxygen therapy are popular with patients but their efficacy has not been demonstrated.</ce:para></ce:section><ce:section id="s1035"><ce:section-title id="st1005">Treatment of symptoms, complications and disability</ce:section-title><ce:para id="p5770">Treatments for the complications of MS are summarised in <ce:cross-ref id="crf1095" refid="b0270">Box 25.50</ce:cross-ref><ce:float-anchor refid="b0270"/>. It is important to provide patients with a careful explanation of the nature of the disease and its outcome. When and if disability occurs, patients and their relatives need appropriate support. Specialist nurses working in a multidisciplinary team of health-care professionals are of great value in managing the chronic phase of the disease. Periods of physiotherapy and occupational therapy may improve functional capacity in those who become disabled, and guidance can be provided on the provision of aids at home, reducing handicap. Bladder care is particularly important. Urgency and frequency can be treated pharmacologically (see <ce:cross-ref id="crf1105" refid="b0145">Box 25.25</ce:cross-ref>, p. 1094) but this may lead to a degree of retention with an attendant risk of infection. Urinary retention can be managed initially by intermittent urinary catheterisation (performed by the patient, if possible) but an in-dwelling catheter may become necessary. Sexual dysfunction is a frequent source of distress. Sildenafil or tadalafil helps impotence in men, and skilled counselling and prosthetic aids may be beneficial. Pregnancy does not increase the risk of progression of MS but relapses may occur post-partum (<ce:cross-ref id="crf1110" refid="b0275">Box 25.51</ce:cross-ref><ce:float-anchor refid="b0275"/>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s1040"><ce:section-title id="st1010">Acute disseminated encephalomyelitis</ce:section-title><ce:para id="p5900">This is an acute monophasic demyelinating condition in which areas of perivenous demyelination are widely disseminated throughout the brain and spinal cord. The illness may arise spontaneously but often occurs a week or so after a viral infection, especially measles or chickenpox, or following vaccination, suggesting that it is immunologically mediated.</ce:para><ce:section id="s1045"><ce:section-title id="st1015">Clinical features</ce:section-title><ce:para id="p5905">Headache, vomiting, pyrexia, delirium and meningism may be presenting features, often with focal or multifocal brain and spinal cord signs. Seizures or coma may occur. A minority of patients who recover have further episodes.</ce:para></ce:section><ce:section id="s1050"><ce:section-title id="st1020">Investigations</ce:section-title><ce:para id="p5910">MRI shows multiple high-signal areas in a pattern similar to that of MS, although often with large confluent areas of abnormality. CSF may be normal or show an increase in protein and lymphocytes (occasionally &#x003E; 100 × 10<ce:sup loc="post">6</ce:sup> cells/L). Oligoclonal bands may be found in the acute episode but, in contrast to MS, do not persist beyond clinical recovery. The clinical picture may be very similar to a first relapse of MS.</ce:para></ce:section><ce:section id="s1055"><ce:section-title id="st1025">Management</ce:section-title><ce:para id="p5915">The prognosis for acute disseminated encephalomyelitis is generally good, although occasionally it may be fatal (probably less than 10%). Treatment with high-dose intravenous methylprednisolone, using the same regimen as for a relapse of MS, is recommended.</ce:para></ce:section></ce:section><ce:section id="s1060"><ce:section-title id="st1030">Transverse myelitis</ce:section-title><ce:para id="p5920">Transverse myelitis is an acute, usually monophasic, demyelinating disorder affecting the spinal cord. It is usually thought to be post-infectious in origin. It occurs at any age and presents with a subacute paraparesis with a sensory level, accompanied by severe pain in the neck or back at the onset. MRI should distinguish this from an external lesion affecting the spinal cord. CSF examination shows cellular pleocytosis, often with polymorphs at the onset. Oligoclonal bands are usually absent. Treatment is with high-dose intravenous methylprednisolone. The outcome is variable: one-third have static deficit, one-third go on to develop MS and one-third recover with no subsequent relapse. Some clinical features may suggest a higher risk of MS after transverse myelitis.</ce:para></ce:section><ce:section id="s1065"><ce:section-title id="st1035">Neuromyelitis optica</ce:section-title><ce:para id="p5925">Neuromyelitis optica (previously Devic's disease) is the occurrence of transverse myelitis and bilateral optic neuritis. The disease has been recognised for many years, particularly in Asia. The majority of cases are associated with an antibody to a neuronal membrane channel, aquaporin 4. If changes are seen on brain MRI (this is variable), they are typically high-signal lesions restricted to periventricular regions. Spinal MRI scans show lesions that are typically longer than three spinal segments (unlike the shorter lesions of MS). Clinical deficits tend to recover less well than in MS, and the disease may be more aggressive with more frequent relapses. Treatment with glucocorticoids, azathioprine or cyclophosphamide, and/or plasmapheresis seems to be more effective than in MS.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1070"><ce:section-title id="st1040">Paraneoplastic neurological disorders</ce:section-title><ce:para id="p5930">Neurological disease may occur with systemic malignant tumours in the absence of cerebral metastases. It is now recognised that, in the majority of these cases, antigen production in the body of the tumour leads to development of antibodies to parts of the CNS. Paraneoplastic conditions are increasingly recognised and the number of antibodies identified is also growing (<ce:cross-ref id="crf1115" refid="b0280">Boxes 25.52</ce:cross-ref><ce:float-anchor refid="b0280"/> and <ce:cross-ref id="crf1120" refid="b0285">25.53</ce:cross-ref><ce:float-anchor refid="b0285"/>). These syndromes are particularly associated with small-cell carcinoma of lung, ovarian tumours and lymphomas. Autoantibodies are found in the serum and/or CSF, and biopsy will show a lymphocytic infiltrate of the neural tissue affected.</ce:para><ce:section id="s1075"><ce:section id="s1080"><ce:section id="s1085"><ce:section-title id="st1045">Clinical features</ce:section-title><ce:para id="p5945">Clinical presentations are summarised in <ce:cross-ref id="crf1130" refid="b0280">Boxes 25.52</ce:cross-ref> and <ce:cross-ref id="crf1135" refid="b0285">25.53</ce:cross-ref>. In most instances, the neurological condition progresses quite rapidly over a few months, preceding the malignant disease in around half of cases. The range of clinical patterns is so wide that paraneoplastic disease should be considered in the diagnosis of any unusual progressive neurological syndrome. The paraneoplastic disorders of the peripheral nervous system particularly affect the synaptic cleft (p. 1065).</ce:para></ce:section><ce:section id="s1090"><ce:section-title id="st1050">Investigations and management</ce:section-title><ce:para id="p5950">The presence of characteristic autoantibodies in the context of a suspicious clinical picture may be diagnostic. The causative tumour may be very small and therefore CT of the chest or abdomen or PET scanning may be necessary to find it. These investigations should be pursued only when paraneoplastic disease has been proven, rather than when it is suspected. The CSF often shows an increased protein and lymphocyte count with oligoclonal bands.</ce:para><ce:para id="p5955">Treatment is directed at the primary tumour. Occasionally, successful therapy of the tumour is associated with improvement of the paraneoplastic syndrome. Some improvement may occur following administration of intravenous immunoglobulin.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1095"><ce:section-title id="st1055">Neurodegenerative diseases</ce:section-title><ce:para id="p5960">While MS is the most common cause of disability in young people in the UK, vascular and neurodegenerative diseases are increasingly important in later life. The neurodegenerative diseases are united in having a pathological process that leads to specific neuronal death, causing relentlessly progressive symptoms, with incidence rising with age. The causes are not yet known, although genetic influences are important. Alzheimer's disease (<ce:intra-ref id="ii0745" xlink:href="pii:B978-0-7020-7028-0.00028-7#s0515">p. 1192</ce:intra-ref>) and Parkinson's disease are the most common.</ce:para><ce:section id="s1100"><ce:section-title id="st1060">Movement disorders</ce:section-title><ce:para id="p5965">Movement disorders present with a wide range of symptoms. They may be genetic or acquired, and the most important is Parkinson's disease. Most movement disorders are categorised clinically, with few confirmatory investigations available other than for those with a known gene abnormality.</ce:para><ce:section id="s1105"><ce:section-title id="st1065">Idiopathic Parkinson's disease</ce:section-title><ce:para id="p5970">Parkinsonism is a clinical syndrome characterised primarily by bradykinesia (p. 1084), with associated increased tone (rigidity), tremor and loss of postural reflexes. There are many causes (<ce:cross-ref id="crf1140" refid="b0290">Box 25.54</ce:cross-ref><ce:float-anchor refid="b0290"/>) but the most common is Parkinson's disease (PD). PD has an annual incidence of about 18/100 000 in the UK and a prevalence of about 180/100 000. Age has a critical influence on incidence and prevalence, the latter rising to 300–500/100 000 after 80 years of age. Average age of onset is about 60 years and fewer than 5% of patients present under the age of 40. Genetic factors are increasingly recognised and several single genes causing parkinsonism have been identified, although they account for a very small proportion of cases overall. Having a first-degree relative with PD confers a 2–3 times increased risk of developing the disorder. It is progressive and incurable, with a variable prognosis. While motor symptoms are the most common presenting features, non-motor symptoms (particularly cognitive impairment, depression and anxiety) become increasingly prominent as the disease progresses, and significantly reduce quality of life.</ce:para><ce:section id="s1110"><ce:section-title id="st1070">Pathophysiology</ce:section-title><ce:para id="p6070">Although mutations in several genes have been identified in a few cases, in most patients the cause remains unknown. The discovery that methyl-phenyl-tetrahydropyridine (MPTP) caused severe parkinsonism in young drug users suggested that PD might be due to an environmental toxin but none has been convincingly identified. The pathological hallmarks of PD are depletion of the pigmented dopaminergic neurons in the substantia nigra and the presence of α-synuclein and other protein inclusions in nigral cells (Lewy bodies; <ce:cross-ref id="crf1145" refid="f0185">Fig. 25.31</ce:cross-ref><ce:float-anchor refid="f0185"/>). It is thought that environmental or genetic factors alter the α-synuclein protein, rendering it toxic and leading to Lewy body formation within the nigral cells. Lewy bodies are also found in the basal ganglia, brainstem and cortex, and increase with disease progression. PD is recognised as a synucleinopathy alongside multiple system atrophy and dementia with Lewy bodies. The loss of dopaminergic neurotransmission is responsible for many of the clinical features.</ce:para></ce:section><ce:section id="s1115"><ce:section-title id="st1075">Clinical features</ce:section-title><ce:para id="p6075">Non-motor symptoms, including reduction in sense of smell (hyposmia), anxiety/depression, constipation and REM sleep behavioural disturbance (RBD), may precede the development of typical motor features by many years but patients rarely present at this stage. The motor symptoms are almost always initially asymmetrical. The hallmark is bradykinesia, leading to classic symptoms such as increasingly small handwriting (‘micrographia’), difficulty tying shoelaces or buttoning clothes, and difficulty rolling over in bed. Tremor is an early feature but may not be present in at least 20% of people with PD. It is typically a unilateral rest tremor (p. 1085) affecting limbs, jaw and chin but not the head. In some patients, tremor remains the dominant symptom for many years. Rigidity causes stiffness and a flexed posture. Although postural righting reflexes are impaired early on in the disease, falls tend not to occur until later. As the disease advances, speech becomes softer and indistinct. There are a number of abnormalities on neurological examination (<ce:cross-ref id="crf1150" refid="b0295">Box 25.55</ce:cross-ref><ce:float-anchor refid="b0295"/>).</ce:para><ce:para id="p6185">Although features are initially unilateral, gradual bilateral involvement evolves with time. Cognition is spared in early disease; if impaired, it should trigger consideration of alternative diagnoses, such as dementia with Lewy bodies.</ce:para><ce:section id="s1120"><ce:section-title id="st1080">Non-motor symptoms</ce:section-title><ce:para id="p6190">While non-motor symptoms may precede the onset of more typical symptoms by many years, for most patients these features become increasingly common and disabling as PD progresses. Cognitive impairment, including dementia, is the symptom most likely to impair quality of life for patients and their carers. Estimates of dementia frequency range from 30% to 80%, depending on definitions and length of follow-up. Other distressing non-motor symptoms include neuropsychiatric features (anxiety, depression, apathy, hallucinosis/psychosis), sleep disturbance and hypersomnolence, fatigue, pain, sphincter disturbance and constipation, sexual problems (erectile failure, loss of libido or hypersexuality), drooling and weight loss.</ce:para></ce:section></ce:section><ce:section id="s1125"><ce:section-title id="st1085">Investigations</ce:section-title><ce:para id="p6195">The diagnosis is clinical. Structural imaging (CT or MRI) is usually normal for age and thus rarely helpful, although it may support a suspected vascular cause of parkinsonism. Functional dopaminergic imaging (SPECT or PET) is abnormal, even in the early stages (<ce:cross-ref id="crf1155" refid="f0190">Fig. 25.32</ce:cross-ref><ce:float-anchor refid="f0190"/>), but does not differentiate between the different forms of degenerative parkinsonism (see <ce:cross-ref id="crf1160" refid="b0290">Box 25.54</ce:cross-ref>) and so is not specific for PD. In younger patients, specific investigations may be appropriate (e.g. exclusion of Huntington's or Wilson's diseases). Some patients with family histories may wish to consider genetic testing, although the role of genetic counselling is uncertain at present.</ce:para></ce:section><ce:section id="s1130"><ce:section-title id="st1090">Management</ce:section-title><ce:section id="s1135"><ce:section-title id="st1095">Drug therapy</ce:section-title><ce:para id="p6200">Drug treatment for PD remains symptomatic rather than curative, and there is no evidence that any of the currently available drugs are neuroprotective. Levodopa (LD) remains the most effective treatment available but other agents include dopamine agonists, anticholinergics, inhibitors of monoamine oxidase (MAOI)-B and catechol-O-methyl-transferase (COMT), and amantadine. Debate continues about when and what treatment should be started. In general, most specialists recommend initiating treatment when symptoms are impacting on everyday life although some favour treatment as soon as the diagnosis is made. Whether it is best to start with LD, a dopamine agonist or MAOI-B remains unclear but most accept that the most effective, best-tolerated and cheapest drug is LD. Many motor symptoms, such as tremor, freezing, falling, head-drop and abnormal flexion, are quite resistant to treatment. Some non-motor symptoms, such as anxiety or depression, may respond to drug or non-drug treatments. In the UK, rivastigmine is licensed for use in PD-associated dementia, although its effect is modest. Many other non-motor symptoms are resistant to treatment. Drugs for PD should not be stopped abruptly, as this can precipitate malignant hyperthermia.</ce:para><ce:section id="s1140"><ce:section-title id="st1100">Levodopa</ce:section-title><ce:para id="p6205">Levodopa is the precursor to dopamine. When administered orally, more than 90% is decarboxylated to dopamine peripherally in the gastrointestinal tract and blood vessels, and only a small proportion reaches the brain. This peripheral conversion is responsible for the high frequency of adverse effects. To avoid this, LD is combined with a dopa decarboxylase inhibitor (DDI); the inhibitor does not cross the blood–brain barrier, thus avoiding unwanted decarboxylation-blocking in the brain. Two DDIs, carbidopa and benserazide, are available as combination preparations with LD (Sinemet and Madopar, respectively).</ce:para><ce:para id="p6210">LD is most effective for relieving akinesia and rigidity; tremor response is often less satisfactory and it has no effect on many motor (posture, freezing) and non-motor symptoms. Failure of akinesia/rigidity to respond to LD (1000 mg/day) should prompt reconsideration of the diagnosis. Although controlled-release versions of LD exist, these are usually best reserved for use overnight, as their variable bioavailability makes them difficult to use throughout the day. Madopar is also available as a dispersible tablet for more rapid-onset effect.</ce:para><ce:para id="p6215">Adverse effects include postural hypotension, nausea and vomiting, which may be offset by domperidone. LD may exacerbate or trigger hallucinations, and abnormal LD-seeking behaviour (dopamine dysregulation syndrome), in which the patient takes excessive doses of LD, may occur uncommonly.</ce:para><ce:para id="p6220">As PD progresses, the response to LD becomes less predictable in many patients, leading to motor fluctuations. This end-of-dose deterioration is due to progressive loss of dopamine storage capacity by dwindling numbers of striatonigral neurons. LD-induced involuntary movements (dyskinesia) may occur as a peak-dose phenomenon or as a biphasic phenomenon (occurring during both the build-up and wearing-off phases). More complex fluctuations present as sudden, unpredictable changes in response, in which periods of parkinsonism (‘off’ phases) alternate with improved mobility but with dyskinesias (‘on’ phases). Motor complication management is difficult; wearing-off effects may respond to increased dose or frequency of LD or the addition of a COMT inhibitor (see below). More complex fluctuations may be improved by the addition of dopamine agonists (including continuous infusion of apomorphine), use of intraintestinal LD via a percutaneous endoscopic jejunostomy, or deep brain stimulator implantation.</ce:para></ce:section><ce:section id="s1145"><ce:section-title id="st1105">Dopamine receptor agonists</ce:section-title><ce:para id="p6225">Originally introduced in the hope of delaying the initiation of LD and thus delaying motor complications, several dopamine agonists are available, and may be delivered orally, transdermally or subcutaneously (<ce:cross-ref id="crf1165" refid="b0300">Box 25.56</ce:cross-ref><ce:float-anchor refid="b0300"/>).</ce:para><ce:para id="p6275">The ergot-derived agonists are no longer recommended because of rare but serious fibrotic effects. With the exception of apomorphine, all the agonists are considerably less effective than LD in relieving parkinsonism, have more adverse effects (nausea, vomiting, disorientation and hallucinations, impulse control disorders) and are more expensive. Their role in the management of PD (monotherapy or adjunctive) remains uncertain, and evidence suggests that their usefulness as initial monotherapy is short-lasting.</ce:para></ce:section><ce:section id="s1150"><ce:section-title id="st1110">MAOI-B inhibitors</ce:section-title><ce:para id="p6280">Monoamine oxidase type B facilitates breakdown of excess dopamine in the synapse. Two inhibitors are used in PD: selegiline and rasagiline. The effects of both are modest, although usually well tolerated. Neither is neuroprotective, despite initial hopes.</ce:para></ce:section><ce:section id="s1155"><ce:section-title id="st1115">COMT inhibitors</ce:section-title><ce:para id="p6285">Catechol-O-methyl-transferase (along with dopa decarboxylase) is involved in peripheral breakdown of LD. Two inhibitors are available: entacapone and tolcapone (which also inhibits central COMT). Entacapone has a modest effect and is most useful for early wearing-off. It is available either as a single tablet taken with each LD/DDI dose, or as a combination tablet with LD and DDI. The more potent tolcapone is less used because of rare but serious hepatotoxicity.</ce:para></ce:section><ce:section id="s1160"><ce:section-title id="st1120">Amantadine</ce:section-title><ce:para id="p6290">This has a mild, usually short-lived effect on bradykinesia and is rarely used unless patients are unable to tolerate other drugs. It is more commonly employed as a treatment for LD-induced dyskinesias, although again benefit is modest and short-lived. Adverse effects include livedo reticularis, peripheral oedema, delirium and other anticholinergic effects.</ce:para></ce:section><ce:section id="s1165"><ce:section-title id="st1125">Anticholinergic drugs</ce:section-title><ce:para id="p6295">These were the main treatment for PD prior to the introduction of LD. Their role now is limited by lack of efficacy (apart from an effect on tremor sometimes) and adverse effects, including dry mouth, blurred vision, constipation, urinary retention, delirium and hallucinosis, as well as long-term concerns regarding cognitive impairment. Several anticholinergics are available, including trihexyphenidyl (benzhexol) and orphenadrine.</ce:para></ce:section></ce:section><ce:section id="s1170"><ce:section-title id="st1130">Surgery</ce:section-title><ce:para id="p6300">Destructive neurosurgery was commonly used before the introduction of LD. In the last 20 years, stereotactic surgery has emerged and most commonly involves deep brain stimulation (DBS), rather than the destructive approach of previous eras. Various targets have been identified, including the thalamus (only effective for tremor), globus pallidus and subthalamic nucleus. DBS is usually reserved for individuals with medically refractory tremor or motor fluctuations, and careful patient selection is vital to success. Intracranial delivery of fetal grafts or specific growth factors remains experimental.</ce:para></ce:section><ce:section id="s1175"><ce:section-title id="st1135">Physiotherapy, occupational therapy and speech therapy</ce:section-title><ce:para id="p6305">Patients at all stages of PD benefit from physiotherapy, which helps reduce rigidity and corrects abnormal posture. Occupational therapists can provide equipment to help overcome functional limitations, such as rails for stairs and the toilet, and bathing equipment. Speech therapy can help where dysarthria and dysphonia interfere with communication, and advice may also be provided to those with dysphagia. As with many complex neurological disorders, patients with PD should ideally be managed by a multidisciplinary team, including PD specialist nurses.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1180"><ce:section-title id="st1140">Other parkinsonian syndromes</ce:section-title><ce:para id="p6310">Cerebrovascular disease and drug-induced parkinsonism are the most common alternative causes of parkinsonism (see <ce:cross-ref id="crf1175" refid="b0290">Box 25.54</ce:cross-ref>). There are several degenerative conditions that cause parkinsonism, including multiple system atrophy, progressive supranuclear palsy and corticobasal degeneration. They typically have a more rapid progression than PD and tend to be resistant to treatment with LD. They are defined pathologically and identification during life is difficult. There are other conditions that may rarely manifest as parkinsonism, including Huntington's and Wilson's diseases.</ce:para><ce:section id="s1185"><ce:section-title id="st1145">Multiple system atrophy</ce:section-title><ce:para id="p6315">Multiple system atrophy (MSA) is characterised by parkinsonism, autonomic failure and cerebellar symptoms, with either parkinsonism (MSA-P) or cerebellar features (MSA-C) predominating. It is much less common than PD, with a prevalence of about 4/100 000. Although early distinction between PD and MSA-P may be difficult, early falls, postural instability and lack of response to LD are clues. The pathological hallmark is α-synuclein-containing glial cytoplasmic inclusions found in the basal ganglia, cerebellum and motor cortex. Management is symptomatic and the prognosis is less good than for PD, with mean survival from symptom onset of fewer than 10 years and early disability. Cognition is usually unaffected.</ce:para></ce:section><ce:section id="s1190"><ce:section-title id="st1150">Progressive supranuclear palsy</ce:section-title><ce:para id="p6320">Progressive supranuclear palsy (PSP) presents with symmetrical parkinsonism, cognitive impairment, early falls and bulbar symptoms. The characteristic eye movement disorder, with slowed vertical saccades leading to impairment of up- and down-gaze, may take years to emerge. PSP has different pathological features, being associated with abnormal accumulation of tau (τ) proteins and degeneration of the substantia nigra, subthalamic nucleus and mid-brain. It is therefore a tauopathy rather than synucleinopathy. The prevalence is about 5/100 000, with average survival similar to that in MSA. There is no treatment, and the parkinsonism usually does not respond to LD.</ce:para></ce:section><ce:section id="s1195"><ce:section-title id="st1155">Corticobasal degeneration</ce:section-title><ce:para id="p6325">Corticobasal degeneration (CBD) is less common than MSA or PSP, and the clinical manifestations are variable, including parkinsonism, dystonia, myoclonus and ‘alien limb’ phenomenon, whereby a limb (usually upper) moves about or interferes with the other limb without apparent conscious control. Cortical symptoms, including dementia and especially apraxia, are common and may be the only features in some cases. A number of other diseases may present with a corticobasal syndrome, including other dementias. CBD is a tauopathy with widespread deposition throughout the brain, and has similar survival rates to MSA and PSP.</ce:para></ce:section><ce:section id="s1200"><ce:section-title id="st1160">Wilson's disease</ce:section-title><ce:para id="p6330">This is an autosomal recessive disorder resulting from mutation in the <ce:italic>ATP7B</ce:italic> gene, causing a defect of copper metabolism (<ce:intra-ref id="ii0760" xlink:href="pii:B978-0-7020-7028-0.00022-6#s1300">p. 896</ce:intra-ref>). It is a treatable cause of various movement disorders, including tremor, dystonia, parkinsonism and ataxia; psychiatric symptoms may also occur. Wilson's disease should always be excluded in patients under the age of 50 presenting with any movement disorder.</ce:para></ce:section><ce:section id="s1205"><ce:section-title id="st1165">Huntington's disease</ce:section-title><ce:para id="p6335">Huntington's disease (HD) is an autosomal dominant disorder, presenting in adults usually but occasionally in children. It is due to expansion of a trinucleotide CAG repeat in the <ce:italic>Huntingtin</ce:italic> gene on chromosome 4 (<ce:intra-ref id="ii0765" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0075">p. 43</ce:intra-ref>). The disease frequently demonstrates the phenomenon of anticipation, in which there is a younger age at onset as the disease is passed through generations, due to progressive expansion of the repeat. The prevalence is about 4–8/100 000.</ce:para><ce:section id="s1210"><ce:section-title id="st1170">Clinical features</ce:section-title><ce:para id="p6340">HD typically presents with a progressive behavioural disturbance, abnormal movements (usually chorea), and cognitive impairment leading to dementia. Onset under 18 years is rare but patients may then present with parkinsonism rather than chorea (the ‘Westphal variant’). There is always a family history, although this may be concealed.</ce:para></ce:section><ce:section id="s1215"><ce:section-title id="st1175">Investigations and management</ce:section-title><ce:para id="p6345">The diagnosis is confirmed by genetic testing; pre-symptomatic testing for other family members is available but must be preceded by appropriate counselling (<ce:intra-ref id="ii0770" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0330">p. 59</ce:intra-ref>). Brain imaging may show caudate atrophy but is not a reliable test. There are a number of HD mimics.</ce:para><ce:para id="p6350">Management is symptomatic. The chorea may respond to neuroleptics such as risperidone or sulpiride, or tetrabenazine. Depression and anxiety are common and may be helped by medication.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s1220"><ce:section-title id="st1180">Ataxias</ce:section-title><ce:para id="p6355">The ataxias are a heterogeneous group of inherited and acquired disorders, presenting either with pure ataxia or in association with other neurological and non-neurological features. The differential is wide (<ce:cross-ref id="crf1180" refid="b0305">Boxes 25.57</ce:cross-ref><ce:float-anchor refid="b0305"/> and <ce:cross-ref id="crf1185" refid="b0310">25.58</ce:cross-ref><ce:float-anchor refid="b0310"/>), and diagnosis is guided by age of onset, evolution and clinical features. A significant proportion of cases remain idiopathic despite investigation.</ce:para><ce:para id="p6480">The hereditary ataxias are a group of inherited disorders in which degenerative changes occur to varying extents in the cerebellum, brainstem, pyramidal tracts, spinocerebellar tracts and optic and peripheral nerves, and influence the clinical manifestations. Onset ranges from infancy to adulthood, with recessive, sex-linked or dominant inheritance (see <ce:cross-ref id="crf1190" refid="b0310">Box 25.58</ce:cross-ref>). While the genetic abnormality has been identified for some, allowing diagnostic testing, this is not currently the case for many of the hereditary ataxias.</ce:para></ce:section><ce:section id="s1225"><ce:section-title id="st1185">Tremor disorders</ce:section-title><ce:para id="p6485">Tremor (p. 1085) is a feature of many disorders but the most important clinical syndromes are PD, essential tremor, drug-induced tremors (<ce:cross-ref id="crf1195" refid="b0315">Box 25.59</ce:cross-ref><ce:float-anchor refid="b0315"/>) and functional (psychogenic) tremors.</ce:para><ce:section id="s1230"><ce:section-title id="st1190">Essential tremor</ce:section-title><ce:para id="p6540">This has a prevalence of about 300/100 000 and may display a dominant pattern of inheritance, although no genes have thus far been identified. It may present at any age with a bilateral arm tremor (8–10 Hz), rarely at rest but typical with movement. The head and voice may be involved. The tremor improves in about 50% of patients with small amounts of alcohol. There are no specific tests and essential tremor should be distinguished from other tremor syndromes, including dystonic tremor. Beta-blockers and primidone are sometimes helpful, and DBS of the thalamus is an effective treatment for severe cases.</ce:para></ce:section></ce:section><ce:section id="s1235"><ce:section-title id="st1195">Dystonia</ce:section-title><ce:para id="p6545">Dystonia is characterised by a focal increase in tone affecting muscles in the limbs or trunk. It may be a feature of a number of neurological conditions (PD, Wilson's disease), or occur secondary to brain damage (trauma, stroke) or drugs (tardive syndromes). Dystonia also occurs as a primary disorder. With childhood onset the cause is usually genetic and dystonia is generalised, but adult onset is usually focal; examples include a twisted neck (torticollis), repetitive blinking (blepharospasm) or tremor. Task-specific symptoms (e.g. writer's cramp, musician's dystonia) are often dystonic. Treatment is difficult but botulinum toxin injections or DBS may be useful.</ce:para></ce:section><ce:section id="s1240"><ce:section-title id="st1200">Hemifacial spasm</ce:section-title><ce:para id="p6550">This usually presents after middle age with intermittent twitching around one eye, spreading ipsilaterally to other facial muscles. The spasms are exacerbated by talking, eating and stress. Hemifacial spasm is usually idiopathic, similar to trigeminal neuralgia; it has been suggested that it may be due to an aberrant arterial loop irritating the 7th nerve just outside the pons. It may, however, be symptomatic and secondary to structural lesions. Drug treatment is not effective but injections of botulinum toxin into affected muscles help, although these usually have to be repeated every 3 months or so. In refractory cases, microvascular decompression may be considered.</ce:para></ce:section><ce:section id="s1245"><ce:section-title id="st1205">Motor neuron disease</ce:section-title><ce:para id="p6555">Motor neuron disease (MND) is a neurodegenerative condition caused by loss of upper and lower motor neurons in the spinal cord, cranial nerve nuclei and motor cortex. Annual incidence is about 2/100 000, with a prevalence of about 7/100 000. Most cases are sporadic but 10% of cases are familial. Abnormalities in the superoxide dismutase (<ce:italic>SOD1</ce:italic>) gene account for about 20% of such cases, and an expanded repeat sequence in the <ce:italic>C9orf72</ce:italic> gene on chromosome 9 is associated with MND and frontotemporal dementia. The most common form of MND (<ce:cross-ref id="crf9015" refid="f0195">Fig. 25.33</ce:cross-ref><ce:float-anchor refid="f0195"/>) is amyotrophic lateral sclerosis (ALS), and many use the terms MND and ALS interchangeably. ALS is characterised by a combination of upper and lower motor neuron signs; there are rarer, pure lower (progressive muscular atrophy) or upper (progressive lateral sclerosis) motor neuron variants of MND. The average age of onset is 65, with 10% presenting before 45 years.</ce:para><ce:section id="s1250"><ce:section id="s1255"><ce:section-title id="st1210">Clinical features</ce:section-title><ce:para id="p6560">Diagnosis can be difficult and is often delayed. MND typically presents focally, either with limb onset (e.g. foot drop or loss of manual dexterity) or with bulbar symptoms (dysarthria, swallowing difficulty); respiratory onset is rare but type II respiratory failure is a common terminal event. Sensory, autonomic and visual symptoms do not occur, although cramp is common (<ce:cross-ref id="crf1210" refid="b0320">Box 25.60</ce:cross-ref><ce:float-anchor refid="b0320"/>). Examination reveals a combination of lower and upper motor neuron signs (e.g. brisk reflexes in wasted, fasciculating muscles) without sensory involvement (<ce:cross-ref id="crf1215" refid="f0195">Fig. 25.33</ce:cross-ref>). Cognitive impairment is under-recognised in MND: up to 50% will have a mainly executive impairment on formal testing, and around 10% develop a frontotemporal dementia (FTD). About 10% of patients presenting with FTD will develop ALS within a few years of dementia onset. Even with treatment, MND is relentlessly progressive, but median survival is improved with specialist follow-up offering non-invasive ventilation, feeding measures and access to pharmacological treatment.</ce:para></ce:section><ce:section id="s1280"><ce:section-title id="st1235">Investigations</ce:section-title><ce:para id="p6650">Clinical features are often typical but alternative diagnoses should be excluded. Exclusion of treatable causes, such as immune-mediated multifocal motor neuropathy with conduction block (p. 1140) and cervical myeloradiculopathy, is essential. Blood tests are usually normal, other than a mildly raised creatine kinase. Sensory and motor nerve conduction studies are normal but there may be reduction in amplitude of motor action potentials due to axonal loss. EMG will usually confirm the typical features of widespread denervation and re-innervation. Spinal fluid analysis is not usually necessary. Genetic testing is increasing in importance, with mutations found in <ce:italic>SOD1</ce:italic>, <ce:italic>FUS</ce:italic>, <ce:italic>TARDBP</ce:italic> and <ce:italic>C9orf72</ce:italic> that may help predict risk and phenotype of disease in those with a family history of MND.</ce:para></ce:section><ce:section id="s1285"><ce:section-title id="st1240">Management</ce:section-title><ce:para id="p6655">Patients should be managed within a multidisciplinary service, including physiotherapists, speech and occupational therapists, dietitians, ventilatory and feeding support, and palliative care teams, with neurological and respiratory input. Riluzole, a glutamate release antagonist, is licensed for ALS but has only a modest effect, prolonging median survival by about 2–3 months.</ce:para><ce:para id="p6660">Non-invasive ventilation significantly prolongs survival and improves or maintains quality of life in people with ALS. Survival and some measures of quality of life are significantly improved in the subgroup of people with better baseline bulbar function but not in those with severe bulbar impairment. Feeding by percutaneous gastrostomy may improve quality of life and prolong survival, even when done at a late stage. Rapid access to palliative care teams is essential for patients as they enter the terminal stages of MND.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1290"><ce:section-title id="st1245">Spinal muscular atrophy</ce:section-title><ce:para id="p6665">This is a group of genetically determined disorders affecting spinal and cranial lower motor neurons, characterised by proximal and distal wasting, fasciculation and weakness of muscles. Involvement is usually symmetrical but occasional localised forms occur. With the exception of the infantile form, progression is slow and the prognosis better than for MND.</ce:para></ce:section></ce:section><ce:section id="s1295"><ce:section-title id="st1250">Infections of the nervous system</ce:section-title><ce:para id="p6670">The clinical features of nervous system infections depend on the location of the infection (the meninges or the parenchyma of the brain and spinal cord), the causative organism (virus, bacterium, fungus or parasite), and whether the infection is acute or chronic. The major infections of the nervous system are listed in <ce:cross-ref id="crf1220" refid="b0325">Box 25.61</ce:cross-ref><ce:float-anchor refid="b0325"/>. The frequency of these varies geographically. Helminthic infections, such as cysticercosis and hydatid disease, and protozoal infections are described in <ce:intra-ref id="ii0810" xlink:href="pii:B978-0-7020-7028-0.00011-1#c00011">Chapter 11</ce:intra-ref>.</ce:para><ce:section id="s1300"><ce:section-title id="st1255">Meningitis</ce:section-title><ce:para id="p6825">Acute infection of the meninges presents with a characteristic combination of pyrexia, headache and meningism. Meningism consists of headache, photophobia and stiffness of the neck, often accompanied by other signs of meningeal irritation, including Kernig's sign (extension at the knee with the hip joint flexed causes spasm in the hamstring muscles) and Brudzinski's sign (passive flexion of the neck causes flexion of the hips and knees). Meningism is not specific to meningitis and can occur in patients with subarachnoid haemorrhage. The severity of clinical features varies with the causative organism, as does the presence of other features such as a rash. Abnormalities in the CSF (see <ce:cross-ref id="crf1275" refid="b0050">Box 25.6</ce:cross-ref>, p. 1078) are important in distinguishing the cause of meningitis. Causes of meningitis are listed in <ce:cross-ref id="crf1280" refid="b0330">Box 25.62</ce:cross-ref><ce:float-anchor refid="b0330"/>.</ce:para><ce:section id="s1305"><ce:section-title id="st1260">Viral meningitis</ce:section-title><ce:para id="p6955">Viruses are the most common cause of meningitis, usually resulting in a benign and self-limiting illness requiring no specific therapy. It is much less serious than bacterial meningitis unless there is associated encephalitis. A number of viruses can cause meningitis (see <ce:cross-ref id="crf1290" refid="b0330">Box 25.62</ce:cross-ref>), the most common being enteroviruses. Where specific immunisation is not employed, the mumps virus is a common cause.</ce:para><ce:section id="s1310"><ce:section-title id="st1265">Clinical features</ce:section-title><ce:para id="p6960">Viral meningitis occurs mainly in children or young adults, with acute onset of headache and irritability and the rapid development of meningism. The headache is usually the most severe feature. There may be a high pyrexia but focal neurological signs are rare.</ce:para></ce:section><ce:section id="s1315"><ce:section-title id="st1270">Investigations</ce:section-title><ce:para id="p6965">The diagnosis is made by lumbar puncture. CSF usually contains an excess of lymphocytes. While glucose and protein levels are commonly normal, the latter may be raised. It is important to verify that the patient has not received antibiotics (for whatever cause) prior to the lumbar puncture, as CSF lymphocytosis can also be found in partially treated bacterial meningitis.</ce:para></ce:section><ce:section id="s1320"><ce:section-title id="st1275">Management</ce:section-title><ce:para id="p6970">There is no specific treatment and the condition is usually benign and self-limiting. The patient should be treated symptomatically in a quiet environment. Recovery usually occurs within days, although a lymphocytic pleocytosis may persist in the CSF. Meningitis may also occur as a complication of a systemic viral infection such as mumps, measles, infectious mononucleosis, herpes zoster and hepatitis. Whatever the virus, complete recovery without specific therapy is the rule.</ce:para></ce:section></ce:section><ce:section id="s1325"><ce:section-title id="st1280">Bacterial meningitis</ce:section-title><ce:para id="p6975">Many bacteria can cause meningitis but geographical patterns vary, as does age-related sensitivity (<ce:cross-ref id="crf1295" refid="b0335">Box 25.63</ce:cross-ref><ce:float-anchor refid="b0335"/>). In the ‘meningitis belt’ of sub-Saharan Africa, drought and dust storms are often associated with meningococcal outbreaks (Harmattan meningitis). Bacterial meningitis is usually part of a bacteraemic illness, although direct spread from an adjacent focus of infection in the ear, skull fracture or sinus can be causative. Antibiotics have rendered this less common but mortality and morbidity remain significant. An important factor in determining prognosis is early diagnosis and the prompt initiation of appropriate therapy. The meningococcus and other common causes of meningitis are normal commensals of the upper respiratory tract. New and potentially pathogenic strains are acquired by the air-borne route but close contact is necessary. Epidemics of meningococcal meningitis occur, particularly in cramped living conditions or where the climate is hot and dry. The organism invades through the nasopharynx, producing sepsis and leading to meningitis.</ce:para><ce:section id="s1330"><ce:section-title id="st1285">Pathophysiology</ce:section-title><ce:para id="p7040">The meningococcus (<ce:italic>Neisseria meningitidis</ce:italic>) is now the most common cause of bacterial meningitis in Western Europe after <ce:italic>Streptococcus pneumoniae</ce:italic>, while in the USA <ce:italic>Haemophilus influenzae</ce:italic> remains common. In India, <ce:italic>H. influenzae</ce:italic> B and <ce:italic>Strep. pneumoniae</ce:italic> are probably the most common causes of bacterial meningitis, especially in children. <ce:italic>Streptococcus suis</ce:italic> is a rare zoonotic cause of meningitis associated with porcine contact. Infection stimulates an immune response, causing the pia–arachnoid membrane to become congested and infiltrated with inflammatory cells. Pus then forms in layers, which may later organise to form adhesions. These may obstruct the free flow of CSF, leading to hydrocephalus, or they may damage the cranial nerves at the base of the brain. Hearing loss is a frequent complication. The CSF pressure rises rapidly, the protein content increases, and there is a cellular reaction that varies in type and severity according to the nature of the inflammation and the causative organism. An obliterative endarteritis of the leptomeningeal arteries passing through the meningeal exudate may produce secondary cerebral infarction. Pneumococcal meningitis is often associated with a very purulent CSF and a high mortality, especially in older adults.</ce:para></ce:section><ce:section id="s1335"><ce:section-title id="st1290">Clinical features</ce:section-title><ce:para id="p7045">Headache, drowsiness, fever and neck stiffness are the usual presenting features. In severe bacterial meningitis the patient may be comatose, later developing focal neurological signs. Ninety per cent of patients with meningococcal meningitis will have two of the following: fever, neck stiffness, altered consciousness and rash. When accompanied by sepsis, presenting signs may evolve rapidly, with abrupt onset of obtundation due to cerebral oedema. Complications of meningococcal sepsis are listed in <ce:cross-ref id="crf1300" refid="b0340">Box 25.64</ce:cross-ref><ce:float-anchor refid="b0340"/>. Chronic meningococcaemia is a rare condition in which the patient can be unwell for weeks or even months with recurrent fever, sweating, joint pains and transient rash. It usually occurs in the middle-aged and elderly, and in those who have previously had a splenectomy. In pneumococcal and <ce:italic>Haemophilus</ce:italic> infections there may be an accompanying otitis media. Pneumococcal meningitis may be associated with pneumonia and occurs especially in older patients and alcoholics, as well as those with hyposplenism. <ce:italic>Listeria monocytogenes</ce:italic> is an increasing cause of meningitis and rhombencephalitis (brainstem encephalitis) in the immunosuppressed, people with diabetes, alcoholics and pregnant women (<ce:intra-ref id="ii0820" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1370">p. 259</ce:intra-ref>). It can also cause meningitis in neonates.</ce:para></ce:section><ce:section id="s1340"><ce:section-title id="st1295">Investigations</ce:section-title><ce:para id="p7095">Lumbar puncture is mandatory unless there are contraindications (p. 1077). If the patient is drowsy and has focal neurological signs or seizures, is immunosuppressed, has undergone recent neurosurgery or has suffered a head injury, it is wise to obtain a CT to exclude a mass lesion (such as a cerebral abscess) before lumbar puncture because of the risk of coning. This should not, however, delay treatment of presumed meningitis. If lumbar puncture is deferred or omitted, it is essential to take blood cultures and to start empirical treatment (<ce:cross-ref id="crf1305" refid="f0200">Fig. 25.34</ce:cross-ref><ce:float-anchor refid="f0200"/>). Lumbar puncture will help differentiate the causative organism: in bacterial meningitis the CSF is cloudy (turbid) due to the presence of many neutrophils (often &#x003E; 1000 × 10<ce:sup loc="post">6</ce:sup> cells/L), the protein content is significantly elevated and the glucose reduced. Gram film and culture may allow identification of the organism. Blood cultures may be positive. PCR techniques can be used on both blood and CSF to identify bacterial DNA. These methods are useful in detecting meningococcal infection and in typing the organism.</ce:para></ce:section><ce:section id="s1345"><ce:section-title id="st1300">Management</ce:section-title><ce:para id="p7100">There is an untreated mortality rate of around 80%, so action must be swift. In suspected bacterial meningitis the patient should be given parenteral benzylpenicillin immediately (intravenous is preferable) and prompt hospital admission should be arranged. The only contraindication is a history of penicillin anaphylaxis. Recommended empirical therapies are outlined in <ce:cross-ref id="crf1310" refid="b0345">Box 25.65</ce:cross-ref><ce:float-anchor refid="b0345"/>, and the preferred antibiotic when the organism is known after CSF examination is stipulated in <ce:cross-ref id="crf1315" refid="b0350">Box 25.66</ce:cross-ref><ce:float-anchor refid="b0350"/>. Adjunctive glucocorticoid therapy is useful in reducing hearing loss and neurological sequelae in both children and adults in developed countries where the incidence of penicillin resistance is low, but its role where there are high rates of resistance or in countries where there are high rates of untreated HIV is unclear.</ce:para><ce:para id="p7270">In meningococcal disease, mortality is doubled if the patient presents with features of sepsis rather than meningitis. Individuals likely to require intensive care facilities and expertise include those with cardiac, respiratory or renal involvement, and those with CNS depression prejudicing the airway. Early endotracheal intubation and mechanical ventilation protect the airway and may prevent the development of the acute respiratory distress syndrome (ARDS, <ce:intra-ref id="ii0830" xlink:href="pii:B978-0-7020-7028-0.00010-X#u1540">p. 198</ce:intra-ref>). Adverse prognostic features include hypotensive shock, a rapidly developing rash, a haemorrhagic diathesis, multisystem failure and age over 60 years.</ce:para></ce:section><ce:section id="s1375"><ce:section-title id="st1330">Prevention of meningococcal infection</ce:section-title><ce:para id="p7275">Close contacts of patients with meningococcal infection (<ce:cross-ref id="crf1345" refid="b0355">Box 25.67</ce:cross-ref><ce:float-anchor refid="b0355"/>) should be given 2 days of oral rifampicin. In adults, a single dose of ciprofloxacin is an alternative. If not treated with ceftriaxone, the index case should be given similar treatment to clear infection from the nasopharynx before hospital discharge. Vaccines are available for most meningococcal subgroups but not group B, which is one of the most common serogroups isolated in many countries.</ce:para></ce:section></ce:section><ce:section id="s1390"><ce:section-title id="st1345">Tuberculous meningitis</ce:section-title><ce:para id="p7350">Tuberculous meningitis is now uncommon in developed countries except in immunocompromised individuals, although it is still seen in those born in endemic areas and in developing countries. It is seen more frequently as a secondary infection in patients with the acquired immunodeficiency syndrome (AIDS).</ce:para><ce:section id="s1395"><ce:section-title id="st1350">Pathophysiology</ce:section-title><ce:para id="p7355">Tuberculous meningitis most commonly occurs shortly after a primary infection in childhood or as part of miliary tuberculosis (<ce:intra-ref id="ii0835" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1030">p. 588</ce:intra-ref>). The usual local source of infection is a caseous focus in the meninges or brain substance adjacent to the CSF pathway. The brain is covered by a greenish, gelatinous exudate, especially around the base, and numerous scattered tubercles are found on the meninges.</ce:para></ce:section><ce:section id="s1400"><ce:section-title id="st1355">Clinical features</ce:section-title><ce:para id="p7360">The clinical features and staging criteria are listed in <ce:cross-ref id="crf1350" refid="b0360">Box 25.68</ce:cross-ref><ce:float-anchor refid="b0360"/>. Onset is much slower than in other bacterial meningitis – over 2–8 weeks. If untreated, tuberculous meningitis is fatal in a few weeks but complete recovery is usual if treatment is started at stage I (<ce:cross-ref id="crf1355" refid="b0360">Box 25.68</ce:cross-ref>). When treatment is initiated later, the rate of death or serious neurological deficit may be as high as 30%.</ce:para></ce:section><ce:section id="s1405"><ce:section-title id="st1360">Investigations</ce:section-title><ce:para id="p7445">Lumbar puncture should be performed if the diagnosis is suspected. The CSF is under increased pressure. It is usually clear but, when allowed to stand, a fine clot (‘spider web’) may form. The fluid contains up to 500 × 10<ce:sup loc="post">6</ce:sup> cells/L, predominantly lymphocytes, but can contain neutrophils. There is a rise in protein and a marked fall in glucose. The tubercle bacillus may be detected in a smear of the centrifuged deposit from the CSF but a negative result does not exclude the diagnosis. The CSF should be cultured but, as this result will not be known for up to 6 weeks, treatment must be started without waiting for confirmation. Brain imaging may show hydrocephalus, brisk meningeal enhancement on enhanced CT or MRI, and/or an intracranial tuberculoma.</ce:para></ce:section><ce:section id="s1410"><ce:section-title id="st1365">Management</ce:section-title><ce:para id="p7450">As soon as the diagnosis is made or strongly suspected, chemotherapy should be started using one of the regimens that include pyrazinamide, described on <ce:intra-ref id="ii0840" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1140">page 592</ce:intra-ref>. The use of glucocorticoids in addition to antituberculous therapy has been controversial. Recent evidence suggests that it improves mortality, especially if given early, but not focal neurological damage. Surgical ventricular drainage may be needed if obstructive hydrocephalus develops. Skilled nursing is essential during the acute phase of the illness, and adequate hydration and nutrition must be maintained.</ce:para></ce:section></ce:section><ce:section id="s1415"><ce:section-title id="st1370">Other forms of meningitis</ce:section-title><ce:para id="p7455">Fungal meningitis (especially cryptococcosis; <ce:intra-ref id="ii0845" xlink:href="pii:B978-0-7020-7028-0.00011-1#s2910">p. 302</ce:intra-ref>) usually occurs in patients who are immunosuppressed and is a recognised complication of HIV infection (<ce:intra-ref id="ii0850" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0300">p. 321</ce:intra-ref>). The CSF findings are similar to those of tuberculous meningitis, but the diagnosis can be confirmed by microscopy or specific serological tests.</ce:para><ce:para id="p7460">In some areas, meningitis may be caused by spirochaetes (leptospirosis, Lyme disease and syphilis; <ce:intra-ref id="ii0855" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1305">pp. 257</ce:intra-ref>, <ce:intra-ref id="ii0860" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">255</ce:intra-ref> and <ce:intra-ref id="ii0865" xlink:href="pii:B978-0-7020-7028-0.00013-5#s0150">337</ce:intra-ref>), rickettsiae (typhus fever; <ce:intra-ref id="ii0870" xlink:href="pii:B978-0-7020-7028-0.00011-1#p5980">p. 270</ce:intra-ref>) or protozoa (amoebiasis; <ce:intra-ref id="ii0875" xlink:href="pii:B978-0-7020-7028-0.00011-1#p7065">p. 286</ce:intra-ref>).</ce:para><ce:para id="p7465">Meningitis can also be due to non-infective pathologies. This is seen in recurrent aseptic meningitis resulting from systemic lupus erythematosus (SLE), Behçet's disease or sarcoidosis, as well as a condition of previously unknown origin known as Mollaret's syndrome, in which the recurrent meningitis is associated with epithelioid cells in the spinal fluid (‘Mollaret’ cells). Recent evidence suggests that this condition may be due to herpes simplex virus type 2 and is therefore infective after all. Meningitis can also be caused by direct invasion of the meninges by neoplastic cells (‘malignant meningitis’; see <ce:cross-ref id="crf1360" refid="b0330">Box 25.62</ce:cross-ref>).</ce:para></ce:section></ce:section><ce:section id="s1420"><ce:section-title id="st1375">Parenchymal viral infections</ce:section-title><ce:para id="p7470">Infection of the substance of the nervous system will produce symptoms of focal dysfunction (deficits and/or seizures) with general signs of infection, depending on the acuteness of the infection and the type of organism.</ce:para><ce:section id="s1425"><ce:section-title id="st1380">Viral encephalitis</ce:section-title><ce:para id="p7475">A range of viruses can cause encephalitis but only a minority of patients report recent systemic viral infection. In Europe, the most serious cause of viral encephalitis is herpes simplex (<ce:intra-ref id="ii0880" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0895">p. 247</ce:intra-ref>), which probably reaches the brain via the olfactory nerves. Varicella zoster is also an important cause. The development of effective therapy for some forms of encephalitis has increased the importance of clinical diagnosis and virological examination of the CSF. In some parts of the world, viruses transmitted by mosquitoes and ticks (arboviruses) are an important cause of encephalitis. The epidemiology of some of these infections is changing. Japanese encephalitis (<ce:intra-ref id="ii0885" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0985">p. 249</ce:intra-ref>) has spread relentlessly across Asia to Australia, and there have been outbreaks of West Nile encephalitis in Romania, Israel and New York. Zika virus has mutated in the last decades and become a more significant global health problem. HIV may cause encephalitis with a subacute or chronic presentation but occasionally has an acute presentation with seroconversion.</ce:para><ce:section id="s1430"><ce:section-title id="st1385">Pathophysiology</ce:section-title><ce:para id="p7480">The infection provokes an inflammatory response that involves the cortex, white matter, basal ganglia and brainstem. The distribution of lesions varies with the type of virus. For example, in herpes simplex encephalitis, the temporal lobes are usually primarily affected, whereas cytomegalovirus can involve the areas adjacent to the ventricles (ventriculitis). Inclusion bodies may be present in the neurons and glial cells, and there is an infiltration of polymorphonuclear cells in the perivascular space. There is neuronal degeneration and diffuse glial proliferation, often associated with cerebral oedema.</ce:para></ce:section><ce:section id="s1435"><ce:section-title id="st1390">Clinical features</ce:section-title><ce:para id="p7485">Viral encephalitis presents with acute onset of headache, fever, focal neurological signs (aphasia and/or hemiplegia, visual field defects) and seizures. Disturbance of consciousness ranging from drowsiness to deep coma supervenes early and may advance dramatically. Meningism occurs in many patients. Rabies presents a distinct clinical picture and is described below.</ce:para></ce:section><ce:section id="s1440"><ce:section-title id="st1395">Investigations</ce:section-title><ce:para id="p7490">Imaging by CT scan may show low-density lesions in the temporal lobes but MRI is more sensitive in detecting early abnormalities. Lumbar puncture should be performed once imaging has excluded a mass lesion. The CSF usually contains excess lymphocytes but polymorphonuclear cells may predominate in the early stages. The CSF may be normal in up to 10% of cases. Some viruses, including the West Nile virus, may cause a sustained neutrophilic CSF. The protein content may be elevated but the glucose is normal. The EEG is usually abnormal in the early stages, especially in herpes simplex encephalitis, with characteristic periodic slow-wave activity in the temporal lobes. Virological investigations of the CSF, including PCR, may reveal the causative organism but treatment initiation should not await this.</ce:para></ce:section><ce:section id="s1445"><ce:section-title id="st1400">Management</ce:section-title><ce:para id="p7495">Optimum treatment for herpes simplex encephalitis (aciclovir 10 mg/kg IV 3 times daily for 2–3 weeks) has reduced mortality from 70% to around 10%. This should be given early to all patients suspected of having viral encephalitis.</ce:para><ce:para id="p7500">Some survivors will have residual epilepsy or cognitive impairment. For details of post-infectious encephalomyelitis, see page 1110. Antiepileptic treatment may be required (p. 1101) and raised intracranial pressure may indicate the need for dexamethasone.</ce:para></ce:section></ce:section><ce:section id="s1450"><ce:section-title id="st1405">Brainstem encephalitis</ce:section-title><ce:para id="p7505">This presents with ataxia, dysarthria, diplopia or other cranial nerve palsies. The CSF is lymphocytic, with a normal glucose. The causative agent is presumed to be viral. However, <ce:italic>Listeria monocytogenes</ce:italic> may cause a similar syndrome with meningitis (and often a polymorphonuclear CSF pleocytosis) and requires specific treatment with ampicillin (500 mg 4 times daily; see <ce:cross-ref id="crf1365" refid="b0350">Box 25.66</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1455"><ce:section-title id="st1410">Rabies</ce:section-title><ce:para id="p7510">Rabies is caused by a rhabdovirus that infects the central nervous tissue and salivary glands of a wide range of mammals. It is usually conveyed by saliva through bites or licks on abrasions or on intact mucous membranes. Humans are most frequently infected from dogs and bats. In Europe, the maintenance host is the fox. The incubation period varies in humans from a minimum of 9 days to many months but is usually between 4 and 8 weeks. Severe bites, especially if on the head or neck, are associated with shorter incubation periods. Human rabies is a rare disease, even in endemic areas. However, because it is usually fatal, major efforts are directed at limiting its spread and preventing its importation into uninfected countries, such as the UK.</ce:para><ce:section id="s1460"><ce:section-title id="st1415">Clinical features</ce:section-title><ce:para id="p7515">At the onset there may be fever, and paraesthesia at the site of the bite. A prodromal period of 1–10 days, during which the patient becomes increasingly anxious, leads to the characteristic ‘hydrophobia’. Although the patient is thirsty, attempts at drinking provoke violent contractions of the diaphragm and other inspiratory muscles. Delusions and hallucinations may develop, accompanied by spitting, biting and mania, with lucid intervals in which the patient is markedly anxious. Cranial nerve lesions develop and terminal hyperpyrexia is common. Death ensues, usually within a week of the onset of symptoms.</ce:para></ce:section><ce:section id="s1465"><ce:section-title id="st1420">Investigations</ce:section-title><ce:para id="p7520">During life, the diagnosis is usually made on clinical grounds but rapid immunofluorescent techniques can detect antigen in corneal impression smears or skin biopsies.</ce:para></ce:section><ce:section id="s1470"><ce:section-title id="st1425">Management</ce:section-title><ce:section id="s1475"><ce:section-title id="st1430">Established disease</ce:section-title><ce:para id="p7525">Only a few patients with established rabies have survived. All received some post-exposure prophylaxis (see below) and needed intensive care facilities to control cardiac and respiratory failure. Otherwise, only palliative treatment is possible once symptoms have appeared. The patient should be heavily sedated with diazepam, supplemented by chlorpromazine if needed. Nutrition and fluids should be given intravenously or through a gastrostomy.</ce:para></ce:section><ce:section id="s1480"><ce:section-title id="st1435">Pre-exposure prophylaxis</ce:section-title><ce:para id="p7530">Pre-exposure prophylaxis is required by those who handle potentially infected animals professionally, work with rabies virus in laboratories or live at special risk in rabies-endemic areas. Protection is afforded by intradermal injections of human diploid cell strain vaccine, or two intramuscular injections given 4 weeks apart, followed by yearly boosters.</ce:para></ce:section><ce:section id="s1485"><ce:section-title id="st1440">Post-exposure prophylaxis</ce:section-title><ce:para id="p7535">The wounds should be thoroughly cleaned, preferably with a quaternary ammonium detergent or soap; damaged tissues should be excised and the wound left unsutured. Rabies can usually be prevented if treatment is started within a day or two of biting. Delayed treatment may still be of value. For maximum protection, hyperimmune serum and vaccine are required.</ce:para><ce:para id="p7540">The safest antirabies antiserum is human rabies immunoglobulin. The dose is 20 IU/kg body weight; half is infiltrated around the bite and half is given intramuscularly at a different site from the vaccine. Hyperimmune animal serum may be used but hypersensitivity reactions, including anaphylaxis, are common.</ce:para><ce:para id="p7545">The safest vaccine, free of complications, is human diploid cell strain vaccine; 1.0 mL is given intramuscularly on days 0, 3, 7, 14, 30 and 90. In developing countries, where human rabies globulin may not be obtainable, 0.1 mL of vaccine may be given intradermally into eight sites on day 1, with single boosters on days 7 and 28. Where human products are not available and when risk of rabies is slight (licks on the skin, or minor bites of covered arms or legs), it may be justifiable to delay starting treatment while observing the biting animal or awaiting examination of its brain, rather than use the older vaccine.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1490"><ce:section-title id="st1445">Poliomyelitis</ce:section-title><ce:section id="s1495"><ce:section-title id="st1450">Pathophysiology</ce:section-title><ce:para id="p7550">Disease is caused by one of three polioviruses, which constitute a subgroup of the enteroviruses. Poliomyelitis has become much less common in developed countries following the widespread use of oral vaccines but is still a problem in the developing world, especially parts of Africa. Infection usually occurs through the nasopharynx.</ce:para><ce:para id="p7555">The virus causes a lymphocytic meningitis and infects the grey matter of the spinal cord, brainstem and cortex. There is a particular propensity to damage anterior horn cells, especially in the lumbar segments.</ce:para></ce:section><ce:section id="s1500"><ce:section-title id="st1455">Clinical features</ce:section-title><ce:para id="p7560">The incubation period is 7–14 days. <ce:cross-ref id="crf1370" refid="f0205">Figure 25.35</ce:cross-ref><ce:float-anchor refid="f0205"/> illustrates the various features of the infection. Many patients recover fully after the initial phase of a few days of mild fever and headache. In other individuals, after a week of well-being, there is a recurrence of pyrexia, headache and meningism. Weakness may start later in one muscle group and can progress to widespread paresis. Respiratory failure may supervene if intercostal muscles are paralysed or the medullary motor nuclei are involved. Epidemics vary widely in terms of the incidence of non-paralytic cases and in mortality rate. Death occurs from respiratory paralysis. Muscle weakness is maximal at the end of the first week and gradual recovery may then take place over several months. Muscles showing no signs of recovery after a month will probably not regain useful function. Second attacks are very rare but occasionally patients show late deterioration in muscle bulk and power many years after the initial infection (this is termed the ‘post-polio syndrome’).</ce:para></ce:section><ce:section id="s1505"><ce:section-title id="st1460">Investigations</ce:section-title><ce:para id="p7565">The CSF shows a lymphocytic pleocytosis, a rise in protein and a normal sugar content. Poliomyelitis virus may be cultured from CSF and stool.</ce:para></ce:section><ce:section id="s1510"><ce:section-title id="st1465">Management</ce:section-title><ce:section id="s1515"><ce:section-title id="st1470">Established disease</ce:section-title><ce:para id="p7570">In the early stages, bed rest is imperative because exercise appears to worsen the paralysis or precipitate it. At the onset of respiratory difficulties, a tracheostomy and ventilation are required. Subsequent treatment is by physiotherapy and orthopaedic measures.</ce:para></ce:section><ce:section id="s1520"><ce:section-title id="st1475">Prophylaxis</ce:section-title><ce:para id="p7575">Prevention of poliomyelitis is by immunisation with live (Sabin) vaccine. In developed countries where polio is now very rare, the live vaccine has been replaced by the killed vaccine in childhood immunisation schedules.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1525"><ce:section-title id="st1480">Herpes zoster (shingles)</ce:section-title><ce:para id="p7580">Herpes zoster is the result of reactivation of the varicella zoster virus that has lain dormant in a nerve root ganglion following chickenpox earlier in life. Reactivation may be spontaneous (as usually occurs in the middle-aged or elderly) or due to immunosuppression (as in patients with diabetes, malignant disease or AIDS). Full details are given on <ce:intra-ref id="ii0900" xlink:href="pii:B978-0-7020-7028-0.00011-1#s0615">page 239</ce:intra-ref>.</ce:para></ce:section><ce:section id="s1530"><ce:section-title id="st1485">Subacute sclerosing panencephalitis</ce:section-title><ce:para id="p7585">This is a rare, chronic, progressive and eventually fatal complication of measles, presumably a result of an inability of the nervous system to eradicate the virus. It occurs in children and adolescents, usually many years after the primary virus infection. There is generalised neurological deterioration and onset is insidious, with intellectual deterioration, apathy and clumsiness, followed by myoclonic jerks, rigidity and dementia.</ce:para><ce:para id="p7590">The CSF may show a mild lymphocytic pleocytosis and the EEG demonstrates characteristic periodic bursts of triphasic waves. Although there is persistent measles-specific IgG in serum and CSF, antiviral therapy is ineffective and death ensues within a few years.</ce:para></ce:section><ce:section id="s1535"><ce:section-title id="st1490">Progressive multifocal leucoencephalopathy</ce:section-title><ce:para id="p7595">This was originally described as a rare complication of lymphoma, leukaemia or carcinomatosis but has become more frequent as a feature of AIDS (<ce:intra-ref id="ii0905" xlink:href="pii:B978-0-7020-7028-0.00012-3#p1260">p. 319</ce:intra-ref>) or secondary to immunosuppression, e.g. following organ transplantation or use of disease-modifying drugs for MS. It is an infection of oligodendrocytes by human polyomavirus JC, causing widespread demyelination of the white matter of the cerebral hemispheres. Clinical signs include dementia, hemiparesis and aphasia, which progress rapidly, usually leading to death within weeks or months. Areas of low density in the white matter are seen on CT but MRI is more sensitive, showing diffuse high signal in the cerebral white matter on T2-weighted images. The only treatment available is restoration of the immune response (by treating AIDS or reversing immunosuppression).</ce:para></ce:section></ce:section><ce:section id="s1540"><ce:section-title id="st1495">Parenchymal bacterial infections</ce:section-title><ce:section id="s1545"><ce:section-title id="st1500">Cerebral abscess</ce:section-title><ce:para id="p7600">Bacteria may enter the cerebral substance through penetrating injury, by direct spread from paranasal sinuses or the middle ear, or secondary to bacteraemia. Untreated congenital heart disease is a recognised risk factor. The site of abscess formation and the likely causative organism are both related to the source of infection (<ce:cross-ref id="crf1375" refid="b0365">Box 25.69</ce:cross-ref><ce:float-anchor refid="b0365"/>). Initial infection leads to local suppuration followed by loculation of pus within a surrounding wall of gliosis, which in a chronic abscess may form a tough capsule. Haematogenous spread may lead to multiple abscesses.</ce:para><ce:section id="s1550"><ce:section-title id="st1505">Clinical features</ce:section-title><ce:para id="p7715">A cerebral abscess may present acutely with fever, headache, meningism and drowsiness, but more commonly presents over days or weeks as a cerebral mass lesion with little or no evidence of infection. Seizures, raised intracranial pressure and focal hemisphere signs occur alone or in combination. Distinction from a cerebral tumour may be impossible on clinical grounds.</ce:para></ce:section><ce:section id="s1555"><ce:section-title id="st1510">Investigations</ce:section-title><ce:para id="p7720">Lumbar puncture is potentially hazardous in the presence of raised intracranial pressure and CT should always precede it. CT reveals single or multiple low-density areas, which show ring enhancement with contrast and surrounding cerebral oedema (<ce:cross-ref id="crf1385" refid="f0210">Fig. 25.36</ce:cross-ref><ce:float-anchor refid="f0210"/>). There may be an elevated white blood cell count and ESR in patients with active local infection. The possibility of cerebral toxoplasmosis or tuberculous disease secondary to HIV infection (<ce:intra-ref id="ii0910" xlink:href="pii:B978-0-7020-7028-0.00012-3#s0275">p. 320</ce:intra-ref>) should always be considered.</ce:para></ce:section><ce:section id="s1560"><ce:section-title id="st1515">Management and prognosis</ce:section-title><ce:para id="p7725">Optimal management of cerebral abscess consists of antimicrobial therapy plus surgical evacuation or excision, unless surgery is contraindicated. Surgery not only removes the focus of infection but also enables identification of the causative organism(s), without which targeted treatment is impossible. Initial antibiotic choice depends on the likely causative organism(s) (see <ce:cross-ref id="crf1390" refid="b0365">Box 25.69</ce:cross-ref>) and should be adjusted according to subsequent microbiology results. Antibiotics are usually continued for 4–6 weeks. Epilepsy frequently develops and is often late-onset and resistant to treatment.</ce:para><ce:para id="p7730">Despite advances in therapy, mortality remains 10–20% and may partly relate to delay in diagnosis and treatment.</ce:para></ce:section></ce:section><ce:section id="s1565"><ce:section-title id="st1520">Subdural empyema</ce:section-title><ce:para id="p7735">This is a rare complication of frontal sinusitis, osteomyelitis of the skull vault or middle ear disease. A collection of pus in the subdural space spreads over the surface of the hemisphere, causing underlying cortical oedema or thrombophlebitis. Patients present with severe pain in the face or head and pyrexia, often with a history of preceding paranasal sinus or ear infection. The patient then becomes drowsy, with seizures and focal signs such as a progressive hemiparesis.</ce:para><ce:para id="p7740">The diagnosis rests on a strong clinical suspicion in patients with a local focus of infection. Careful assessment with contrast-enhanced CT or MRI may show a subdural collection with underlying cerebral oedema. Management requires aspiration of pus via a burr hole and appropriate parenteral antibiotics. Any local source of infection must be treated to prevent re-infection.</ce:para></ce:section><ce:section id="s1570"><ce:section-title id="st1525">Spinal epidural abscess</ce:section-title><ce:para id="p7745">The characteristic clinical features are pain in a root distribution and progressive transverse spinal cord syndrome with paraparesis, sensory impairment and sphincter dysfunction. Features of the primary focus of infection may be less obvious and thus can be overlooked. The resurgence of resistant staphylococcal infection and intravenous drug misuse has contributed to a recent marked rise in incidence.</ce:para><ce:para id="p7750">X-ray changes occur late, if present, so MRI or myelography should precede urgent neurosurgical intervention. Decompressive laminectomy with abscess drainage relieves the pressure on the dura. Organisms may be grown from the pus or blood. Surgery, together with appropriate antibiotics, may prevent complete and irreversible paraplegia.</ce:para></ce:section><ce:section id="s1575"><ce:section-title id="st1530">Lyme disease</ce:section-title><ce:para id="p7755">Infection with <ce:italic>Borrelia burgdorferi</ce:italic> can cause numerous neurological problems, including polyradiculopathy, meningitis, encephalitis and mononeuritis multiplex (<ce:intra-ref id="ii0915" xlink:href="pii:B978-0-7020-7028-0.00011-1#s1275">p. 255</ce:intra-ref>).</ce:para></ce:section><ce:section id="s1580"><ce:section-title id="st1535">Neurosyphilis</ce:section-title><ce:para id="p7760">Neurosyphilis may present as an acute or chronic process and may involve the meninges, blood vessels and/or parenchyma of the brain and spinal cord. The decade to 2008 saw a 10-fold increase in the incidence of syphilis, mostly as a result of misguided relaxation of safe sex measures with the advent of effective antiretroviral treatments for AIDS. Paralleled future increases in neurosyphilis are inevitable. The clinical manifestations are diverse and early diagnosis and treatment are essential.</ce:para><ce:section id="s1585"><ce:section-title id="st1540">Clinical features</ce:section-title><ce:para id="p7765">The clinical and pathological features of the three most common presentations are summarised in <ce:cross-ref id="crf1395" refid="b0370">Box 25.70</ce:cross-ref><ce:float-anchor refid="b0370"/>. Neurological examination reveals signs indicative of the anatomical localisation of lesions. Delusions of grandeur suggest general paresis of the insane, but more commonly there is simply progressive dementia. Small and irregular pupils that react to convergence but not light, as described by Argyll Robertson (see <ce:cross-ref id="crf1400" refid="b0130">Box 25.22</ce:cross-ref>, p. 1092), may accompany any neurosyphilitic syndrome but most commonly tabes dorsalis.</ce:para></ce:section><ce:section id="s1590"><ce:section-title id="st1545">Investigations</ce:section-title><ce:para id="p7875">Routine screening for syphilis is warranted in many neurological patients. Treponemal antibodies (<ce:intra-ref id="ii0930" xlink:href="pii:B978-0-7020-7028-0.00013-5#s0180">p. 338</ce:intra-ref>) are positive in the serum in most patients, but CSF examination is essential if neurological involvement is suspected. Active disease is suggested by an elevated cell count, usually lymphocytic, and the protein content may be elevated to 0.5–1.0 g/L with an increased gamma globulin fraction. Serological tests in CSF are usually positive but progressive disease can occur with negative CSF serology.</ce:para></ce:section><ce:section id="s1595"><ce:section-title id="st1550">Management</ce:section-title><ce:para id="p7880">The injection of procaine benzylpenicillin (procaine penicillin) and probenecid for 17 days is essential in the treatment of neurosyphilis of all types (<ce:intra-ref id="ii0935" xlink:href="pii:B978-0-7020-7028-0.00013-5#s0180">p. 338</ce:intra-ref>). Further courses of penicillin must be given if symptoms are not relieved, if the condition continues to advance or if the CSF continues to show signs of active disease. The cell count returns to normal within 3 months of completion of treatment, but the elevated protein takes longer to subside and some serological tests may never revert to normal. Evidence of clinical progression at any time is an indication for renewed treatment.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1600"><ce:section-title id="st1555">Diseases caused by bacterial toxins</ce:section-title><ce:section id="s1605"><ce:section-title id="st1560">Tetanus</ce:section-title><ce:para id="p7885">This disease results from infection with <ce:italic>Clostridium tetani</ce:italic>, a commensal in the gut of humans and domestic animals that is found in soil. Infection enters the body through wounds, which may be trivial. It is rare in the UK, occurring mostly in gardeners and farmers, but a recent increase has been seen in intravenous drug misusers. By contrast, the disease is common in many developing countries, where dust contains spores derived from animal and human excreta. Unhygienic practices soon after birth may lead to infection of the umbilical stump or site of circumcision, causing tetanus neonatorum. Tetanus is still one of the major killers of adults, children and neonates in developing countries, where the mortality rate can be nearly 100% in the newborn and around 40% in others.</ce:para><ce:para id="p7890">In circumstances unfavourable to growth of the organism, spores are formed and these may remain dormant for years in the soil. Spores germinate and bacilli multiply only in the anaerobic conditions that occur in areas of tissue necrosis or if the oxygen tension is lowered by the presence of other organisms, particularly if aerobic. The bacilli remain localised but produce an exotoxin with an affinity for motor nerve endings and motor nerve cells.</ce:para><ce:para id="p7895">The anterior horn cells are affected after the exotoxin has passed into the blood stream and their involvement results in rigidity and convulsions. Symptoms first appear from 2 days to several weeks after injury: the shorter the incubation period, the more severe the attack and the worse the prognosis.</ce:para><ce:section id="s1610"><ce:section-title id="st1565">Clinical features</ce:section-title><ce:para id="p7900">By far the most important early symptom is trismus – spasm of the masseter muscles, which causes difficulty in opening the mouth and in masticating; hence the name ‘lockjaw’. Lockjaw in tetanus is painless, unlike the spasm of the masseters due to dental abscess, septic throat or other causes. Conditions that can mimic tetanus include hysteria and phenothiazine overdosage, or overdose in intravenous drug misusers.</ce:para><ce:para id="p7905">In tetanus, the tonic rigidity spreads to involve the muscles of the face, neck and trunk. Contraction of the frontalis and the muscles at the angles of the mouth leads to the so-called ‘risus sardonicus’. There is rigidity of the muscles at the neck and trunk of varying degree. The back is usually slightly arched (‘opisthotonus’) and there is a board-like abdominal wall.</ce:para><ce:para id="p7910">In the more severe cases, violent spasms lasting for a few seconds to 3–4 minutes occur spontaneously, or may be induced by stimuli such as movement or noise. These episodes are painful and exhausting, and suggest a grave outlook, especially if they appear soon after the onset of symptoms. They gradually increase in frequency and severity for about 1 week and the patient may die from exhaustion, asphyxia or aspiration pneumonia. In less severe illness, periods of spasm may not commence until a week or so after the first sign of rigidity, and in very mild infections they may never appear. Autonomic involvement may cause cardiovascular complications, such as hypertension. Rarely, the only manifestation of the disease may be ‘local tetanus’ – stiffness or spasm of the muscles near the infected wound – and the prognosis is good if treatment is commenced at this stage.</ce:para></ce:section><ce:section id="s1615"><ce:section-title id="st1570">Investigations</ce:section-title><ce:para id="p7915">The diagnosis is made on clinical grounds. It is rarely possible to isolate the infecting organism from the original locus of entry.</ce:para></ce:section><ce:section id="s1620"><ce:section-title id="st1575">Management</ce:section-title><ce:section id="s1625"><ce:section-title id="st1580">Established disease</ce:section-title><ce:para id="p7920">Management of established disease should begin as soon as possible, as shown in <ce:cross-ref id="crf1405" refid="b0375">Box 25.71</ce:cross-ref><ce:float-anchor refid="b0375"/>.</ce:para></ce:section></ce:section><ce:section id="s1650"><ce:section-title id="st1605">Prevention</ce:section-title><ce:para id="p7990">Tetanus can be prevented by immunisation and prompt treatment of contaminated wounds by débridement and antibiotics. In patients with a contaminated wound, the immediate danger of tetanus can be greatly reduced by the injection of 1200 mg of penicillin followed by a 7-day course of oral penicillin. For those allergic to penicillin, erythromycin should be used. When the risk of tetanus is judged to be present, an intramuscular injection of 250 IU of human tetanus antitoxin should be given, along with toxoid, which should be repeated 1 month and 6 months later. For those already immunised, only a booster dose of toxoid is required.</ce:para></ce:section></ce:section><ce:section id="s1655"><ce:section-title id="st1610">Botulism</ce:section-title><ce:para id="p7995">Botulism is caused by the neurotoxins of <ce:italic>Clostridium botulinum</ce:italic>, which are extremely potent and cause disease after ingestion of even picogram amounts. Its classical form is an acute onset of bilateral cranial neuropathies associated with symmetric descending weakness.</ce:para><ce:para id="p8000">Anaerobic conditions are necessary for the organism's growth. It may contaminate and thrive in many foodstuffs, where sealing and preserving provide the requisite conditions. Contaminated honey has been implicated in infant botulism, in which the organism colonises the gastrointestinal tract. Wound botulism is a growing problem in injection drug-users.</ce:para><ce:para id="p8005">The toxin causes predominantly bulbar and ocular palsies (difficulty in swallowing, blurred or double vision, ptosis), progressing to limb weakness and respiratory paralysis. Criteria for the clinical diagnosis are shown in <ce:cross-ref id="crf1410" refid="b0380">Box 25.72</ce:cross-ref><ce:float-anchor refid="b0380"/>.</ce:para><ce:para id="p8060">Management includes assisted ventilation and general supportive measures until the toxin eventually dissociates from nerve endings 6–8 weeks following ingestion. A polyvalent antitoxin is available for post-exposure prophylaxis and for the treatment of suspected botulism. It specifically neutralises toxin types A, B and E and is not effective against infantile botulism (in which active growth of the organism allows continued toxin production).</ce:para></ce:section></ce:section><ce:section id="s1670"><ce:section-title id="st1625">Prion diseases</ce:section-title><ce:para id="p8065">Prions are unique amongst infectious agents in that they are devoid of any nucleic acid. They appear to be transmitted by acquisition of a normal mammalian protein (prion protein, PrP<ce:sup loc="post">C</ce:sup>) that is in an abnormal conformation (PrP<ce:sup loc="post">SC</ce:sup>, containing an excess of beta-sheet protein); the abnormal protein inhibits the 26S proteasome, which can degrade misfolded proteins, leading to accumulation of the abnormally configured PrP<ce:sup loc="post">SC</ce:sup> protein instead of normal PrP<ce:sup loc="post">C</ce:sup>. The result is accumulation of protein that forms amyloid in the CNS, causing a transmissible spongiform encephalopathy (TSE) across several species.</ce:para><ce:para id="p8070">Human prion diseases (<ce:cross-ref id="crf1415" refid="b0385">Box 25.73</ce:cross-ref><ce:float-anchor refid="b0385"/>) are characterised by the histopathological triad of cortical spongiform change, neuronal cell loss and gliosis. Associated with these changes there is deposition of amyloid, made up of an altered form of a normally occurring protein, the prion protein. Prion proteins are not inactivated by cooking or conventional sterilisation, and transmission is thought to occur by consumption of infected CNS tissue or by inoculation (e.g. via depth EEG electrodes, corneal grafts, cadaveric dura mater grafts and pooled cadaveric growth hormone preparations). The same diseases can occur in an inherited form, due to mutations in the <ce:italic>PrP</ce:italic> gene.</ce:para><ce:para id="p8080">The apparent transmission of bovine spongiform encephalopathy (BSE) to humans was thought to be responsible for the emergence of a new variant of CJD (vCJD) in the UK (see below). This outbreak led to nationwide precautionary measures, such as leucodepletion of all blood used for transfusion, and the mandatory use of disposable surgical instruments wherever possible for tonsillectomy, appendicectomy and ophthalmological procedures.</ce:para><ce:section id="s1675"><ce:section-title id="st1630">Creutzfeldt–Jakob disease</ce:section-title><ce:para id="p8085">Creutzfeldt–Jakob disease (CJD) is the best-characterised human TSE. Some 10% of cases arise from a mutation in the gene coding for the prion protein. The sporadic form is the most common, occurring in middle-aged to elderly patients. Clinical features usually involve a rapidly progressive dementia, with myoclonus and a characteristic EEG pattern (repetitive slow-wave complexes), although a number of other features, such as visual disturbance or ataxia, may also be seen. These are particularly common in CJD transmitted by inoculation (e.g. by infected dura mater grafts). Death occurs after a mean of 4–6 months. There is no effective treatment.</ce:para></ce:section><ce:section id="s1680"><ce:section-title id="st1635">Variant Creutzfeldt–Jakob disease</ce:section-title><ce:para id="p8090">This type of CJD (vCJD) emerged in the late 1990s, affecting a small number of patients in the UK. The causative agent appears to be identical to that causing BSE in cows, and the disease may have been a result of the epidemic of BSE in the UK a decade earlier. Patients affected by vCJD are typically younger than those with sporadic CJD and present with neuropsychiatric changes and sensory symptoms in the limbs, followed by ataxia, dementia and death. Progression is slightly slower than in patients with sporadic CJD (mean time to death is over a year). Characteristic EEG changes are not present, but MRI brain scans show characteristic high-signal changes in the pulvinar thalami in a high proportion of cases (<ce:cross-ref id="crf1420" refid="f0215">Fig. 25.37</ce:cross-ref><ce:float-anchor refid="f0215"/>). Brain histology is distinct, with very florid plaques containing the prion proteins. Abnormal prion protein has been identified in tonsil specimens from patients with vCJD, leading to the suggestion that the disease could be transmitted by reticulo-endothelial tissue (like TSEs in animals but unlike sporadic CJD in humans). It was the emergence of this form of the disorder that led to the changes in public health and farming policy in the UK; while the incidence of vCJD has declined dramatically, surveillance and research continue.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1685"><ce:section-title id="st1640">Intracranial mass lesions and raised intracranial pressure</ce:section-title><ce:para id="p8095">Many different types of mass lesion may arise within the intracranial cavity (<ce:cross-ref id="crf1425" refid="b0390">Box 25.74</ce:cross-ref><ce:float-anchor refid="b0390"/>). In developing countries tuberculoma and other infections are frequent causes, but in the West intracranial haemorrhage and brain tumours are more common. The clinical features depend on the site of the mass, its nature and its rate of expansion. Symptoms and signs (see <ce:cross-ref id="crf1435" refid="b0395">Box 25.75</ce:cross-ref>) are produced by a number of mechanisms.</ce:para><ce:section id="s1710"><ce:section-title id="st1665">Raised intracranial pressure</ce:section-title><ce:para id="p8220">Raised intracranial pressure (RICP) may be caused by mass lesions, cerebral oedema, obstruction to CSF circulation leading to hydrocephalus, impaired CSF absorption and cerebral venous obstruction (see <ce:cross-ref id="crf1440" refid="b0390">Box 25.74</ce:cross-ref>).</ce:para><ce:section id="s1715"><ce:section id="s1720"><ce:section-title id="st1670">Clinical features</ce:section-title><ce:para id="p8225">In adults, intracranial pressure is less than 10–15 mmHg. The features of RICP are listed in <ce:cross-ref id="crf1445" refid="b0395">Box 25.75</ce:cross-ref><ce:float-anchor refid="b0395"/>. The speed of pressure increase influences presentation. If slow, compensatory mechanisms may occur, including alteration in the volume of fluid in CSF spaces and venous sinuses, minimising symptoms. Rapid pressure increase (as in aggressive tumours) does not permit these compensatory mechanisms to take place, leading to early symptoms, including sudden death. Papilloedema is not always present, either because the pressure rise has been too rapid or because of anatomical anomalies of the meningeal sheath of the optic nerve.</ce:para><ce:para id="p8310">A false localising sign is one in which the pathology is remote from the site of the expected lesion; in RICP, the 6th cranial nerve (unilateral or bilateral) is most commonly affected but the 3rd, 5th and 7th nerves may also be involved. Sixth nerve palsies are thought to be due either to stretching of the long slender nerve or to compression against the petrous temporal bone ridge. Transtentorial herniation of the uncus may compress the ipsilateral 3rd nerve and usually involves the pupillary fibres first, causing a dilated pupil; however, a false localising contralateral 3rd nerve palsy may also occur, perhaps due to extrinsic compression by the tentorial margin. Vomiting, coma, bradycardia and arterial hypertension are later features of RICP.</ce:para><ce:para id="p8315">The rise in intracranial pressure from a mass lesion may cause displacement of the brain. Downward displacement of the medial temporal lobe (uncus) through the tentorium due to a large hemisphere mass may cause ‘temporal coning’ (<ce:cross-ref id="crf1450" refid="f0220">Fig. 25.38</ce:cross-ref><ce:float-anchor refid="f0220"/>). This may stretch the 3rd and/or 6th cranial nerves or cause pressure on the contralateral cerebral peduncle (giving rise to ipsilateral upper motor neuron signs), and is usually accompanied by progressive coma. Downward movement of the cerebellar tonsils through the foramen magnum may compress the medulla – ‘tonsillar coning’ (<ce:cross-ref id="crf1455" refid="f0225">Fig. 25.39</ce:cross-ref><ce:float-anchor refid="f0225"/>). This may result in brainstem haemorrhage and/or acute obstruction of the CSF pathways. As coning progresses, coma and death occur unless the condition is rapidly treated.</ce:para></ce:section><ce:section id="s1725"><ce:section-title id="st1675">Management</ce:section-title><ce:para id="p8320">Primary management of RICP should be targeted at relieving the cause (e.g. surgical decompression of mass lesion, glucocorticoids to reduce vasogenic oedema or shunt procedure to relieve hydrocephalus). Supportive treatment includes maintenance of fluid balance, blood pressure control, head elevation, and use of diuretics such as mannitol. Intensive care support may be needed (<ce:intra-ref id="ii0950" xlink:href="pii:B978-0-7020-7028-0.00010-X#s0790">p. 208</ce:intra-ref>).</ce:para></ce:section></ce:section></ce:section><ce:section id="s1730"><ce:section-title id="st1680">Brain tumours</ce:section-title><ce:para id="p8325">Primary brain tumours are a heterogeneous collection of neoplasms arising from the brain tissue or meninges, and vary from benign to highly malignant. Primary malignant brain tumours (<ce:cross-ref id="crf1460" refid="b0400">Box 25.76</ce:cross-ref><ce:float-anchor refid="b0400"/>) are rare, accounting for 1% of all adult tumours but a higher proportion in children. The most common benign brain tumour is a meningioma. Primary brain tumours do not metastasise due to the absence of lymphatic drainage in the brain. There are rare pathological subtypes, however, such as medulloblastoma, which do have a propensity to metastasise; the reasons for this are not clear. Most cerebral tumours are sporadic but may be associated with genetic syndromes such as neurofibromatosis or tuberous sclerosis. Brain tumours are not classified by the usual TNM system but by the World Health Organisation (WHO) grading I–IV; this is based on histology (e.g. nuclear pleomorphism, presence of mitoses and presence of necrosis), with grade I the most benign and grade IV the most malignant. Gliomas account for 60% of brain tumours, with the aggressive glioblastoma multiforme (WHO grade IV) the most common glioma, followed by meningiomas (20%) and pituitary tumours (10%). Although the lower-grade gliomas (I and II) may be very indolent, with prognosis measured in terms of many years, these may transform to higher-grade disease at any time, with a resultant sharp decline in life expectancy.</ce:para><ce:para id="p8400">Most malignant brain tumours are due to metastases, with intracranial metastases complicating about 20% of extracranial malignancies. The rate is higher with primaries in the bronchus, breast and gastrointestinal tract (<ce:cross-ref id="crf1465" refid="f0230">Fig. 25.40</ce:cross-ref><ce:float-anchor refid="f0230"/>). Metastases usually occur in the white matter of the cerebral or cerebellar hemispheres but there are diffuse leptomeningeal types.</ce:para><ce:section id="s1735"><ce:section id="s1740"><ce:section-title id="st1685">Clinical features</ce:section-title><ce:para id="p8405">The presentation is variable and usually influenced by the rate of growth. High-grade disease (WHO grades III and IV) tends to present with a short (weeks) history of mass effect (headache, nausea secondary to RICP), while more indolent tumours can present with slowly progressive focal neurological deficits, depending on their location (see <ce:cross-ref id="crf1470" refid="b0395">Box 25.75</ce:cross-ref>); generalised or focal seizures are common in either. Headache, if present, is usually accompanied by focal deficits or seizures, and isolated stable headache is almost never due to intracranial tumour.</ce:para><ce:para id="p8410">The size of the primary tumour is of far less prognostic significance than its location within the brain. Tumours within the brainstem will result in early neurological deficits, while those in the frontal region may be quite large before symptoms occur.</ce:para></ce:section><ce:section id="s1745"><ce:section-title id="st1690">Investigations</ce:section-title><ce:para id="p8415">Diagnosis is by neuroimaging (<ce:cross-ref id="crf1475" refid="f0235">Figs 25.41</ce:cross-ref><ce:float-anchor refid="f0235"/> and <ce:cross-ref id="crf1480" refid="f0240">25.42</ce:cross-ref><ce:float-anchor refid="f0240"/>) and pathological grading following biopsy or resection where possible. The more malignant tumours are more likely to demonstrate contrast enhancement on imaging. If the tumour appears metastatic, further investigation to find the primary is required.</ce:para></ce:section><ce:section id="s1750"><ce:section-title id="st1695">Management</ce:section-title><ce:para id="p8420">Brain tumours are treated with a combination of surgery, radiotherapy and chemotherapy, depending on the type of tumour and the patient. Advancing age is the most powerful negative prognostic factor in CNS tumours, so best supportive care (including glucocorticoid therapy) may be most appropriate in older patients with metastases or high-grade disease. Treatment may not always be indicated in low-grade gliomas and watchful waiting may be appropriate, although a more aggressive approach is increasingly favoured.</ce:para><ce:para id="p8425">Dexamethasone given orally (or intravenously where RICP is acutely or severely raised) may reduce the vasogenic oedema typically associated with metastases and high-grade gliomas.</ce:para><ce:para id="p8430">Prolactin- or growth hormone-secreting pituitary adenomas (<ce:intra-ref id="ii0955" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1470">p. 683</ce:intra-ref>) may respond well to treatment with dopamine agonists (such as bromocriptine, cabergoline or quinagolide); in this situation, imaging and hormone levels may be all that is required to establish a formal diagnosis, precluding the need for surgery.</ce:para><ce:section id="s1755"><ce:section-title id="st1700">Surgical</ce:section-title><ce:para id="p8435">The mainstay of primary treatment is surgery, either resection (full or partial debulking) or biopsy, depending on the site and likely radiological diagnosis. Clearly, if a tumour occurs in an area of brain that is highly important for normal function (e.g. motor strip), then biopsy may be the only safe surgical intervention but, in general, maximal safe resection is the optimal surgical management. Meningiomas and acoustic neuromas offer the best prospects for complete removal and thus cure. Some meningiomas can recur, however, particularly those of the sphenoid ridge, when partial excision is often all that is possible. Thereafter, post-operative surveillance may be required, as radiotherapy is effective at preventing further growth of residual tumour. Pituitary adenomas may be removed by a trans-sphenoidal route, avoiding the need for a craniotomy. Unfortunately, gliomas, which account for the majority of brain tumours, cannot be completely excised, since infiltration spreads well beyond the apparent radiological boundaries of the intracranial mass. Recurrence is therefore the rule, even if the mass of the tumour is apparently removed completely; partial excision (‘debulking’) may be useful in alleviating symptoms caused by RICP, but although there is increasing evidence that the degree of surgical excision may have a positive influence on survival, this has not yet been convincingly demonstrated.</ce:para></ce:section><ce:section id="s1760"><ce:section-title id="st1705">Radiotherapy and chemotherapy</ce:section-title><ce:para id="p8440">In the majority of primary CNS tumours, radiation and chemotherapy are used to control disease and extend survival rather than for cure. Meningioma and pituitary adenoma offer the best chance of life-long remission. The gliomas are incurable; high-grade, WHO grade IV disease still carries a median survival of just over 1 year. In this situation, patient and family should always be involved in decisions regarding treatment. The diagnosis, and often the symptoms, are devastating, and support from palliative care and social work is crucial at an early stage. In WHO grade III disease, prognosis is a little better (2–4 years), and in rarer, more indolent tumours very prolonged survival is possible.</ce:para><ce:para id="p8445">Advances have been made recently in terms of therapeutic outcome. Standard care for WHO grade IV glioblastoma multiforme is now combination radiotherapy with temozolomide chemotherapy; although this improves median survival of the population from only 12 to 14.5 months, up to 25% of patients survive for more than 2 years (compared to approximately 10% with radiotherapy alone). Ten percept will survive more than 5 years with temozolomide (virtually unheard of with radiotherapy alone). Benefits are more likely in well-debulked patients who are younger and fitter. Implantation of chemotherapy gives a small survival benefit.</ce:para><ce:para id="p8450">Understanding of the molecular biology of brain tumours has allowed the use of biomarkers to guide therapy and prognostic discussions. In patients with methylation of the promoter region of the <ce:italic>MGMT</ce:italic> (methyl guanine methyl transferase) gene (about 30% of the population), 2-year survival is almost 50%. MGMT reduces the cytotoxicity of temozolomide and this mutation also reduces the enzyme's activity, rendering the tumour more sensitive to chemotherapy. In grade II and III gliomas, the presence of the loss of heterozygosity (LOH) 1p19q chromosomal abnormality confers chemosensitivity and thus improves prognosis. The presence of a rare mutation in the <ce:italic>IDH-1</ce:italic> (isocitrate dehydrogenase) gene confers a more favourable prognosis in patients with glioblastoma.</ce:para><ce:para id="p8455">There is a small group of highly malignant grade IV tumours that can be cured with aggressive therapy. Medulloblastomas have a good chance of long-term remission with maximal surgery followed by irradiation of the whole brain and spine; younger patients may also benefit from concomitant and adjuvant chemotherapy. Older patients do not tolerate this, however.</ce:para><ce:para id="p8460">Once tumours relapse, chemotherapy response rates are low and survival is short in high-grade disease. In the more uncommon low-grade tumours, repeated courses of chemotherapy can result in much more prolonged survival.</ce:para><ce:para id="p8465">In metastatic disease, radiotherapy offers a modest improvement in survival but with costs in terms of quality of life; treatment therefore needs careful discussion with the patient. Benefits may be superior in breast cancer but there is little to separate other pathologies. Occasional chemosensitive cancers, such as small-cell lung cancer, may benefit from systemic chemotherapy but intracerebral metastases represent a late stage of disease and have a short prognosis.</ce:para></ce:section></ce:section><ce:section id="s1765"><ce:section-title id="st1710">Prognosis</ce:section-title><ce:para id="p8470">The WHO histological grading system is a powerful predictor of prognosis in primary CNS tumours, though it does not yet take account of individual biomarkers. For each tumour type and grade, advancing age and deteriorating functional status are the next most important negative prognostic features. The overall 5-year survival rate of about 14% in adults masks a wide variation that depends on tumour type.</ce:para></ce:section></ce:section><ce:section id="s1770"><ce:section-title id="st1715">Acoustic neuroma</ce:section-title><ce:para id="p8475">This is a benign tumour of Schwann cells of the 8th cranial nerve, which may arise in isolation or as part of neurofibromatosis type 2 (see below). When sporadic, acoustic neuroma occurs after the third decade and is more frequent in females. The tumour commonly arises near the nerve's entry point into the medulla or in the internal auditory meatus, usually on the vestibular division. Acoustic neuromas account for 80–90% of tumours at the cerebellopontine angle.</ce:para><ce:section id="s1775"><ce:section-title id="st1720">Clinical features</ce:section-title><ce:para id="p8480">Acoustic neuroma typically presents with unilateral progressive hearing loss, sometimes with tinnitus. Vertigo is an unusual symptom, as slow growth allows compensatory brainstem mechanisms to develop. In some cases, progressive enlargement leads to distortion of the brainstem and/or cerebellar peduncle, causing ataxia and/or cerebellar signs in the limbs. Distortion of the fourth ventricle and cerebral aqueduct may cause hydrocephalus (see below), which may be the presenting feature. Facial weakness is unusual at presentation but facial palsy may follow surgical removal of the tumour. The tumour may be identified incidentally on cranial imaging.</ce:para></ce:section><ce:section id="s1780"><ce:section-title id="st1725">Investigations</ce:section-title><ce:para id="p8485">MRI is the investigation of choice (see <ce:cross-ref id="crf1485" refid="f0240">Fig. 25.42</ce:cross-ref>).</ce:para></ce:section><ce:section id="s1785"><ce:section-title id="st1730">Management</ce:section-title><ce:para id="p8490">Surgery is the treatment of choice. If the tumour can be completely removed, the prognosis is excellent, although deafness is a common complication of surgery. Stereotactic radiosurgery (radiotherapy) may be appropriate for some lesions.</ce:para></ce:section></ce:section><ce:section id="s1790"><ce:section-title id="st1735">Neurofibromatosis</ce:section-title><ce:para id="p8495">Neurofibromatosis encompasses two clinically and genetically separate conditions, with an autosomal dominant pattern of inheritance. The more common neurofibromatosis type 1 (NF1) is caused by mutations in the <ce:italic>NF1</ce:italic> gene on chromosome 17, half of which are new mutations. NF1 is characterised by neurofibromas (benign peripheral nerve sheath tumours) and skin involvement (<ce:cross-ref id="crf1490" refid="f0245">Fig. 25.43</ce:cross-ref><ce:float-anchor refid="f0245"/>), and may affect numerous systems (<ce:cross-ref id="crf1495" refid="b0405">Box 25.77</ce:cross-ref><ce:float-anchor refid="b0405"/>). Neurofibromatosis type 2 (NF2) is caused by mutations of the <ce:italic>NF2</ce:italic> gene on chromosome 22, and is characterised by schwannomas (benign peripheral nerve sheath tumours comprising Schwann cells only) with little skin involvement; the clinical manifestations are more restricted to the eye and nervous system (<ce:cross-ref id="crf1500" refid="b0405">Box 25.77</ce:cross-ref>). Malignant change may occur in NF1 neurofibromas but is rare in NF2 schwannomas. The prevalence of NF1 and NF2 is about 20–50 per 100 000 and 1.5 per 100 000, respectively.</ce:para></ce:section><ce:section id="s1795"><ce:section-title id="st1740">Von Hippel–Lindau disease</ce:section-title><ce:para id="p8695">This rare autosomal dominant disease is caused by mutations of the <ce:italic>VHL</ce:italic> tumour suppressor gene on chromosome 3. It promotes development of tumours affecting the kidney, adrenal gland, CNS, eye, inner ear, epididymis and pancreas, which may undergo malignant change. Benign haemangiomas and haemangioblastomas affect about 80% of patients, and are mostly cerebellar and retinal.</ce:para></ce:section></ce:section><ce:section id="s1800"><ce:section-title id="st1745">Paraneoplastic neurological disease</ce:section-title><ce:para id="p8700">Paraneoplastic neurological syndromes often present before the underlying tumour declares itself and cause considerable disability. They are discussed in full on page 1110.</ce:para></ce:section><ce:section id="s1805"><ce:section-title id="st1750">Hydrocephalus</ce:section-title><ce:para id="p8705">Hydrocephalus is the excessive accumulation of CSF within the brain, and may be caused either by increased CSF production, by reduced CSF absorption, or by obstruction of the circulation (<ce:cross-ref id="crf1505" refid="f0250">Fig. 25.44</ce:cross-ref><ce:float-anchor refid="f0250"/>). Symptoms range from none to sudden death, depending on the speed at which and degree to which hydrocephalus develops. The causes are listed in <ce:cross-ref id="crf1510" refid="b0410">Box 25.78</ce:cross-ref><ce:float-anchor refid="b0410"/>. The terms ‘communicating’ and ‘non-communicating’ (also known as obstructive) hydrocephalus refer to blockage either outside or within the ventricular system, respectively (<ce:cross-ref id="crf1515" refid="f0255">Fig. 25.45</ce:cross-ref><ce:float-anchor refid="f0255"/>).</ce:para><ce:section id="s1810"><ce:section-title id="st1755">Normal pressure hydrocephalus</ce:section-title><ce:para id="p8790">Normal pressure hydrocephalus (NPH) is a controversial entity, said to involve intermittent rises in CSF pressure, particularly at night. It is described in old age as being associated with a triad of gait apraxia, dementia and urinary incontinence.</ce:para><ce:section id="s1815"><ce:section-title id="st1760">Management</ce:section-title><ce:para id="p8795">Diversion of the CSF by means of a shunt placed between the ventricular system and the peritoneal cavity or right atrium may result in rapid relief of symptoms in obstructive hydrocephalus. The outcome of shunting in NPH is much less predictable and, until a good response can be predicted, the management of individual cases will remain uncertain.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1820"><ce:section-title id="st1765">Idiopathic intracranial hypertension</ce:section-title><ce:para id="p8800">This usually occurs in obese young women. The annual incidence is about 3 per 100 000. RICP occurs in the absence of a structural lesion, hydrocephalus or other identifiable cause. The aetiology is uncertain but there is an association with obesity in females, perhaps inducing a defect of CSF reabsorption by the arachnoid villi. A number of drugs may be associated, including tetracycline, vitamin A and retinoid derivatives.</ce:para><ce:section id="s1825"><ce:section id="s1830"><ce:section-title id="st1770">Clinical features</ce:section-title><ce:para id="p8805">The usual presentation is with headache, sometimes accompanied by diplopia and visual disturbance (most commonly, transient obscurations of vision associated with changes in posture). Clinical examination reveals papilloedema but little else. False localising cranial nerve palsies (usually of the 6th nerve) may be present. It is important to record visual fields accurately for future monitoring.</ce:para></ce:section><ce:section id="s1835"><ce:section-title id="st1775">Investigations</ce:section-title><ce:para id="p8810">Brain imaging is required to exclude a structural or other cause (e.g. cerebral venous sinus thrombosis, <ce:intra-ref id="ii0965" xlink:href="pii:B978-0-7020-7028-0.00026-3#s0330">p. 1162</ce:intra-ref>). The ventricles are typically normal in size or small (‘slit’ ventricles). The diagnosis may be confirmed by lumbar puncture, which shows raised normal CSF constituents at increased pressure (usually &#x003E; 30 cmH<ce:inf loc="post">2</ce:inf>O CSF).</ce:para></ce:section><ce:section id="s1840"><ce:section-title id="st1780">Management</ce:section-title><ce:para id="p8815">Management can be difficult and there is no evidence to support any specific treatment. Weight loss in overweight patients may be helpful if it can be achieved. Acetazolamide or topiramate may help to lower intracranial pressure, the latter perhaps aiding weight loss in some patients. Repeated lumbar puncture is an effective treatment for headache but may be technically difficult in obese individuals and is often poorly tolerated. Patients failing to respond, in whom chronic papilloedema threatens vision, may require optic nerve sheath fenestration or a lumbo-peritoneal shunt.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1845"><ce:section-title id="st1785">Head injury</ce:section-title><ce:para id="p8820">Diagnosis of head trauma is usually clear – either from the history or from signs of external trauma to the head. Brain injury is more likely with skull fracture but can occur without. Individual cranial nerves may be damaged in fractures of the facial bones or skull base. Intracranial effects can be substantial and take several forms: extradural haematoma (collection of blood between the skull and dura); subdural haematoma (collection of blood between the dura and the surface of the brain); intracerebral haematoma; or diffuse axonal injury.</ce:para><ce:para id="p8825">Whatever pathology occurs, the resultant RICP may lead to coning (see <ce:cross-ref id="crf1520" refid="f0220">Figs 25.38</ce:cross-ref> and <ce:cross-ref id="crf1525" refid="f0225">25.39</ce:cross-ref>). Haematomas are identified by CT and management is by surgical drainage, usually via a burr hole. Penetrating skull fractures lead to increased infection risk. Long-term sequelae include headache, cognitive decline and depression, all contributing to significant social, work, personality and family difficulties.</ce:para><ce:para id="p8830">Subdural haematoma may occur spontaneously, particularly in patients on anticoagulants, in old age, and with alcohol misuse. There may or may not be a history of trauma. Patients present with subacute impairment of brain function, both globally (obtundation and coma) and focally (hemiparesis, seizures). Headache may not be present. The diagnosis should always be considered in those who present with reduced conscious level.</ce:para><ce:para id="p8835">Beyond the immediate consequences of brain injury, there is increasing suspicion of long-term consequences, including dementia, postulated after either single (moderate or severe) injuries or even after multiple mild injuries, such as in boxers. If substantiated, this would encourage more effort to go into prevention of repeated brain injury in sporting contexts.</ce:para></ce:section></ce:section><ce:section id="s1850"><ce:section-title id="st1790">Disorders of cerebellar function</ce:section-title><ce:para id="p8840">Cerebellar dysfunction can manifest as incoordination of limb function, gait ataxia (p. 1087), speech or eye movements. Acute dysfunction may be caused by alcohol or prescription drugs (especially the sodium channel-blocking antiepileptic drugs phenytoin and carbamazepine).</ce:para><ce:para id="p8845">Inflammatory changes in the cerebellum may cause symptoms in the aftermath of some infections (especially herpes zoster) or as a paraneoplastic phenomenon. The hereditary spinocerebellar ataxias are described on page 1115; they manifest as progressive ataxias in middle and old age, often with other neurological features that aid specific diagnosis.</ce:para></ce:section><ce:section id="s1855"><ce:section-title id="st1795">Disorders of the spine and spinal cord</ce:section-title><ce:para id="p8850">The spinal cord and spinal roots may be affected by intrinsic disease or by disorders of the surrounding meninges and bones. The clinical presentation of these conditions depends on the anatomical level at which the cord or roots are affected, as well as the nature of the pathological process involved. It is important to recognise when the spinal cord is at risk of compression (<ce:cross-ref id="crf9040" refid="s1965">p. 1136</ce:cross-ref>) so that urgent action can be taken.</ce:para><ce:section id="s1860"><ce:section-title id="st1800">Cervical spondylosis</ce:section-title><ce:para id="p8855">Cervical spondylosis is the result of osteoarthritis in the cervical spine. It is characterised by degeneration of the intervertebral discs and osteophyte formation. Such ‘wear and tear’ is extremely common and radiological changes are frequently found in asymptomatic individuals over the age of 50. Spondylosis may be associated with neurological dysfunction. In order of frequency, the C5/6, C6/7 and C4/5 vertebral levels affect C6, C7 and C5 roots, respectively (<ce:cross-ref id="crf1530" refid="f0260">Fig. 25.46</ce:cross-ref><ce:float-anchor refid="f0260"/>).</ce:para><ce:section id="s1865"><ce:section-title id="st1805">Cervical radiculopathy</ce:section-title><ce:para id="p8860">Acute onset of compression of a nerve root occurs when a disc prolapses laterally. More gradual onset may be due to osteophytic encroachment of the intervertebral foramina.</ce:para><ce:section id="s1870"><ce:section-title id="st1810">Clinical features</ce:section-title><ce:para id="p8865">The patient complains of pain in the neck that may radiate in the distribution of the affected nerve root. The neck is held rigidly and neck movements may exacerbate pain. Paraesthesia and sensory loss may be found in the affected segment and there may be lower motor neuron signs, including weakness, wasting and reflex impairment (<ce:cross-ref id="crf1535" refid="f0265">Fig. 25.47</ce:cross-ref><ce:float-anchor refid="f0265"/>).</ce:para></ce:section><ce:section id="s1875"><ce:section-title id="st1815">Investigations</ce:section-title><ce:para id="p8870">Where there is no trauma, imaging should not be carried out for isolated cervical pain. MRI is the investigation of choice in those with radicular symptoms. X-rays offer limited benefit, except in excluding destructive lesions, and electrophysiological studies rarely add to clinical examination with MRI.</ce:para></ce:section><ce:section id="s1880"><ce:section-title id="st1820">Management</ce:section-title><ce:para id="p8875">Conservative treatment with analgesics and physiotherapy results in resolution of symptoms in the great majority of patients, but a few require surgery in the form of discectomy or radicular decompression.</ce:para></ce:section></ce:section><ce:section id="s1885"><ce:section-title id="st1825">Cervical myelopathy</ce:section-title><ce:para id="p8880">Dorsomedial herniation of a disc and the development of transverse bony bars or posterior osteophytes may result in pressure on the spinal cord or the anterior spinal artery, which supplies the anterior two-thirds of the cord (see <ce:cross-ref id="crf1540" refid="f0260">Fig. 25.46</ce:cross-ref>).</ce:para><ce:section id="s1890"><ce:section-title id="st1830">Clinical features</ce:section-title><ce:para id="p8885">The onset is usually insidious and painless but acute deterioration may occur after trauma, especially hyperextension injury. Upper motor neuron signs develop in the limbs, with spasticity of the legs usually appearing before the arms are involved. Sensory loss in the upper limbs is common, producing tingling, numbness and proprioception loss in the hands, with progressive clumsiness. Sensory manifestations in the legs are much less common. Neurological deficit usually progresses gradually and disturbance of micturition is a very late feature.</ce:para></ce:section><ce:section id="s1895"><ce:section-title id="st1835">Investigations</ce:section-title><ce:para id="p8890">MRI (see <ce:cross-ref id="crf1545" refid="f0260">Fig. 25.46</ce:cross-ref>) (or rarely myelography) will direct surgical intervention. The former provides information on the state of the spinal cord at the level of compression.</ce:para></ce:section><ce:section id="s1900"><ce:section-title id="st1840">Management</ce:section-title><ce:para id="p8895">Surgical procedures, including laminectomy and anterior discectomy, may arrest progression of disability but neurological improvement is not the rule. The decision as to whether surgery should be undertaken may be difficult. Manual manipulation of the cervical spine is of no proven benefit and may precipitate acute neurological deterioration.</ce:para></ce:section><ce:section id="s1905"><ce:section-title id="st1845">Prognosis</ce:section-title><ce:para id="p8900">The prognosis of cervical myelopathy is variable. In many patients, the condition stabilises or even improves without intervention. If progression results in sphincter dysfunction or pyramidal signs, surgical decompression should be considered.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1910"><ce:section-title id="st1850">Lumbar spondylosis</ce:section-title><ce:para id="p8905">This term covers degenerative disc disease and osteoarthritic change in the lumbar spine. Pain in the distribution of the lumbar or sacral roots (‘sciatica’) is almost always due to disc protrusion but can be a feature of other rare but important disorders, including spinal tumour, malignant disease in the pelvis and tuberculosis of the vertebral bodies.</ce:para><ce:section id="s1915"><ce:section-title id="st1855">Lumbar disc herniation</ce:section-title><ce:para id="p8910">While acute lumbar disc herniation is often precipitated by trauma (usually lifting heavy weights while the spine is flexed), genetic factors may also be important. The nucleus pulposus may bulge or rupture through the annulus fibrosus, giving rise to pressure on nerve endings in the spinal ligaments, changes in the vertebral joints or pressure on nerve roots.</ce:para><ce:section id="s1920"><ce:section-title id="st1860">Pathophysiology</ce:section-title><ce:para id="p8915">The altered mechanics of the lumbar spine result in loss of lumbar lordosis and there may be spasm of the paraspinal musculature. Root pressure is suggested by limitation of flexion of the hip on the affected side if the straight leg is raised (Lasègue's sign). If the third or fourth lumbar root is involved, Lasègue's sign may be negative, but pain in the back may be induced by hyperextension of the hip (femoral nerve stretch test). The roots most frequently affected are S1, L5 and L4; the signs of root pressure at these levels are summarised in <ce:cross-ref id="crf1550" refid="f0270">Figure 25.48</ce:cross-ref><ce:float-anchor refid="f0270"/>.</ce:para></ce:section><ce:section id="s1925"><ce:section-title id="st1865">Clinical features</ce:section-title><ce:para id="p8920">The onset may be sudden or gradual. Alternatively, repeated episodes of low back pain may precede sciatica by months or years. Constant aching pain is felt in the lumbar region and may radiate to the buttock, thigh, calf and foot. Pain is exacerbated by coughing or straining but may be relieved by lying flat.</ce:para></ce:section><ce:section id="s1930"><ce:section-title id="st1870">Investigations</ce:section-title><ce:para id="p8925">MRI is the investigation of choice if available, since soft tissues are well imaged. Plain X-rays of the lumbar spine are of little value in the diagnosis of disc disease, although they may demonstrate conditions affecting the vertebral body. CT can provide helpful images of the disc protrusion and/or narrowing of exit foramina.</ce:para></ce:section><ce:section id="s1935"><ce:section-title id="st1875">Management</ce:section-title><ce:para id="p8930">Some 90% of patients with sciatica recover following conservative treatment with analgesia and early mobilisation; bed rest does not help recovery. The patient should be instructed in back-strengthening exercises and advised to avoid physical manœuvres likely to strain the lumbar spine. Injections of local anaesthetic or glucocorticoids may be useful adjunctive treatment if symptoms are due to ligamentous injury or joint dysfunction. Surgery may have to be considered if there is no response to conservative treatment or if progressive neurological deficits develop. Central disc prolapse with bilateral symptoms and signs and disturbance of sphincter function requires urgent surgical decompression.</ce:para></ce:section></ce:section><ce:section id="s1940"><ce:section-title id="st1880">Lumbar canal stenosis</ce:section-title><ce:para id="p8935">This occurs with a congenitally narrowed lumbar spinal canal, exacerbated by the degenerative changes that commonly occur with age.</ce:para><ce:section id="s1945"><ce:section-title id="st1885">Pathophysiology</ce:section-title><ce:para id="p8940">The symptoms of spinal stenosis are thought to be due to local vascular compromise secondary to the canal stenosis, rendering the nerve roots ischaemic and intolerant of the increased demand that occurs on exercise.</ce:para></ce:section><ce:section id="s1950"><ce:section-title id="st1890">Clinical features</ce:section-title><ce:para id="p8945">Patients, who are usually elderly, develop exercise-induced weakness and paraesthesia in the legs (‘spinal claudication’). These symptoms progress with continued exertion, often to the point that the patient can no longer walk, but are quickly relieved by a short period of rest. Physical examination at rest shows preservation of peripheral pulses with absent ankle reflexes. Weakness or sensory loss may only be apparent if the patient is examined immediately after exercise.</ce:para></ce:section><ce:section id="s1955"><ce:section-title id="st1895">Investigations</ce:section-title><ce:para id="p8950">The investigation of first choice is MRI, but contraindications (body habitus, metallic implants) may make CT or myelography necessary.</ce:para></ce:section><ce:section id="s1960"><ce:section-title id="st1900">Management</ce:section-title><ce:para id="p8955">Lumbar laminectomy may provide relief of symptoms and recovery of normal exercise tolerance.</ce:para></ce:section></ce:section></ce:section><ce:section id="s1965"><ce:section-title id="st1905">Spinal cord compression</ce:section-title><ce:para id="p8960">Spinal cord compression is one of the more common neurological emergencies encountered in clinical practice and the usual causes are listed in <ce:cross-ref id="crf1555" refid="b0415">Box 25.79</ce:cross-ref><ce:float-anchor refid="b0415"/>. A space-occupying lesion within the spinal canal may damage nerve tissue either directly by pressure or indirectly by interference with blood supply. Oedema from venous obstruction impairs neuronal function, and ischaemia from arterial obstruction may lead to necrosis of the spinal cord. The early stages of damage are reversible but severely damaged neurons do not recover; hence the importance of early diagnosis and treatment.</ce:para><ce:section id="s1970"><ce:section id="s1975"><ce:section-title id="st1910">Clinical features</ce:section-title><ce:para id="p9005">The onset of symptoms of spinal cord compression is usually slow (over weeks) but can be acute as a result of trauma or metastases (see <ce:cross-refs id="crfs0010" refid="f0260 f0275 f0280">Figs 25.46, 25.49 and 25.50</ce:cross-refs>), especially if there is associated arterial occlusion. The symptoms are shown in <ce:cross-ref id="crf1560" refid="b0420">Box 25.80</ce:cross-ref><ce:float-anchor refid="b0420"/>.</ce:para><ce:para id="p9050">Pain and sensory symptoms occur early, while weakness and sphincter dysfunction are usually late manifestations. The signs vary according to the level of the cord compression and the structures involved. There may be tenderness to percussion over the spine if there is vertebral disease and this may be associated with a local kyphosis. Involvement of the roots at the level of the compression may cause dermatomal sensory impairment and corresponding lower motor signs. Interruption of fibres in the spinal cord causes sensory loss (p. 1083) and upper motor neuron signs below the level of the lesion, and there is often disturbance of sphincter function. The distribution of these signs varies with the level of the lesion (<ce:cross-ref id="crf1565" refid="b0425">Box 25.81</ce:cross-ref><ce:float-anchor refid="b0425"/>).</ce:para><ce:para id="p9110">The Brown–Séquard syndrome (see <ce:cross-ref id="crf1570" refid="f0120">Fig. 25.18E</ce:cross-ref>, p. 1084) results if damage is confined to one side of the cord; the findings are explained by the anatomy of the sensory tracts (see <ce:cross-ref id="crf1575" refid="f0070">Fig. 25.11</ce:cross-ref>, p. 1072). With compressive lesions, there is usually a band of pain at the level of the lesion in the distribution of the nerve roots subject to compression.</ce:para></ce:section><ce:section id="s2020"><ce:section-title id="st1955">Investigations</ce:section-title><ce:para id="p9115">Patients with a history of acute or subacute spinal cord syndrome should be investigated urgently, as listed in <ce:cross-ref id="crf1580" refid="b0430">Box 25.82</ce:cross-ref><ce:float-anchor refid="b0430"/>. The investigation of choice is MRI (<ce:cross-ref id="crf1585" refid="f0275">Fig. 25.49</ce:cross-ref><ce:float-anchor refid="f0275"/>), as it can define the extent of compression and associated soft-tissue abnormality (<ce:cross-ref id="crf1590" refid="f0280">Fig. 25.50</ce:cross-ref><ce:float-anchor refid="f0280"/>). Plain X-rays may show bony destruction and soft-tissue abnormalities. Routine investigations, including chest X-ray, may provide evidence of systemic disease. If myelography is performed, CSF should be taken for analysis; in cases of complete spinal block, this shows a normal cell count with a very elevated protein causing yellow discoloration of the fluid (Froin's syndrome). The risk of acute deterioration after myelography in spinal cord compression means that the neurosurgeons should be alerted before it is undertaken. Where a secondary tumour is causing the compression, needle biopsy may be required to establish a tissue diagnosis.</ce:para></ce:section><ce:section id="s2025"><ce:section-title id="st1960">Management</ce:section-title><ce:para id="p9150">Treatment and prognosis depend on the nature of the underlying lesion. Benign tumours should be surgically excised, and a good functional recovery can be expected unless a marked neurological deficit has developed before diagnosis. Extradural compression due to malignancy is the most common cause of spinal cord compression in developed countries and has a poor prognosis. Useful function can be regained if treatment, such as radiotherapy, is initiated within 24 hours of the onset of severe weakness or sphincter dysfunction; management should involve close cooperation with both oncologists and neurosurgeons.</ce:para><ce:para id="p9155">Spinal cord compression due to tuberculosis is common in some areas of the world and may require surgical treatment. This should be followed by appropriate antituberculous chemotherapy (<ce:intra-ref id="ii1000" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1140">p. 592</ce:intra-ref>) for an extended period. Traumatic lesions of the vertebral column require specialised neurosurgical treatment.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2030"><ce:section-title id="st1965">Intrinsic diseases of the spinal cord</ce:section-title><ce:para id="p9160">There are many disorders that interfere with spinal cord function due to non-compressive involvement of the spinal cord itself. A list of these disorders is given in <ce:cross-ref id="crf1595" refid="b0435">Box 25.83</ce:cross-ref><ce:float-anchor refid="b0435"/>. The symptoms and signs are generally similar to those that would occur with extrinsic compression (see <ce:cross-ref id="crf1610" refid="b0420">Boxes 25.80</ce:cross-ref> and <ce:cross-ref id="crf1615" refid="b0425">25.81</ce:cross-ref>), although a suspended sensory loss (see <ce:cross-ref id="crf1620" refid="f0120">Fig. 25.18F</ce:cross-ref>, p. 1084) can occur only with intrinsic disease such as syringomyelia. Urinary symptoms usually occur earlier in the course of an intrinsic cord disorder than with compressive disorders.</ce:para><ce:para id="p9315">Investigation of intrinsic disease starts with imaging to exclude a compressive lesion. MRI provides most information about structural lesions, such as diastematomyelia, syringomyelia (<ce:cross-ref id="crf1625" refid="f0285">Fig. 25.51</ce:cross-ref><ce:float-anchor refid="f0285"/>) or intrinsic tumours. Non-specific signal change may be seen in the spinal cord in inflammatory (see <ce:cross-ref id="crf1630" refid="f0180">Fig. 25.30</ce:cross-ref>, p. 1109) or infective conditions and metabolic disorders such as vitamin B<ce:inf loc="post">12</ce:inf> deficiency. Lumbar puncture or blood tests may be required to make a specific diagnosis.</ce:para></ce:section></ce:section><ce:section id="s2035"><ce:section-title id="st1970">Diseases of peripheral nerves</ce:section-title><ce:para id="p9320">Disorders of the peripheral nervous system are common and may affect the motor, sensory or autonomic components, either in isolation or in combination. The site of pathology may be nerve root (radiculopathy), nerve plexus (plexopathy) or nerve (neuropathy). Neuropathies may present as mononeuropathy (single nerve affected), multiple mononeuropathies (‘mononeuritis multiplex’) or a symmetrical polyneuropathy (<ce:cross-ref id="crf1635" refid="b0440">Box 25.84</ce:cross-ref><ce:float-anchor refid="b0440"/>). Cranial nerves 3–12 share the same tissue characteristics as peripheral nerves elsewhere and are subject to the same range of diseases.</ce:para><ce:section id="s2040"><ce:section id="s2045"><ce:section id="s2050"><ce:section-title id="st1975">Pathophysiology</ce:section-title><ce:para id="p9485">Damage may occur to the nerve cell body (axon) or the myelin sheath (Schwann cell), leading to axonal or demyelinating neuropathies. The distinction is important, as only demyelinating neuropathies are usually susceptible to treatment. Making the distinction requires neurophysiology (nerve conduction studies and EMG, p. 1076). Neuropathies can occur in association with many systemic diseases, toxins and drugs (<ce:cross-ref id="crf1640" refid="b0445">Box 25.85</ce:cross-ref><ce:float-anchor refid="b0445"/>).</ce:para></ce:section><ce:section id="s2055"><ce:section-title id="st1980">Clinical features</ce:section-title><ce:para id="p9580">Motor nerve involvement produces features of a lower motor neuron lesion (p. 1082). Symptoms and signs of sensory nerve involvement depend on the type of sensory nerve involved (p. 1083); small-fibre neuropathies are often painful. Autonomic involvement may cause postural hypotension, disturbance of sweating, cardiac rhythm and gastrointestinal, bladder and sexual functions; isolated autonomic neuropathies are rare and more commonly complicate other neuropathies.</ce:para></ce:section><ce:section id="s2060"><ce:section-title id="st1985">Investigations</ce:section-title><ce:para id="p9585">The investigations required reflect the wide spectrum of causes (<ce:cross-ref id="crf1660" refid="b0450">Box 25.86</ce:cross-ref><ce:float-anchor refid="b0450"/>). Neurophysiological tests are key in discriminating between demyelinating and axonal neuropathies, and in identifying entrapment neuropathies. Most neuropathies are of the chronic axonal type.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2065"><ce:section-title id="st1990">Entrapment neuropathy</ce:section-title><ce:para id="p9680">Focal compression or entrapment is the usual cause of a mononeuropathy. Symptoms and signs of entrapment neuropathy are listed in <ce:cross-ref id="crf1670" refid="b0455">Box 25.87</ce:cross-ref><ce:float-anchor refid="b0455"/>. Entrapment neuropathies may affect anyone but diabetes, excess alcohol or toxins, or genetic syndromes may be predisposing causes. Unless axonal loss has occurred, entrapment neuropathies will recover, provided the primary cause is removed, either by avoiding the precipitation of activity or by surgical decompression.</ce:para></ce:section><ce:section id="s2070"><ce:section-title id="st1995">Multifocal neuropathy</ce:section-title><ce:para id="p9690">Multifocal neuropathy (mononeuritis multiplex) is characterised by lesions of multiple nerve roots, peripheral nerves or cranial nerves (<ce:cross-ref id="crf1675" refid="b0460">Box 25.88</ce:cross-ref><ce:float-anchor refid="b0460"/>). Vasculitis is a common cause, either as part of a systemic disease or isolated to the nerves, or it may arise on a background of a polyneuropathy (e.g. diabetes). Multifocal motor neuropathy (MMN) with conduction block is a rare pure motor neuropathy, typically affecting the arms; it is associated with anti-GM1 antibodies in about 50% and responds to intravenous immunoglobulin.</ce:para></ce:section><ce:section id="s2085"><ce:section-title id="st2010">Polyneuropathy</ce:section-title><ce:para id="p9750">A polyneuropathy is typically associated with a ‘length-dependent’ pattern, occurring in the longest peripheral nerves first and affecting the distal lower limbs before the upper limbs. Sensory symptoms and signs develop in an ascending ‘glove and stocking’ distribution (p. 1083). In inflammatory demyelinating neuropathies, the pathology may be more patchy, affecting the upper rather than lower limbs.</ce:para></ce:section><ce:section id="s2090"><ce:section-title id="st2015">Guillain–Barré syndrome</ce:section-title><ce:para id="p9755">Guillain–Barré syndrome (GBS) is a heterogeneous group of immune-mediated conditions with an incidence of 1–2/100 000/year. In Europe and North America, the most common variant is an acute inflammatory demyelinating polyneuropathy (AIDP). Axonal variants, either motor (acute motor axonal neuropathy, AMAN) or sensorimotor (acute motor and sensory axonal neuropathy, AMSAN), are more common in China and Japan, and account for 10% of GBS in Western countries (often associated with <ce:italic>Campylobacter jejuni</ce:italic>). The hallmark is an acute paralysis evolving over days or weeks with loss of tendon reflexes. About two-thirds of those with AIDP have a prior history of infection, and an autoimmune response triggered by the preceding infection causes demyelination. A number of GBS variants have been described, associated with specific anti-ganglioside antibodies; the best recognised is Miller Fisher syndrome, which involves anti-GQ1b antibodies.</ce:para><ce:section id="s2095"><ce:section id="s2100"><ce:section-title id="st2020">Clinical features</ce:section-title><ce:para id="p9760">Distal paraesthesia and pain precede muscle weakness that ascends rapidly from lower to upper limbs and is more marked proximally than distally. Facial and bulbar weakness commonly develops, and respiratory weakness requiring ventilatory support occurs in 20% of cases. Weakness progresses over a maximum of 4 weeks (usually less). Rapid deterioration to respiratory failure can develop within hours. Examination shows diffuse weakness with loss of reflexes. Miller Fisher syndrome presents with internal and external ophthalmoplegia, ataxia and areflexia.</ce:para></ce:section><ce:section id="s2105"><ce:section-title id="st2025">Investigations</ce:section-title><ce:para id="p9765">The CSF protein is raised, but may be normal in the first 10 days. There is usually no increase in CSF white cell count (&#x003E; 10 × 10<ce:sup loc="post">6</ce:sup> cells/L suggests an alternative diagnosis). Electrophysiological changes may emerge after a week or so, with conduction block and multifocal motor slowing, sometimes most evident proximally as delayed F waves (p. 1076). Antibodies to the ganglioside GM1 are found in about 25%, usually the motor axonal form. Other causes of an acute neuromuscular paralysis should be excluded (e.g. poliomyelitis, botulism, diphtheria, spinal cord syndromes or myasthenia), via the history and examination rather than investigations.</ce:para></ce:section><ce:section id="s2110"><ce:section-title id="st2030">Management</ce:section-title><ce:para id="p9770">Active treatment with plasma exchange or intravenous immunoglobulin therapy shortens the duration of ventilation and improves prognosis. In severe GBS, both intravenous immunoglobulin (IVIg) and plasma exchange started within 2 weeks of onset hasten recovery with similar rates of adverse effects but IVIg treatment is significantly more likely to be completed than plasma exchange. Overall, 80% of patients recover completely within 3–6 months, 4% die and the remainder suffer residual neurological disability, which can be severe. Adverse prognostic features include older age, rapid deterioration to ventilation and evidence of axonal loss on EMG. Supportive measures to prevent pressure sores and deep venous thrombosis are essential. Regular monitoring of respiratory function (vital capacity) is needed in the acute phase, as respiratory failure may develop with little warning.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2115"><ce:section-title id="st2035">Chronic polyneuropathy</ce:section-title><ce:para id="p9775">The most common axonal and demyelinating causes of polyneuropathy are shown in <ce:cross-ref id="crf1680" refid="b0445">Box 25.85</ce:cross-ref>. A chronic symmetrical axonal polyneuropathy, evolving over months or years, is the most common form of chronic neuropathy. Diabetes mellitus is the most common cause but in about 25–50% no cause can be found.</ce:para><ce:section id="s2120"><ce:section-title id="st2040">Hereditary neuropathy</ce:section-title><ce:para id="p9780">Charcot–Marie–Tooth disease (CMT) is an umbrella term for the inherited neuropathies. The members of this group of syndromes have different clinical and genetic features. The most common CMT is the autosomal dominantly inherited CMT type 1, usually caused by a mutation in the <ce:italic>PMP-22</ce:italic> gene. Common signs are distal wasting (‘inverted champagne bottle’ legs), often with pes cavus, and predominantly motor involvement. X-linked and recessively inherited forms of CMT, causing demyelinating or axonal neuropathies, also occur.</ce:para></ce:section><ce:section id="s2125"><ce:section-title id="st2045">Chronic demyelinating polyneuropathy</ce:section-title><ce:para id="p9785">The acquired chronic demyelinating neuropathies include chronic inflammatory demyelinating peripheral neuropathy (CIDP), multifocal motor neuropathy (see above) and paraprotein-associated demyelinating neuropathy. CIDP typically presents with relapsing or progressive motor and sensory changes, evolving over more than 8 weeks (in distinction to the more acute GBS). It is important to recognise, as it usually responds to glucocorticoids, plasma exchange or intravenous immunoglobulin.</ce:para><ce:para id="p9790">Some 10% of patients with acquired demyelinating polyneuropathy have an abnormal serum paraprotein, sometimes associated with a lymphoproliferative malignancy. They may also demonstrate positive antibodies to myelin-associated glycoprotein (anti-MAG antibodies).</ce:para></ce:section></ce:section><ce:section id="s2130"><ce:section-title id="st2050">Brachial plexopathy</ce:section-title><ce:para id="p9795">Trauma usually damages either the upper or the lower parts of the brachial plexus, according to the mechanics of the injury. The clinical features depend on the anatomical site of the damage (<ce:cross-ref id="crf1685" refid="b0465">Box 25.89</ce:cross-ref><ce:float-anchor refid="b0465"/>). Lower parts of the brachial plexus are vulnerable to infiltration from breast or apical lung tumours (Pancoast tumour, <ce:intra-ref id="ii1065" xlink:href="pii:B978-0-7020-7028-0.00017-2#s1330">p. 600</ce:intra-ref>) or damage by therapeutic irradiation. The lower plexus may also be compressed by a cervical rib or fibrous band between C7 and the first rib at the thoracic outlet.</ce:para><ce:para id="p9805">Neuralgic amyotrophy (also known as brachial neuritis) presents as an acute brachial plexopathy of probable inflammatory origin. Severe shoulder pain precedes the appearance of a patchy upper brachial plexus lesion, with motor and/or sensory involvement. There is no specific treatment and recovery is often incomplete; it may recur in about 25% and there is a rare autosomal dominant hereditary form. The appearance of vesicles should indicate the alternative diagnosis of motor zoster.</ce:para></ce:section><ce:section id="s2135"><ce:section-title id="st2055">Lumbosacral plexopathy</ce:section-title><ce:para id="p9810">Lumbosacral plexus lesions may be caused by neoplastic infiltration or compression by retroperitoneal haematomas. A small-vessel vasculopathy can produce a unilateral or bilateral lumbar plexopathy in association with diabetes mellitus (‘diabetic amyotrophy’) or an idiopathic form in non-diabetic patients. This presents with painful wasting of the quadriceps with weakness of knee extension and an absent knee reflex.</ce:para></ce:section><ce:section id="s2140"><ce:section-title id="st2060">Spinal root lesions</ce:section-title><ce:para id="p9815">Spinal root lesions (radiculopathy) are described above. Clinical features include muscle weakness and wasting and dermatomal sensory and reflex loss, which reflect the pattern of the roots involved. Pain in the muscles innervated by the affected roots may be prominent.</ce:para></ce:section></ce:section><ce:section id="s2145"><ce:section-title id="st2065">Diseases of the neuromuscular junction</ce:section-title><ce:section id="s2150"><ce:section-title id="st2070">Myasthenia gravis</ce:section-title><ce:para id="p9820">This is the most common cause of acutely evolving, fatigable weakness and preferentially affects ocular, facial and bulbar muscles.</ce:para><ce:section id="s2155"><ce:section id="s2160"><ce:section-title id="st2075">Pathophysiology</ce:section-title><ce:para id="p9825">Myasthenia gravis is an autoimmune disease, most commonly (80% of cases) caused by antibodies to acetylcholine receptors in the post-junctional membrane of the neuromuscular junction. The resultant blockage of neuromuscular transmission and complement-mediated inflammatory response reduces the number of acetylcholine receptors and damages the end plate (<ce:cross-ref id="crf1690" refid="f0290">Fig. 25.52</ce:cross-ref><ce:float-anchor refid="f0290"/>). Other antibodies can produce a similar clinical picture, most notably autoantibodies to muscle-specific kinase (MuSK), which is involved in the regulation and maintenance of acetylcholine receptors.</ce:para><ce:para id="p9830">About 15% of patients (mainly those with late onset) have a thymoma, most of the remainder displaying thymic follicular hyperplasia. Myasthenic patients are more likely to have associated organ-specific autoimmune diseases. Triggers are not always evident but some drugs (e.g. penicillamine) can precipitate an antibody-mediated myasthenic syndrome that may persist after drug withdrawal. Other drugs, especially aminoglycosides and quinolones, may exacerbate the neuromuscular blockade and should be avoided in patients with myasthenia.</ce:para></ce:section><ce:section id="s2165"><ce:section-title id="st2080">Clinical features</ce:section-title><ce:para id="p9835">Myasthenia gravis usually presents between the ages of 15 and 50 years and there is a female preponderance in younger patients. In older patients, males are more commonly affected. It tends to run a relapsing and remitting course.</ce:para><ce:para id="p9840">The most evident symptom is fatigable muscle weakness; movement is initially strong but rapidly weakens as muscle use continues. Worsening of symptoms towards the end of the day or following exercise is characteristic. There are no sensory signs or signs of involvement of the CNS, although weakness of the oculomotor muscles may mimic a central eye movement disorder. The first symptoms are usually intermittent ptosis or diplopia but weakness of chewing, swallowing, speaking or limb movement also occurs. Resting of the eyelids (looking downwards) may be followed by increased reflex elevation with up-gaze (so-called Cogan's lid twitch sign). Any limb muscle may be affected, most commonly those of the shoulder girdle; the patient is unable to undertake tasks above shoulder level, such as combing the hair, without frequent rests. Respiratory muscles may be involved and respiratory failure is an avoidable cause of death. Aspiration may occur if the cough is ineffectual. Ventilatory support is required where weakness is severe or of abrupt onset.</ce:para></ce:section><ce:section id="s2170"><ce:section-title id="st2085">Investigations</ce:section-title><ce:para id="p9845">Intravenous injection of the short-acting anticholinesterase edrophonium bromide (the Tensilon test) is less widely used than before. Improvement in muscle function occurs within 30 seconds and usually persists for 2–3 minutes but the test is not entirely specific or sensitive. Cover with intravenous atropine is necessary to avoid bradycardia. Planning assessment beforehand (e.g. speech or limb movements) allows some objectivity in gauging the effect.</ce:para><ce:para id="p9850">Repetitive stimulation during nerve conduction studies may show a characteristic decremental response (p. 1076) if the muscle has been clinically affected. Anti-MuSK antibodies are more common in acetylcholine receptor antibody-negative patients with prominent bulbar involvement. All patients should have a thoracic CT to exclude thymoma, especially those without anti-acetylcholine receptor antibodies. Screening for associated autoimmune disorders, particularly thyroid disease, is important.</ce:para></ce:section><ce:section id="s2175"><ce:section-title id="st2090">Management</ce:section-title><ce:para id="p9855">The goals of treatment are to maximise the activity of acetylcholine at remaining receptors in the neuromuscular junctions and to limit or abolish the immunological attack on motor end plates.</ce:para><ce:para id="p9860">The duration of action of acetylcholine is prolonged by inhibiting acetylcholinesterase. The most commonly used anticholinesterase drug is pyridostigmine. Muscarinic side-effects, including diarrhoea and colic, may be controlled by propantheline. Overdosage of anticholinesterase drugs may cause a ‘cholinergic crisis’ due to depolarisation block of motor end plates, with muscle fasciculation, paralysis, pallor, sweating, excessive salivation and small pupils. This may be distinguished from severe weakness due to exacerbation of myasthenia (‘myasthenic crisis’) by the clinical features and, if necessary, by the injection of a small dose of edrophonium.</ce:para><ce:para id="p9865">Immunological treatment of myasthenia is outlined in <ce:cross-ref id="crf1695" refid="b0470">Box 25.90</ce:cross-ref><ce:float-anchor refid="b0470"/>. Thymectomy may improve overall prognosis but awaits clinical trial confirmation. Prognosis is variable and remissions may occur spontaneously. When myasthenia is entirely ocular, prognosis is excellent and disability slight. Young female patients with generalised disease may benefit from thymectomy, while older patients are less likely to have a remission despite treatment. Rapid progression of the disease more than 5 years after onset is uncommon.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2215"><ce:section-title id="st2130">Lambert–Eaton myasthenic syndrome</ce:section-title><ce:para id="p9935">Other rarer conditions can present with muscle weakness due to impaired transmission across the neuromuscular junction. The most common of these is the Lambert–Eaton myasthenic syndrome (LEMS), which can occur as an inflammatory or paraneoplastic phenomenon. Antibodies to pre-synaptic voltage-gated calcium channels (see <ce:cross-ref id="crf1700" refid="f0290">Fig. 25.52</ce:cross-ref>) impair transmitter release. Patients may have autonomic dysfunction (e.g. dry mouth) in addition to muscle weakness but the cardinal clinical sign is absence of tendon reflexes, which return after sustained contraction of the relevant muscle. The condition is associated with underlying malignancy in a high percentage of cases and investigation must be directed towards identifying any neoplasm. Diagnosis is made electrophysiologically on the presence of post-tetanic potentiation of motor response to nerve stimulation at a frequency of 20–50/sec. Treatment is with 3,4-diaminopyridine, or pyridostigmine and immunosuppression.</ce:para></ce:section></ce:section><ce:section id="s2220"><ce:section-title id="st2135">Diseases of muscle</ce:section-title><ce:para id="p9940">Muscle disease, either hereditary or acquired, is rare. Most typically, it presents with a proximal symmetrical weakness. Diagnosis is dependent on recognition of clinical clues, such as cardiorespiratory involvement, evolution, family history, exposure to drugs, the presence of contractures, myotonia and other systemic features, and on investigation findings, most importantly EMG and muscle biopsy. Hereditary syndromes include the muscular dystrophies, muscle channelopathies, metabolic myopathies (including mitochondrial diseases) and congenital myopathies.</ce:para><ce:section id="s2225"><ce:section-title id="st2140">Muscular dystrophies</ce:section-title><ce:para id="p9945">These are inherited disorders with progressive muscle destruction and may be associated with cardiac and/or respiratory involvement and sometimes non-myopathic features (<ce:cross-ref id="crf1705" refid="b0475">Box 25.91</ce:cross-ref><ce:float-anchor refid="b0475"/>). Myotonic dystrophy is the most common, with a prevalence of about 12/100 000.</ce:para><ce:section id="s2230"><ce:section id="s2235"><ce:section-title id="st2145">Clinical features</ce:section-title><ce:para id="p9985">The pattern of the clinical features is defined by the specific syndromes. Onset is often in childhood, although some patients, especially those with myotonic dystrophy, may present as adults. Wasting and weakness are usually symmetrical, without fasciculation or sensory loss, and tendon reflexes are usually preserved until a late stage. Weakness is usually proximal, except in myotonic dystrophy type 1, when it is distal.</ce:para></ce:section><ce:section id="s2240"><ce:section-title id="st2150">Investigations</ce:section-title><ce:para id="p9990">The diagnosis can be confirmed by specific molecular genetic testing, supplemented with EMG and muscle biopsy if necessary. Creatine kinase is markedly elevated in the dystrophinopathies (Duchenne and Becker) but is normal or moderately elevated in the other dystrophies. Screening for an associated cardiac abnormality (cardiomyopathy or dysrhythmia) is important.</ce:para></ce:section><ce:section id="s2245"><ce:section-title id="st2155">Management</ce:section-title><ce:para id="p9995">There is no specific therapy for most of these conditions but physiotherapy and occupational therapy help patients cope with their disability. Glucocorticoids can be used in Duchenne muscular dystrophy but side-effects should be anticipated and avoided by dose modification. Ataluren is a compound given by infusion to affected individuals that may ‘override’ the stop sign in Duchenne, theoretically leading to normalisation of muscle proteins and potentially reducing or arresting functional deteriorations. Treatment of associated cardiac failure or arrhythmia (with pacemaker insertion if necessary) may be required; similarly, management of respiratory complications (including nocturnal hypoventilation) can improve quality of life. Improvements in non-invasive ventilation have led to significant improvements in survival for patients with Duchenne muscular dystrophy. Genetic counselling is important.</ce:para></ce:section></ce:section></ce:section><ce:section id="s2250"><ce:section-title id="st2160">Inherited metabolic myopathies</ce:section-title><ce:para id="p10000">There are a large number of rare inherited disorders that interfere with the biochemical pathways that maintain the energy supply (adenosine triphosphate, ATP) to muscles. These are mostly recessively inherited deficiencies in the enzymes necessary for glycogen or fatty acid (β-oxidation) metabolism (<ce:cross-ref id="crf1710" refid="b0480">Box 25.92</ce:cross-ref><ce:float-anchor refid="b0480"/>). They typically present with muscle weakness and pain.</ce:para><ce:section id="s2255"><ce:section-title id="st2165">Mitochondrial disorders</ce:section-title><ce:para id="p10080">Mitochondrial diseases are discussed on <ce:intra-ref id="ii1075" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0195">page 49</ce:intra-ref>. Mitochondria are present in all tissues and dysfunction causes widespread effects on vision (optic atrophy, retinitis pigmentosa, cataracts), hearing (sensorineural deafness) and the endocrine, cardiovascular, gastrointestinal and renal systems. Any combination of these should raise the suspicion of a mitochondrial disorder, especially if there is evidence of maternal transmission.</ce:para><ce:para id="p10085">Mitochondrial dysfunction can be caused by alterations in either mitochondrial DNA or genes encoding for oxidative processes. Genetic abnormalities or mutations in mitochondrial DNA may affect single individuals and single tissues (most commonly muscle). Thus, patients with exercise intolerance, myalgia and sometimes recurrent myoglobinuria may have isolated pathogenic mutations in genes encoding for oxidation pathways.</ce:para><ce:para id="p10090">Inherited disorders of the oxidative pathways of the respiratory chain in mitochondria cause a group of disorders, either restricted to the muscle or associated with non-myopathic features (<ce:cross-ref id="crf1715" refid="b0485">Box 25.93</ce:cross-ref><ce:float-anchor refid="b0485"/>). Many of these mitochondrial disorders are inherited via the mitochondrial genome, down the maternal line (<ce:intra-ref id="ii1080" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0195">p. 49</ce:intra-ref>). Diagnosis is based on clinical appearances, supported by muscle biopsy appearance (usually with ‘ragged red’ and/or cytochrome oxidase-negative fibres), and specific mutations either on blood or, more reliably, muscle testing. Mutations may be due either to point mutations or to deletions of mitochondrial DNA.</ce:para><ce:para id="p10100">A disorder called Leber hereditary optic neuropathy (LHON) is characterised by acute or subacute loss of vision, most frequently in males, due to bilateral optic atrophy. Three point mutations account for more than 90% of LHON cases.</ce:para></ce:section><ce:section id="s2260"><ce:section-title id="st2170">Channelopathies</ce:section-title><ce:para id="p10105">Inherited abnormalities of the sodium, calcium and chloride ion channels in striated muscle produce various syndromes of familial periodic paralysis, myotonia and malignant hyperthermia, which may be recognised by their clinical characteristics and potassium abnormalities (<ce:cross-ref id="crf1720" refid="b0490">Box 25.94</ce:cross-ref><ce:float-anchor refid="b0490"/>). Genetic testing is available.</ce:para></ce:section></ce:section><ce:section id="s2265"><ce:section-title id="st2175">Acquired myopathies</ce:section-title><ce:para id="p10240">These include the inflammatory myopathies, or myopathy associated with a range of metabolic and endocrine disorders or drug and toxin exposure (<ce:cross-ref id="crf1725" refid="f0295">Fig. 25.53</ce:cross-ref><ce:float-anchor refid="f0295"/>).</ce:para></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st2180">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st2185">Journal articles</ce:section-title><ce:bib-reference id="bib1"><ce:label>Scolding et al, 2015</ce:label><sb:reference id="sr0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>N</ce:given-name><ce:surname>Scolding</ce:surname></sb:author><sb:author><ce:given-name>D</ce:given-name><ce:surname>Barnes</ce:surname></sb:author><sb:author><ce:given-name>S</ce:given-name><ce:surname>Cader</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Pract Neurol</sb:maintitle></sb:title><sb:volume-nr>0</sb:volume-nr></sb:series><sb:date>2015</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>7</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:further-reading-sec><ce:further-reading-sec id="fs0015"><ce:section-title id="st2190">Websites</ce:section-title><ce:bib-reference id="bib2"><ce:label>,</ce:label><sb:reference id="sr0015"><sb:host><sb:e-host><ce:inter-ref id="iw0010" xlink:href="http://aneuroa.org/">aneuroa.org/</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0520"><ce:italic>American Neurological Association.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0015" xlink:href="http://brainandspine.org.uk">brainandspine.org.uk</ce:inter-ref></sb:e-host></sb:host><sb:comment>and</sb:comment><sb:host><sb:e-host><ce:inter-ref id="iw0020" xlink:href="http://dizziness-and-balance.com/disorders">dizziness-and-balance.com/disorders</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0525"><ce:italic>Diagnosing benign paroxysmal positional vertigo.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><sb:reference id="sr0030"><sb:host><sb:e-host><ce:inter-ref id="iw0025" xlink:href="http://epilepsydiagnosis.org">epilepsydiagnosis.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0530"><ce:italic>International League Against Epilepsy: free access to videos of different seizure types and clinical summaries of the epilepsies.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib9000"><ce:label>,</ce:label><sb:reference id="sr9000"><sb:host><sb:e-host><ce:inter-ref id="iw9000" xlink:href="http://headinjurysymptoms.org">headinjurysymptoms.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9001"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp9000"><ce:italic>Symptoms and management of mild and moderate head injury.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>,</ce:label><sb:reference id="sr0035"><sb:host><sb:e-host><ce:inter-ref id="iw0035" xlink:href="http://ihs-classification.org/en/">ihs-classification.org/en/</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0535"><ce:italic>International Headache Society: full access to 3rd edition of International Classification of Headache Disorders.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><sb:reference id="sr0040"><sb:host><sb:e-host><ce:inter-ref id="iw0040" xlink:href="http://neurosymptoms.org">neurosymptoms.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0540"><ce:italic>Advice on managing functional neurological symptoms.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><sb:reference id="sr0045"><sb:host><sb:e-host><ce:inter-ref id="iw0045" xlink:href="http://ninds.nih.gov">ninds.nih.gov</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0545"><ce:italic>National Institute of Neurological Disorders and Stroke.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>,</ce:label><sb:reference id="sr0050"><sb:host><sb:e-host><ce:inter-ref id="iw0050" xlink:href="http://sign.ac.uk">sign.ac.uk</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0550"><ce:italic>Scottish Intercollegiate Guidelines network: SIGN 107 Diagnosis and management of headache in adults; SIGN 110 Early management of patients with a head injury; SIGN 113 Diagnosis and pharmacological management of Parkinson's disease; SIGN 143 Diagnosis and management of epilepsy in adults.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0555"><ce:inter-ref id="iw0055" xlink:href="http://wfneurology.org">wfneurology.org</ce:inter-ref></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0560"><ce:italic>World Federation of Neurology.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>